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ABSTRACT 
Developing efficacious, highly specific therapeutics is an ongoing challenge. 
The domain antibody (dAb) fragment platform has shown promise targeting a dAb-
fused therapeutic moiety to a specific tissue. This investigation sought to conclude on 
the optimum binding affinity combination to maximise tissue-targeting specificity and 
localised therapeutic potency by using a panel of dAb fusion proteins with varying 
affinity combinations of asialoglycoprotein receptor (ASGPR)-targeting dAb mutants 
and human interferon (hIFN) mutants – hIFN-ASGPRdAbs. 
The hIFN-ASGPRdAbs were engineered, expressed, 1,4,7-
triazacyclononanetriacetic acid (NOTA)-conjugated and purified with binding affinities 
and potencies characterised. Gallium-68 radiolabelling of the NOTA-hIFN-
ASGPRdAbs was optimised using a high activity fraction in a 10 minute reaction at 
ambient temperature in pH4.4 sodium acetate.  HepG2 xenograft mouse models 
were injected with 68Ga-NOTA-hIFN-dAbs for biodistribution analysis and 
PET/CT imaging, followed by mRNA expression analysis of the xenograft tissue.  
ASGPR binding affinities of the NOTA-hIFN-ASGPRdAbs ranged from 
0.73pM to ~528nM, and their hIFN potency ranged from 6.79pM to ~3.87nM. 
Targeting of HepG2 cells was driven by the dAb-mediated ASGPR targeting. Ga-68 
radiolabelling efficiencies up to 98.4% and specific activities up to 2.47MBq/µg were 
achieved. Xenograft uptake was significantly increased through dAb-mediated 
ASGPR targeting compared to the non-ASGPR targeted control 68Ga-NOTA-hIFN-
CTRLdAb, achieving 2.42%ID/g vs. 0.68%ID/g, respectively. A trend of increasing 
xenograft uptake correlated with increasing ASGPR binding affinity for the panel of 
mutants, in spite of very high murine liver uptake. Increased xenograft uptake also 
correlated with a more potent hIFN-mediated anti-proliferative mRNA response in 
the xenograft tissue. A dAb with a mid-range affinity for ASGPR and maximum 
affinity hIFN was concluded to be the optimum combination.  
These results showed that the efficacy of a dAb fusion protein can be 
influenced by the two intrinsic binding affinities. Hence, dAb-mediated tissue 
targeting of a fused therapeutic and engineered affinity synergism strategies may hold 
the key to novel, selectively cytotoxic biopharmaceutical drugs.  
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 3 - Ph.D. 2014 
ACKNOWLEDGEMENTS 
This project was jointly funded by Queen Mary University of London, 
GlaxoSmithKline (GSK) and the EPRSC. I would like to thank them for enabling this 
project to proceed. The PhD wet work was performed primarily in the Cancer Imaging 
group of Molecular Oncology at Barts Cancer Institute, Queen Mary University of London 
with additional in vitro work performed during extended stays at GlaxoSmithKline in 
Cambridge. It has thus involved the efforts of many people at both institutions.  
 
My primary supervisor, Jane Sosabowski, is the respected matriarch of the Cancer 
Imaging department, rightfully in constant demand for her knowledge and experience. On 
top of this she had to stoically endure my ramblings and flights of scientific fantasy on a daily 
basis, and tussle to ground me back in the realms of scientific reality. Jane has thus been 
instrumental in ensuring I had the scientific competency and understanding necessary to 
complete this project, keeping the project focussed and spending innumerable hours 
troubleshooting with me. Stephen Mather, as my supervising professor, has my gratitude and 
respect for using his wealth of experience and incisive scrutiny of data to always help me find 
solutions with his sharp intellect always invaluable in making the big project decisions.  
As I didn’t hold an animal license, I was highly reliant on the skill sets of other in vivo 
specialists. Julie Foster’s in vivo experience was unrivalled and cheerfully trained me in 
dissection. Julie performed the majority of the xenograft injections, and aided in a plethora of 
other techniques but particularly PET/CT where Julie reconstructed images for time course 
analysis. I owe a debt of gratitude to Julie Andow-Cleaver who went above-and-beyond to 
accommodate my fluid experimental requirements as early as 7am, and was always willing to 
help out. Julie performed the majority of in vivo handling, injections (HepG2 cells and 
radioactive), and also helping significantly with performing PET/CT work and a number of 
dissections. Also, Stella Adamou, without whom the biodistribution work may never have 
been completed because Stella was always willing to give up her spare time to perform 
dissections, as well as ensuring I did not lose my sanity in the process. Ciara Finucane for her 
welcome in vivo input, and excellent VivoQuant training. I am further thankful to Julius 
Leyton and Jerome Burnet who performed some of the initial injections and dissections, and 
Chantelle Hudson and Roxana Kashani for their help with tissue culture.  
 
I am grateful to all at GSK Targeted BDU (Domantis) who were always happy to 
discuss experiments and spend their time on demonstrating new techniques. 
Adam Walker, as my GSK supervisor, played a crucial role in formulating the best 
strategy for achieving the project aims and was always constructive in his analysis of my 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 4 - Ph.D. 2014 
ideas. Indeed it was easy to trust Adam’s judgement, as his knowledge of the liver-targeting 
dAbs science is unrivalled. Prior to Adam, Elena De Angelis was my GSK supervisor and 
provided excellent project guidance and intellectual input from the outset. Thil Batuwangala 
made an inestimable contribution to this project in spite of having absolutely no obligation to 
do so, selflessly allowing me to adopt him as an unofficial lab mentor. Thil was instrumental 
in almost all aspects of the in vitro work by training me in almost all the techniques 
performed. Ed Coulstock was a ray of sunshine, fountain of optimism, and more seriously of 
great intellectual help to this project. Ed also facilitated the majority of the MS data, 
personally overseeing many of the runs.  
Milan Ovecka was an oracle on all matters Biacore, training me on the Biacore 
T200 and patiently troubleshooting all my glitches. Jayne Colebrook was fantastically 
proactive with planning and implementation of the TaqMan experiments. Rob Prince taught 
me how to perform HEK-Blue assays. Laura Goodall happily aided my competency in Flow 
Cytometry. Katy Childerley graciously performed HEK293e mammalian transfections in my 
absence and often harvested the cells too. I would also like to acknowledge the lab help and 
data interpretation input of Marie Davies, Chris Herring, Daniel Badcock, Armin Sepp, 
Oliver Schon, Joanne McGregor, Dan Rycroft, Chris Plummer, Gavin Jones, Ksenia 
Rotislavleva, Clare Mudd, Nadine Clemo, Andrew Sanderson, Helen Sanderson, and Gaby 
Dos Santos Cruz De Matos. My time at GSK ran so much smoother thanks to the help of 
the lab assistants Clare and Jamie, and the administrative staff Grace, Julie & Caron. Finally, 
Laurent Jespers for supporting the project since inception.  
 
Discussions with fellow students stimulated new avenues of enquiry and discovery of 
fresh techniques so I am also grateful to Mark Jackson, Chris Cobb, Constantia Pantelidou, 
Delphine Guillotin, Michael Walsh, Aine McCarthy, Roxana Koshani, Ana Boshoff, 
Benedikt Sandhöfer, Marian Meckel and Berit Kühle. 
I am infinitely grateful to Camilla Tørnqvist-Johnsen for her unwavering belief and 
cheerleading throughout, and in spite of the PhD findings will remain my most amazing 
discovery at the BCI. Moreover, my parents Karen Johnston and Gordon Papple for their 
continued support of my baffling interests.  
 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 5 - Ph.D. 2014 
TABLE OF CONTENTS 
Abstract ................................................................................................. 2 
Acknowledgements .................................................................................. 3 
Figures & Tables ..................................................................................... 9 
Introduction ...................................................................................................................... 9 
Methods ............................................................................................................................ 9 
HepG2 Xenograft Targeting of 68Ga-NOTA-hIFN-dAb .............................................. 9 
Optimising HepG2 Xenograft Targeting of hIFN-dAbs ............................................... 11 
Conclusions & Future Work ........................................................................................... 12 
Appendices ..................................................................................................................... 12 
Abbreviations ........................................................................................ 13 
I Introduction .............................................................................. 17 
1.1 Thesis Rationale ............................................................................... 18 
1.2 Domain Antibodies ........................................................................... 21 
1.2.1 Domain Antibody Engineering ................................................................................. 21 
1.2.2 Domain Antibody Biopharmaceuticals ..................................................................... 26 
1.3 Immuno-Targeting Cancer ................................................................. 28 
1.3.1 Cancer Targeting Antibody Derivatives .................................................................... 28 
1.3.2 Dual-Targeted Fusion Proteins targeting Cancer ..................................................... 31 
1.4 Asialoglycoprotein Receptor ............................................................... 33 
1.4.1 ASGPR Function ....................................................................................................... 33 
1.4.2 ASGPR Structure & Interactions .............................................................................. 34 
1.4.3 ASGPR Expression Profile ........................................................................................ 36 
1.4.4 Targeting ASGPR ..................................................................................................... 39 
1.4.4.1 ASGPR Targeting Fates ..................................................................................... 40 
1.5 Interferon ........................................................................................ 41 
1.5.1 Interferon Protein ...................................................................................................... 41 
1.5.2 IFNAR Structure & Interactions ............................................................................... 42 
1.5.3 IFN Signal Transduction ........................................................................................... 45 
1.5.4 IFN as a Cancer Therapeutic .................................................................................... 48 
1.5.5 IFN Treatment Side Effects ....................................................................................... 50 
1.6 Hepatocellular Carcinoma ................................................................. 52 
1.6.1 HCC Overview .......................................................................................................... 52 
1.6.2 HepG2 HCC Model Cell Line .................................................................................. 53 
1.7 Radiochemistry ................................................................................ 54 
1.7.1 Positron Emission Tomography ................................................................................ 54 
1.7.1.1 PET-CT ............................................................................................................. 56 
1.7.1.2 SPECT Imaging ................................................................................................. 58 
1.7.2 Gallium-68 as a Radiopharmaceutical ...................................................................... 58 
1.7.2.1 Alternative Ga Radioisotopes and Positron Emitters ......................................... 61 
1.7.3 PET Isotope Generators ............................................................................................ 63 
1.7.4 Chelators .................................................................................................................... 65 
1.7.4.1 Bifunctional NOTA Derivatives ......................................................................... 68 
1.8 Concluding Remarks ......................................................................... 72 
 
 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 6 - Ph.D. 2014 
II Methods ................................................................................... 74 
2.1 Mutant Fusion Protein Expression & Purification .................................. 75 
2.1.1 Expression Vector Construction ................................................................................ 75 
2.1.1.1 PCR Cloning & Amplification of the hIFN Mutants ......................................... 75 
2.1.1.2 PCR Cloning & Amplification of the ASGPRdAb Mutants .............................. 77 
2.1.1.3 SOE PCR of hIFN-ASGPRdAb Expression Cassette ....................................... 77 
2.1.1.4 Constructing the Recombinant pDOM50-hIFN-ASGPRdAb Expression 
Vectors ............................................................................................................................ 78 
2.1.2 HEK293E hIFN-ASGPRdAb Expression ................................................................ 80 
2.1.3 hIFN-ASGPRdAb Protein Purification by ÄKTA HiTrap mAbSelect Xtra 
Chromatography ................................................................................................................ 81 
2.2 NOTA Conjugation of Fusion Proteins and in vitro Functional Analysis .... 82 
2.2.1 NOTA Conjugation & Purification ........................................................................... 82 
2.2.1.1 NOTA Conjugation Reaction ........................................................................... 82 
2.2.1.2 Protein-A Batch Purification of NOTA Conjugates .......................................... 82 
2.2.1.3 Mass Spectrometry of Fusion Proteins ............................................................... 83 
2.2.2 SPR Kinetic Analysis of the Fusion Proteins’ interactions with ASGPR & hIFNAR
 ............................................................................................................................................ 83 
2.2.2.1 Biacore T200 Surface Plasmon Resonance ....................................................... 84 
2.2.2.2 Biacore 3000 Surface Plasmon Resonance ........................................................ 85 
2.2.3 HEK-Blue Reporter Assay for hIFN Bioactivity Quantitation ................................. 85 
2.2.4 FACS Flow Cytometry Assays of hIFN-dAb Whole Cell Binding to HepG2 and 
U937 cells ............................................................................................................................ 86 
2.2.5 68Ga Radioligand Binding Assay ............................................................................... 89 
2.3 Radiolabelling .................................................................................. 91 
2.3.1 Gallium-68 Elution Design & Operation .................................................................. 91 
2.3.2 1M NaAc 68Ga-NOTA-hIFN-dAb Labelling ............................................................ 92 
2.3.3 Indium-111 Labelling ................................................................................................ 93 
2.3.4 Instant Thin Layer Chromatography ........................................................................ 94 
2.4 In vivo Analyses ................................................................................ 95 
2.4.1 Animal Research Statement ...................................................................................... 95 
2.4.2 HepG2 Xenograft Murine Models ............................................................................ 95 
2.4.3 Radioactivity Biodistribution Studies ........................................................................ 96 
2.4.3.1 Blocking Dose Biodistribution Study .................................................................. 97 
2.4.4 PET Imaging of Xenograft Uptake ........................................................................... 97 
2.5 TaqMan Gene Expression .................................................................. 98 
2.5.1 RNA Isolation ............................................................................................................ 98 
2.5.2 Reverse-Transcription PCR ...................................................................................... 99 
2.5.3 TaqMan Array ......................................................................................................... 100 
III HepG2 Xenograft Targeting of 68Ga-NOTA-hIFN-dAb .................. 101 
3.1 Introduction ................................................................................... 102 
3.2 In vitro Assays ................................................................................ 103 
3.2.1 Tool Fusion Proteins ................................................................................................ 103 
3.2.2 NOTA Conjugation Reactions ................................................................................ 104 
3.2.2.1 Sodium Bicarbonate Dialysis Buffer Exchange ................................................ 105 
3.2.2.2  SCN-Bn-NOTA Conjugation Reaction Development ................................... 105 
3.2.2.3 Protein A Purification of NOTA Conjugates ................................................... 106 
3.2.2.4 Mass Spectrometry ........................................................................................... 109 
3.2.3 Biacore Surface Plasmon Resonance ....................................................................... 114 
3.2.3.1 ASGPR Binding Assay ..................................................................................... 115 
3.2.3.2 hIFNAR Binding Assay .................................................................................... 120 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 7 - Ph.D. 2014 
3.2.4 HEK-Blue hIFN Potency Assay .............................................................................. 124 
3.2.5 Flow Cytometry ....................................................................................................... 127 
3.2.5.1 HepG2 Whole Cell Binding ............................................................................. 128 
3.2.5.2 U937 Whole Cell Binding ................................................................................ 130 
3.2.6 Radioligand Binding Assay ...................................................................................... 132 
3.4 Ga-68 Radiolabelling Development ................................................... 136 
3.4.1 Reaction Development ............................................................................................ 136 
3.4.2 Ga-68 Radiolabelling Reactions .............................................................................. 137 
3.4.3 Further Reaction Optimisation ............................................................................... 140 
3.4.3.1 Reaction Purification ........................................................................................ 140 
3.4.3.2 Cationic Exchange Reactions .......................................................................... 142 
3.5 Biodistribution Studies .................................................................... 145 
3.5.1 Ga-68 Radiolabelling ............................................................................................... 145 
3.5.2 Dosing Biodistribution Study ................................................................................... 146 
3.5.3 Time Course Biodistribution Study ......................................................................... 148 
3.5.3.1 In-111 Labelling ............................................................................................... 148 
3.5.3.2 Xenograft Uptake Analysis ............................................................................... 149 
3.5.3.3 Full Tissue Analysis .......................................................................................... 151 
3.5.4 Receptor Blocking .................................................................................................... 155 
3.5.5 TaqMan mRNA Expression Profiling ..................................................................... 158 
3.6 PET-CT Imaging ............................................................................. 164 
3.6.1 Ga-68 Radiolabelling ............................................................................................... 164 
3.6.2 PET-CT Quantitation of Xenograft Uptake ........................................................... 165 
IV Optimising HepG2 Xenograft Targeting of hIFN-dAbs ................. 168 
4.1 Introduction ................................................................................... 169 
4.2 Mutant Expression & Purification ..................................................... 170 
4.2.1 Mutant hIFN-dAb Fusion Proteins ......................................................................... 170 
4.2.2 hIFN-ASGPRdAb Expression Constructs ............................................................... 170 
4.2.3 Expression and Purification of hIFN-ASGPRdAb Mutant Fusion Proteins ........... 173 
4.2.4 SCN-Bn-NOTA Conjugation and Purification ...................................................... 175 
4.4 In Vitro Characterisation ................................................................. 178 
4.4.1 Biacore Surface Plasmon Resonance ....................................................................... 178 
4.4.1.1 ASGPR Binding Assay ..................................................................................... 178 
4.4.1.2 hIFNAR Binding Assay .................................................................................... 180 
4.4.2 HEK-Blue hIFN Potency Assay .............................................................................. 183 
4.4.3 Flow Cytometry ....................................................................................................... 185 
4.5 Biodistribution Studies .................................................................... 189 
4.5.1 Ga-68 Radiolabelling ............................................................................................... 189 
4.5.2 Tissue Uptake Biodistribution Study ....................................................................... 189 
4.5.2.1 Full Tissue Analysis .......................................................................................... 189 
4.5.2.2 Xenograft Uptake ............................................................................................. 192 
4.5.3 TaqMan mRNA Expression Profiling ..................................................................... 195 
V Conclusions & Future Work ....................................................... 200 
5.1 Concluding Discussion .................................................................... 201 
5.1.1 Investigation Overview ............................................................................................ 201 
5.1.1.1 hIFN-dAb Characterisation ............................................................................. 202 
5.1.1.2 Gallium Radiolabelling .................................................................................... 204 
5.1.1.3 hIFN-dAb Xenograft Targeting ....................................................................... 204 
5.1.1.4 Targeting and Efficacy ..................................................................................... 206 
5.1.2 Final Thoughts ......................................................................................................... 207 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 8 - Ph.D. 2014 
5.2 Future Work ................................................................................... 208 
5.2.1 NOTA Conjugations ............................................................................................... 208 
5.2.2 Ga-68 and Sc-44 Radiolabelling ............................................................................. 208 
5.2.3 Serum Stability ........................................................................................................ 209 
5.2.4 mRNA TaqMan Repeats ........................................................................................ 209 
5.2.4 Evidence of Anti-Proliferative Therapeutic Action ................................................. 209 
5.2.5 Novel dAb Fusion Tumour PET-CT Modelling & Targets .................................... 210 
VI Appendices ............................................................................. 211 
6.1 Methods Appendix .......................................................................... 212 
6.1.1 Consumable Materials ............................................................................................. 212 
6.1.2 Method Outlines ...................................................................................................... 223 
6.1.3 Common Molecular Biology Methodologies ........................................................... 225 
6.1.3.1 PCR Product DNA Purification ....................................................................... 225 
6.1.3.2 Analytical DNA Gel Electrophoresis ................................................................ 225 
6.1.3.3 Gel Extraction DNA Purification ..................................................................... 225 
6.1.3.4 DH5α E. coli Cell Transformation .................................................................. 226 
6.1.3.5 Colony Screening Taq PCR ............................................................................ 226 
6.1.3.6 DNA Sequencing .............................................................................................. 227 
6.1.3.7 DNA MiniPrep ................................................................................................. 227 
6.1.3.8 Restriction Digest ............................................................................................. 228 
6.1.3.9 DNA MegaPrep ............................................................................................... 229 
6.1.3.10 SDS-PAGE ..................................................................................................... 230 
6.1.3.11 Protein Ethanol Flash Freezing ...................................................................... 230 
6.1.3.12 Biacore Chip Coating ..................................................................................... 231 
6.1.3.13 Biacore 3000 Program Method ...................................................................... 231 
6.1.4 Mammalian Cell Culture ......................................................................................... 232 
6.1.4.1 Cell Sub-Culturing ........................................................................................... 232 
6.1.4.2 Defrosting Cell Lines for Culture ..................................................................... 233 
6.1.4.3 Liquid Nitrogen Cryopreservation ................................................................... 234 
6.1.4.4 Trypan Blue Live/Dead Cell Counting ........................................................... 234 
6.1.5 Alternative Radiolabelling Strategies ....................................................................... 234 
6.1.5.1 5M NaOH 68Ga-NOTA-hIFN- dAb Labelling ............................................... 234 
6.1.5.2 5M NaAc 68Ga-NOTA-hIFN-dAb Labelling .................................................. 235 
6.1.6 Bond-Elut SCX Cationic Exchange 68Ga-NOTA-hIFN-dAb Labelling ................ 235 
6.1.7 Radiolabelled NOTA-hIFN-dAb Purification ........................................................ 236 
6.1.7.1 0.22μm Filtration Purification .......................................................................... 236 
6.1.7.2 Protein A Spin Purification .............................................................................. 236 
6.1.7.3 Illustra NAP-5 Column Purification ................................................................ 236 
6.1.8 Radioactive SE-HPLC ............................................................................................ 237 
6.1.9 Additional Methodologies ........................................................................................ 237 
6.1.9.1 SDM of hIFN-ASGPRdAbs to Mutate NGS Glycosylation Site to NGA ....... 237 
6.1.9.2 PNGase F Deglycosylation Assay ..................................................................... 238 
6.1.9.3 ASGPR-H1-CRD Expression and Purification ............................................... 238 
6.3 Results Appendix ............................................................................ 240 
6.3.1 Analytical QC Data ................................................................................................. 240 
6.3.2 Gallium Labelling Data ........................................................................................... 242 
6.3.3 Site Directed Mutagenesis Data .............................................................................. 243 
VII References ............................................................................ 244 
 
  
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 9 - Ph.D. 2014 
FIGURES & TABLES 
Introduction 
Figure 1.1  Antibody Technologies 
Figure 1.2  ASGPR-H1 Carbohydrate Recognition Domain Crystal Structure 
Figure 1.3  Interaction of hIFNα2 with hIFNAR  
Figure 1.4  Human Interferon α/β and γ Signalling Pathways 
Figure 1.5  68Ge/68Ga Generator IG100 
Figure 1.6  NOTA Chelating a Gallium atom 
Figure 1.7  SCN-Bn-NOTA Nucleophilic Addition reaction with Lysine  
 
Table 1.1  ASGPR Subunit Human Tissue Expression Levels 
Table 1.2  hIFNAR Subunit Human Tissue Expression Levels 
 
Methods 
Figure 2.1  Ga-68 Elution Diagram 
 
Table 2.1 PCR Primers for hIFN-ASGPRdAb Expression Cassette 
Table 2.2  Pwo PCR for hIFN Mutant Amplification 
Table 2.3  Pwo PCR for ASGPRdAb Mutant Amplification 
Table 2.4  SOE Pwo PCR for hIFN-ASGPRdAb Splicing 
Table 2.5  Flow Cytometry Buffer Recipes 
Table 2.6  Radioligand Binding Assay Buffer Recipes 
Table 2.7 Thin Layer Chromatography Recipes 
Table 2.8 RT-PCR Reaction Mix Recipe 
Table 2.9  RT-PCR to Amplify cDNA for TaqMan 
Table 2.10 TaqMan Reaction Mix Recipe 
Table 2.11  TaqMan Thermal Cycling Standard Assay 
 
HepG2 Xenograft Targeting of 68Ga-NOTA-hIFN-dAb 
Figure 3.0  Outline of Experimental Development 
Figure 3.1  Comparison of the Amino Acid Sequences of hIFN-MAXdAb and hIFN-
CTRLdAb  
Figure 3.2  Non-Reducing SDS-PAGE of pre-conjugation and post-Protein A 
purification hIFN-dAbs  
Figure 3.3  Mass Spectrum of NOTA-hIFN-dAb 
Figure 3.4  Analyte interactions with ASGPR-H1-CRD CM5 Chip in SPR Experiment 
Figure 3.5  Biacore T200 SPR Analysis of Analytes’ binding interaction with 
recombinant ASGPR-H1-CRD 
Figure 3.6  Biacore T200 SPR Analysis of NOTA-hIFN-MAXdAb binding to ASGPR-
H1-CRD 
Figure 3.7  Analyte interactions with hIFNAR2 CM5 Chip in SPR Experiment 
Figure 3.8  Biacore 3000 SPR Analysis of Analytes’ binding interaction with 
recombinant hIFNAR2 
Figure 3.9  HEK-Blue hIFN Potency Assay 
Figure 3.10  HEK-Blue hIFN Potency Assay 
Figure 3.11  Flow Cytometry with HepG2 cells 
Figure 3.12  Flow Cytometry for Receptor detection on HepG2 
Figure 3.13  Flow Cytometry of hIFN-dAb Fusions with HepG2 
Figure 3.14  Flow Cytometry of MAXdAb & hIFN with HepG2 
Figure 3.15  Flow Cytometry for Receptor detection on U937 cell line 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 10 - Ph.D. 2014 
Figure 3.16  Flow Cytometry of hIFN-dAb Fusions with U937 
Figure 3.17  68Ga-NOTA-hIFN-MAXdAb Binding Assay 
Figure 3.18  68Ga-NOTA-hIFN-MAXdAb vs 68Ga-NOTA-hIFN-MAXdAb in a HepG2 
Binding Assay 
Figure 3.19  Scatchard Plot of 68Ga-NOTA-hIFN-MAXdAb  
Figure 3.20  Ga-68 NOTA-hIFN-MAXdAb Radiolabelling Reactions with 1M NaAc 
Method 
Figure 3.21  Biacore T200 SPR Analysis of the NOTA-hIFN-MAXdAb pre- and post-
reaction 
Figure 3.22  G-25 MiniTrap Purification of a Ga-68 NOTA-hIFN-MAXdAb 
Radiolabelling Reaction 
Figure 3.23  SE-HPLC of G25-Purified 68Ga-NOTA-hIFN-MAXdAb Fraction 
Figure 3.24 Biacore T200 SPR Analysis of the NOTA-hIFN-MAXdAb post SCX 
Cationic Exchange Radiolabelling Reaction 
Figure 3.25  Biodistribution of 68Ga-NOTA-hIFN-MAXdAb in SCID Beige HepG2 
Xenograft Model at 3hr with varying dose 
Figure 3.26  Xenograft Uptake of 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-
CTRLdAb in SCID Beige HepG2 Xenograft Model with 1µg dose over 
time 
Figure 3.27  Xenograft Uptake versus Blood Concentration of 68Ga-NOTA-hIFN-
MAXdAb in SCID Beige HepG2 Xenograft Model with 1µg dose over time 
Figure 3.28  Biodistribution of NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb in 
SCID Beige HepG2 Xenograft Model at 1h, 3h and 24h 
Figure 3.29  Tissue Uptake of 68Ga-NOTA-hIFN-MAXdAb in SCID Beige HepG2 
Xenograft Model with and without MAXdAb Blocking Dose 
Figure 3.30  Liver Tissue Uptake and Intestinal Tissue Uptake relative to Tissue Mass 
Figure 3.31  Liver Tissue Uptake of 68Ga-NOTA-hIFN-MAXdAb in SCID Beige 
HepG2 Xenograft Model with and without MAXdAb Blocking Dose 
Figure 3.32  TaqMan RT-PCR of hIFN Pathway associated mRNA sequences in 
Xenografts targeted by hIFN-dAbs 
Figure 3.33  TaqMan mRNA Copy Number Changes in HepG2 Xenografts with hIFN-
MAXdAb or hIFN(A)-ASGPRdAb Treatment 
Figure 3.34 PET-CT Imaging of HepG2 Xenograft Uptake of 68Ga-NOTA-hIFN-
MAXdAb and 68Ga-NOTA-hIFN-CTRLdAb 
Figure 3.35 Xenograft Uptake of 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-
hIFN-CTRLdAb between 1h and 3h post-injection 
 
Table 3.1  Tool hIFN-dAbs and constituent controls 
Table 3.2  NOTA Conjugation Metrics 
Table 3.3 NOTA-hIFN-dAb Purification Metrics 
Table 3.4  Mass Spectrum of hIFN-MAXdAb Post NOTA Conjugation 
Table 3.5  Group Molecular Masses 
Table 3.6  Biacore T200 ASGPR-H1-CRD Binding Kinetics 
Table 3.7  Biacore 3000 hIFNAR2 Binding Kinetics 
Table 3.8  HEK-Blue hIFN Bioactivity Reporter Assay 
Table 3.9  Flow Cytometric Analysis of hIFN-dAbs’ HepG2 Cell Binding 
Table 3.10  Flow Cytometric Analysis of hIFN-dAbs’ U937 Binding 
Table 3.11  Ga-68 Labelling Method Results 
Table 3.12  Ga-68 Bond-Elut SCX Labelling Method Results 
Table 3.13  Ga-68 Radiolabelling for Biodistribution Studies 
Table 3.14  In-111 Radiolabelling for Biodistribution Studies 
Table 3.15  Time Course Biodistribution Analysis Tissue Uptake Values 
Table 3.16  Percentage Difference in mRNA Copy Number relative to untreated 
Xenograft Tissue 
Table 3.17  Ga-68 Radiolabelling for PET-CT Imaging 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 11 - Ph.D. 2014 
Optimising HepG2 Xenograft Targeting of hIFN-dAbs 
Figure 4.0  Outline of Experimental Development 
Figure 4.1  Gel Electrophoresis of PCR Purification products of individual DNA 
sequences of ASGPRdAb and hIFN mutants 
Figure 4.2 Gel Electrophoresis of SOE PCR products of DNA sequence fusions of 
ASGPRdAb and hIFN mutants 
Figure 4.3  Gel Electrophoresis of MegaPrep DNA products for pDOM50-hIFN-
ASGPRdAb expression constructs 
Figure 4.4  SDS-PAGE of hIFN-ASGPRdAb ÄKTA Purification Steps 
Figure 4.5  Non-Reducing SDS-PAGE of post-Protein A purification hIFN-
ASGPRdAbs  
Figure 4.6  Mass Spectrum of NOTA-hIFN(E)-LodAb 
Figure 4.7  Biacore 3000 SPR Analysis of Analytes’ binding interaction with 
recombinant ASGPR-H1-CRD 
Figure 4.8  Biacore 3000 SPR Analysis of Analytes’ binding interaction with 
recombinant hIFNAR2 
Figure 4.9  HEK-Blue hIFN Potency Assay 
Figure 4.10  Flow Cytometry of hIFN-dAb Fusions with HepG2 
Figure 4.11  Flow Cytometry of hIFN-dAb Fusions with U937 
Figure 4.12  Biodistribution of 68Ga-NOTA-hIFN-MAXdAb in SCID Beige HepG2 
Xenograft Model at 3hr with varying dose 
Figure 4.13  Xenograft Uptake of mutant 68NOTA-hIFN-ASGPRdAbs in SCID Beige 
HepG2 Xenograft Model 
Figure 4.14  TaqMan RT-PCR of hIFN Pathway associated mRNA sequences in 
Xenografts targeted by mutant hIFN-dAbs 
Figure 4.15  TaqMan RT-PCR of HIST, NET1 and PRKCD mRNA sequences in 
Xenografts targeted by hIFN-MidAbs 
 
Table 4.1  Mutant hIFN-ASGPRdAb Fusion Proteins 
Table 4.2  Mutant hIFN-ASGPRdAb Fusion Proteins 
Table 4.3  PCR Primers 
Table 4.4  Mutant hIFN-dAb Fusion Protein Production Data 
Table 4.5  Biacore T200 ASGPR Binding Kinetics of Mutant hIFN-ASGPRdAbs 
Table 4.6  Biacore 3000 hIFNAR2 Binding Kinetics 
Table 4.7  HEK-Blue EC50 of Unconjugated hIFN-ASGPRdAbs 
Table 4.8  HEK-Blue EC50 of Conjugated NOTA-hIFN-ASGPRdAbs 
Table 4.9  Flow Cytometric Analysis of NOTA-hIFN-ASGPRdAbs’  
HepG2 Cell Binding 
Table 4.10  Mutants Biodistribution Study Tissue Uptake Values 
Table 4.11  Xenograft Tissue Uptake of Mutant 68Ga-NOTA-hIFN-ASGPRdAbs at 3h 
with Liver Uptake Correction 
Table 4.12  Percentage Difference in mRNA Copy Number relative to untreated 
Xenograft Tissue 
 
 
 
  
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 12 - Ph.D. 2014 
Conclusions & Future Work 
Figure 5.1  In vitro binding data for NOTA-hIFN-MAXdAb and NOTA-hIFN-
CTRLdAb 
 
Table 5.1  Mutant hIFN-dAb Fusion Proteins’ Relative Receptor Affinities 
 
Appendices 
Figure 6.1 NOTA Conjugation and Analytical in vitro Assays 
Figure 6.2  Ga-68 Radiolabelling Reaction 
Figure 6.3  In vivo Xenograft Biodistribution Modelling 
Figure 6.4  DNA In-Line Fusions 
Figure 6.5  Expression Construct and Protein Expression 
Figure 6.6  pDOM50-hIFN-ASGPRdAb Expression Vector Construct 
Figure 6.7  Non-Reducing SDS-PAGE of Protein A Batch Purification steps  
Figure 6.8 Non-Reducing SDS-PAGE of IMAC purified and ÄKTA polished ASGPR-
H1-CRD 
Figure 6.9  Biacore T200 SPR Analysis of hIFN-MAXdAb 
Figure 6.10  Biacore T200 SPR Analysis of MAXdAb 
Figure 6.11  Flow Cytometry HepG2 Cell Gating 
Figure 6.12  EZ IG100 68Ge/68Ga Generator Elution Profile 
Figure 6.13  EZ IG100 68Ge/68Ga Generator Decay Monitoring 
Figure 6.14  Optimum pH Scouting for NOTA-hIFN-MAXdAb Ga-68 Radiolabelling 
Figure 6.15  AM-iTLC Example 
Figure 6.16  G-25 MiniTrap Purification of a SCX Cationic Exchange Ga-68 NOTA-
hIFN-CTRLdAb Radiolabelling Reaction  
Figure 6.17  SDS-PAGE of PNGaseF Assay with Mutant hIFN-ASGPRdAbs including 
SDM Mutants lacking N-linked Glycosylation 
Figure 6.18  Sequencing of NGS to NGA SDM Mutant 
 
Table 6.1  Chemical Reagents 
Table 6.2  Biological Reagents 
Table 6.3  Lab Consumables 
Table 6.4  Reagent Kits 
Table 6.5  Restriction Enzymes 
Table 6.6  Plasmid Vectors 
Table 6.7  Buffer & Reagent Recipes 
Table 6.8 HPLC Solvent Recipes 
Table 6.9 Taq PCR for Colony Screening 
Table 6.10 Sub-culturing Cell Lines 
Table 6.11  Culture Medium Recipes 
Table 6.12  SDM Pwo PCR to mutate NGS Glycosylation to NGA 
Table 6.13 PNGase F Deglycosylation 
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 13 - Ph.D. 2014 
ABBREVIATIONS 
%ID/g  % injected dose per gram 
177Lu  lutetium-177 
124I  iodine-124 
18F  fluorine-18 
44Sc   scandium-44 
44Ti  titanium-44 
68Ga   gallium-68 
68Zn   zinc-68 
89Zr   zirconium-89 
82Rb  rubidium-82 
90Y  yttrium-90 
99mTc   technetium-99m 
2D   two-dimensional 
3D   three-dimensional 
AA   amino acid 
ADCC   antibody dependent cell mediated cytotoxicity 
Alexa647 goat anti-mAb pAb with Alexa647 fluorophore 
AM   ammonia-methanol 
APD   avalanche photodiodes  
ASGP   asialoglycoprotein 
ASGPR  asialoglycoprotein receptor 
B-FN   fibronectin isoform B 
BSA   bovine serum albumin  
bsmAb   bi-specific monoclonal antibody 
CA   citric acid 
CCV   clathrin coated vesicle 
cDNA   complementary deoxyribonucleic acid 
CDR   complementarity determining region 
cgH2O  clinical grade water 
CRD   carbohydrate recognition domain 
CT   computer tomography  
Cu   copper 
CV   column volumes 
dAb   domain antibody 
ddH2O  double deionised water 
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DMEM  Dulbecco's Modified Eagle Medium  
DNA   deoxyribonucleic acid  
DOTA  1,4,7,10-tetraazacyclododecanetetraacetic acid 
DR   death receptor 
ds-RNA  double-stranded ribonucleic acid 
DTPA   diethylene triamine pentaacetic acid 
DTT  dithiothreitol 
EC   electron capture 
EDTA  ethylenediaminetetraacetic acid 
EEF2  elongation factor 2 
EGFR   epithelial growth factor receptor  
EMAX  maximum end point energy  
EpCam  epithelial cell adhesion molecule 
EtOH   ethanol 
F-18  fluorine-18 
Fab   fragment binding antibody 
FACS   fluorescence-activated cell sorting 
FBS   fetal bovine serum 
FC   flow cell 
Fc   fragment crystallisable 
FcRn   neonatal Fc receptor 
FDA   Food and Drug Administration  
FDG  fluorodeoxyglucose 
FeIII   ferric iron 
FPKM  fragments per kilobase of exon per million fragments mapped  
Ga-68   gallium-68 
Gal   galactose 
Gal-Nac N-acetylgalactosamine 
GAPDH glyceraldehyde-3-phophate 
Ge-68  germanium-68 
GSK   GlaxoSmithKline 
GuHCl  guanidine hydrochloric acid 
HAIC   hepatic arterial infusion chemotherapy  
HBED  N,N’-bis(2-hydroxybenzyl)-ethylenediamine-N,N’-diacetic acid   
HCC   hepatocellular carcinoma  
HCV   hepatitis C virus 
HER2   human epidermal growth factor receptor 2 
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hIFN   human interferon 
HPLC   high pressure liquid chromatography  
HSA   human serum albumin 
HU   Houndsfield units 
ID  injected dose 
IFN   interferon 
IFNAR  interferon alpha receptor 
IFNGR  interferon gamma receptor 
IgG   immunoglobulin G 
IL-12   interleukin-12 
IL-1RA  interleukin-1 receptor antagonist 
IL-2   interleukin-2 
IMAC  immobilised metal ion affinity chromatography 
IRF9   interferon regulatory factor 9 
ISG   interferon stimulated gene 
ISGF3   interferon stimulated gene factor 3 
ISRE   interferon stimulated response element  
JAK   Janus kinase 
KML   chelator stability constant 
L-Trp   L-tryptophan  
mAb   monoclonal antibody 
MAPK  mitogen activated protein kinase 
mASGPR murine asialoglycoprotein receptor 
MCSP   melanoma chondroitin sulphate proteoglycan 
MEK   mitogen activate protein kinase/extracellular signal regulated kinase 
mIFNAR  murine interferon alpha receptor 
MRI   magnetic resonance imaging 
mRNA  messenger ribonucleic acid 
MWCO  molecular weight cut off 
NaAc   sodium acetate 
NEB  New England Biolabs 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NHS  N-hydroxysuccinimide 
NHS-NOTA 2,2'-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7-
triazonane-1,4-diyl)diacetic acid 
NK   natural killer 
NO   nitrous oxide  
Investigating Dual-Targeted Domain Antibody Fusion Proteins in a Cancer Model 
 
Alex G. Papple - 16 - Ph.D. 2014 
NOTA  1,4,7-triazacyclononanetriacetic acid 
OAS   2',5'-oligoadenylate synthetase  
OSEM   ordered subset expectation maximisation 
pAb   polyclonal antibody 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PET   positron emission tomography 
PI   propidium iodide 
PKR   protein kinase R  
PMT   photomultiplier tube 
PVDF   polyvinylidene fluoride 
RHL-1  rat hepatic lectin  
RNase   ribonuclease 
ROI  region of interest 
RT-PCR  reverse transcription polymerase chain reaction  
RU   resonance units 
scFv   single chain variable fragment 
SCID   severe combined immunodeficiency  
SCN-Bn-NOTA S-2-(4-Isothiocyanatobenzyl)-1,4,7-triazacyclononanetriacetic acid 
SDM   site directed mutagenesis  
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SE-HPLC  size exclusion high pressure liquid chromatography 
SOC   optimal broth with catabolite suppression 
SOE  Splice Overlap Extension (PCR) 
STAT   signal transducers and activators of transcription 
TLC   instant thin layer chromatography  
TNF   tumour necrosis factor 
TRAIL  TNF-related apoptosis inducing ligand 
UV   ultraviolet  
Vκ   variable kappa  
VEGF   vascular endothelial growth factor 
VH   variable heavy 
VHH   Camelidae heavy chain antibody 
VL   variable light 
WEA   Water-Ethanol-Ammonia  
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1.1 THESIS RATIONALE 
It is an ongoing challenge to develop therapeutics with not only enhanced 
efficacy, but also increased specificity, thus ameliorating side effects and toxicity from 
off target activity. There are many examples of potent molecules, such as cytokines, 
which are limited in their application as therapeutics due to prohibitively broad 
toxicity. They could therefore benefit from increased specificity against only diseased 
tissue. Combining such therapeutics with a targeting moiety designed to selectively 
interact with a target disease tissue could deliver the attached therapeutic payload to 
its intended site of action at a localised efficacious concentration, thus reducing non-
specific toxicity by decreasing systemic exposure and precluding activating 
concentrations in off-target tissues. Engineered selective targeting is achievable 
utilising antibody-derived protein fragments. Therefore it is an attractive prospect to 
engineer potentially highly selective and efficacious fusion proteins comprised of 
cytotoxic therapeutics fused with targeted antibody fragments.  
One such fusion protein technology is the domain antibody (dAb) fusion 
protein1. The dAb technology is a highly adaptable single polypeptide antibody 
fragment platform. Their small size (11-15kDa), low-immunogenic fully-humanised 
scaffold, high stability in physiological conditions and ease of in vitro genetic 
manipulation mean dAbs hold great potential as the targeting moiety of a therapeutic 
fusion protein. Hence, the development of dAb fusions may be useful in the 
development of highly efficacious biopharmaceutical drugs for patients, perhaps as 
one of the initial steps towards personalised medicine. 
However, dAb fusions have a potential problem arising from the presence of 
two competing intrinsic binding affinities. There is a molecular level tussle between 
the specific tissue targeting of the dAb and the systemic ‘off-target’ binding 
(interacting with receptors outside the target tissue) of the fused therapeutic. 
Conventional wisdom would ordinarily dictate that the highest possible achievable 
binding affinities are appropriate. However, it may require much more subtlety to 
create the most optimised dAb fusion. A maximised dAb target affinity may increase 
specific tissue uptake, but it may also prevent effective tissue percolation or prevent 
effective delivery of the attached therapeutic to its respective receptor target2-4. A 
maximised therapeutic binding affinity may increase potency but target tissue 
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concentration-limiting systemic interactions and dose dependent side effects may 
compromise the overall efficacy5,6. 
Hence, it is clear that there may be a delicate balancing act to be performed 
in engineering the binding affinities of the targeting moiety and therapeutic payload 
in an optimised fusion protein. This investigation will seek to investigate how best to 
maximise tissue targeting specificity and localised therapeutic potency with two 
binding affinity influences, by experimenting with different binding affinity 
combinations in vivo. 
 
Hypothesis 
The efficacy – targeting selectivity and localised potency – of a 
dAb fusion protein will be significantly influenced by its two intrinsic 
binding affinities 
 
Testing the hypothesis necessitates a model system to analyse tissue targeting 
and a tool dAb fusion comprised of a tissue selective dAb and a potent therapeutic 
with a systemically distributed receptor. A dAb fusion protein consisting of human 
interferon (hIFN) fused to an asialoglycoprotein receptor (ASGPR)-targeting dAb, a 
IFN-ASGPRdAb, is a possible tool for investigating the approach. Such a molecule 
has been conceived as a potential treatment for liver malignancies. hIFN derivatives 
are already the primary treatment for the hepatitis C virus (HCV) and are indicated 
in treating hepatocellular carcinoma (HCC), but are linked to severe side effects. 
ASGPRdAbs have been engineered to discretely target liver tissue. Hence the hIFN 
and dAb proteins’ genetic sequences have been fused as an in-line genetic fusion, 
conferring the resultant recombinant fusion protein with a dual-targeting capability 
for ASGPR and IFNα receptor (IFNAR).  
ASGPR is abundantly expressed almost exclusively on the liver hepatocytes 
beneath the endothelium, and so a dAb engineered to target ASGPR allows liver 
tissue specificity. This contrasts with IFN binding to the ubiquitously expressed 
IFNAR activating the JAK-STAT intracellular signalling pathway, which can 
activate downstream mechanisms such as anti-proliferation, apoptosis and immune 
system activation.  
IFN-ASGPRdAbs thus possess dual affinity for ASGPR and IFNAR. 
Therefore, these two potentially conflicting binding properties can be probed in 
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order to assess the validity of the hypothesis. IFN-ASGPRdAb mutants, with varying 
binding affinity combinations, can be engineered for testing in an in vivo model 
system.  
In order to quantify the targeting of the IFN-ASGPRdAbs in vivo, it is a 
fortuitous opportunity to develop gallium-68 (Ga-68/68Ga) labelling of IFN-
ASGPRdAbs. Ga-68 is an increasingly promising imaging isotope but is yet to have 
been utilised for radiolabelling dAbs. The positron emitting Ga-68 in conjunction 
with a chelator such as 1,4,7-triazacyclononanetriacetic acid (NOTA) also enables 
the use of radioactive biodistribution studies and positron emission tomography 
(PET) computed tomography (CT) to quantify uptake of dAb fusion in xenograft 
tissue over time, which would be an important addition to the experimental toolbox 
for dAb fusion development.  
It is important to note that the motivation is thus not to create a new 
therapeutic hIFN-ASGPRdAb for liver disease but rather this is a convenient model 
for a proof of principle based on the hypothesis. 
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1.2 DOMAIN ANTIBODIES 
1.2.1 Domain Antibody Engineering 
Immunoglobulins are the B-cell antigen-recognition molecules of the adaptive 
immune system and are secreted as antibodies7. Antibodies recognise a discrete target 
molecule, the antigen, by interacting with a specific antigenic component sequence 
known as the epitope. Full antibody isotype immunoglobulin G (IgG)1 is the most 
abundant immunoglobulin in human serum and the most exploited antibody 
technology for engineering therapies8. It is a large ~150kDa protein comprising two 
identical ~50kDa heavy peptide chains and two identical ~25kDa light chains 
arranged in a tetrameric quaternary ‘Y’ conformation connected by disulphide 
bridges and non-covalent interactions. A dAb is comprised of a single variable 
domain of an antibody variable region and is thus the smallest functional antigen 
binding unit of an immunoglobulin at 11-15kDa7. Therefore, the small size of a dAb 
markedly contrasts with the full IgG, comprising approximately one twelfth of the 
mass of an entire IgG whilst maintaining binding activity.  
The dAb comprises only a single variable domain, and is a purely targeting 
antibody fragment. A variable domain is comprised of four highly conserved 
framework β-sheet barrel regions linked by three hypervariable region loops. It is 
through the hypervariable sequence diversity that antigen-epitope specific binding 
activity is encoded and together form a complementary antigen-binding site. Hence 
they are termed the complementarity determining regions (CDRs). A dAb thus has 
three CDRs with a VH or variable kappa (Vκ) domain framework forming its antigen-
binding site. This contrasts with the six CDRs in a full antibody afforded by the 
presence of both a variable heavy (VH) and a variable light (VL). 
The potential of dAb antibody fragments was first described in the late 1980s* 
by Ward et al1. Three dAb sequences were isolated from anti-lysozyme antibody 
D1.3 and the deoxyribonucleic acid (DNA) of the variable domains of murine-
derived anti-lysozyme antibodies by polymerase chain reaction (PCR)9, and 
subsequently expressed in E. coli and homogenously purified as single functional 
polypeptides. They were shown to maintain a low nanomolar affinity for lysozyme, 
similar to those of the full antibody. Hence, this indicated that the rest of the 
                                                
* Initially at the MRC lab in Cambridge and were subsequently developed, patented and pioneered by 
Domantis, now a subsidiary of GlaxoSmithKline (GSK) 
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antibody protein scaffold, including the other associated variable domain, was not 
essential to achieve independently mediated VH antigen binding.  
However, the lack of partnering variable domain initially caused problems 
with dAb synthesis attempts. They demonstrated poor solubility, dimerisation, 
aggregation and precipitation1,10 because of the solvent exposure of hydrophobic 
residues ordinarily shielded by the interaction with the other variable domain11. 
Heating at low concentrations lead to irreversible aggregation12. For a potential 
therapeutic this was less than ideal, as high concentrations are needed for 
administration and aggregation increases immunogenicity. This VL-absence 
hydrophobicity problem had in fact already been solved by evolution twice: 
Elasmobranchii Nurse Shark antigen receptors13 and Camelidae heavy chain antibodies 
(HCAbs). The latter are naturally occurring antibody analogues possessing only 3 
CDRs, similar to dAbs, and lack light chains14. This just leaves a single variable 
heavy (VHH) domain functionally binding antigens in the absence of VL domains. 
Camelidae have evolved conserved VHH mutations to hydrophilic residues in the 
framework sequences and an increase in CDR1 CDR3 length. These prevent a 
hydrophobic interface exposure due to the absence of a VL domain and increase 
specific epitope binding potential respectively15-18. VHH domains thus exist as highly 
soluble monomeric species under physiological conditions and can even maintain 
specific binding activity up to 90°C19 and resist aggregation in spite of exposure to 
extremes20. The human VH3 family of dAbs are the most similar in stability to VHH 
compared to the unfolding energies of other variable domain families18,21. Therefore, 
one strategy was for the ‘camelisation’ of the VH dAb protein framework sequences 
by selectively mutating the hydrophobic residues to hydrophilic residues conforming 
to conserved Camelidae germline substitutions (such as G44E, L45R and W47I22) in 
addition to CDR3 elongation23. This indeed allowed selection of viable thermostable 
soluble dAbs24,25.  
Furthermore, it is also possible to achieve ‘camelisation-like’ results whilst 
maintaining a native VH residue sequence. Selection for an elongated CDR3 to mask 
the hydrophobic residues26, decreased CDR hydrophobicity27, decreased beta sheet 
folding28, reoriented residues to mask hydrophobic patches12, or rare native 
mutations (such as G44K29) have also been shown to allow for the purification of 
active highly soluble monomeric dAbs. Moreover, having an isoelectric point away 
from physiological pH appears to correlate with aggregation-resistance. This is 
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particularly the case if the CDRs contain kosmotropic negatively charged residues 
aspartate or glutamate30 or by the selection of charged residues at the periphery of 
the CDRs27, both of which can be introduced by mutagenesis. However, these 
modifications are dAb specific relative to the charged residues’ spatial distribution 
and the net charge of the protein as a whole31.  
An effective method of dAb selection was to create a selection pressure during 
initial dAb isolation from a library. For instance, high transient heating to 80°C of 
candidate human VH3 family dAb proteins expressed on the surface of bacteriophage 
promoted full dAb unfolding followed by re-cooling to promote refolding, allowed 
identification of thermostable aggregation-resistant dAbs by Protein A ELISA 
capture assay, thus yielding the sequences of highly stable VH3 dAbs that can be 
produced at high titres24,28,32,33. 
 
The generation of dAbs traditionally involves the creation of a phage display 
library34,35, allowing a vast repertoire of potential dAbs to be amassed36. Error prone 
PCR, mutator bacterial strains, CDR shuffling, and oligonucleotide mutagenesis can 
efficiently create an indefinite array of affinity matured sequences of dAb biophysical 
phenotypes, mimicking the endogenous mammalian hypermutagenic engineering of 
antibody CDRs in response to exogenous antigen challenge32,37,38. The hypermutated 
dAb genetic sequences are encoded in filamentous bacteriophage by genetic fusion to 
gene III which encodes minor coat protein III, expressed at the tip of the phage39, 
and is ordinarily responsible for attachment to bacterial pili. The phage thus express 
protein III-dAb fusion proteins, displaying their encoded dAb on their tip and so 
screening the library against a target antigen by affinity capture can rapidly match 
phenotype to genotype40 in an entirely automatable process, enriching phages 
encoding candidate dAb. After several more rounds of amplification in E. coli and 
further affinity capture refinement, the bacteriophage DNA of this subset of active 
antigen-binders can be sequenced to analyse for consensus. The genetic template is 
subsequently cloned into an E. coli expression vector and the affinity matured to 
encode a recombinant dAb protein structure with the desired biophysical 
properties41. This generation method bestows the dAb platform with a vast potential 
antigen-targeting repertoire without the need for animal immunisation and harvest.  
A primary limitation of the phage display platform includes the biology of the 
phage-host system and its interaction with the displayed protein, which can lead to 
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library censorship42, and so precludes some domain antibody sequences. There is a 
limit to the potential library size/diversity (1015 sequences) through sequence bias 
against sequences deleterious to the host43,44. For instance, there may be too high a 
metabolic strain on the parasitised bacterial host to produce the display progeny 
phage, inhibition of the insertion of the pIII protein into the assembling virion, poor 
pIII translocation within the bacterium, or disruption to viral protein-protein 
interactions such as through interfering disulphide bonding of odd numbers of 
encoded cysteine residues. Alternative strategies could be mRNA or ribosomal 
display with their larger libraries (1017 sequences)45. 
 
The in vitro bacteriophage based method of dAb generation contrasts with 
exploiting in vivo antibody generation. Native antibodies are ‘bio-engineered’ in 
mammals through hypermutation in B-lymphocyte germinal centres46 so as to attain 
antibodies for specific antigens. Therefore originally host mammals were challenged 
repeatedly with the antigen and the serum harvested, attaining a polyclonal antibody 
(pAb) mix. However attaining standardised therapeutic sera with consistent pAb 
yields was not possible. The Nobel Prize in Physiology or Medicine 1984 was shared 
by Jerne, Köhler and Milstein for theorising and developing monoclonal antibodies 
(mAbs)47, solving the pAb problems. They created immortal hybridomas by fusing 
sheep red blood cell immunised mouse spleen cells with myeloma cells48,49, which 
were refined to only produce specific mAb species50. Nevertheless effective 
hybridoma generation is constrained by the initial immunised hosts’ endogenous 
antibody generation, thus the repertoire attained is restricted and requires long 
dosing regimes, bleeds and sacrifice to attain the genetic sequences conferring 
immunity. On the other hand, phage display is theoretically only limited by the 
number of plasmids encoding the dAbs.  
Another drawback of non-human mammalian antibody derivatives such as 
hybridoma mAbs is the presence of ‘foreign’ non-human protein sequences which 
may cause an immune response in humans. Strategies can be employed to minimise 
the foreign protein sequences by ‘humanising’ the antibody scaffold (non-CDRs)51, 
for instance, by selectively mutagenising non-human sequences of a chimeric 
recombinant mAb52 or grafting the CDR sequences into a full human antibody 
scaffold53. However, the CDRs may still nonetheless contain foreign immunogenic 
sequences. By contrast phage-display generated dAbs have a lower potential 
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immunogenicity owing to a fully humanised recombinant scaffold and human CDR3 
sequences. Nevertheless, this is no guarantee against an anti-idiotypic reaction in 
some patients as seen with fully-humanised phage display selected tumour necrosis 
factor (TNF) antagonist adalimumab54.  
 
A dAb lacks the fragment crystallisable (Fc) domain that is present on full 
antibodies. The Fc domain is responsible for the long serum half-life of 
immunoglobulin through the endothelial cell neonatal Fc receptor (FcRn) 
endocytosis recycling system55 and Fcγ receptor effector interactions such as 
phagocytosis by macrophages and neutrophils2, Antibody-Dependent Cell-Mediated 
Cytotoxicity (ADCC) by Natural Killer (NK) cells56 and instigating a classical 
complement dependent cytotoxicity by interacting with C1q57. These Fc interactions 
may contribute to the positive pharmacokinetics and potency of antibody therapies, 
such as for adalimumab58,59 but particularly anti-tumour rituximab and trastuzumab 
(Section 1.3.1). Therefore, the lack of Fc in dAbs can be considered a drawback of 
the dAb technology as it precludes dAbs from the FcRn recycling mechanism, 
concordantly lowering dAb half-life compared to Fc constructs. This also precludes 
dAbs as potential direct antagonistic therapies for immune system mediated clinical 
response strategies. Nonetheless, the upside is that the decreased immunogenicity 
from not engaging the immune system, whether mediated by antigenic sequence 
motifs or Fc, increases the potential applications for dAbs as non-immunogenic 
targeting agents. 
The dAb’s 12-15kDa size, although potentially beneficial for increased tissue 
penetration2, may result in rapid renal clearance. In conjunction with no FcRn 
recycling mechanism, these factors conspire towards a dAb terminal circulatory half-
life of approximately 25 minutes in in vivo murine models7. An alternative perspective 
though is that the small size potentially allows more homologous biodistribution to 
access the maximum number of possible targets, and rapid clearance ought to ensure 
that the dAb only accumulates locally at high concentrations of target. These 
properties would be especially useful if dAbs were to be utilised as tracers in 
molecular imaging, for instance. Nevertheless increasing the half-life sufficiently to 
ensure an efficacious response to a dAb-mediated therapy is an important 
developmental challenge.  
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1.2.2 Domain Antibody Biopharmaceuticals 
One of the first applications of the dAb platform was for extending the half-
life of quickly metabolised therapeutics such as IFN (Introduction 1.5). IFN is an 
important HCV treatment but it has poor pharmacokinetics. However, extending the 
half-life of IFN improves its antiviral efficacy. For example, IFN was enhanced with 
polyethylene glycol pegylation, extending IFN’s in vivo half-life from approximately 8 
to 40 hours due to an increase in hydrodynamic radius decreases renal clearance 
rates and the inert coating of the protein protects against proteolysis60. This 
concordantly led to an improved sustained virological response was obtained with a 
weekly subcutaneous dosing strategy61-63. However, heterogeneous pegylated IFN 
production challenges64 left the door open for alternative half-life extension 
technologies. 
The dAb platform was utilised for achieving increased IFN in vivo serum half-
life through mediating an association between IFN and the 67kDa human serum 
albumin (HSA) protein65. HSA has a circulatory half-life of approximately three 
weeks owing to protection from non-specific pinocytotic-lysosomal degradation by 
pH-dependent FcRn-mediated recycling of HSA back to the extracellular matrix66. 
Hence, association with HSA would both increase size and limit proteolysis, as seen 
with the pegylation strategy, thus increasing IFN half-life. Therefore, dAb fusions of 
hIFNα2b fused N-terminally by a small peptide linker to a dAb with affinity for HSA 
called an AlbudAb were engineered, such as hIFNα2b-DOM7h-1467. This compares 
to a strategy based on the same principles with Albuferon, achieved by genetically 
fusing human IFN-alpha 2b (hIFNα2b) N-terminally directly to HSA68, with a 
reported increased half life of effective concentrations in vivo up to seven days 
allowing less frequent dosing in comparison to pegylated IFN69,70. 
It was shown, however, that in comparison to an Albuferon equivalent, the 
IFN-AlbudAbs possessed a 1.5x longer serum half-life, a 5.8 fold greater antiviral 
effect on encephalomyocarditis virus in a A549 lung carcinoma cell line, and a 
significant retardation of human melanoma xenograft growth in severe combined 
immunodeficient (SCID) mice. In vitro, neither AlbudAb or Albuferon demonstrate 
anti-viral efficacy greater than IFN-α2b alone due to the steric hindrances of their 
respective extensive additional protein scaffold, however in vivo the increased half-life 
through FcRn mediated recycling through the HSA association evidently 
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compensated for the decrease in potency as the IFN-AlbudAb’s half-life was 19-fold 
higher than IFN alone.  
An increase in efficacy was similarly observed with AlbudAbs fused to 
interleukin-1 receptor antagonist (IL-1RA) (an approved treatment for rheumatoid 
arthritis71) in an arthritis model, with a significantly decreased disease progression 
over IL-1RA alone72. This was linked to an albumin-mediated increase in half-life 
owing to a comparable IL-1RA-AlbudAb half-life as rat serum albumin in rats, 
which was a 20% half-life improvement over non-targeted IL-ra-dAb.  
Hence, the AlbudAb platform presented a viable treatment improvement in 
different disease states, and clear demonstrations that IFN-dAb fusions can be 
efficacious in vivo. 
 
The dAb research has now progressed to the concept of selectively targeting a 
therapeutic agent to a diseased tissue by way of dAb mediated tissue targeting 
whereby the therapeutic agent and the dAb are expressed as a single recombinant 
protein fusion known as a dAb fusion. In principle, the targeting leads to discrete 
biodistribution and thus localised high concentration, therefore enhancing 
therapeutic efficacy. This has been applied to targeting IFNα directly to the liver in 
the treatment of hepatitis C73 (Section 1.5.4), rather than extending the half-life as 
seen with AlbudAbs. The first published data involved a murine IFNα genetically 
fused with a dAb targeting ASGPR, an ASGPRdAb (Section 1.4), which was shown 
in vitro to retain both ASGPR targeting and IFN function as a fusion protein. In vivo 
specific ASGPR targeting accounted for a 23.8% increase in liver uptake at 3h versus 
a non-targeted IFN fusion protein control74.  
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1.3 IMMUNO-TARGETING CANCER 
1.3.1 Cancer Targeting Antibody Derivatives 
The anti-neoplastic chemotherapeutics have serious toxic side effects for the 
host in the treatment of cancer. These include alkylating agents, anti-metabolites and 
plant alkaloids. Therefore antibody biopharmaceuticals have been developed to 
increase targeted cytotoxicity to supplement chemotherapy. There is currently no 
published data on the targeting of cancerous cells or tissues utilising dAbs. However, 
alternative antibody based derivatives (Figure 1.1) provide numerous precedents for 
targeting cancerous cells in vivo, functioning as antagonistic therapeutics or tracers.  
 
In 1997 the first approved anti-cancer antibody therapy called Rituximab was 
released against B cell non-Hodgkin’s lymphoma75. A chimaeric monoclonal anti-
CD20 IgG1 antibody76, Rituximab sensitises B-Cells to chemotherapy, inducing 
ADCC and crosslinking CD20 to induce apoptosis77. The first approved 
biopharmaceutical against an epithelial malignancy was the breast cancer treatment 
monoclonal humanised IgG1 trastuzumab, which targets the epidermal growth 
factor receptor Her2.78 Trastuzumab is efficacious in 20-30% of cases79, which 
constitutes a predominantly poor prognosis patient subset, increasing response rates 
by 14% independently80 and ~37% in combination with chemotherapy81. 
Trastuzumab’s clinical effect is through a combination of ADCC82 and targeting the 
Her2 receptor for ubiquitination83. There are also anti-CD52 leukaemia therapy 
Figure 1.1 – Antibody Technologies 
Diagram showing cartoon representations of a selection of antibody 
fragment technologies including the secondary structures. Visualised 
using Jmol: an open-source Java viewer for chemical structures in 3D. 
http://www.jmol.org/ 
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altuzumab51,84 which was subsequently redeveloped for treating multiple sclerosis85, 
plus cetuximab86 and panitumumab87 targeting the epidermal growth factor receptor 
(EGFR) overexpression in metastatic colorectal cancer88. 
However, mAbs have proven widely ineffective against solid tumours even in 
those where they are the primary indication89,90. Indeed the majority of oncological 
antibody therapies focus on haematological malignancies. The optimum molecular 
size for tumour penetration is <100kDa. Hence, smaller antibody fragment 
biopharmaceuticals open up the potential for hitting intratumoural and intracellular 
epitopes, owing to greater tumour percolation91. 
Fragment antigen binding (Fab) antibodies (Figure 1.1) are produced by 
enzymatic cleavage of the Fc region above the hinge91. Ranibizumab is a 
recombinant monoclonal anti-vascular endothelial growth factor (VEGF) humanised 
Fab derived from parent IgG1 bevacizumab. It was developed for the treatment of 
age-related macular degeneration. Ranibizumab inhibits vascular growth and could 
theoretically perform the same role in a cancerous disease state.  
Bi-specific mAbs (bsmAb) demonstrate dual-targeted efficacy. BsmAbs are 
derived from two independent mAbs with discrete targets to create a hybrid 
comprised of the one heavy and one light chain from each mAb. For instance, the 
first approved trifunctional bsmAb, catumaxomab for the treatment of malignant 
ascites, is a rat-mouse hybrid92,93. The hybridisation bestows the bsmAb with both 
anti-epithelial cell adhesion molecule (EpCam)94 (a tumour associated proliferative 
signal transducer95) and anti-CD396,97 variable domains. Therefore it will target 
EpCam positive ascites and also sequester CD3-positive T Cells to stimulate an 
ADCC or phagocytosis against the ascites tissue. 
Single chain variable fragments (scFv)98,99 possess a VH domain linked to a VL 
domain via a polypeptide linker (Figure 1.1)100. Fibronectin isoform B (B-FN)101 is 
expressed in neoplastic blood vessels, such as in actively angiogenic tumours102, and 
an scFv targeting B-FN demonstrated the cancer targeting potential in vivo by 
specifically accumulating in the vessels of actively growing teratocarcinomas by 
infrared-fluorescent tagging103. Furthermore, anti-human epidermal growth factor 
receptor 2 (HER2) scFvs demonstrated specific accumulation in SKOV-3 
xenografts104. SKOV-3 targeting increased with scFv-HER2 affinity3, dimerisation 
and phage display derivation105. Conversely, SKOV-3 uptake was limited by renal 
clearance and lower tumour diffusion was observed with higher HER2 affinities4.  
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Nanobodies106, also known as single domain antibodies or VHH domains, are 
homologous to dAbs but crucially are derived by cleaving VHH domains from isolated 
from HCAbs harvested from immunised Lama glama16,107. The VHH undergo genetic 
recombination from the harvested VHH sequences for in vitro scaffold 
humanisation108. VHH domains also possess many non-canonical CDR 
architectures109. Nanobodies have been raised against the angiogenic and metastasis 
facilitating chemokine receptors CXCR4110 and CXCR7111, inhibiting the invasive 
phenotype through antagonising the interaction with ligand CXCL12. Hepatocyte 
growth factor targeting nanobodies antagonising c-Met proliferative signalling have 
demonstrated glioblastoma xenograft outgrowth regression. EGFR targeting 
nanobodies have been utilised as imaging agents112,113 and solid tumour xenograft 
antagonists114, including in combination with albumin half-life extension115 (Section 
1.2.2) or multiparatopic strategies116 to increase efficacy. Anti-HER2 nanobodies are 
potentially promising tracers for diagnostic PET breast cancer imaging117,118.  
Affibodies119 are only 7kDa 58 amino acid (AA) scaffolds arranged in a three-
helix bundle structure (Figure 1.1)120, possessing low picomolar target affinities121,122. 
They are however not derived from antibodies but rather from staphylococcal 
protein A123,124, which could be problematic for achieving low-immunogenicity with 
repeat dosing. However, the rationale for affibody development is similar to dAbs as 
they are small and highly specific with potential for therapeutic half-life extension125 
and are also selected utilising phage display library (Section 1.2.1)126. In development 
for the diagnostic imaging of HER2-positive metastases, the platform could be 
extended to deliver a cytotoxic. HER2 diagnostic imaging is the predominating goal, 
correlating imaged receptor number with likely prognosis127. Radiolabelled 68Ga-
1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) anti-HER2 affibodies with 
injected into an in vivo HER2-overexpressing xenograft model demonstrated specific 
accumulation of the affibody in the tumour at higher concentrations than the non-
targeted affibody and in comparison to other tissues (ex. kidneys), with rapid blood 
clearance of unbound ligand128. Furthermore, a correlation between receptor density 
and affibody tumour concentration was demonstrated utilising PET-CT of xenografts 
derived from cell lineages with varying HER2 expression profiles. Similar results 
were achieved with fluorine-18 (F-18/18F) labelling129,130, in addition to nanoparticle 
fluorescence imaging of significant tumour affibody targeting versus tissues not 
involved in excretion131.  
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1.3.2 Dual-Targeted Fusion Proteins targeting 
Cancer 
The dAb fusion platform has been shown to allow discrete liver tissue 
targeting in vivo by a dual-targeted hIFN-dAb74, however it is yet to be demonstrated 
for cancer tissue. Nonetheless there are a number of precedents for in vivo cancer 
tissue targeting with an antibody derivative linked to a therapeutic cytotoxic payload. 
Many of these antibody-drug conjugate strategies involve chemically conjugated 
antimitotic chemotherapies such as the United States Food & Drug Administration 
(FDA)-approved anti-CD30 brentuximab monomethyl auristatin E conjugate for B-
cell lymphomas132,133 or anti-HER2 trastuzumab-DM1 for HER2-positive metastatic 
breast cancer134,135. However, this investigation is focussed on the recombinant 
biopharmaceutical drug strategy with spliced fusion proteins targeted towards solid 
tumours. 
A humanised mAb-derived scFv fusion is Oportuzumab-monatox. The scFv 
component binds an EpCam epitope whereupon it delivers its cytotoxic payload to 
the tumourous tissue. Exotoxin A from Pseudomonas aeruginosa, as designated by 
‘monatox’, is an adenosine diphosphate ribosyltransferase which inhibits eukaryotic 
elongation factor 2 (EEF2) and thereby causes cessation of polypeptide synthesis, 
killing the cell136-138. The cytotoxic payload could also be an enzyme such as 
ribonuclease (RNase), for example amphibian onconase, with survival time in SCID 
mice increased ~150%139.  
Cytokines have potent anti-tumourigenic properties and serious potential side 
effects for bystander cells with systemic application, which can be expeditiously 
controlled by the employment of targeting as antibody-cytokine fusion proteins. 
Endogenous tumouricidal mechanisms can be stimulated by scFv controlled delivery 
of cytokine TNF Fas ligand to effector sites by targeting fibroblast activation protein 
inhibiting tumour outgrowth in 78% of models whilst crucially not instigating septic 
shock140.  
Anti-EGFR nanobody fused with TNF-related apoptosis inducing ligand 
(TRAIL) was shown to localise in glioblastoma xenografts and retard tumour 
growth141. Similarly, melanoma chondroitin sulphate proteoglycan (MCSP), a poor-
prognosis marker for metastatic melanoma, targeted by an anti-MSCP scFv fused to 
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TRAIL also significantly retarded outgrowth synergistically by sensitising and 
instigating an apoptotic state in a melanoma xenograft model142. 
An anti-B-FN scFv fused with heterodimeric interleukin-12 (IL-12), a 
mediator of T-cell and NK cell activation, had 100% greater xenograft uptake over 
the non-targeted control. The scFv improved the therapeutic index (tumour volume, 
metastasis, histochemical analysis of cytokine recruitment to the tumour 
neovasculature) of IL-12 approximately 25-fold against teratocarcinoma and by 
400% against adenocarcinoma143. However, the tumour:organ ratios were quite low, 
indicating potential non-specific off-target uptake. Indeed there was evidence of side 
effects in immuno-competent models.  
The same anti-B-FN scFv fused with interleukin-2 (IL-2), another lymphocyte 
mediator, accumulated in the tumour vasculature, recruited lymphocytes and 
instigated teratocarcinoma necrosis144. This therapeutic significantly reduced 
orthotopic pancreatic tumour load to 2% that of untreated disease by NK cell 
recruitment145. An scFv targeting tenascin-C, a multifunctional extracellular matrix 
glycoprotein strongly expressed in breast cancer neovasculature but low in normal 
tissue146, fused to IL-2 exhibited specific xenograft uptake in a breast cancer model. 
However, significant therapeutic efficacy relied upon synergism with a high dose of 
chemotherapeutic147.  
Another anti-fibronectin scFv fused this time with IFNα formed a non-
covalent diabody targeted to the tumour neovasculature. It demonstrated selective 
tumour uptake in teratocarcinomas and melanoma murine-xenograft models148. 
However, this failed to correlate with a significant targeting-linked therapeutic effect 
in spite of a 20-fold higher uptake. On the other hand, fusion with IFNγ 
demonstrated low xenograft uptake149 owing to IFNγ-mediated off-target 
sequestering. However, if off-targeting was artificially circumvented by IFNγ receptor 
knock-out or blocking, then a therapeutic effect was witnessed150. 
These outlined studies employ a highly similar therapeutic fusion strategy to 
the one to be investigated in this study and exemplify the ability of antibody fragment 
cytokine based fusion proteins to target in vivo xenografts and instigate a measurable 
response. 
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1.4 ASIALOGLYCOPROTEIN RECEPTOR 
A target protein for a dAb must be preferably abundantly and discretely 
expressed in the selected diseased tissue. Cell surface markers, such as receptor 
proteins, are of particular merit owing to the relative ease of access for a circulating 
biopharmaceutical. In the instance of a therapeutic dAb fusion designed to modify 
cellular function, rather than for example antagonising a receptor-ligand interaction, 
the target receptor must also facilitate the therapeutic payload’s cellular interaction. 
In this instance, IFN must be targeted discretely to the liver as part of a dAb fusion. A 
potential target receptor adhering to these criteria is ASGPR, thus rationalising the 
creation of the ASGPRdAb. 
 
1.4.1 ASGPR Function 
ASGPR, also known as the Ashwell Receptor151 or Human Hepatic Lectin, 
was first identified in 1974 in rats152-154. ASGPR is a mammalian long-form C-type 
lectin, a carbohydrate binding glycoprotein reliant on Ca2+ ions containing three 
disulphide bridges155-158. ASGPRs are expressed on parenchymal epithelial 
hepatocytes’ sinusoidal plasma membranes159. The ASGPRs are concentrated in 
clathrin coated pits facing capillaries160,161, and are effectively absent from the apical 
membrane, thus prioritising maximum exposure to macromolecules through the 
fenestrated endothelium162. This localisation highlights the suitability of ASGPR for 
targeting because circulatory access may enable effective targeting dynamics.  
The ASGPR mediates stochastic endocytosis of desialyted (terminal sialic acid 
removed) N-linked glycoproteins with terminal galactose (Gal) or N-
acetylgalactosamine (Gal-NAc) residues, i.e. asialoglycoproteins (ASGP)163. Spatial 
interaction of an ASGP with ASGPR causes a conformational change in ASGPR’s 
structure which instigates the internalisation of the ASGPR-ASGP complex into a 
clathrin coated vesicle (CCV)164,165, thus removing ASGPs from circulation by 
receptor mediated endocytosis166 for degradation in lysosomes via the endosome167. 
The acidic conditions of the endosome propagate the release of ASGP from the 
complex, probably by the dissociation of the complexed Ca2+ 168, and ASGPR is 
rapidly recycled back constitutively to the cell plasma membrane161,169. Owing to the 
dissociation at low pH, ASGP binding by ASGPR is reliant on >pH6.5157. This 
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ASGPR cycle occurs within 6.5min in vitro170, with ~60% ASGPR available on the 
surface at anytime171. This mechanism has implications for the potential fate of an 
ASGPRdAb fusion binding ASGPR (Section 1.4.4.1), avoiding the degradation 
pathway. 
In vivo, ASGPR is thought to regulate von Willebrand factors such as 
coagulation factor VIII172 and to prevent the accumulation of deleterious circulating 
glycoproteins, such as cancer mucins173 and desialyted platelets151, maintaining 
glycoprotein homeostasis174. The hepatitis viruses HAV, HBV and HCV also exploit 
ASGPR for cell entry175-177. However, generally, endogenous ligands of ASGPR are 
not well characterised in the literature as they exist endogenously in a sialyted state 
and are therefore degraded. This necessitates a binding efficiency between the dAb 
and ASGPR which may out-compete the endogenous ligands, assuming the epitopes 
overlap in order to ensure therapeutic levels of payload delivery. However, given the 
high receptor density and the recycling of ASGPR, there ought to be minimal 
interference with overall ASGPR function in vivo and therefore one would expect no 
side effects from the interaction of the dAb and ASGPR. Indeed the knock out of 
ASGPR is a non-deleterious phenotype178. Moreover, ASGPR has no downstream 
effectors given its purpose as a delivery medium to the endosome. Therefore, binding 
ASGPR ought not to have a modulatory effect on the cells. This is beneficial 
experimentally as it removes a potential variable, ensuring that observed cellular 
effects are likely to be the result of the attached therapeutic payload.  
 
1.4.2 ASGPR Structure & Interactions 
Human ASGPR exists as a heterooligomer of two integral type-II single-span 
transmembrane subunits designated H1 (major subunit 46kDa) and H2 (minor 
subunit 50kDa). The two are further subdivided into homologous RNA splice 
variants: H1a, H1b, H2a, H2b, and H2c179-181. H2b for instance has a five AA 
insertion at the C-terminus versus H2a. H1 and H2 have a protein sequence 
homology of 58%180 and are also highly conserved between mammals. Although 
cellular messenger ribonucleic acid (mRNA) encoding H1 & H2 is approximately 
equal, they are expressed at a ratio of 6:1 respectively in vitro171,180.  
The structure of H1 includes a ~40AA N-terminal cytoplasmic domain, 
~20AA hydrophobic single-span transmembrane domain, with the ectodomain 
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consisting of an ~80AA extracellular stalk oligomerisation domain, and the ~140AA 
Ca2+-reliant (for example, three Ca2+ in H1) carbohydrate recognition domain 
(CRD)158,182,183.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The native plasma membrane conformation of ASGPR involves a stable 
complex of H1a, H1b, H2b, and H2c179, which are cotranslationally inserted into the 
rough endoplasmic reticulum before glycosylation and maturation in the Golgi 
apparatus163. The exact composition of H1 & H2 is poorly understood but is 
proposed to be at least a 2:1 heterotrimer184 or 3:1 heterotetramer but potentially a 
2:2 heterotetramer185 or even H1 homotrimers. The heterooligomeric conformation, 
achieved through an α-helical coiled-coil interaction of the respective subunits' 
heptad repeats of the extracellular stalk domains186, is necessary for ASGPR’s high 
specific binding affinity for ASGPs187. The H1 subunit must associate with the H2 
subunit to function effectively, because the interaction arranges the high affinity 
ASGP binding conformation of the CRDs188, and H2 must make the association for 
transport to the plasma membrane184. The function of the CRD is independent of 
glycosylation189.  
There are reports of a soluble ASGPR variant consisting of the H1b and 
H2a, which has been hypothesised to be a buffer against a rapid increase in ASGPs 
Figure 1.2 – ASGPR-H1 
Carbohydrate Recognition 
Domain Crystal Structure 
Diagram showing cartoon representation of 
the secondary structure of the carbohydrate 
recognition domain of the H1 subunit of 
ASGPR including co-ordinated Ca2+ ions 
(green spheres) and amino acids (various 
colours). Visualised using Jmol: an open-
source Java viewer for chemical structures in 
3D. http://www.jmol.org/ 
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during infection179. It is reported H1b lacks an effective transmembrane domain 
when translated alone and so can be excreted from the cell, where it can oligomerise 
with H2a, which is proteolytically cleaved from the plasma membrane into the 
extracellular fluid. Therefore this could explain the reported uncomplexed ‘third’ of 
H2 protein detected on plasma membranes190. The presence of this soluble ASGPR 
complex is relevant when choosing an epitope for the ASGPR targeting dAb, thus 
favouring a subunit of the native membrane-bound ASGPR. 
 
The structural nuances and subunit expression profiles of ASGPR suggest 
that an anti-ASGPR dAb ought to be targeted to H1, as it is more highly expressed. 
Furthermore, the dAb ought to be preferably targeted to the H1a subunit, thus 
avoiding potential off-target non-cellular binding to H1b of the soluble ASGPR. 
However the differences between H1a and H1b lie in the transmembrane domain, 
which is unavailable for targeting. Hence, given the stalk domain interactions, the 
most freely accessible extracellular domain is the CRD. Therefore, dAbs ought to be 
selected to target a H1 CRD epitope, with the caveat that blood sequestration by 
soluble ASGPR is a possibility. 
 
1.4.3 ASGPR Expression Profile 
The liver is an attractive organ to target with biopharmaceuticals because the 
high blood volume supply increases the chances for successful dAb fusion delivery at 
a therapeutic concentration. The primary reason cited for ASGPR's selection as a 
target for liver-specific drug delivery is that ASGPR is “exclusively expressed”191, and 
has “selective expression on hepatocytes”192. Indeed, the tissue mRNA expression 
data shows conserved predominantly liver transcription of ASGPR-H1 and ASGPR-
H2 transcripts (Table 1.1)193-197. Studies of liver parenchymal cell lineages has 
demonstrated a high ASGPR expression level in the order of 1x105 to 5x105 
receptors per cell170,198, even up to 1.2x106 depending on the reaction conditions for 
quantitative functional binding of the trace ligand199.  
There are examples, however, of expression on non-hepatic tissues. 
Expression of the rat hepatic lectin 1 (RHL1), which is highly H1 homologous, on rat 
thyrocyte apical membranes has been identified with rabbit polyclonal serum200. This 
is in addition to RHL1 mRNA in rat brain and kidney201. In this instance RHL1 is 
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responsible for binding and internalising thyroglobulin202. However, dAb fusion liver 
targeting ought to predominate as expression levels of RHL1 are 80% lower than in 
rat liver and, crucially, thyroid ASGPR is expressed on the apical plasma membrane, 
thus circulating ASGPRdAb fusion is unlikely to encounter the thyroidal ASGPR. A 
RHL2 homolog was identified on the dorsal spermatid tip203, but given the locale 
and lack of RHL1 subunit, there would be no interference with liver targeting. 
 
Table 1.1  
ASGPR Subunit Human Tissue Expression Levels 
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0.7 2.0 4.0 1.0 0.8 7.0 0.7 2.0 2.0 - 0.8 7.0 265 1.4 - - 
 
ASGPR-
H2 
 
0.6 2.0 8.0 1.0 4.0 0.7 - - 9.0 - 1.4 31 344 1.0 0.9 - 
 Units: Fragments Per Kilobase Of Exon Per Million Fragments Mapped (FPKM) 
Data compiled from several studies, as accessed on Expression Atlas http://www.ebi.ac.uk 
 
A study with mAb ASSA-1 against H1 indicated ASGPR expression on 
activated T-cells204, although it is conceded that this is a seemingly non-logical result 
and perhaps the epitope is homologous to another C-type lectin which are common 
on immunological cells. Similarly identification in immature dendritic cells205 could 
be another C-type lectin. 
The most compelling potential alternative interfering ASGPR locale is in the 
kidneys. Both H1 & H2 subunits have been identified in renal proximal tubular 
epithelial cells by mRNA analysis, histology, flow cytometry and confocal 
microscopy206. There is no receptor density quantification and thus it is unclear if the 
kidney would detract from liver targeting. Furthermore given that the kidneys will 
most likely excrete unbound dAb fusion, deciphering specific from non-specific 
kidney targeting would be difficult in vivo. 
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Therefore, there is evidence for extra hepatic expression, thus raising 
implications for ASGPR targeted dAb-fusions to tissues other than hepatic. 
Nevertheless, it is apparent that ASGPR liver expression predominates. A dAb 
selected for its ability to bind ASGPR should therefore allow the discrete delivery of a 
therapeutic payload to liver endothelial tissue rather than a homogenous systemic 
distribution as the abundant expression in the liver should reduce any potential off-
tissue binding.  
 
There are also some doubts over the expression of ASGPR in the disease 
state. H1b expression has been observed in vitro to decrease in hepatic cells infected 
with HBV/HCV, and H1a with HCV179. However, this was an mRNA study in vitro 
and thus may not reflect expression in vivo. ASGPR is the cell entry medium for the 
hepatitis viruses, and so it would seem logical for a down regulation of ASGPR post 
infection.  
Moreover, an investigation of hepatic cell carcinoma patients found a 
negligible level of ASGPR activity on the cancerous cells, including a correlation 
between tumour size and hyperasialoglycoproteinemia thus indicating reduced 
endocytic function by ASGPR207. There could be potential for application in 
glycomic patient stratification208. This is supported by the observation that 
hepatocytes with low ASGPR expression levels have a higher proliferative 
tendency209,210.  The former investigation was however only performed with 30 
patients, which raises a question of significance. Furthermore there is no data to 
suggest that the ASGPR is no longer being expressed on the plasma membrane but 
rather only that ASGPR is functioning sub-optimally. This could perhaps be due to 
tissue restructuring, an issue with endocytosis, or pH in the tumour 
microenvironment; all of which ought to have no bearing on the ability of an 
ASGPRdAb to bind the ASGPR. The latter studies are related to proliferation for 
artificial liver growth and are not related to cancer, and so the ASGPR expression 
may be due to cell cycle stage rather than a clinical phenotype.  
In fact in another study, HCC tissue histology showed an increase in ASGPR 
expression and no change in binding affinity211. Nonetheless, for the purposes of this 
investigation, cancerous hepatic cell lines can be selected which do express ASGPR 
at relatively high levels such as HepG2 (Section 1.6.2).  
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1.4.4 Targeting ASGPR 
There are precedents for the selection of ASGPR as the target of 
biopharmaceuticals for therapeutic payload delivery. Foremost examples are gene 
delivery for hepatocyte gene therapy applications utilising asialyted glycosylated 
liposomes212,213, such as Gal-pOrn-mHA2214.  
More relevant to this investigation, the indirect delivery of a therapeutic 
protein payload via ASGPR as a proxy target has been shown to augment 
therapeutic effect. For instance with IFNβ, an increased therapeutic effectiveness was 
observed through desialytion of the branched oligosaccharide chain on the Asn80-
Glu81-Thr82 tripeptide sequence215 by neuraminidase, producing asialo-IFNβ191. A 
significant anti-HBV effect was observed versus conventional IFNα/β utilising viral 
particle and downstream effector quantification in vitro and in vivo inhibition of HBV 
in athymic nude mice. Hence, targeting ASGPR, an extracellular receptor with no 
downstream effector functionality, can still produce significant therapeutic results.  
A strategy to target ASGPR with antibody fragment technology to deliver an 
immunotoxin has been developed. A payload of cytotoxic EEF2 inhibitor B11-
PE38KDEL, a potential HBV therapeutic, was delivered to various hepatic cell lines 
through fusion to an anti-ASGPR scFv216. The scFv-fusion targeted the extracellular 
H1 domain, whereupon internalisation reputedly instigated cell death217,218. B11-
PE38KDEL delivery was shown to be ASGPR dependent through Gal competition 
assays216, and although it is assumed the mechanism involves internalisation followed 
by cytoplasmic release of the cytotoxin, there was however no evidence to confirm 
the exact mechanism of ASGPR involvement. The scFv-fusion is shown to be less 
efficacious than application of PE-KDEL alone in vitro. However the low IC50 
nanomolar concentrations necessary to induce cell death demonstrate dual targeting 
does not forego effective cytotoxicity. Furthermore, it is conceded that the scFv 
binding affinity is not fully matured. Hence, there is positive evidence for antibody 
fragment mediated therapeutic payload delivery via ASGPR targeting.  
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1.4.4.1 ASGPR Targeting Fates 
As described, the majority of treatments thus far have selected ASGPR with 
the aim of internalisation. The interaction of a dAb fusion with the ASGPR receptor 
can have essentially three different outcomes. Firstly the dAb may bind the ASGPR 
without inducing the conformational change necessary to induce CCV 
internalisation, and hence remain on the periphery of the cell219. This scenario would 
involve the dAb simply associating with ASGPR and then dissociating, hopefully 
allowing the therapeutic payload moiety to engage its receptor whether by cis, as seen 
with nanobody-IFN fusion proteins220, or trans .  
A second potential interaction would cause endocytosis of the ASGPR dAb-
fusion complex into a CCV, transporting the complex to the endosome. The 
endosome is mildly acidic221 (pH5-6), therefore the affinity of the dAb for ASGPR 
may not be overcome, thus not releasing the dAb fusion into the lumen. The 
recycling of ASGPR to the plasma membrane would in turn return the dAb-fusion to 
the extracellular space for further interactions. 
The third possibility would follow the second except that there is no recycling 
of the dAb-fusion to the plasma membrane. This could either occur because 
complexing the dAb fusion prevents the ASGPR recycling mechanism, or the dAb 
fusion dissociates into the lumen such as with dendrimer delivery of 
chemotherapeutics222. Assuming there is no re-binding, the dAb fusion could be 
broken down. 
All three scenarios would allow kinetic modelling of ASGPR interactions and 
would require investigation to determine which model is appropriate. As the binding 
affinities may be an inextricable determining factor in receptor complex fate, it is 
especially imperative to this study. The latter retention scenario would not be 
conducive to delivery of the therapeutic moiety and so ASGPR would prove to be a 
poor target choice. However, the two former possibilities do not preclude an IFN 
therapeutic payload binding its receptor, as the receptor is similarly recycled via 
CCVs223,224. Indeed the IFN moiety may potentially bind its receptor simultaneously, 
exerted either in a cis (same cell192) and/or trans (bystander cell225,226). Hence, the 
tissue-targeting efficacy of a dAb fusion may prove to be linked to the dAb binding 
affinity for ASGPR. 
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1.5 INTERFERON 
IFN has been cited as a potential anti-HCC therapeutic after numerous years 
in the clinic as a treatment for HCV, and even championed as a cancer cure-all in 
Time Magazine March 31st 1980227. However, despite IFNα being a multi billion 
dollar treatment for hepatitis, IFN has not reached its full potential owing to several 
major drawbacks. In this investigation, IFNα is fused to a liver targeting ASGPRdAb, 
with a view to harnessing IFN’s cytotoxicity by controlling its biodistribution, 
potentially localising IFN to the diseased tissue to maximise therapeutic efficacy. 
Therefore it is important to comprehensively understand IFN’s endogenous activity, 
in order to optimise its utilisation in the IFN-ASGPRdAb fusion. 
 
1.5.1 Interferon Protein 
IFN was seminally attributed the role of a vertebrate antiviral, blocking active 
intracellular influenza viral replication228.  IFNs, as a part of the innate immunity, act 
as the first line defence against viruses229 and other pathogens, but are also known to 
be immunomodulatory230 and anti-neoplastic231. The IFN cytokine family members 
are classified based on the receptor through which they signal. Type-I subtypes such 
as the thirteen variants of IFNα or IFNß bind IFNAR. The immune cell specific 
Type-II IFNγ binds IFNγ-Receptor (IFNGR), although it can cross-talk with the 
IFNα/β signalling pathways 232. In spite of only two known receptors, the different 
IFNs have highly coordinated, discrete, synergistic effects for specific cell types and 
disease states233-235. For instance, IFNα5 can instigate a stronger anti-viral response 
than IFNα2 through the IFNAR in HCV infected liver cells.  
Human IFNα exists as twelve 19kDa mature protein subtypes, encoded by 
thirteen IFNA genes (IFNA1 and IFNA13 encode for an identical IFNα), with the 
hydrophobic 23 amino acid signalling peptide cleaved during post-translation 
modification236. The 165-residue mature peptide sequences share broad amino acid 
consensus of ~80%*. IFNα2 is an exception owing to a single D44 deletion, plus 
three additional polymorphic forms. For example, the predominating 165-amino 
acid K23R His34 †  IFNα2b237, which is also unusual for its post-translational 
                                                
* UniProt BLAST search against P01563 IFNA2_Human, performed 02/06/14 
† UniProt ALIGN analysis of H2DF54_HUMAN vs IFNA2_HUMAN 
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heterogeneous O-linked glycosylation on Thr106 comprised of a core disaccharide 
galactosamine-GalNAc with varying α-N-acetylneuraminic acid (Neu5Ac) 
residues238,239. There are seven reported glycan variants*. The specific implications of 
glycosylation for IFNα2 are currently un-established but glycosylation generally plays 
an important role in protein folding and pharmacokinetics240, perhaps by slowing 
dynamic tertiary structure conformation modifications241. Indeed in feline IFNα 
variants, which is 60% homologous to human IFNα†, glycosylation has been linked to 
increased stability and in vitro bioactivity242. Nevertheless most human variants have a 
Val106 residue‡, and so glycosylation cannot be entirely essential to function.  
IFN forms a conserved cuboidal tertiary structure consisting of five alpha 
helices linked by loops243. The largest, the 30 residue AB loop, being the 
predominating site for subtype sequence variation and also critical receptor 
interactions244 (Section 1.5.2). IFNα subtypes have four conserved cysteine residues, 
which form two disulphide bridges (C1-C98 & C29-C138)245 critical to anti-viral 
function246. IFNα2b has been observed to reversibly dimerise in vitro in the presence 
of Zinc (Zn)2+ through interaction of superficial charged residues247 in a pH and 
concentration dependent manner248, although the in vivo relevance remains 
unresolved.  
 
1.5.2 IFNAR Structure & Interactions 
Human IFNAR is the receptor protein complex responsible for transducing 
the signalling cascade for all type I IFNs and comprises two heterologous 
transmembrane subunits designated 1 & 2: IFNAR1 & IFNAR2249,250.  
IFNAR1 exists as the 135kDa full chain251 or as the IFNAR1s splice variant 
lacking exons 4-6252, although this latter conformation has been challenged253, and 
has a unique extracellular domain (ECD). IFNAR2 has three variants: soluble 
(IFNAR2a), short (IFNAR2b), which is thought to be a dominant negative regulator 
of IFNα/β254, and long (IFNAR2c)255,256. Two apposing subunits are always found in 
the full quaternary hIFNAR, and the most stable conformation is believed to be 
IFNAR1+IFNAR2c257 binding opposing sides of IFN258 (Figure 1.3). IFNAR2c binds 
                                                
* UniCarbKB GlycoSuiteDB database searched with Interferon Alpha 2b 18/06/14 
† UniProt BLAST search against Q8MIL4_FELCA performed 02/06/14 
‡ UniProt BLAST search against P01563 IFNA2_Human, performed 14/06/14 
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IFN via a discrete aliphatic hydrophobic patch259,260 interacting with the AB loop of 
IFNα2247 which also possesses a highly motile electrostatic segment for interaction243. 
However, IFNAR1 is necessary to induce the highly potent ‘active’ ternary hIFNAR 
structure as a result of, for instance, IFNα2 helix C’s247,261 highly plastic interaction at 
Val69 and Tyr70262-264 which transduces the signal through the IFNAR1 
ectodomain265. IFNAR1 has differential binding chemistry to each IFN subtype266,267 
creating a tertiary conformation unique to each subtype thus inducing discrete 
signalling268.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 – Interaction of hIFNα2 with hIFNAR  
Diagram showing cartoon representation of the discrete binding of hIFNα2 (red) to the ECDs of 
the hIFNAR1 (orange) and hIFNAR2 (green) subunits of the hIFNAR, in the specific ternary 
conformation for hIFNα2 signalling. Visualised using Jmol: an open-source Java viewer for 
chemical structures in 3D. http://www.jmol.org/ 
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Therefore, it would appear that the optimum strategy for interacting with the 
hIFNAR within cancerous tissue utilising an IFN-dAb fusion would be to create a 
hIFN with decreased affinity to IFNAR2. This would decrease off-target binding and 
thus would potentially reduce side effects (Section 1.5.5). The affinity reduction 
would be compensated through the increase in localised target-tissue concentration 
mediated by a dAb. Additionally an increase in affinity to IFNAR1 would stabilise 
the ternary receptor conformation thus increasing potency262. Hence, the dAb-fusion 
would be highly potent only in the target hepatic tissue. Nevertheless modifying the 
ternary interaction with hIFNAR could completely change the signalling cascade 
profile creating a different cellular phenotype263,269. 
 
Both IFNAR subunits’ mRNA is found systemically transcribed (Table 
1.2)193,194,196,197,270. The expression of IFNAR1 is related to the disease state271 and is 
down-regulated in many cancers, significantly negating response to IFN272 and so 
must be established for each cell lineage specifically.  
 
Table 1.2  
hIFNAR Subunit Human Tissue Expression Levels 
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18 13 19 21 9.0 11 17 13 17 7.3 12 31 17 17 16 16 
 
hIFNAR2 
 
13 16 37 25 10 6.0 9.0 7.8 20 5.7 7.7 34 7.3 14 18 18 
 Units: FPKM 
Data compiled from several studies, as accessed on Expression Atlas http://www.ebi.ac.uk 
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1.5.3 IFN Signal Transduction 
IFNα is most markedly upregulated during infection, signalling a diverse 
cellular response (Figure 1.4). For example, T-lymphocytes (T-Cells) produce IFN in 
response to viral antigen recognition273. Alternatively, a potent initiator is the 
detection of double-stranded ribonucleic acid (ds-RNA) by ds-RNA detecting protein 
kinase R (PKR), which inhibits nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor to allow nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB) to upregulate IFN production274. 
  
Figure 1.4 – Human Interferon α/β and γ Signalling Pathways  
Diagram showing an abridged representation of the protein signalling cascades of the interferon 
pathways integrating a discrete cellular response, including the cross-talk with the MAPK and 
PI3K signalling pathways. Adapted from Life Technologies Cell Signalling Pathways, accessed 
September 2014. 
http://www.lifetechnologies.com/uk/en/home/life-science/cell-analysis/signaling-pathways.html 
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IFN's influence is pleiotropic, with binding of IFNα to IFNAR (Section 1.5.2) 
inducing transcription of a diverse ‘interferome’ of over 300 IFN stimulated genes 
(ISGs)275,276. IFNAR1 and IFNAR2c have no endogenous kinase activity and 
therefore interact with Janus kinases (JAKs). Tyrosine kinase 2 (Tyk2) is constitutively 
associated with IFNAR1277 and JAK1 interacts with IFNAR2c via a non-Box1 motif 
upon formation of the ECD IFNα complex278, resulting in transphosphorylating of 
Tyr residues. These activated JAKs then phosphorylate associated signal transducers 
and activators of transcription (Stat) proteins, which results in a Stat1αβ/Stat2 
heterodimer 279,280. Stat1/Stat2 interacts with IFN-regulatory factor-9 (IRF9) to form 
the IFN-stimulated gene factor 3 (ISGF3)281 which translocates to an interferon 
stimulated response element (ISRE) of an ISG in the nucleus282. IFNα/β can self-
regulate by inducing IFNAR inhibitors such as UBP43 enzyme283, SHP 
phosphatase284 and SOCS-1285. There are numerous ISG expression products which 
integrate the IFNα induced phenotype286. PKR inhibits protein production through 
phosphorylation of the α-subunit Ser51 of eukaryotic initiation factor-2287, leading to 
translational arrest288-290. 2’,5’-oligoadenylate synthetase (OAS) is also upregulated291, 
which can inhibit protein production through activating dimeric endoribonuclease 
RNAseL292, resulting in mRNA degradation293,294.  
IFNα/β utilises p53, for instance, to integrate an apoptotic response295. The 
tumour suppressor protein p53 has been described as ‘the guardian of the 
genome’296, inducing apoptosis if stress signals are detected to suppress tumour 
outgrowth. The downstream influence of p53, to achieve tumour suppression and 
induce mitochondrial-mediated apoptosis, is wide ranging. IFNα/β stimulates the 
induction of p53 transcription in vitro231,297, notably in liver malignant cell line 
HepG2. Inhibition of the ISGF3 complex demonstrated a decrease in p53 levels in 
vitro231, and TP53 contains two characteristic ISRE sequences within its intron. 
However, p53 is not so readily expressed as OAS for instance. Through p53, IFNα/β 
has been shown to indirectly increase apoptotic factors FasR and Bcl-2, and p53 
inhibitor Mdm2295. 
IFNα has no reported effect on p53 activation (Ser54 phosphorylation) but 
rather primes the cell with increased p53 concentrations to counteract, for example, 
human papilloma virus E6 induced ubiquitin degradation of p53298, pre-empting 
stress signals. IFN lacks specificity to only cancerous cells, and the dAb doesn’t 
discriminate beyond ASGPR expressing hepatic cells. Hence, there is the potential 
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for collateral damage to bystander normal non-compromised cell populations within 
the hepatic tissue. However, the action of IFN on non-compromised cells is to modify 
the cell’s transcriptome to resist hijacking of the cellular machinery231. Additional 
aberrations must be present in the cell to instigate the apoptotic signal cascades, thus 
making IFN cytotoxicity specific to abnormal cells. Thus the potential for bystander 
death ought not be an issue for IFN-dAb fusions. 
IFN’s reliance on p53 is however a potential drawback. Inactivation of p53 
and its pathways is an almost universal step in cancer progression299, and the p53 
downstream redundancy attempts to counteract this cancerous selective pressure. 
IFN tumour suppression, as with other chemotherapeutics300, has decreased efficacy 
with tumour stage due to decreasing influence of p53 with cancer progression301. The 
TP53 gene encoding p53 is mutated in ~50% cancers, and so a key connection 
between cell damage detection and apoptosis is lost302. This would logically indicate 
that IFN is a poor therapeutic choice as IFN’s intrinsic action may be impotent. 
However, IFN can be an effective anti-HCC agent in certain patient subsets (Section 
1.5.4), which may have a mutation profile conducive to treatment such as, for 
example, non-mutated TP53, and/or functional PKR and OAS. Furthermore, 
decreasing p53 concentrations ensures only high affinity promoters are engaged, 
which encode apoptotic responses303-305. 
 
In addition to ISGF3 formation, IFNα/ß stimulated Jak-Stat signal 
transduction can also cross talk with additional signalling pathways such as the 
mitogen-activated protein kinase (MAPK)/extracellular signal response kinase 
(MEK) signalling pathway306, inhibiting MEK to prevent cell-cycle progression at the 
Go/G1 checkpoint, thus inhibiting cellular proliferation307,308. Furthermore IFNα/ß 
interferes with cyclin A expression, which is overexpressed in 40% of hepatic 
malignancies309, to stall the cell in S-phase310. 
The marshalling of extrinsic factors may also become more influential, i.e. the 
effect on the immune system (Section 1.1.4.2). IFNγ is referred to as the ‘immune’ 
IFN311, however IFNα can also stimulate indirect effects through an 
immunomodulatory influence. IFNα stimulates expression of TRAIL on the surfaces 
of NK cells312,313, T-Cell lymphocytes314, CD11c+ dendritic cells315 and monocytes316. 
Also, TRAIL’s promoter contains an ISRE for ISGF3 TF binding312. TRAIL binds 
death receptor (DR)-4 or DR-5 to instigate a FAS-associated death domain mediated 
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apoptotic signal cascade leading to caspase cancer cell death 317. In monocytes a 
decrease in DR-5 expression was also noted316, which is presumably to desensitise 
them to the increase in extracellular TRAIL, and an increase in nitric oxide (NO) 
synthase with concordant antiviral NO production318. IFNα/β can also stimulate the 
expression of major histocompatibility complex-I on the cell surface of 
lymphocytes319 to increase compromised cell recognition. IFNα/β increases memory 
T-cell turnover, extending their half-lives320.  
It is thought TRAIL can act in a p53 independent manner if the TP53 gene is 
damaged, although this is not substantiated in human tissue321,322. Furthermore, 
there are additional indications as it has been suggested that IFNα/β anti-metastatic 
effects are mediated by CD4+ T-Cells in ESb lymphomas323 and CD8+ T-Cells in 
adenocarcinoma324. IFNα/β has been observed to be less effective in immuno-
compromised mice325,326, further supporting the necessity for the immune system. 
 
1.5.4 IFN as a Cancer Therapeutic 
IFNα has been chosen for this investigation owing to the wide systemic 
expression of IFNAR, in contrast to the hepatic tissue specific expression of ASGPR. 
In addition, IFN is widely utilised as a treatment for various cancers. Injection with 
anti-IFNα/ß polyclonal antiserum abrogates syngeneic/xenogeneic tumour 
implantation rejection by an immuno-competent mouse host327,328. This indicates the 
importance of IFN’s role in endogenous anti-tumour activities. IFN has also been 
reported to negatively influence cancerous phenotypes such as angiogenesis329 and 
cell motility330.  
IFNα2b administration in patients with high-risk cutaneous melanoma 
showed a statistically significant increase in disease-free survival and overall 
survival331, and is currently the only FDA approved treatment for this malignancy. 
Previously, IFNα has been trialled for multiple malignancies with varied success332, 
particularly in renal cell carcinomas. 
An anti-cancer combination therapy of IFNα and fluorouracil was first 
characterised in colorectal cancer333, before being demonstrated as a treatment to 
illicit a partial response in HCC patients334. Subsequently studies have provided 
clinical support for this combination therapy showing a number of those examined 
reaching steady state disease335,336. However, none of the studies analysed a large 
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patient subset to provide total confidence and survival appears patient specific. 
Therefore, it is apparent that within the HCC population there is a subset of tumours 
that will respond to IFN treatment with a full disease remission. 
 
It has been hypothesised that endogenous IFNs are involved in ‘cancer 
immunosurveillance’, whereby stress ligands or cancer antigens are recognised, and 
immune response elicited337. However, a potential effect is an immunoselective 
‘Darwinian’ environment for the ‘fittest’ tumour cells from a heterogeneous 
population, promoting an immunoevasive plastic phenotype, thus facilitating tumour 
outgrowth338-340. This has been termed ‘immunoediting’341. These are similar to the 
selective pressures applied by such classical mechanisms of regulation, such as growth 
factor regulation, the evasion of which comprise one of the original ‘hallmarks of 
cancer’ 342. Immunoevasion and inflammatory response are now cited to be new 
hallmarks 343. 
Cancerous tissues acquire a multifactorial, high mutation, resistance 
phenotype. It has been argued that genomic instability is a phenotype of cancerous 
cells rather than a single crisis event, therefore leading to a highly heterogeneous and 
continually 'evolving' population of cells. Hence, the application of IFN results in a 
new selective niche for a reduced immunogenic cancer cell subpopulation to thrive, 
potentially later resulting in cancer progression and an ever increasingly poor 
prognosis. It is a comparable scenario to the effect of antibiotic over usage on 
bacterial strains 344. 
The tumour phenotype is thus a product of its immunological environment. 
Tumours harvested from Ifnar1-/- knock-out mice subsequently transplanted into 
wild-type hosts showed increased immunogenicity (lymphocyte-dependent rejection) 
in comparison to tumours harvested from immunocompetent hosts which form 
progressive tumours in a wild-type recipient340. This may be seen as counterintuitive, 
as it may be expected a tumour growing in the presence of a fully competent immune 
system to be severely compromised and unable to progress in a new host. Hence, this 
is strong evidence for immunoediting of the tumour through the action of IFN in the 
fully competent immune system, creating a less immunogenic cancer phenotype.  
Immunoediting highlights the need for patient stratification based on their 
likely prognosis, perhaps utilising the principles of theranostics345, by for instance a 
cancer tissue specific dAb as a radiotracer. It would also necessitate multi-targeted 
I – Introduction 
Alex G. Papple - 50 - Ph.D. 2014 
combination strategies attempting to obviate the evolution of resistant tumours 
through different angles of attack346. The combination of therapeutic antibodies and 
small molecule drugs347 is the standard for breast cancer with trastuzumab plus DNA 
intercalater doxorubicin and mitosis inhibitor paclitaxel.  
Thus, IFN has been shown to be an effective treatment for cancer in defined 
patient subsets with drawbacks related to cancer immunoediting. It also serves as an 
additional rationale for IFN targeted delivery localised to the tumour at subsequently 
more efficacious concentrations, by for example a dAb fusion, which can then 
integrate an anti-tumour effect6.  
 
1.5.5 IFN Treatment Side Effects 
Treatment with IFN has prohibitive side effects that limit optimal dose 
schedules348. Side effects of chronic IFN therapy include neutropenia349, flu-like 
symptoms350, and serious cognitive impairments such as depression351. In one trial on 
Western HCC patients more than 50% of participants had to withdraw owing to side 
effects, resulting in a non-significant survival rate versus control352. The treatment 
durations are substantial, lasting months or years, requiring regular injections, which 
further decreases patient compliance. Even with the decreased dosing of Albuferon 
treatment, for instance, side effects remain similar to pegylated IFN5 (Section 1.2.2). 
The neuropsychiatric episodes experienced by patients receiving IFN 
treatment are attributed to pro-inflammatory cytokine interference with mood 
pathways and neuroprotection in the brain. Precisely, L-Tryptophan (L-Trp) 
catabolism is channelled through the kynurenine pathway through the action of IFN 
increasing the activity of enzymes indoleamine 2–3, dioxygenase and kynurenine 3-
monooxygenase, inhibiting astrocyte neuroprotection and modifying microglia 
metabolism351. L-Trp is normally channelled into the serotonin pathway, a 
neurotransmitter responsible for euphoria. The diversion of L-Trp, thus decreasing 
serotonin levels, could be the root of the depression associated with IFN treatment.  
One solution to decrease side effects was Hepatic Arterial Infusion 
Chemotherapy (HAIC) whereby a catheter is inserted into the hepatic artery to 
deliver a localised high concentration dose336,353. HAIC is highly invasive and can 
thus introduce more complications than it solves, particularly patient discomfort. It is 
an unsuitable alternative to routine parenteral administration. 
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Therefore, localising therapeutic IFN to the diseased tissue would hopefully 
decrease the aforementioned side effects. A decrease in off-target binding to 
systemically expressed IFNAR may be potentially achieved by coupling IFN to a 
highly stringent ASGPRdAb. This could be assessed in vivo by perhaps monitoring 
markers of depression during a long term toxicity study, such as the hormones of the 
hypothalamic-pituitary-adrenal axis354 including cortisol levels by the dexamethasone 
suppression test355. Alternatively, subjective assessments of behaviour could be 
performed such as measures of appetite, lethargy or stress356.  
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1.6 HEPATOCELLULAR CARCINOMA 
1.6.1 HCC Overview 
The chosen model for testing the hypothesis in this investigation is a HCC 
xenograft model, specifically a subset of cells expressing ASGPR and IFNAR. Thus 
HCC is good choice for a cancer model to analyse specific xenograft tissue targeting 
by hIFN-ASGPRdAbs. Also, investigating the targeting hypothesis may also 
demonstrate a quantifiable anti-tumour effect. Therefore, it is useful to put HCC in 
context, even though this investigation is not tasked with creating a HCC 
therapeutic.  
In 2012 14.1 million people were diagnosed with cancer worldwide, with 8.2 
million succumbing to the disease357. Liver cancer was the second highest cause of 
mortality accounting for 9.1% of the total deaths. Prognosis for liver cancer is poor, 
with a 95% mortality rate. The predominating liver cancer is HCC with a 3-5% 
incidence rate of HCC development in cirrhosis patients observed globally358. The 
underlying cirrhosis is often caused by alcohol abuse, chronic hepatitis, diabetes and 
potentially cigarette smoke359, linked to patient genotype. HCC is most prevalent in 
Eastern Asia and Sub-Saharan Africa. The underlying cause has been mooted as 
ingestion of mouldy grains, whereby exposure to hepatocarcinogenic aflatoxins 
exacerbates the carcinogenic effects of an underlying hepatitis infection360. 
There are presently no unequivocal treatments for HCC. Sofranib has been 
approved by the FDA as a treatment for HCC, but it has been rejected by United 
Kingdom regulators for its lack of cost effectiveness, as the average patient life 
expectancy is increased by only 6 months. The dire lack of treatments is highlighted 
by the use of herbal remedies in Eastern Asia361. IFN has been widely researched as a 
therapeutic for HCC and the frequently underlying hepatitis but has been restricted 
by its inhibitory side effects (Section 1.5.5).  
Therefore investigation of a targeted IFN treatment in the form of an IFN-
ASGPRdAb fusion could be a useful addition to the field where new treatments are 
desperately needed. This however is a secondary consideration in this investigation. 
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1.6.2 HepG2 HCC Model Cell Line 
The most studied cell lines for endogenous ASGPR activity have been rat 
hepatocytes or human HepG2 cell lines. The HCC epithelial cell line HepG2 
(Figure1.5) was immortalised from a 15-year-old adolescent human male362. Under 
the correct conditions they will form sub-cutaneous xenograft tumours in an 
immuno-compromised mouse363 and are frequently utilised to model HCC in vivo. 
ASGPR is known to be expressed on the cell surface of the HepG2 cell line364. 
Therefore, HepG2 cells present themselves as the appropriate cell line for inducing 
ASGPR expressing xenografts.  
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1.7 RADIOCHEMISTRY 
1.7.1 Positron Emission Tomography 
Non-invasively imaging the biodistribution of a radiolabelled molecule (a 
radioligand) in vivo at the molecular level facilitates an invaluable insight into the 
biochemical properties of the molecule and biological mechanisms within an 
organism. PET is a molecular imaging modality that exploits a radioisotopic subset 
with unique positron emission decay characteristics to trace a radioligand’s 
biodistribution. Acquired three-dimensional (3D) spatial data is utilised to construct a 
3D image of radioligand biodistribution.  
PET is a highly sensitive imaging modality, which is derived from capturing a 
high proportion of decay events within the scope of the scanner, and thus the derived 
signal is directly proportional to the radioactivity present. This facilitates an 
extrapolation to the molar concentration of the ligand or target, within 3D space, 
through compartmental modelling. Current microPET scanners have a resolution of 
1.2mm. Hence, the biophysical parameters of the radioligand can be calculated.  
PET utilises the radioactive beta decay properties of radioisotopes that 
undergo weak force mediated nuclear transmutation, involving a proton decaying to 
a neutron. Specifically, beta positive decay whereby a positron (ß+), the anti-particle 
to an electron365, along with a negative neutrino (√), are emitted from the atomic 
nucleus. For example, the radioactive isotope Ga-68: 
 
68Ga à  68Zn + ß+ + √  
 
A positron is emitted with kinetic energy equating to a proportion of an 
observed maximum endpoint energy (Emax). In vivo, as the positron encounters local 
proton rich tissue, the repulsive forces result in the positron’s emission vector being 
erratic. These repulsive nuclear interactions dissipate the positron’s kinetic energy 
and the positron is attracted to an electron. The positron and electron interact to 
form a very short-lived (1x10-7s) non-nuclear ‘element’ known as a positronium366. As 
the electron and positron combine, the positronium annihilates and the mass is 
converted into gamma (γ) photon radiation. The total energy of the annihilation can 
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be calculated using the principles of mass-energy equivalence dictated in Einstein’s 
Theory of Special Relativity: 
  
E  = mc2   
= mec2 + mpc2  
 = (9.11x10-31 x (3.00x108)2) x 2 
 = 1.64x10-13 J 
 = 1.022 MeV (3dp) 
 
The momentum of the positronium at annihilation is close to zero, therefore 
conservation of momentum dictates that the energy is emitted simultaneously in 
coincidence as anti-parallel γ photons. Hence the energy of each γ photon is thus 511 
keV (to 3 significant figures). This emission energy is constant for all positron-
emitting radioisotopes and is independent of the positron Emax. Higher order 
annihilations such as four emissions at right angles occur in only 0.003% of 
annihilations 
The γ photons from a positron annihilation event can traverse biological 
tissues and air to impinge on the scintillation medium of photomultiplier tubes 
(PMTs), positioned within a cylindrical PET scanner to detect both of the anti-
parallel 511keV γ photons. The co-linearity of the detected γ photons allows the use 
of electronic collimation to determine the line of coincidence, along which the loci of 
the annihilation events can be predicted within 3D space. For instance, Filtered Back 
Projection, Expectation Maximised Algorithms or Ordered Subset Expectation 
Maximisation (OSEM) computed tomographic calculations assimilate the 
coincidence data to quantitatively iterate the total radioactivity along the lines of 
coincidence between detector pairs into cross sectional two dimensional (2D) images. 
The data is collectively reconstituted into 3D pixels, known as voxels, which are 
assigned an intensity value relative to the detected radioactivity present at the 
represented locus within the tissue, and thus a 3D image of radiotracer 
biodistribution is attained.  
‘Time of flight’ modelling can also predict the locus of the annihilation event 
along the line of coincidence by measuring the difference in detection time of the γ 
photons. This ‘time of flight’ method, however, can yield poor resolutions due to the 
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lack of technology capable of measuring the necessary picosecond differentials. For 
instance, an accuracy to within 300ps would only equate to a resolution of ~4.5cm. 
The significant gains in sensitivity provided by PET through not excluding 
decay events from detection, compared to for example Single Photon Emission 
Computed Tomography (SPECT) (Section 1.7.1.2), results in a necessity to correct 
for unwanted detected events such as random decay events or scattered γ photons. 
Also corrections must be made for the decreased PMT sensitivity with the varying 
angles of incidence and the dead-time increase from the volume of detected events. 
Furthermore, there is a need to correct for tissue attenuation of the γ photons 
to correct for decay in deeper tissues. Another error is due to non-colinearity, 
whereby the small momentum of the positronium causes a small deviation from 180° 
by ±0.25°. Moreover, the annihilation point is utilised as an approximation for the 
location of the β+-emitting radioisotope, and thus the attached ligand, as the two 
points are relatively very close367. Error in this approximation is related to the Emax, 
as the higher the energy, the further the positron is likely to travel before 
annihilation. However, the current detector technologies do not have sufficient 
resolution for these differences to be significant, and can be broadly corrected within 
the reconstruction algorithms. 
 
1.7.1.1 PET-CT 
PET is utilised in unison with a tissue imaging modality, such as X-Ray CT 
scanning (PET-CT). CT images are derived from the differential tissue absorption of 
X-Rays, which are detected in cross sections for interpretation and reconstruction 
into 3D image utilising computerised attenuation algorithms. Therefore, CT images 
hyperdense tissues rich in heavy atoms appear white on scans. For example, dense 
bones appear very prominently (3000 Houndsfield Units (HU)), as do dense carbon-
rich tumours. Hypodense soft water (~0HU) rich tissues are poorly imaged and 
appear black. Therefore, PET-CT multimodality approach delivers morphological 
data to spatially position PET data relative to hyperdense tissues. 
The poor soft tissue contrast prejudices CT against accurate anatomical 
positioning of PET data to a specific tissue type. Magnetic Resonance Imaging (MRI) 
scanning offers higher contrast resolution and thus tissue discrimination. MRI utilises 
a strong magnetic field to manipulate the spin of hydrogen atoms’ proton nuclei in 
the imaged tissues368, systematically altering their magnetic alignment with radio 
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pulses at the Lamor frequency369. As the nuclei realign to their thermodynamically 
stable spin they emit at a detectable radiofrequency. Stacking of the 2D isotropic 
resolution images, and defining the threshold of penetration, allows subsequent 
compilation into a high-resolution anatomical image. There is the additional option 
of acquiring functional MRI to attain blood flow data or magnetic resonance 
spectroscopy spectrums to ascertain the metabolite composition within the tissues. 
Therefore, PET-MRI would overcome some of the drawbacks of PET-CT and 
provide additional imaging options370. 
Nonetheless, although progress is continually being made towards a robust 
PET-MRI machine371, MRI is presently expensive and requires long acquisition 
times to produce high-resolution images. Moreover, its combination with PET is a 
troublesome exercise in engineering as traditional PET PMTs are extremely sensitive 
to magnetic fields372, and MRI is incompatible with the metal components of the 
PET imager, thus impractical levels of shielding are necessary. However, there are 
efforts to develop PET-MRI with components that do not interfere with the imaging 
of either system. This could be solved with sequential imaging and computerised 
image reconstruction, although this would potentially decrease the imaging accuracy 
due to decay correction and imperfect image alignments from subject movement. A 
simultaneous acquisition would be more beneficial with initial attempts utilising fibre 
optics to carry scintillation light outside the MRI shielding for detection373; however, 
this diminishes resolution and field of view. A more effective solution is the use of 
silicon based avalanche photodiodes (APD), which are not magnet sensitive. By 
inserting an APD PET into an existing MRI, in vivo functional PET data plus 
morphological MRI data was acquired374. The MRI even provided tumour 
morphological indications, such as inflammation. Nonetheless the system was 
affected by temperature fluctuations, space restrictions, and an inability to neither 
instigate attenuation correction utilising MRI data nor scatter correction. Hence, 
owing to the outlined challenges there is yet to be a commercially available pre-
clinical isochronous fully integrated PET-MRI. It is however possible to acquire 
separate image data and stitch the images back together using appropriate 
software375. This tissue targeting study would benefit from the additional tissue 
uptake discretion offered by MRI, however a xenograft is relatively hyperdense so 
will be visible using conventional CT.  
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1.7.1.2 SPECT Imaging  
There is presently a debate about the relative merits of PET versus 
SPECT376-378. SPECT captures γ photon and X-ray emissions from electron capture 
(EC), via lead collimators, with a ring of detectors. The collimator allows precise 
directional sourcing of a decay event emission to within 1mm resolution after 
computed tomography of all detected events, whereas PET can achieve 1.2mm with 
tight scintillation crystal densities. However, the collimator precludes the detection of 
99.9% of decay events, and thus the sensitivity is over 100x less than for PET. In 
order to compensate for SPECT’s reduced sensitivity, image acquisition times must 
be extended and a higher radioactive dose injected.  
SPECT radioisotopes can emit photons at a variety of energies, therefore 
multiple radioisotopes can be employed within the same host and the individual 
biodistribution of their attached ligands be discriminated. On the other hand, as all 
positron decay annihilation events emit at an energy of 511keV, PET cannot discern 
between different radioisotopes and thus only one radioligand can be employed per 
scan. However, there is no requirement for detecting multiple ligands in this study, 
only whole tissue targeting. SPECT would be a viable alternative to PET but for this 
investigation Ga-68 will be utilised and so the comparison is academic.  
 
1.7.2 Gallium-68 as a Radiopharmaceutical 
The post-transition metal 31Ga stably exists as 69Ga and 71Ga. Ga has an 
electronic configuration 3d10 4s2 4p1, existing in the +3 oxidation state Ga(III)379. Ga 
is classified as a ‘hard’ metal and thus coordinates stably predominantly with oxygen 
and nitrogen electron donors forming a spherically symmetrical tripositive cation 
arrangement. Ga is not a biologically essential metal as ferric iron Fe(III) has very 
similar chemistry and is more abundantly available in the natural environment380. 
A radioisotope of 31Ga is 68Ga. 68Ga decays to 68Zn with the emission of a 
positron and a neutrino (Section 1.7.1), of which positrons comprise 89% of 68Ga 
nuclear decay emissions. This high abundance of positron emissions enables the use 
of 68Ga in quantitative PET imaging. 68Ga’s half-life is 67.71min, which provides a 
useful tracer window of approximately 4.5hours (depending on dosage)381. 68Ga’s 
positron emission Emax is 1.90MeV. The short half-life and relatively high Emax are 
68Ga’s primary drawbacks, as this precludes studying long time points and decreases 
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resolution in preclinical imaging respectively. However, 68Ga is well suited for 
studying biomolecules with rapid pharmacokinetics such as in preclinical imaging, 
and minimising patient radiation burden in the clinic382,383.  
68Ga was first utilised for clinical positron scintillation imaging of the brain 
through complexation by ethylenediaminetetraacetic acid (EDTA)384. 68Ga today is 
increasingly being utilised for PET imaging through conjugation to biomolecules, as 
68Ga is readily attained from a germanium-68 (68Ge)/68Ga generator (Section 1.7.3) 
for immediate experimentation. A primary goal of some within the field is to develop 
pharmaceutical agents which can be utilised for both diagnoses through molecular 
imaging but similarly utilise this targeting to deliver a therapeutic radioactive dose. 
This is achieved by exchanging the PET radionuclide for a β- emitter, such as 
Yttrium-90 (90Y) or Lutetium-177 (177Lu). The diagnostic data from PET, including 
target quantification, can be utilised to determine patient dosimetry for therapeutic 
isotopes.  This combination of the diagnostic and therapeutic has been coined 
‘Theranostics’345. This is particularly prevalent with small peptide imaging agents.  
 Indeed the most developed usage of 68Ga labelling is for small peptide 
molecular probes. For instance, the somatostatin analogous octreotide derivatives 
68Ga-DOTA-[Tyr3]-octreotide (68Ga-DOTA-TOC), 68Ga-DOTA-[Nal3]-octreotide 
(68Ga-DOTA-NOC) and 68Ga-DOTA-[DPhe1]-[Tyr3]-octreotide (68Ga-DOTA-
TATE) target overexpressed somatostatin receptors for octreoscan scintigraphic 
diagnostic imaging of neuroendocrine tumours385-388, in addition to therapeutic β-
emitter 90Y or 177Lu therapeutic dose delivery389-391. Moreover, there is research with 
labelled RGD based peptides for targeting cancer αvβ3 vitronectin receptor integrins 
for angiogenesis in ischemic tissues392-394.  
Radioimmunoconjugates have been researched for over 50 years, either 
pretargeting cancers395-397 or direct targeting of coupled radionuclides398 for 
radioimmunodetection or radioimmunotherapy. The use of bsmAbs (Section 1.3.1) 
for 68Ga imaging, involving affinity for a cancer marker and 68Ga labelled hapten, 
has been investigated to improve tumour contrast versus conventionally directly 
labelled antibody derivatives399,400. This is achieved by chase blocking all circulatory 
hapten binding sites before administering the 68Ga-hapten, which binds the pre-
administered tumour localised bsmAbs, thus giving a low background signal401. 
Affibodies (Section 1.3.1) have been extensively labelled, including for PET 
18F imaging129,130, demonstrating that small antibody fragments can be successfully 
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utilised for PET imaging. DOTA (Section 1.7.4) conjugated anti-HER2 affibodies 
labelled with 68Ga were shown to have high tissue retention in HER2-positive 
xenografts, in addition to a high tumour-to-blood/organ ratio post injection due to 
rapid renal clearance of circulating labelled affibodies127. This was in comparison to 
111In labelled affibodies which demonstrated poorer pharmacokinetic properties. 
However, the main precedent comparable to this investigation involves 
nanobodies (Section 1.3.1). NOTA conjugated (Section 1.7.4.1) α-HER2 nanobodies 
were successfully 68Ga labelled for non-invasive detection of HER2-positive breast 
cancers118. A 4% injected dose per gram (%ID/g) uptake was observed versus 
0.26%ID/g in HER2-negative cells, and good molecular stability. 
Hence these examples demonstrate 68Ga is likely an effective labelling strategy 
in vivo for an IFN-dAb fusion. 
 
Nevertheless, 68Ga usage has some associated issues. A Ga(III) ion is a redox-
inert ‘hard’ metal acid (Ered = -0.6) and so under acidic conditions is stable as a free 
hydrated ion with a pKa of 2.6380,402. Hence, when eluted from a generator with 0.1M 
HCl, 68Ga will exist as free hydrated ions.  However, with increasing pH above 
pH3.0 Ga(III) will begin to form insoluble amphoteric hydroxy complexes that 
redissolve to gallate Ga(OH)4- ions, known as 68Ga-Colloid. Once added to a 
chelation reaction mixture and exposed to free hydroxy ions at a higher pH, the 
gallate ion formation will preclude high labelling efficiencies. A low pH alone is not 
sufficient to prevent hydrolysis, however403. Therefore a high kinetic rate multi-
dentate chelator, combined with a low pH, should minimise 68Ga hydrolysis by 
biasing the equilibrium away from hydrolysis (Section 1.7.4). An alternative is to use 
a ligand-exchange reaction using a low affinity but rapidly binding chelator, such as 
citrate, but this is time consuming for an isotope with a 68min half-life. 
Another possible problem in vivo concerns transferrin, whose natural 
biological ligand is Fe(III). Transferrin is the blood plasma glycoprotein responsible 
for controlling free Fe(III) levels in biological fluids. Before undergoing transferrin-
receptor mediated endocytotic internalisation, transferrin sequesters two Fe(III) ions. 
An intra-vesicle increase in H+ ion concentration facilitates release of the Fe(III) ions 
into the cytoplasm. The highly similar inorganic properties of Fe(III) to Ga(III), such 
as charge density, mean that transferrin also has a high affinity for Ga(III) . Indeed 
transferrin’s affinity for Ga and mechanism for removal is the basis of 67Ga scanning 
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and 68Ga-citrate infection site imaging. Therefore, in vivo a chelator must offer greater 
thermodynamic stability than transferrin in order to prevent transchelation and thus 
loss of radiolabelling.  
Moreover, unlike the use of covalently bonded 18F or an imaging agent fused 
in the protein structure404, 68Ga must be chelated to the protein. This can result in a 
stoichiometry greater than one to one thus potentially making subsequent 
quantitation less robust (Section 1.7.4.1). 
Thus, the favoured predisposition to Ga hydrolysis, and in vivo transchelation 
to transferrin, necessitates a chelator with more favourable thermodynamic 
properties, for example NOTA (Section 1.7.4.1).  
  
1.7.2.1 Alternative Ga Radioisotopes and Positron Emitters 
There are several Ga radioisotopes, of which three are important to Nuclear 
Medicine: 66Ga, 67Ga and 68Ga. 66Ga and 67Ga are both produced from 
bombardment of Zn or copper (Cu) in a cyclotron. 66Ga’s half-life of 9.5 hours makes 
it an attractive radioactive label for long-lived biomolecules. Various circulatory 
proteins have been labelled with 66Ga but it provides poor spatial resolutions when 
imaged due to its high-energy positron (4.15 MeV) and an undesirable subject 
radiation dosage owing to 4.0 MeV gamma emissions. Moreover, the necessary 
cation exchange chromatography purification step can actually introduce numerous 
metal impurities405. Hence, 66Ga is not appropriate for this study quantitatively 
imaging a small biomolecule. 
On the other hand, 67Ga has been widely utilised as a 67Ga-citrate or 67Ga-
nitrate radiotracer for Gallium Scanning whereby inflammation marking is used as a 
proxy for tumour staging. Indeed 67Ga was for a long time the gold standard for 
cancer detection but has since been superseded by fluorodeoxyglucose (FDG)-
PET406. FDG is a glucose uptake quantification imaging strategy exploiting increased 
tumour metabolism. A Gamma Camera or SPECT imaging visualises 67Ga 
distribution by its EC decay emissions. 67Ga’s emissions are over a range of energies 
(93.3keV, 184.6keV, and 0.2keV) bestowing 67Ga with a highly detectable emission 
profile. Despite being a very feasible isotope for this study, as PET is the preferred 
imaging system, 67Ga could be a viable alternative if required.  
The alternative positron emitting isotopes to 68Ga include 18F, which has a 
slightly longer half-life of 109.8min. Hence, this would provide more experimentation 
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time with a higher activity by comparison to 68Ga. Moreover, 18F has a smaller Emax 
of 0.63MeV and thus would provide higher resolution (tissue range ~0.3mm vs. 
~1mm for 68Ga), in addition to 97% decay by positron emission providing a higher 
initial activity from source. However, the source of 18F is a cyclotron and must be 
specially created to order from an oxygen-18 target, compared with the convenience 
of a 68Ga generator407. The 18F must also be covalently bonded to the protein which 
adds additional complex reaction steps. 
Another alternative is incorporating the positron emitting isotopes carbon-11, 
nitrogen-13 and oxygen-15 directly into the structure of the entity one wishes to 
study for PET imaging408-410. This reduces the uncertainty regarding whether 
detected radiation is still attached to the entity of interest, rather than existing as free 
entities through endogenous proteolytic cleavage events, as may be the case with 
chelated isotopes for instance. However, these must also be produced in a cyclotron 
and instantly be utilised in the synthesis reaction, thus precluding these isotopes as 
practical for a protein labelling application despite recent progress in microfluidic 
reactors411. 
Iodine-124 (124I) and Zirconium-89 (89Zr) are additional alternatives412,413. 
They have relatively long half-lives of 4.17 days and 3.27 days respectively, which 
would allow a longer imaging strategy to be performed, and this has made them 
popular for labelling mAbs. Their Emax is high which would likely decrease 
resolution, and most importantly only 23% of decay is by positron emission and so a 
lot of activity is required to compensate for the lower signal this causes. 89Zr must be 
produced in a cyclotron and its chelation chemistry is still unproven414, so it has its 
drawbacks, even though it has been utilised to create an imaging agent through 
labelling anti-EGFR nanobodies with a deferoxamine chelator113. 64Cu also has 
positron emissions415,416, and has been used previously to label cetuximab417, but it 
emits beta-particles which are cytotoxic thus potentially introducing an unwanted 
variable, and has an unfavourable redox potential. Therefore, if 68Ga is utilised in 
efficient protocols, to negate the downsides of its relatively short half-life, then it is 
preferable to 18F, 124I, 89Zr and 64Cu for chelation-based labelling.  
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1.7.3 PET Isotope Generators 
Generators offer the convenience of providing on-demand high-activity 
radioisotopes for instant radiopharmaceutical synthesis, and are often mooted as the 
way forward for nuclear medicine in the clinic418. An effective generator must 
provide radiochemically pure daughter radionuclides effectively separated from the 
decayed parent radionuclide. The Molybdenum-99/Technetium-99m (99mTc) 
generator provided the radiation source for approximately 80% of all nuclear 
medicine applications in the first decade of this century. It provided convenient 
access to the 99mTc SPECT isotope, but most importantly was good manufacturing 
practice approved and in reliable kit-friendly form, thus allowing extensive use in 
humans419.  
68Ga can be generated in situ from a 68Ge source based generator, rather than 
relying on a cyclotron418. 68Ge decays by EC with a half-life of 270.95 days, to evolve 
68Ga(III) ions. The principle has been in existence since the 1960s with the first 
68Ge/68Ga ‘Cows’ ‘milked’ for 68Ga-EDTA, but this required a laborious process to 
achieve free 68Ga(III) ions for further experimentation420,421. 
Modern commercially available generators, such as the Eckert & Ziegler 
IG100 (Figure 1.6) or Cyclotron Co Obninsk, adsorb the 68Ge onto an inorganic 
matrix resin of TiO2, and 68Ga(III) can be eluted with 0.1M HCl. Alternatives are 
the SnO2 based IDB Holland iThemba or the organic silica matrix ITG generator, 
which requires only weak acid elution. Elution is routinely followed by microfluidic 
anionic422,423 or cationic424,425 chromatography exchange columns to remove any free 
metal contaminants and increase the activity per unit volume128, which can improve 
labelling efficiencies426 and specific activity in order of 1GBq/nmol. However in 
some instances yields can be compromised and imaging time wasted, even with 
automation427.  
 
There are at least seven potential parent/daughter PET radionuclide 
combinations other than 68Ge/68Ga428, however most are undeveloped due to 
daughter radionuclides with very short half-lives in the order of minutes which are 
only relevant for perfusion studies. Labelling of pharmaceuticals with these isotopes 
would be inappropriate, as the life of the radioactivity does not reflect that of the 
drug.  
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Figure 1.5 – 68Ge/68Ga 
Generator IG100 
Image of the IGG100 gallium-68 generator 
for in situ production from the contained 
Germanium-68 core. 
 
http://www.icmedical.eu/pet-
imaging/eckert-ziegler 
Rubidium-82 (82Rb) is a commercially available generator-produced PET 
radioisotope, derived from parent isotope Strontium-82, and has proven clinical 
applications429. However, 82Rb’s 1.2min half-life restricts its usage to rapid low-dose 
imaging such as myocardial perfusion PET imaging.  
A titanium-44 (44Ti)/scandium-44 (44Sc) generator system would produce the 
PET isotope 44Sc, with t1/2 3.93h and 94% β+ emission430, presents a potentially 
superior PET imaging agent by comparison to 68Ga in contexts where a longer 
physical half-life is necessitated431,432. However this generator is not commercially 
available due to radiochemical challenges with 45Sc(p,2n)44Ti production. Hence, 
68Ga is alone as an efficient commercially available generator derived PET imaging 
radioisotope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However generators are not devoid of drawbacks. There is the possibility for 
parent isotope such as 68Ge breakthrough into the eluate, in addition to any 
contaminating metal impurities. Contamination can be reduced by regular generator 
usage and purging consumables and glassware with HCl. As the generator’s parent 
isotope decays, yield activity concentrations decrease. Experimental time points are 
restricted by the necessity to allow the generators to re-generate. The necessity for 
HCl elution produces an eluate at pH1.0, which must be buffered to prevent 
I – Introduction 
Alex G. Papple - 65 - Ph.D. 2014 
degradation of a protein ligand. Radioactivity is eluted in a relatively large volume, 
which can impact on specific activity. Nevertheless, these negative points are however 
outweighed by the outlined benefits. Also the IG100 generator is noted for its low 
68Ge breakthrough and the ITG for its >90% yields within the first 200days.  
The alternative means of isotope production is in a cyclotron, an 
electromagnetic particle accelerator that manipulates charged particles to hit target 
nuclei at high energies of approximately 10s MeV and collects the resultant products 
of the collision. The process is reliable and can produce numerous radioactive 
isotopes merely by changing the target nuclei. However, potential contamination 
sources, especially when utilising aqueous targets, include metals from the target 
body cooling housing and these can preclude efficient labelling yields in downstream 
reactions. However, niobium usage has forgone this problem to an extent433. 
Cyclotrons are limited to specialist institutions, which are few in number, and 
therefore their availability is significantly restricted. Moreover the costs are very high. 
Hence, the relatively simple 68Ga generator is preferential434. 
 
1.7.4 Chelators 
Trivalent radioisotope cations such as 68Ga(III) do not ordinarily strongly 
interact with a protein structure and the protein must be chemically altered to allow 
radioisotope chelation. This is achieved by first bioconjugating a specifically designed 
chelating agent to the protein before the addition of the isotope to promote a 
thermodynamically stable interaction, thus creating the radioligand. 
When selecting a chelating agent one must consider numerous factors. Firstly, 
and most importantly, the agent must have a strong interaction to the radionuclide 
even within the biological ionic environment of the host. The chelator-radionuclide 
complex must be kinetically inert in vivo. Free isotopes may give potentially false 
positive results and a high background. Furthermore, the conjugation of the chelator 
with the protein must not affect the others’ ability to function whether sterically or 
chemically. Each radioisotope requires a specialist chelator whose structure reflects 
the coordination chemistry required to maximise thermodynamic chelation stability. 
Chelator properties are inherent to their structure. Acyclic chelators have fast 
metal binding rates due to their open structure435, which is an advantage when 
utilising short-lived radioisotopes, however this is at the expense of kinetic inertness. 
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Macrocyclic chelators are comparably more stable and resistant to transchelation436. 
It is difficult to predict in vivo stabilities in vitro437 although good indications can be 
obtained from a serum stability assay for instance, but only in vivo performance data 
provides the necessary elucidation.  
 
68Ga(III) will strongly bind to a chelator featuring multiple anionic pendant 
arm oxygen donors due to 68Ga(III) being a hard acidic cation (Section 1.7.2). 
68Ga(III) also has a good affinity for thiolates, such as in N,N’-Ethylenedi-L-
cysteine438 and 1,4,7-tris(2-mercaptoethyl)-1,4,7-triazacyclononane (TACN-TM). A 
successful 68Ga(III) chelator must prevent transchelation with the biological iron 
transporter transferrin. Therefore, a macrocyclic chelator will be most appropriate 
for 68Ga chelation.  
68Ga(III) has a maximum coordination number of 6, which preferably 
involves a distorted octahedral geometry in a macrocyclic structure for maximum 
stability, but tetradentate chelators do exist. There are many chelator complexes 
identified for usage with 68Ga(III). EDTA is a highly effective metal chelator with a 
stability constant (KML) of 21.0 for Ga(III)439 but it is acyclic.  Diethylene triamine 
pentaacetic acid (DTPA) derivatives (KML = ~26) and N,N’-bis(2-hydroxybenzyl)-
ethylenediamine-N,N’-diacetic acid  (HBED) derivatives  (KML = ~38) have been 
utilised to successfully label mAbs and antibody fragments440,441. HBED’s high 
stability 68Ga(III) chelation allows high specific activities to be achieved at ambient 
temperatures. A similar chelator named CP256 can achieve over double the 
radiolabelling efficiency of HBED442. Similarly, 6,9,15-tetraazabicyclopentadeca-
1(15),11,13-triene-3,6,9-triacetic acid (PCTA) can be 68Ga-labelled to 99% within 
5min at room temperature, although this decreased temporally post-conjugation443. 
Triazacyclononane-phosphinic acid (TRAP) chelator has been shown to incorporate 
68Ga(III) with ligand concentrations as low as 0.1μM with >90% efficiency at 
25°C444, which is the highest published efficiency achieved at the time of writing. 
However, these highly efficient chelators are not currently commercially available.  
 
DOTA is the current ‘gold standard’ for 68Ga labelling of small peptides due 
to the long in vivo stability of peptide conjugates and reliable chemistry. DOTA 
conjugation has been exhaustively investigated for somatostatin analogues (Section 
1.7.2) in addition to gastrin receptor substrates445 and glucagon-like peptide 1 
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receptor446. However DOTA’s large macrocyclic cavity size can create poor 
thermodynamic stability and potential non-selectivity under the wrong conditions. 
Moreover, the hexadentate coordination can leave a deprotonated carboxylate group 
at physiological pH, which can lead to rapid kidney clearance447.  
In relation to dAbs, however, DOTA has a major drawback. DOTA requires 
a high temperature (~100°C) to rapidly chelate 68Ga or extended incubation time at 
lower temperatures due to DOTA’s slow complexing kinetics, therefore precluding its 
use to rapidly label heat labile proteins such as a dAb. Furthermore, these DOTA 
properties are not conducive to 68Ga’s 67.71min half-life and optimum imaging 
radioactivity. For example, for EGFR-targeted scFv and 50kDa diabodies, HBED 
was preferred440. DOTA labelling has been performed at 37°C for conjugated 
antibody fragments443,448,449, but this necessitated additional purification steps, 20min 
reaction time and high pHs, which is detrimental to effective 68Ga labelling. 
 
NOTA, or a derivative thereof, has been utilised previously for the labelling 
of the octreotide small peptides and RGD peptides in place of DOTA. NOTA is 
itself a derivative of TACN with an additional tris-acetate pendant arm450. NOTA 
envelops its chelated metal atom in the macrocyclic cavity through a N3O3 distorted 
octahedral conformation451-453 as deciphered by X-ray crystallography (Figure 1.7). 
This conformation confers a Ga(III) chelating stability constant of 31.0454, affording 
inertness in nitric acid for up to 6 months for instance453, with the pendant 
carboxymethyl arms providing transchelation protection from nucleophilic attack on 
the Ga(III). NOTA derivatives possess modified pendant groups, which allows 
influence over final charge or peptide conjugation (Section 1.7.4.1).   
NOTA's primary advantage over its commercially available chelation peers is 
the favourable reaction conditions in which it can be radio labelled with 68Ga(III). If 
the half-life of 68Ga is not to be restrictive the reaction must be quick (Section 1.7.2), 
and at low pH to inhibit the formation of 68Ga-colloid. NOTA can be successfully 
labelled within 10min at an optimum pH3.5381 which meets the desired criteria. The 
published data does not provide details of specific activities achieved, instead 
focussing on labelling efficiencies, which is a misleading measure as it does not take 
into account the amount of protein present in the assay; although greater than 
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Figure 1.6 – NOTA Chelating a 
Gallium atom 
Cartoon representation of the chelation of a 
Ga3+ ion by NOTA in a distorted octahedral 
hexadentate formation, as determined by X-
Ray Crystallography.  
 
Wadas, T.J. et al. (2010) 
 
1GBq/nmol has been suggested*. Moreover, the NOTA labelling reaction can be 
performed at room temperature without major loss of labelling efficiency, which is 
perfect for not denaturing a folded protein as was the main issue with DOTA 
labelling. The thermodynamic stability of Ga-NOTA is reported to be ten-fold 
higher than Ga-DOTA454. This initial evidence from the literature and unpublished 
anecdotal NOTA usage from fellow researchers has created a compelling case for 
choosing NOTA as the chelator for labelling the IFN-dAb fusion proteins with Ga-
68.  
 
1.7.4.1 Bifunctional NOTA Derivatives 
NOTA can be chemically bestowed with a variety of reactive cross-linker 
groups to facilitate covalent bioconjugation to a protein. These bifunctional NOTA 
compounds each have unique reactive properties that, in addition to controlled 
reaction conditions, enable NOTA bioconjugation to discrete sites on the protein.  
For instance, an isothiocyanate reactive group can interact with amino acid 
nucleophile groups such as amines of histidine’s imidazolyl nitrogen and arginine’s 
guanidinyl group, a tyrosine phenolic hydroxyl group, or sulphydryl groups on 
cysteine residues455. However, the only reactions yielding stable products are 
akylation reactions with the primary N-terminal α-amines or lysine side chain ε-
amines. Therefore, NOTA with an isothiocyanate reactive group can be 
bioconjugated to proteins specifically through an amine group.  
A commercially available isothiocyanate derivative of NOTA is S-2-(4-
Isothiocyanatobenzyl)-NOTA (SCN-Bn-NOTA). The isothiocyanate group can react 
with α/ε-amines by nucleophilic addition reaction under basic conditions, such as in 
carbonate buffer393,456,457 (Figure 1.8). The alkaline pH yields a reactive unprotonated 
                                                
* Prof. Bengt Långström, personal communication 
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Figure 1.7 – SCN-Bn-NOTA Nucleophilic Addition reaction with 
Lysine  
Diagram representing the nucleophilic substitution reaction of the isothiocyanate group of a SCN-
Bn-NOTA with the ε-amine of a lysine amino acid side chain by nucleophilic addition reaction 
under basic conditions, yielding the NOTA-conjugated protein by a isothiourea bond. 
 
primary amine group, with free electrons able to instigate nucleophilic attack on the 
electrophilic carbon of the isothiocyanate. The electron-rich nitrogen will 
subsequently abstract a proton, creating a covalent isothiourea bond between the 
protein and the Bn-NOTA458.  
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The alkaline pH at which the amine groups become deprotonated varies with 
the pKa range of the group in situ. The pKa of N-terminal α-amines with a pKa range 
7.6-8.0 (also quoted 8.0-9.0) is lower than that of the ε-amine lysine groups with a 
pKa range 9.3-9.5 (also quoted as 9.8-10.4). Based on these values, according to the 
Henderson-Hasselbach equation, pH9.0 reaction conditions will equate to ≥91% of 
α-amines in an unprotonated state compared to <50% ε-amine458. Therefore, 
controlling the pH to bias ionisation of the α-amine groups can promote coupling to 
the protein N-termini, yielding a predominantly singularly bioconjugated protein 
species459. 
However, in reality the microenvironmental influences of the protein 
superstructure on the ionisation potential of the amine groups can cause a decrease in 
the pKa range. For instance, α-lymphocyte monoclonal antibody Lym-1 was 
selectively bioconjugated at the N-terminus at neutral pH7 with ε-amine 
bioconjugation predominating at pH9.0460, and both α- and ε-amine NOTA-
conjugated metabolites of a disulphide-stabilised Fv antibody of could be detected461 
after bioconjugation at pH8.5462. Moreover, the number of lysines available within 
the amino acid sequence, and their polar hydrophilic nature resulting in protein 
surface localisation, can shift the equilibrium towards ε-amine bioconjugation. 
Therefore, the ability to control the conjugation reaction comes with the caveat that 
it is very much protein specific and must be determined experimentally. 
 
The foremost alternative to an isothiocyanate reactive group for stable 
coupling of NOTA primarily with α-/ε-amines is a N-hydroxysuccinimide (NHS) 
ester reactive cross-linker, such as 2,2'-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-
oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NHS-NOTA). The NHS ester 
undergoes a nucleophilic acylation reaction with the unprotonated amine via the 
carbonyl group to form a covalent amide bond between the protein and the NOTA, 
with the NHS being released.  
The chemistry is efficient but using a NHS ester has several drawbacks. Like 
the isothiocyanate reaction, the pH must be elevated to promote efficient amine 
reactivity, and so the same issues with α-/ε-amine specificity will be realised. Even at 
pH7.0 five chelator units per protein can be achieved463. However the more acute 
issue is that NHS esters are very susceptible to hydrolysis464 with increasing pH465 
with the equilibrium shifting towards hydrolysis over amide formation above pH8.5 
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under certain conditions. The half-life could be a matter of minutes at room 
temperature in aqueous solution. Hydroxide ions are more reactive nucleophiles than 
water466, hence the increase in hydrolysis with increasing pH. An isothiocyanate 
group is electrophilic and so is also vulnerable to hydrolysis in aqueous reaction 
conditions because a water molecule or hydroxide ion hydrates the isothiocyanate 
carbon by nucleophilic addition* yielding a thiocarbamic acid derivative of Bn-
NOTA. However, the half-life of SCN-Bn-NOTA is substantially higher than NHS-
NOTA in aqueous conditions. The lability of NHS-NOTA is therefore a major 
drawback to NHS chemistry, and must be overcome by using wasteful 
concentrations of material to improve the reaction kinetics, making SCN-Bn-NOTA 
the most appropriate choice.  
  
                                                
* The nitrogen is oxidised and will abstract a proton from water 
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1.8 CONCLUDING REMARKS 
The evidence from the literature provides a compelling evidence base for 
pursuing the objectives of this investigation (Section 1.1) with Ga-68 radiolabelled, 
NOTA conjugated hIFN-ASGPRdAbs in vivo.  
The properties of dAbs of small size, low immunogenicity, ease of genetic 
manipulation for desired pharmacodynamics, and high target specificity bestow the 
platform with potential for applications as novel antibody molecules. The efficacy of 
the IFN-AlbudAbs for half-life extension and IFN-ASGPRdAb for specific liver 
uptake (Section 1.2.2) demonstrates the potential of the therapeutic dAb fusion 
platform to yield quantifiable efficacy improvements in vivo. The dAb platform fits 
into a well established history of efficacious antibody based therapies (Section 1.3.1) 
and dual targeting of antibody derivatives in combination with biological cytotoxic 
proteins now has precedents for effective xenograft uptake in vivo (Section1.3.2). 
Examples include an anti-EGFR nanobody fused to TRAIL, anti-B-FN scFv-IL12, 
and anti-fibronectin scFv-IFNα. 
ASGPR’s characteristics make it a highly suitable target for localised tissue 
concentration as there are no signalling functions or downstream effectors to 
antagonise (Section 1.4.1 & 1.4.2), it is predominantly expressed in the liver (Section 
1.4.3), in addition to targeting precedents in vivo (Section 1.4.4). There is though a 
caveat that the molecule fate upon binding could influence the targeting result 
(Section 1.4.4.1). 
The hIFN has a discrete interaction with the systemically expressed hIFNAR 
(Section 1.5.2) to initiate a diverse cellular response (Section 1.5.2), priming for a 
potent anti-viral or anti-proliferative phenotype (Section 1.5.3 & 1.5.4). This potency 
comes at a cost as it also results in debilitating side effects due to off-target 
interactions. Hence, it is prime candidate for dAb-mediated localised targeting.  
Ga-68 (Section 1.7.2) labelling of dAb fusions is a novel approach for in vivo 
tracing of the dAb fusion pharmacology. It can be readily produced in situ from a Ge-
68/Ga-68 generator, and emits 89% positrons for effective potential PET-CT 
quantitation (Section 1.7.1.1). The short half-life could be a drawback, but the dAb 
fusions’ expected systemic half-lives are conducive to Ga-68 use. SCN-Bn-NOTA 
(Section 1.7.4.1) presented itself as a conjugation mechanism to reliably synthesise a 
broadly homogenous species of stable NOTA conjugated protein, in mild reaction 
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conditions and without necessitating protein modification. The NOTA is also known 
to stably chelate Ga3+ ions without stringent reaction conditions. SPECT sensitivity is 
low, and PET-MRI is presently unavailable (Section 1.7.1.2); thus in a study 
focussing on the quantitation of tissue uptake, the highly sensitive PET-CT presents 
itself as the optimum imaging modality to quantitatively visualise dAb-fusion receptor 
targeting in vivo. 
 
The chosen model system to build upon this knowledge base is an immuno-
compromised murine HepG2 xenograft model of HCC (Section 1.6.1). Modelling 
targeting in a liver cancer model provides a tissue exhibiting discrete expression of 
ASGPR and IFNAR expression within a full biological system comprising many 
potential non-specific binding sites. Through diligent comparison to control 
molecules, it will be possible to discern specific HCC xenograft tissue targeting 
mediated by ASGPR. Moreover, as a model of human disease, it also allows analysis 
of the activity of the targeting methodology as a therapeutic strategy. 
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2.1 MUTANT FUSION PROTEIN 
EXPRESSION & PURIFICATION 
For the initial pilot study as to whether hIFN-dAbs could target tissue in vivo 
stocks of two HEK293-expressed tool hIFN-dAb fusion proteins were supplied: 
hIFN-MAXdAb and hIFN-CTRLdAb* (as utilised in Chapter III, starting with 
Methods 2.2 onwards). However, a further panel of affinity mutant hIFN-
ASGPRdAbs were required for more detailed analysis of tissue targeting (Chapter 
IV). These latter mutants were chosen to be fusion proteins of hIFN mutants 
hIFN(A), hIFN(C) and hIFN(E) with ASGPRdAb mutants HidAb, MidAb and 
LodAb (Table 4.1). The DNA templates for these individual proteins were supplied 
in holding vectors†. Therefore, it was necessary to clone the sequences and splice 
them together as in line hIFN-ASGPRdAb genetic fusion expression cassettes within 
a mammalian expression pDOM50 vector with subsequent HEK293e expression 
and ÄKTA purification (see Appendix Figures 6.4 & 6.5 for a schematic overview).  
 
2.1.1 Expression Vector Construction 
This section details the construction of the pDOM50-hIFN-ASGPRdAb 
expression vectors, specifically: pDOM50-hIFN(A)-HidAb, pDOM50-hIFN(C)-
HidAb, pDOM50-hIFN(E)-HidAb, pDOM50-hIFN(A)-MidAb, pDOM50-hIFN(C)-
MidAb, pDOM50-hIFN(E)-MidAb, pDOM50-hIFN(A)-LodAb, pDOM50-hIFN(C)-
LodAb, and pDOM50-hIFN(E)-LodAb. 
 
2.1.1.1 PCR Cloning & Amplification of the hIFN Mutants  
High fidelity Pwo‡ PCR reactions were performed for each individual hIFN 
mutant to clone and amplify its sequence from its holding vector. The sense primer 
AGP-P1 (Table 2.1) was complementary to the 5’ end of the hIFN sequences and 
introduce a BamHI restriction site (GGATCC) and the mammalian post-
translational cleavage/excretion leader sequence Threonine-Glycine (ACCGGC) as 
                                                
* Kindly supplied by Dr Adam Walker and Dr Ed Coulstock, GSK. 
† Kindly supplied by Dr Thil Batuwangala and Dr Armin Sepp, GSK. 
‡ Pwo is a proofreading polymerase and so is 18x more accurate than Taq polymerase for DNA <3kb 
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a 5’ overhang. The anti-sense primer AGP-P2 maintained the 3’-end of the hIFN 
sequence. 
The 50μl PCR reaction mixture of 1μl respective hIFN vector DNA (1ng), 1μl 
(2µM final) AGP-P1 primer, 1μl (2µM final) AGP-P2 primer, 25μl Roche Pwo 
MasterMix and 22μl clinical grade water (cgH2O) underwent PCR cycling in a Bio-
Rad DNA Engine Tetrad 2 Peltier Thermal Cycler using the protocol outlined in 
Table 2.2. 
  The temperature decrease between the denature step and anneal step was 
slowed using a cooling gradient of 2.5°C/s. The PCR machine lid temperature 
tracked 5°C above the sample temperature. The amplified DNA was isolated by 
PCR Purification into 50µl cgH2O (Appendix 6.1.3.1) and visualised by DNA gel 
electrophoresis (Appendix 6.1.3.2). 
 
Table 2.2  
Pwo PCR for hIFN Mutant Amplification 
Step Temperature (°C) Time (min:s) # Cycles 
Initial Denaturation 94 2:00 1 
Denature 94 0:30 
30 Anneal 42 0:30 
Extension 72 2:00 
Final Extension 72 10:00 1 
Soak 4 ∞ 1 
Table 2.1  
PCR Primers for hIFN-ASGPRdAb Expression Cassette 
Primer 
Name Primer Sequence* Tm (°C) 
AGP-P1 
(Sense) 
5’-ggatccaccggcTGTGATCTGCCTCAAA-3’ 46 
AGP-P2 
(Anti-Sense) 
5’–TTCCTTACTTCTTAAACT–3’ 46 
AGP-P3 
(Sense) 
5’–gaaagtttaagaagtaaggaaGAGGTGCAGCTGTTGGA–
3’ 54 
AGP-P4 
(Anti-Sense) 
5’-aagcttcattaGCTCGAGACGGTGACC-3’ 54 
AGP-P1s 
(Sense) 
5’-GGATCCTGTGATCTGC-3’ 50 
AGP-P4s 
(Anti-Sense) 
5’-AAGCTTCAGCTCGAGAC-3’ 52 
 *lower case represents overhang DNA 
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2.1.1.2 PCR Cloning & Amplification of the ASGPRdAb Mutants  
High fidelity Pwo PCR reactions were performed for each individual 
ASGPRdAb mutant to clone and amplify its sequence from its holding vector. The 
sense primer AGP-P3 (Table 2.1) was designed to anneal to the 5’ end of the 
ASGPRdAb sequences and introduce a splice overlap extension (SOE) PCR 
overhang complementary to the hIFN mutants’ 3’ sequence. The dAb anti-sense 
primer AGP-P4 (Table 2.1) introduced a double transcriptional stop codon 
(TAATGA) and a HindIII restriction site (AAGCTT).  
The 50μl PCR reaction mixture of 1μl of the respective ASGPRdAb vector 
DNA (1ng), 1μl (2µM final) AGP-P3 primer, 1μl (2µM final) AGP-P4 primer, 25μl 
Roche Pwo MasterMix and 22μl cgH2O underwent PCR cycling in a Bio-Rad DNA 
Engine Tetrad 2 Peltier Thermal Cycler using the protocol outlined in Table 2.3. 
 The temperature decrease between the denature step and anneal step was 
slowed using a cooling gradient of 2.5°C/s. The PCR machine lid temperature 
tracked 5°C above the sample temperature. The amplified DNA was isolated by 
PCR Purification into 50µl cgH2O (Appendix 6.1.3.1) and visualised by DNA gel 
electrophoresis (Appendix 6.1.3.2). 
 
 
 
2.1.1.3 SOE PCR of hIFN-ASGPRdAb Expression Cassette 
The constructs for the required hIFN and ASGPRdAb sequences (Table 4.1) 
were spliced together and amplified by SOE PCR to create the hIFN-ASGPRdAb 
fusion sequences as blunt-ended expression cassettes.  
The 50μl PCR reaction mixture of 1μl (1ng) PCR product encoding the 
respective hIFN mutant, 1μl (1ng) PCR product encoding the respective ASGPRdAb 
mutant with SOE overhang, 25μl Roche Pwo MasterMix, 21μl cgH2O underwent 
Table 2.3  
Pwo PCR for ASGPRdAb Mutant Amplification 
Step Temperature (°C) Time (min:s) # Cycles 
Initial Denaturation 94 2:00 1 
Denature 94 0:30 
30 Anneal* 51 0:30 
Extension 72 2:00 
Final Extension 72 10:00 1 
Soak 4 ∞ 1 
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PCR thermal cycling in a Bio-Rad DNA Engine Tetrad 2 Peltier Thermal Cycler as 
outlined in Table 2.4. After four cycles 1μl (2µM final) sense primer AGP-P1s (Table 
2.1) and 1μl (2µM final) α-sense primer AGP-P4s (Table 2.1) were added. 
The temperature decrease between the denature step and anneal step was 
slowed using a cooling gradient of 2.5°C/s. The PCR machine lid temperature 
tracked 5°C above the sample temperature. The amplified fused DNA sequences 
were isolated by gel extraction purification (Appendix 6.1.3.3) and visualised by DNA 
gel electrophoresis (Appendix 6.1.3.2). 
 
Table 2.4  
SOE Pwo PCR for hIFN-ASGPRdAb Splicing 
Step Temperature (°C) Time (min:s) # Cycles 
Initial Denature 94 2:00 1 
Denature 94 0:30 
4 Anneal 55 0:30 
Extension 72 2:00 
Soak 4 ∞ 1 
***ADD PRIMERS*** 
Denature 94 0:30 
26 Anneal 55 0:30 
Extension 72 2:00 
Final Extension 72 10:00 1 
Soak 4 ∞ 1 
 
 
2.1.1.4 Constructing the Recombinant pDOM50-hIFN-ASGPRdAb 
Expression Vectors 
Each of the hIFN-ASGPRdAb expression cassettes was recombined into the 
expression vector pDOM50, a vector based on pTT5 vector derivative with an N-
terminal Kozak consensus sequence and a murine-derived secretion V-J2-C signal 
sequence (Appendix Figure 6.6). 
Firstly, the Invitrogen Zero Blunt TOPO PCR Cloning Kit was utilised to 
clone all the hIFN-ASGPRdAbs’ blunt end SOE PCR constructs into pCR-Blunt II-
TOPO holding vector for amplification of the hIFN-ASGPRdAb expression 
cassette*. The 6μl reaction mixture consisted of 1μl (25ng) pCR-Blunt, 4μl (4ng) 
                                                
* The covalently attached TOPO isomerases catalyse the direct insertion of the blunt ended hIFN-
ASGPRdAb constructs into the pCR-Blunt vectors. 
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hIFN-ASGPRdAb SOE construct and 1μl Salt Solution. This was incubated at room 
temperature for 10min, before resting on ice. The reaction mix was then utilised 
immediately to transform DH5α E. coli (Appendix 6.1.3.4) with kanamycin selective 
culturing. Colony Taq PCR (Appendix 6.1.3.5) of subsequent cultures utilised the 
insert’s internal annealing sense primer AGP-P1s (1µM final) (Table 4.3) and the 
pCR-Blunt specific anti-sense primer M13R (1µM final) to confirm the correct pCR-
Blunt-hIFN-ASGPRdAb recombination orientation was achieved based on the 
presence of a PCR product as seen by DNA gel electrophoresis (Appendix 6.1.3.2). 
The chosen clones were sequenced using commercial primers M13F & M13R 
(Appendix 6.1.3.6) and any non-recombinant or incorrectly mutated clones were 
excluded and a colony selected for each mutant pCR-Blunt-hIFN-ASGPRdAb 
construct. The selected pCR-Blunt-hIFN-ASGPRdAb recombinant plasmids from 
those colonies were subsequently amplified and purified by DNA MiniPrep 
(kanamycin selection pressure during growth) (Appendix 6.1.3.7). The purified pCR-
Blunt-hIFN-ASGPRdAb plasmids were resolved by DNA gel electrophoresis, the 
concentrations measured by UV spectrophotometry at 260nm and DNA sequencing 
performed.  
A BamHI/HindIII (12.5U) double restriction digest in buffer SuRE/Cut B 
(Appendix 6.1.3.8) was then performed on all the MiniPrep pCR-Blunt-hIFN-dAb 
samples (~2µg) in addition to the pDOM50 vector. The cut constructs and pDOM50 
were purified by gel extraction (Appendix 6.1.3.3).  
T4 DNA ligase recombined the respective pDOM50-hIFN-ASGPRdAb 
expression constructs. A 10μl reaction mix consisted of 1μl (25ng) cut pDOM50 
vector DNA, 5μl (5ng) cut insert DNA, 1μl 10x T4 Ligase Buffer, 2μl ddH2O and 1μl 
New England Biolabs (NEB) T4 DNA Ligase. This was incubated for 10min at room 
temperature, before being immediately used in its entirety to transform DH5α E. coli 
with carbenicillin selective culturing. Colony Taq PCR of subsequent cultures 
utilising the pDOM50 upstream sense primer DT039 AATGACATCCACTTTGC 
(1µM) and the pDOM50 downstream anti-sense primer DT045 
TCAGGTTTAGTTCGTCCGGG (1µM) was performed to confirm recombination 
was achieved by DNA gel electrophoresis. The chosen clones were then sequenced 
using the DT039 and DT045 primers, with any non-recombinant or incorrectly 
mutated clones excluded and a colony selected for each mutant pDOM50-hIFN-
ASGPRdAb construct. These chosen colonies were subsequently used in DNA 
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MiniPrep (carbenicillin selection pressure during growth) to amplify the respective 
pDOM50-hIFN-ASGPRdAb expression vectors. The purified vectors were resolved 
by DNA gel electrophoresis and the concentrations measured by UV 
spectrophotometry at 260nm. As above, the process of DH5α transformation 
followed by Colony Taq PCR and sequencing was used to select a colony for each 
pDOM50-hIFN-ASGPRdAb. These colonies were used to amplify and purify the 
pDOM50-hIFN-ASGPRdAbs by DNA MegaPrep (carbenicillin selection pressure 
during growth) (Appendix 6.1.3.9). The purified pDOM50-hIFN-ASGPRdAb 
plasmids were resolved by DNA gel electrophoresis and the concentrations of a 1:100 
TE dilution sample measured using UV spectrophotometry at 260nm, plus DNA 
sequencing with DT039 and DT045 to confirm full fidelity to the designed 
sequences.  
 
2.1.2 HEK293E hIFN-ASGPRdAb Expression 
A HEK293E mammalian cell expression system was utilised to produce the 
hIFN-ASGPRdAb mutants as recombinant proteins with full post-translational 
modifications* with one preparation for each pDOM50-hIFN-ASGPRdAb.  
HEK293e cells were incubated at 37°C 5% CO2 in 500ml Geneticin-selective 
Gibco 293 Freestyle Expression Medium with 10ml Anti-Shear contained in 
Erlenmeyer flasks with 125rpm horizontal shaking. The cells were grown to a seeding 
density between ~1.75x106 cells/ml and a viability >95% for transfection†.  
Transfection reagent 293Fectin was added to 10ml Opti-MEM media to a 
1.33μl/ml final concentration and incubated at room temperature for 5min. The 
relevant pDOM50-hIFN-ASGPR (50µg) was added to 10ml Opti-MEM and 
incubated at room temperature for 5min. The 293Fectin and plasmid solutions were 
mixed and incubated at room temperature for 30min before addition to the primary 
cell culture. Cells were returned to 125rpm shake incubation 37°C 5% CO2 until 
cellular viability had reached <90% (~5 days). 
To harvest the protein, the cell culture was transferred to a 500ml centrifuge 
tube and centrifuged for 30min at 3600rpm 4°C and the supernatants vacuum 
filtrated with a 500ml Rapid-Flow 0.2µm filter unit.  
                                                
* Graciously performed in my absence by Katy Childerley 
† Cells were not utilised beyond passage 25 
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2.1.3 hIFN-ASGPRdAb Protein Purification by 
ÄKTA HiTrap mAbSelect Xtra Chromatography 
Each batch of hIFN-ASGPRdAb from the panel of nine proteins underwent 
purification using this method.  
All lines and pumps of the ÄKTA Purifier were purged with 6M guanidine 
hydrochloric acid (GuHCl) followed by 20% ethanol (EtOH) by executing the 
SamplePumpPurify protocol. All pump lines were purged of air using a 20ml syringe. 
Lines were primed with 0.1M pH6 sodium acetate (NaAc) and 0.1M pH3.3 NaAc. A 
HiTrap mAb-Select Xtra 5ml column* was installed, taking care not to introduce any 
air bubbles. The column was primed with 4 column volumes (CV) 6M GuHCl 
followed by 4CV 20% EtOH. A column wash with 4CV 0.1M pH6 NaAc completed 
the column priming. A 96-well deep plate was filled with 500µl 1M pH6 NaAc per 
well and loaded onto a FC950 fraction collector. The method parameters, as 
assigned in UNICORN software, included 480ml of protein expression filtered 
supernatant loaded at a 5ml/min flow-rate, followed by 1.5ml fraction collection in 
the 96 well plate with a serpentine elution pattern and an elution gradient of 20CV 
0.1M pH6 NaAc with 0-100% 0.1M pH3.3 NaAc.  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Appendix 6.1.3.10) was performed on 9µl of those wells containing protein eluate, as 
indicated by the UV elution trace, to qualify the amount of protein present as well as 
assess its purity. All fractions with a high concentration of expressed protein were 
pooled and 0.22μm filtered. The final concentration was measured by UV 
spectrophotometry at 280 nm and purity was determined by SDS-PAGE (2µg). 
Fractions were flash frozen using ethanol freezing (Appendix 6.1.3.11) and 
stored at -20°C. 
  
                                                
* 5mg/ml maximum load 
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2.2 NOTA CONJUGATION OF FUSION 
PROTEINS AND IN VITRO FUNCTIONAL 
ANALYSIS 
In order to radiolabel the dAb fusions they were first conjugated with NOTA 
and then their new biophysical and biological in vitro properties characterised, as 
detailed in these methodologies (see Appendix Figure 6.1 for a schematic overview). 
 
2.2.1 NOTA Conjugation & Purification 
2.2.1.1 NOTA Conjugation Reaction 
The hIFN-MAXdAb, hIFN-CTRLdAb and all nine of the hIFN-ASGPRdAb 
mutants (Table 4.2; created in Methods 2.1) were NOTA conjugated.  
All buffers were formulated with TraceSelect reagents. The fusion protein (up 
to 3 ml) was dialysed for ≥16hours at room temperature using a GeBAflex Maxi 
3.5kDa dialysis tube immersed in Chelex-containing 0.05M pH9.2 HCO3- buffer, 
with pH adjustment with TraceSelect 0.1M HCl or additional Chelex. The dialysed 
protein was transferred to a 2ml Lo-Bind tube. The protein concentration was 
measured using UV spectrophotometry at 280 nm to calculate recovery.  
A 10µg/µl solution of Macrocyclics p-SCN-Bn-NOTA was prepared in 
0.05M pH 9.2 HCO3- buffer immediately before addition to the dialysed protein in a 
10:1 NOTA:protein molar ratio. The reaction was incubated at room temperature in 
the dark for ~4 hours with 20rpm rocking, and stored at 4˚C until purification. 
 
2.2.1.2 Protein-A Batch Purification of NOTA Conjugates 
All buffers were formulated with TraceSelect reagents. GE Healthcare 
Protein A Sepharose 4 FastFlow was bedded in a 10ml Bio-Rad Poly-Prep 
chromatography column using 1ml of Protein A sepharose per 5mg of fusion protein 
and equilibrated with 20CV 25mM pH6 NaAc.  
The respective NOTA conjugation reaction mix from Method 2.2.1.1 was 
loaded onto the column and the eluate collected. The eluate was reloaded onto the 
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column ≥5 times to ensure all dAb fusion was captured, as confirmed by SDS-PAGE 
loading 9µl (Appendix 6.1.3.10) and UV spectrophotometry at 280nm. 
The column was washed with 20CV 25mM pH6 NaAc. The flow-through 
was analysed by SDS-PAGE loading 9µl and UV spectrophotometry at 280nm for 
protein breakthrough. 
The column was eluted in 5 fractions of 1CV 25mM pH3.3 NaAc into 
0.02CV 1M pH6 NaAc pre-loaded into 2.0ml polypropylene tubes. Fraction protein 
concentration was measured using UV spectrophotometry at 280 nm and the sample 
purity was analysed by SDS-PAGE (2µg). Free NOTA contamination was also 
determined using 111In labelling (see Section 2.3.3 without the purification step), with 
Ammonia:Methanol (AM) instant Thin Layer Chromatography (iTLC) analysis 
(Section 2.3.4). Fractions were flash frozen using ethanol freezing (Appendix 6.1.3.11) 
and stored at -20°C. 
 
2.2.1.3 Mass Spectrometry of Fusion Proteins 
Samples of the fusion proteins were diluted as required in pH4.5 NaAc to 
0.5mg/ml, in a total volume of 50μl, and transferred into 300μl fused glass insert vials 
with a 9mm Screw Top seal. A Micromass LCT Mass Spectrometer, in conjunction 
with an Agilent 1100 Series High Pressure Liquid Chromatography (HPLC) 
machine, was utilised to analyse samples. Samples were arranged in the auto-sampler 
and the runs controlled by MassLynx software. 
Alternatively, proteins were prepared in the same manner and sent away to 
GSK Analytical Chemistry Services (GSK, Stevenage) for mass spectroscopic protein 
mass fingerprinting analysis. The data was analysed utilising Waters MassLynx Mass 
Spectrometry software. 
 
2.2.2 SPR Kinetic Analysis of the Fusion 
Proteins’ interactions with ASGPR & hIFNAR 
GE Healthcare Biacore SPR was utilised to determine the kinetics of the 
various fusion proteins (with and without NOTA conjugation) with their target 
receptors ASGPR and hIFNAR. The Biacore machines were used based on 
availability with a preference for the Biacore T200. The hIFN-MAXdAb, NOTA-
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hIFN-MAXdAb and NOTA-hIFN-CTRLdAb’s interaction with ASGPR was 
determined on both the Biacore T200 and Biacore 3000, and their interaction with 
hIFNAR on the Biacore 3000. The hIFN-ASGPRdAb mutant’s interaction with 
ASGPR was determined on both the Biacore T200 and Biacore 3000, whereas the 
NOTA-hIFN-ASGPRdAb mutants were analysed only on the Biacore 3000. The 
hIFN-ASGPRdAbs and the NOTA-hIFN-ASGPRdAb mutants’ interactions with 
hIFNAR were determined on the Biacore 3000 only.  
The respective protocols, as described in Methods 2.2.2.1 and 2.2.2.2, were 
performed the same regardless of the sample analytes. 
 
2.2.2.1 Biacore T200 Surface Plasmon Resonance 
Before each new run the Biacore T200 system was desorbed and sanitised 
with the GE Healthcare Biacore Maintenance Kit, and primed with HBS-P+ buffer*.  
A Biacore S-Series CM5 chip coated with approximately 500RU of the 
recombinant ASGPR-H1-CRD ligand† by amine coupling to the carboxymethylated 
dextran surface in pH5.5 NaAc (Appendix 6.1.3.12) was primed with HBS-P+ at a 
flow rate 30μl/min until the baseline RU value stabilised to less than 3 resonance 
units (RU) drift in all flow cells (FC).  
Sample analytes were prepared in a 1:2 serial dilution from 64nM to 0.5nM 
in HBS-P+ buffer from 1μM protein stock solutions in a 96 Square Well Storage 
Plate. The HBS-P+ buffer flow rate was constant at 30μl/min and the chip 
compartment at 25°C (sample bay was cooled to 4°C). Samples were injected in a 
randomised order onto the chip in an association phase totalling 30s, followed by a 
dissociation phase of 300 seconds. Samples were interspersed with HBS-P+ ‘Blank’ 
injections to monitor baseline drift and provide a baseline RU value during analysis 
The chip surface was regenerated by a single 6μl Glycine 2.0 injection, in addition to 
two conditional regeneration repeats to maintain a less than 3 RU baseline drift.  
Results were analysed using BIA Evaluation software and the curves exported 
to Microsoft Office Excel. The chip was stored in HBS-P+ buffer at 4°C. 
 
  
                                                
* This was to remove any EDTA present in the system as this would chelate the Ca2+ ions necessary 
for effective ASGPR function 
† Kindly provided by Peggy Luong and Dr Thil Batuwangala 
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2.2.2.2 Biacore 3000 Surface Plasmon Resonance 
Before each new run the Biacore 3000 system was sanitised and desorbed 
with the GE Healthcare Biacore Maintenance Kit, then rinsed and primed with 
degassed HBS-P+ buffer. 
A Biacore CM5 chip was coated with approximately 500RU of self-made 
recombinant ASGPR-H1-CRD (Appendix 6.1.9.3) and R&D Systems recombinant 
hIFNAR2 by amine coupling to the carboxymethylated dextran surface in pH5.5 
NaAc (Appendix 6.1.3.12) (FC was left blank, whilst FC2 was coated with ASGPR 
and FC3 with hIFNAR2). Before each usage, the CM5 chip was primed with 
degassed HBS-P+ at a flow rate of 30μl/min at 25°C until the baseline RU value 
stabilised to less than 3RU sensogram drift in all flow cells.  
Samples were prepared in serial dilution, normally 1:2 from 250nM to 1nM 
in HBS-P+ buffer from 1μM protein stock solutions in a 96-well round-bottom plate. 
A text file (Appendix 6.1.3.13) was written detailing constant HBS-P+ buffer flow 
rate of 30μl/min, sample injections in ascending concentration order (interspersed 
with HBS-P+ ‘Blank’ injections), an association phase totalling 30s, followed by a 
dissociation phase of 300 seconds and regeneration by two 5μl Glycine 2.0 injections. 
Results were analysed using BIA Evaluation software and exported to 
Microsoft Office Excel. The chip was stored in HBS-P+ buffer at 4°C. 
 
2.2.3 HEK-Blue Reporter Assay for hIFN 
Bioactivity Quantitation  
HEK-Blue cells were cultured to ~70%-80% confluency in a humidified 
incubator at 37°C 5% CO2 (Appendix 6.1.4.1). The weakly adherent cell monolayer 
was gently washed with 10ml PBS, resuspended with the addition of 10ml culture 
medium and pipetted over the cell culture surface to ensure full re-suspension of all 
HEK-Blue cells. The total live cell count was determined by Trypan Blue automated 
counting (Appendix 6.1.4.4), and the cells were pelleted by centrifugation at 1250rpm 
4°C for 5min, and resuspended to a final cell density of 1x106cells/ml in culture 
medium. 
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HEK-Blue cell suspension aliquots of 50µl were pipetted to each relevant well 
of a 96-Well Flat Bottom Cell Culture Plate, for a cell count of 50000 cells per well. 
Cell plates were incubated in a humidified incubator at 37°C 5% CO2 until required. 
Sample proteins were diluted in a 1:3.33/1:3 logarithmic serial dilution of 
1nM to 3fM starting from 300µl 2nM, by a 90μl serial transfer into alternating 210µl 
and 180µl volumes of culture medium with thorough mixing. Sample aliquots of 50μl 
were pipetted in series into the cell culture plate in triplicate. A hIFNα positive 
control row and a culture medium only negative control row were included on each 
plate. Reaction plates were incubated at 37°C 5% CO2 for 16 hours.  
A sachet of QUANTI-Blue reagent was reconstituted in 100ml of ddH2O. 
The reaction culture plates were mirrored into fresh optical flat-bottomed 96 well 
plates by transferring 40μl of all supernatants and 160μl QUANTI-Blue reagent 
added to each well. Plates were developed at room temperature until the hIFNα 1nM 
control well had reached approximately 1.0A colour intensity, as observed on a Bio-
Rad Spectrophotometric Plate Reader at an optical density of 640nm. 
Data was analysed using GraphPad Prism graphical software, with plates 
normalised relative to the hIFNα control for inter-plate comparisons. 
 
2.2.4 FACS Flow Cytometry Assays of hIFN-dAb 
Whole Cell Binding to HepG2 and U937 cells 
Fluorescence-Activated Cell Sorting (FACS) *  was performed on NOTA-
hIFN-MAXdAb, hIFN-MAXdAb, NOTA-hIFN-CTRLdAb, hIFN-CTRLdAb, 
MAXdAb, hIFN, and all the NOTA-hIFN-ASGPRdAb mutants to measure their 
binding to whole cells HepG2 (ASGPR+/hIFNAR+) and U937 (ASGPR-
/hIFNAR+).  
The HepG2 and U937 were first incubated with the primary analyte in 
suspension, followed by staining with either a secondary anti-dAb mouse mAb for 
dAb detection or a secondary anti-hIFN mAb, and finally stained with a tertiary goat 
anti-mAb pAb carrying the Alexa647 fluorophore (Alexa647) (Figure 3.11). The cells 
were also stained with DNA binding Live/Dead PI stain, a cell membrane 
impermeant. Data on 50000 events was collected for each analyte sample. Cells were 
                                                
* Adapted from a protocol provided by Dr Laura Goodall (personal communication) 
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first gated based on their uptake of PI stain into live (i.e. no PI staining) and dead cells 
based on their 614nm emissions (Appendix Figure 6.11). The live cells were 
subsequently analysed for the presence of Alexa647 at 647nm (representing hIFN-
dAb binding) and a histogram plotted of the FL4-H intensity data. The calculated 
mean intensity can thus be used as a semi-quantitative proxy for binding levels*. 
In addition to the analyte samples, data was acquired for the presence of the 
receptors with anti-ASGPR, anti-hIFNAR1, and anti-hIFNAR2 mouse mAbs by 
running these mAbs in the same manner. Non-specific binding by the analyte 
detection secondary antibodies anti-dAb and anti-hIFN was similarly controlled for. 
The general non-specific binding background was controlled for using an irrelevant 
IgG1 mouse λ isotype control with no specific affinity for either cell line. Non-specific 
staining was controlled for using PI, Alexa647 and PI+Alexa647 only controls and 
necessary primary and secondary antibody controls to gauge non-specific staining. 
 
HepG2 and U937 cells were cultured to 70-80% confluency in a humidified 
incubator at 37°C 5%-CO2. Cells were processed to the pellet stage of their 
respective subculture protocol (Appendix 6.1.4.1) Sample proteins were diluted to 
1μM in FACS Buffer (Table 2.5), all antibodies were diluted to 1μg/ml in Staining 
Buffer and propidium iodide (PI) dead cell stain to 1μg/ml in PBS.  
The supernatant was aspirated and the cell pellet resuspended in 20ml 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 1% (v/v) Fetal 
Bovine Serum (FBS) by gentle mixing. The total live cell count was determined, and 
the cell resuspension was centrifuged again at 1250rpm 4°C for 5min, and then 
resuspended in DMEM supplemented with 1% (v/v) FBS for a final concentration of 
5x106 cells/ml. 
                                                
* Assumes a 1:1 stoichiometry for the primary antibodies with their respective targets and binding of 
Alexa647 being equal for each of the primary antibodies – a multimeric primary antibody 
stoichiometry or multiple Alexa647 binding profiles would artificially amplify the signal giving false 
positive data – and so the relevance of data must be judged on their individual merits 
Table 2.5  
Flow Cytometry Buffer Recipes 
REAGENT* COMPONENTS VOLUME (ml) 
FACS Buffer PBS (+Mg
2+/Ca2+) 500 
FBS 50 
Staining Buffer PBS (+Mg
2+/Ca2+) 500 
FBS 5 
*Stored at 4°C 
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Cells were multipipetted as 200μl aliquots into relevant wells of a 96-Well V-
bottom plate for 1x106 cells per well. The cells were then pelleted by centrifugation at 
1200rpm 4°C for 3min. The supernatants were discarded by carefully inverting the 
plate over a sink and the pellets dried by gently striking the upturned plate against a 
pile of paper towel. The pellets were washed with 200μl of FACS Buffer, and then re-
pelleted by centrifugation at 1200rpm 4°C for 3min and the liquid removed as 
before.  
 
Cell pellets were resuspended either in 50μl 1μM sample protein PBS+ 
solution or 50μl FACS Buffer only for controls. The cell plates were then incubated 
at 4°C for 1 hour before cells were then pelleted by centrifugation at 1200rpm 4°C 
for 3min. The cell pellets were subsequently washed with 200μl FACS Buffer, 
pelleted by centrifugation at 1200rpm 4°C for 3min, and the supernatants discarded. 
This wash process was repeated twice more.  
Cell pellets were resuspended in 100μl of the relevant 1μg/ml primary 
antibody Staining Buffer solution and relevant control pellets resuspended in 100μl 
Staining Buffer only. The cell plates were then incubated at 4°C for 30min before 
cells were then pelleted by centrifugation at 1200rpm 4°C for 3min. The cell pellets 
were subsequently washed with 200μl FACS Buffer three times as above.  
Cell pellets were resuspended in 100μl of AlexaFluor 647 1μg/ml primary 
antibody Staining Buffer solution and relevant control pellets resuspended in 100μl 
Staining Buffer. The cell plates were then incubated at 4°C for 30min before cells 
were then pelleted by centrifugation and washed three times as above. 
Cell pellets were resuspended in 100μl PI stain PBS+ solution and relevant 
control pellets resuspended in 100μl PBS+. The cell plates were then incubated at 
4°C for 10min. The cells were transferred to 5ml FACS tubes containing 1ml PBS. 
Cells were kept in suspension by gentle vortexing. 
Cell staining data was acquired using a BD Biosciences FACSCalibur 
equipped with a 15mW argon ion laser emitting at 488nm (Alexa647) in addition to a 
635nm red laser (PI Stain). Cells were gated with BD FACSDiva software, and 50000 
events captured. Results were analysed using FlowJo analysis software. 
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2.2.5 68Ga Radioligand Binding Assay 
A radioligand binding assay was developed for a 96-well format to attempt to 
quantify binding of Ga-68 radiolabelled NOTA-hIFN-MAXdAb and NOTA-hIFN-
CTRLdAb to whole HepG2 cells.  
 HepG2 cells were cultured to 70-80% confluency in a humidified incubator 
at 37°C 5%-CO2 (Appendix 6.1.4.1). The cells were washed with 10ml of PBS before 
adding 5ml of Gibco Cell Dissociation Buffer for cell detachment. The flasks were 
returned to 37°C incubation until all cells were detached before resuspension with an 
additional 5ml DMEM 10%-FBS.  
Cell resuspensions were combined and centrifuged at 1250rpm 4°C for 5min. 
The supernatant was aspirated and the cell pellet resuspended in 20ml Binding 
Buffer (Table 2.6) by gentle mixing. The total live cell count was determined by 
Trypan Blue cell counting. The cell resuspension was centrifuged again at 1250rpm 
4°C for 5min, and then resuspended in Binding Buffer to a final concentration of 
2x106 cells/ml.  
The cell suspension was multi-pipetted in 50μl aliquots (1x105 cells) into a v-
bottomed 96 well plate, three wells per radioligand and competitor concentration, in 
addition to a row for total protein quantitation. Plates were stored at 4°C until 
required. A 4μM competitor mix stock of hIFN-MAXdAb alone was prepared in 
Binding Buffer and 25μl aliquots were pipetted into competitor wells. All remaining 
wells were topped up with 25µl Binding Buffer. 
 
The NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb were 
radiolabelled with Ga-68 using the 1M NaAc labelling method (see Method 2.3.2) 
with an extended 15min incubation and no EDTA reaction quench*. The 1μM Ga-
                                                
* Reaction was not quenched with EDTA to avoid Ca2+ chelation which is necessary for ASGPR 
binding 
Table 2.6  
Radioligand Binding Assay Buffer Recipes 
Reagent Components Volume (ml) 
Binding Buffer DMEM 500 FBS 5 
Wash Buffer PBS w/ Mg
2+/Ca2+ 500 
FBS 5 
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68 reaction mix was serially diluted 1:2 in Binding Buffer to give a serial dilution 
series ranging from 128nm-1nm in a final volume of 200μl*.  
25μl aliquots of the serially diluted radioligand were multi-pipetted into the 
binding and competitor wells of the cell plate and 10μl aliquots of each radioligand 
concentration added to 0.5ml tubes in triplicate as counting controls. The total 
protein wells were topped up with 25μl binding buffer. 
The plate was incubated at 18°C for 1 hour , centrifuged at 1200rpm for 
5mins and the supernatant removed.. The cell pellets were resuspended in 150μl 
Wash Buffer (Table 2.15) and re-centrifuged at 1200rpm for 5min. The wash step 
was repeated twice more, and finally re-pelleted by centrifugation at 1200rpm for 
5min. 
The cell pellets were resuspended in 100μl PBS and multi-pipetted to 0.5ml 
tubes and counted along with the controls in a LKB Wallac 1282 Compugamma CS 
Universal Gamma Counter. Data was analysed using Microsoft Excel and GraphPad 
Prism. 
To estimate the amount of protein added to each well, the Bio-Rad DC 
Protein Assay was carried out ontotal protein wells.e. Cell pellets were resuspended in 
50μl 1M NaOH and incubated at room temperature for 10mins. The samples were 
made up to 100μl with PBS. A 10mg/ml BSA in ddH2O mix was created by the 
same preparation process as the cell samples, before serial dilution 1:2 to create a 
BSA standard curve. Aliquots of 5μl of samples and standards in triplicate were 
added to a 96-Well flat-bottomed optical microtitre plate followed by 25μl of Reagent 
A and 200μl of Reagent B. The plate was agitated to mix the reagents and left for 
15mins at room temperature. The plate was read using a Bio-Rad 
Spectrophotometric Plate Reader at 640nm, and the standard BSA protein curve 
utilised to estimate the total protein content of the cells. 
  
                                                
* 75μl for binding assay wells n=3, 75μl for blocking assay wells n=3, and 30μl for loading controls 
n=3 
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2.3 RADIOLABELLING 
2.3.1 Gallium-68 Elution Design & Operation  
An Eckhert & Ziegler 370MBq (1MCi) IG100 68Ge/68Ga Generator was used 
to produce 68Ga for all experimentation, and was eluted using 0.1M HCl made with 
TraceSelect reagents. The generator was eluted at least once within 24 hours prior to 
experimentation and no more than once every four hours. 
An elution system was designed applying the principles of ALARP with lead 
shielding >1cm in thickness used as appropriate and the generator housed within a 
Hot Cell. Fluorinated ethylene propylene tubing, in conjunction with polypropylene 
Luer-Luer connectors and polyvinylidene fluoride (PVDF) three-way stopcocks, were 
utilised to construct an adaptable manual elution system for 68GaCl3 collection, which 
could be controlled from outside the Hot Cell (Figure 2.1). The system also included 
a Bio-Rad peristaltic pump with a timer to facilitate automatically eluting the 
generator every 24hours. An inline airlock protected the generator from gaseous 
contaminants. No rubber was used within the system, neither in airlock seals nor 
Figure 2.1 – Ga-68 Elution Diagram  
Schematic diagram of the set-up designed for efficient Ga-
68 elution from the IG100 generator with 0.1M HCl with 
fraction collection. To elute the generator for 
experimentation 0.1M HCl would be taken up in a syringe 
from the stock and re-injected into the system as required. 
There was also an-line peristaltic pump for automated 
daily elution to waste to preserve the generator. The closed 
system reduced the chance of impurity contamination. 
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syringes. The valves allowed for direct injections, bypassing the pump, for the manual 
elutions. The outflow could be directed for collection or to a shielded waste bottle by 
three-way PVDF stopcock. The outflow was either connected to a catheter for 
accurate elution volumes or a cationic exchange column. Another three-way valve 
prior to the outflow allowed injection of buffers or air directly onto an attached 
cationic exchange column. 
 
 Radioactivity measurements were performed using a Capintec CRC-15PET 
radioisotope dose calibration chamber. Labelling was quantified in all instances by a 
combination of AM)-iTLC, Citric Acid (CA)-EDTA iTLC and 2% bovine serum 
albumin (BSA) solid phase with water-ethanol-ammonia (WEA) liquid phase iTLC, 
and corroborated with size exclusion (SE)-HPLC as appropriate.  
 
2.3.2 1M NaAc 68Ga-NOTA-hIFN-dAb Labelling 
Radiolabelling and subsequent purification of 68Ga-NOTA-hIFN-MAXdAb, 
68Ga-NOTA-hIFN-CTRLdAb, and all the mutant 68Ga-NOTA-hIFN-ASGPRdAbs 
was performed as detailed below.  
All buffers were formulated with TraceSelect reagents. NOTA conjugated 
fusion proteins were rapidly thawed to room temperature prior to starting the assay. 
The generator was manually eluted with 0.1M HCl. Fractions of 500μl (radioligand 
binding assays and biodistribution studies) or 250µl (PET studies) were collected 
covering the top of the elution peak (Appendix Figures 6.12 & 6.13).  
A 200μl aliquot of the eluted 68GaCl3 in 0.1M HCl was pipetted from the 
high activity fraction into a 2ml Lo-Bind tube. This was followed by 30.6µl of 1M 
NaAc*, pipetted slowly with gentle pipette swirling to ensure homogeneity and 
minimise colloid formation. NOTA conjugated protein in 0.14 M pH 4.5 NaAc was 
added to give a final concentration of ~2µM for radioligand binding assays and 
biodistribution studies or 1.1µM for PET studies made up to a total reaction volume 
of 250μl with 0.14M NaAc pH4.5. The reaction was gently mixed, the total activity 
measured and incubated at room temperature (37˚C for PET studies) for 10min. A 
control reaction with a relevant volume of 0.14M NaAc pH4.5 replacing the protein, 
                                                
* Method was devised utilising the Henderson-Hasselbach equation to reliably buffer the reaction to 
pH4.4 
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was run in parallel. Radiolabelling efficiency was quantified by a combination of 
0.02M CA-EDTA iTLC and WEA-iTLC (Section 2.3.4). At this stage the specific 
activity (MBq/µg) could be calculated for t=0: 
 
=
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦  𝑀𝐵𝑞 ×𝑒 ! !.!"#∗ !! !"#$  !"#$!".!"# ×𝑅𝑎𝑑𝑖𝑜𝑙𝑎𝑏𝑒𝑙𝑙𝑖𝑛𝑔  𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦  %100
𝑀𝑎𝑠𝑠  µμ𝑔   
 
A PBS equilibrated PD MiniTrap G-25 column was used to purify labelled 
product from radiochemical impurities into PBS. The column was equilibrated with 
~4ml PBS without Ca2+/Mg2+ (PBS-) by gravity flow. The whole radiolabelling 
reaction (250µl) was loaded onto the column and topped up with PBS to a total 
stacked volume of 0.5ml. The purified radiolabelled product was eluted in a 0.5ml 
PBS primary fraction (radioligand binding assays), or two of 0.25ml and the second 
fraction utilised (biodistribution and PET studies). Recovery purity was quantified by 
a combination of 0.02M CA-EDTA iTLC and WEA-iTLC and the activity of the 
recovered fraction was measured.  
The total radiolabelled protein recovery was calculated from the iTLC values 
and the activity measurements: 
= 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛  𝑃𝑢𝑟𝑖𝑡𝑦  %100 × 𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛  𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦  𝑀𝐵𝑞 ∗ 𝑒 ! !.!"#∗
!! !"#$  !"#$!".!"#(𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐  𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑀𝐵𝑞 µμ𝑔)   
 
2.3.3 Indium-111 Labelling 
The NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAbs were 
radiolabelled with In-111 for the 24 hours biodistribution time point.  
A 20μl aliquot of 111InCl3 in 0.1M HCl was added to a 0.5ml polypropylene 
tube, followed by 0.2M pH5 NaAc buffer and the NOTA conjugated fusion protein 
for a final protein concentration of 3μM in a total reaction volume of 80μl. The 
reaction mix was gently mixed and the total activity measured using a Capintec 
CRC-15PET radioisotope dose calibration chamber. The reaction was incubated at 
37°C for 2hrs. A control containing 0.14M pH4.5 NaAc buffer instead of the protein 
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aliquot was incubated in parallel. Labelling was quantified by a combination of 
0.02M CA-EDTA iTLC and WEA-iTLC (Section 2.3.4). 
A PBS equilibrated PD MiniTrap G-25 column was subsequently used to 
purify into PBS as described above (Section 2.3.2). Purity was subsequently 
quantified by a combination of 0.02M CA-EDTA iTLC and WEA-iTLC (Section 
2.3.4). The specific activity and radiolabelled protein recovery could be calculated as 
in Section 2.3.2 exchanging the half-life from 67.629min to 4038.77min.  
 
2.3.4 Instant Thin Layer Chromatography 
Three types (Table 2.7) of iTLC were utilised to differentiate between the 
radioactive species present at the end of radiolabelling reactions (radioligand and 
radioimpurities), and are relevant for both Ga-68 and In-111 radiolabelling. AM-
iTLC identified free NOTA. CA-EDTA iTLC showed the amount of free unreacted 
radioactivity. WEA-iTLC showed the amount of radioactive colloid. The two values 
for the radioimpurities together allow the deduction of the radiolabelling efficiency of 
the radioligand, e.g. 68Ga-NOTA-hIFN-MAXdAb, as a percentage. 
Chromatographic Instant TLC Silica Gel (iTLC-SG) was cut into strips of 
approximately 1cm width and 8cm height. Strips were dried overnight in a 50°C 
oven and were stored in a sealed container with silica gel desiccant.  
 
To make iTLC-SG 2%-BSA strips, iTLC-SG strips were submerged in an 
excess of 2%(w/v) BSA in ddH2O at room temperature with gentle rocking for 3 
Table 2.7 
Thin Layer Chromatography Recipes 
iTLC Name Stationary Phase 
Mobile Phase* 
Reagent Volume (ml) 
AM iTLC-SG 
Ammonia 35% 0.1 
Methanol 100% 1 
ddH2O 0.9 
0.02M CA-EDTA iTLC-SG Citric Acid 0.04M 1 EDTA 0.1M 1 
WEA 2%-BSA iTLC-SG 
Ammonia 35% 0.25 
Ethanol 100% 0.5 
ddH2O 1.25 
* 2ml Total Volume 
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hours. The strips were then baked in an oven at 50°C for ~16 hours. The strips were 
stored in a sealed container with silica gel desiccant.  
For the analysis, a 1µl sample of the radiolabelling reaction was centrally 
spotted 2cm above the base of the iTLC-SG strip. Once the spot had air-dried onto 
the strip, it was placed in a 50ml tube and eluted with 2ml of freshly prepared mobile 
phase. The strips were exposed to a phosphoscreen for ~30s, before being removed 
from the cassette in a darkened room and scanned using a PerkinElmer Cyclone 
Phosphor Imager. Images were analysed using PerkinElmer OptiQuant Software.  
 
2.4 IN VIVO ANALYSES 
2.4.1 Animal Research Statement 
 All in vivo work was performed using SCID Beige mice from Charles River 
Laboratories, kindly shared by Dr John Maher (Kings College London, London). 
All procedures were carried out under the Home Office project license of 
Professor Stephen Mather (Queen Mary University of London, London) by Home 
Office individual licensees. All animal work was ethically reviewed and carried out in 
accordance with the Animals (Scientific Procedures) Act 1986 and the GSK Policy 
on the Care, Welfare and Treatment of Animals.  
Experimental design was guided by the principles of the ‘Three Rs’. All in vitro 
avenues of data acquisition were performed before proceeding to in vivo data 
collection. 
 
2.4.2 HepG2 Xenograft Murine Models 
HepG2 cells were cultured to 70-80% confluency in a humidified incubator 
at 37°C 5%-CO2 (Appendix 6.1.4.1). Cells were incubated with 10ml Cell 
Dissociation Buffer per flask for ~10min in the incubator until cells had dissociated. 
Cells were resuspended with the addition of 10ml DMEM, 10% FBS Cell 
resuspensions from several flasks, with total cell count sufficient to exceed 5x106 cells 
per xenograft injection, were combined and centrifuged at 1250rpm 4°C for 5min. 
The supernatant was discarded and the cell pellet resuspended in 20ml DMEM 
10%-FBS. The total live cell count was determined using a Trypan Blue cell counting 
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(Appendix 6.1.4.4) after which the cell resuspension was centrifuged as before and 
resuspended in DMEM, 10% FBS to a final concentration of 25x106 cells/ml. 
A 1ml syringe and attached 23-gauge needle were purged of air using 
DMEM 10%-FBS, and a 200μl xenograft dose (5x106 cells) drawn up. This process 
was repeated for each dose, and the cell suspension was constantly agitated to ensure 
a homogenous cell concentration for even xenograft dosing.  
The murine SCID Beige mice were dosed subcutaneously in the left flank for 
biodistribution studies or left shoulder for PET studies. Xenografts were grown for 
~20 days, until they had reached a mass of ~250µg, before further experimentation. 
 
2.4.3 Radioactivity Biodistribution Studies 
The radiolabelled NOTA-hIFN-MAXdAb, NOTA-hIFN-CTRLdAb, 
NOTA-hIFN(A)-HidAb, NOTA-hIFN(E)-HidAb, NOTA-hIFN(A)-MidAb, NOTA-
hIFN(C)-MidAb, NOTA-hIFN(E)-MidAb, NOTA-hIFN(A)-LodAb and NOTA-
hIFN(E)-LodAb were used for in vivo biodistribution studies to determine HepG2 
xenograft tissue uptake (see Appendix Figures 6.2 & 6.3 for a schematic overview). 
The NOTA conjugated protein was radiolabelled with Ga-68 (Section 2.3.2) 
or In-111 (Section 2.3.3) to a specific activity sufficient for a total activity greater than 
0.5MBq/dose at injection. The subsequently purified 250µl G-25 eluate was diluted 
with PBS supplemented with 1%(w/v) BSA* to the final required radiolabelled 
protein concentration in 200μl doses (mostly 1µg at 0.005µg/µl†) with an excess for 
dosing standards. The 200μl doses were injected into the tail veins of female SCID 
Beige HepG2 xenograft bearing mice (Section 2.4.2). The dose syringe was both 
weighed and the dose radioactivity measured in a Capintec CRC-15PET 
radioisotope dose calibration chamber before and after injection. 
At pre-determined timepoints (1h, 3h or 24h) the mice were anaesthetised for 
cardiac puncture procedure to remove blood and subsequently euthanasia confirmed 
by cervical dislocation. The carcass was weighed and the tissues and organs were 
dissected out. The tumour was placed in a labelled, pre-weighed scintillation tube 
and the new tube mass noted. RNAlater was then added to the tube at 
approximately 2X the xenograft volume. The intestines, spleen, pancreas, stomach, 
                                                
* The additional of BSA could reduce the residual dose adhering to the syringe by up to 500% 
† For higher injected doses, cold protein was added to give the necessary concentration e.g. 6µg/16µg 
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kidneys, liver, heart, lungs, blood, muscle and tail were deposited in pre-weighed 
gamma counter tubes. 
Tubes were counted using a 1282 Compugamma CS Universal Gamma 
Counter, alongside weighed dosing standards (to allow calculation of injected dose). 
Samples were counted for 60 seconds over a 177-277 energy window with half-life 
and dead time corrections applied. The tubes with their enclosed tissue were weighed 
to determine tissue mass. The tumour samples in RNAlater were stored at 4°C for a 
minimum of 24 hours before being stored at -80°C until required for TaqMan 
analysis. Results were analysed in Microsoft Excel and graphed using GraphPad 
Prism. 
 
2.4.3.1 Blocking Dose Biodistribution Study 
To test if xenograft tissue uptake binding was specific then an excess of cold 
MAXdAb ligand was co-injected with a 1µg 68Ga-NOTA-hIFN-MAXdAb dose. 
Unconjugated MAXdAb protein was concentrated to 204µM in 0.14M 
pH6.5 NaAc (a pH that allows direct IV injection into mice, whilst avoiding the pI of 
the protein thus preventing potential protein aggregation) using a Sartorius Vivaspin-
6 5kDa molecular weight cut off (MWCO) concentrator column. 
Preparing a blocking dose followed the same protocol as for a normal 1µg 
biodistribution dose (Section 2.4.3) using a 2µM Ga-68 reaction, attaining post-G25 
purified 68Ga-NOTA-hIFN-MAXdAb in PBS. At this stage the eluate was divided to 
make three normal 1µg doses of 68Ga-NOTA-hIFN-MAXdAb diluted with PBS 
supplemented with 1%(w/v) BSA in 200µl and three blocking 1µg doses of 68Ga-
NOTA-hIFN-MAXdAb diluted with the 204µM MAXdAb solution. This resulted in 
~333µg of MAXdAb in the blocking doses. The remainder of the protocol for 
biodistributions was followed from this point (Section 2.4.3).  
 
2.4.4 PET Imaging of Xenograft Uptake 
The NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb were 
radiolabelled with Ga-68 to a specific activity sufficient for a total activity greater 
than 5MBq/dose at injection (Section 2.3.2). The purified G-25 eluate was diluted to 
the final required dose of ~4µg per 200μl in PBS supplemented with 1%(w/v) BSA 
or used directly. The 200μl dose was injected into the tail vein of a female SCID 
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Beige HepG2 xenograft bearing mice (Section 2.4.2). The dose syringe was both 
weighed and the dose radioactivity measured in a Capintec CRC-15PET 
radioisotope dose calibration chamber before and after injection. The mouse was left 
for one hour. 
The mouse was anaesthetised using isofluorane, placed on the heated bed of a 
Siemens Inveon Micro PET/CT system and PET images were acquired for 2 hours, 
followed by a CT scan. PET images were reconstructed using the OSEM3D 
algorithm. The images were analysed using Siemens Analysis software. 
Once the scans were complete, the mice were sacrificed by cervical 
dislocation and a biodistribution dissection was performed as described in Method 
2.4.3. 
 
2.5 TAQMAN GENE EXPRESSION 
2.5.1 RNA Isolation 
The HepG2 tumours samples from the NOTA-hIFN-MAXdAb, NOTA-
hIFN-CTRLdAb, NOTA-hIFN(A)-HidAb, NOTA-hIFN(A)-MidAb, NOTA-
hIFN(C)-MidAb, NOTA-hIFN(E)-MidAb and NOTA-hIFN(A)-LodAb 
biodistribution studies, as well as tumours from untreated mice, were used for the 
TaqMan study.  
All steps were performed using aseptic technique to prevent RNA 
contamination, and samples kept on ice. Working solutions for a Qiagen RNeasy 
Maxi Kit were prepared and xenograft tissue samples preserved in RNAlater were 
thawed from -80C on ice. The RNAlater was decanted off carefully and each 
xenograft tissue transferred into a gentleMACS M tube containing 7.5ml of Buffer 
RLT. The tissue was homogenised using a gentleMACS dissociator.  
The homogenate was centrifuged at 5000g for 10min. The supernatant was 
removed with a pipette (taking care not to disturb the fatty top layer) and transferred 
into a 15ml tube. An equal volume of 70% EtOH was added and the mixture 
vigorously shaken to resuspend all precipitates. The sample was decanted onto a 
RNeasy Maxi Column in a 50ml centrifuge tube, before centrifugation at 5000xg for 
between 5 and 20min and the discarding of the flow-through. 15ml of Buffer RW1 
was added to the column and it was again centrifuged for 5min at 5000g, followed by 
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discarding the flow-through. 10ml Buffer RPE was added to the column and it was 
centrifuged for 2min at 5000g, followed by discarding the flow-through. 10ml Buffer 
RPE was added to the column and it was centrifuged for 5min at 5000g to dry the 
silica-gel membrane, followed by discarding the flow-through.  
The column was eluted into a fresh 50ml centrifuge tube by pipetting 1.2ml 
RNase-free ddH2O directly onto the silica-gel membrane, allowing it to stand for 
1min, followed by centrifugation at 5000g for 3min. This step was repeated with 
another 1.2ml of RNase-free ddH2O to maximise the RNA yield.  
 
2.5.2 Reverse-Transcription PCR 
An Applied Biosystems High Capacity complementary DNA (cDNA) Reverse 
Transcription Kit was utilised to formulate a 2X Master Mix containing MultiScribe 
Reverse Transcriptase for a 300µl reverse transcription (RT)-PCR reaction per 
xenograft RNA sample (Table 2.8). The RT-PCR was run using a Bio-Rad DNA 
Engine Tetrad 2 Peltier Thermal Cycler (Table 2.9). The resultant cDNA 
concentration was measured using UV spectrophotometry at 280nm. 
 
Table 2.9  
RT-PCR to Amplify cDNA for TaqMan 
Step Temperature (°C) Time  (min:s) # Cycles 
Reverse 
Transcription 25 10 1 
Amplification 37 120 1 
Hold 4 ∞ - 
 
Table 2.8  
RT-PCR Reaction Mix Recipe 
Reagent Components Volume (µl) 
RT-PCR Master 
Mix 
10X RT Buffer 12 
25X dNTP Mix 12 
10X RT Random Primers 30 
MultiScribe Reverse Transcriptase 15 
RNase Free ddH2O 63 
Purified Tumour 
Tissue RNA - 150 
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2.5.3 TaqMan Array 
The TaqMan Array Human Interferon Pathway Fast 96-well plate was 
prepared by centrifugation at 1000rpm for 1min. The TaqMan reaction mix was 
prepared with ~100ng cDNA (Table 2.10) and TaqMan Universal PCR Master Mix, 
and thoroughly mixed by gentle inversion. A 10µl aliquot of the TaqMan reaction 
mix was pipetted into each well of the TaqMan Array plate using a multi-pipette with 
constant agitation of the stock solution to ensure homogeneity. The plate was sealed 
with a MicroAmp Optical Adhesive Film and centrifuged at 1000rpm for 1min. The 
plate was loaded into an Applied Biosystems StepOnePlus, and the software 
programmed to perform a Standard assay protocol (Table 2.11)* for a 96-Well plate 
with a 10μl sample volume and to collect fluorescence data at the end of each cycle. 
Plates were analysed by normalisation to the expression levels of control gene 
glyceraldehyde-3-phophate (GAPDH) utilising the ΔCt-method in Microsoft Excel. 
 
Table 2.11  
TaqMan Thermal Cycling Standard Assay 
Step Temperature (°C) Time (min:s) # Cycles 
AMPErase UNG 
Activation 50 2:00 1 
AmpliTaq Gold 
Activation 95 10:00 1 
Melt 95 0:15 40 
Anneal / Extend 60 1:00 40 
 
 
                                                
* The TaqMan Array plates utilised were of the Fast variety, but as the TaqMan Universal PCR Mix 
was not a Fast grade reagent, the Standard protocol was chosen 
Table 2.10 
TaqMan Reaction Mix Recipe 
Reagent Volume (μl) 
TaqMan Universal PCR Master Mix 540 
RNase Free ddH2O 270 
Tumour Tissue cDNA 270 
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HepG2 Xenograft Targeting of 68Ga-
NOTA-hIFN-dAb 
 
Does fusion of hIFN to an ASGPR targeting dAb 
increase tumour specific uptake of hIFN in a 
HepG2 xenograft model? 
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3.1 INTRODUCTION 
The ability of dAb fusions to target xenograft tissue in vivo had never 
previously been shown. Therefore, the specific uptake of a 68Ga-NOTA-hIFN-dAb in 
an in vivo HepG2 model was to be used to validate the model as the basis for further 
uptake modelling work using biodistribution and PET-CT studies. This would was 
intended to be demonstrated with pre-made fusion proteins hIFN-MAXdAb with its 
ASGPR and hIFNAR affinity (Table 3.1) compared to hIFN-CTRLdAb with its lack 
of ASGPR affinity. Furthermore, it was not known whether any observed 
ASGPRdAb-mediated specific uptake could result in increased efficacy of the fused 
hIFN, so this was also to be investigated by TaqMan gene expression analysis. 
Foremost however, the experimental process for producing functional NOTA-
conjugated hIFN-dAbs, and subsequent Ga-68 labelling had also to be established. 
The following chapter details the results of the experimental development (Figure 
3.0) towards quantifying the in vivo targeting of 68Ga-NOTA-hIFN-dAbs to HepG2 
xenografts.  
 
 
 
 
 
 
 
Figure 3.0 – Outline of Experimental Development 
Experimental steps involved in producing validated 68Ga-NOTA-hIFN-dAbs and subsequent in 
vivo modelling, towards establishing effective xenograft targeting and optimised potency. 
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3.2 IN VITRO ASSAYS 
3.2.1 Tool Fusion Proteins 
Two tool HEK293e expressed hIFN-dAb fusion proteins called hIFN-
MAXdAb and hIFN-CTRLdAb were supplied for the project *  based on their 
contrasting affinities for ASGPR (Table 3.1).  
 
Table 3.1  
Tool hIFN-dAbs and constituent controls  
Fusion Protein Molecular Mass (Da) 
Targeting Affinity 
ASGPR hIFNAR 
 
hIFN-MAXdAb 
 
32547 YES YES 
 
hIFN-CTRLdAb 
 
32877 NO YES 
 
MAXdAb 
 
13299 YES NO 
 
hIFN 
 
20090 NO YES 
 
 
The fusion protein hIFN-MAXdAb is a 32.5kDa dual-targeted fusion protein, 
comprised of a high affinity ASGPR targeting dAb called MAXdAb fused to the C-
terminus of wild-type hIFNα2b (henceforth referred to as hIFN) (Figure 3.1). The 
hIFN-MAXdAb fusion protein was therefore designed to bind the two target 
receptors† ASGPR and hIFNAR and thus in theory any tissue expressing either, or 
both, of these receptors.  
The protein hIFN-CTRLdAb is a 32.9kDa single-target fusion protein, 
comprised of a VH domain protein scaffold with no known specific receptor or tissue 
affinity‡  called CTRLdAb and hIFN. The hIFN-CTRLdAb fusion protein was 
therefore designed to only specifically bind hIFNAR.  
                                                
* Kindly supplied by Dr Adam Walker and Dr Edward Coulstock at GSK 
† Not necessarily simultaneously (Section 1.4.4) 
‡ Personal communication with Dr Adam Walker 
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Additionally, the individual MAXdAb and hIFN proteins were included as 
positive controls for ASGPR and hIFNAR targeting respectively. 
Hence, the two fusion proteins are highly homologous in structure but differ 
in their respective ability to bind ASGPR. The hIFN-CTRLdAb was therefore a 
suitable control for potential ASGPR-mediated tissue uptake of the hIFN-MAXdAb 
fusion.  
 
3.2.2 NOTA Conjugation Reactions 
Covalent bioconjugation of the chelator NOTA to hIFN-MAXdAb and 
hIFN-CTRLdAb would allow radiolabelling with Ga-68, thus functioning as a 
radiotracer for the biodistribution of hIFN-dAbs in vivo. The bifunctional chelator 
SCN-Bn-NOTA enabled the coupling of the NOTA to sterically unhindered 
primary amine groups on the protein by nucleophilic substitution under basic 
reaction conditions, forming an isothiourea bond. The aim of these experiments was 
thus to purify predominantly homogenous, singly conjugated NOTA-hIFN-
MAXdAb and NOTA-hIFN-CTRLdAb (Methods 2.2). 
  
Figure 3.1 – Comparison of the Amino Acid Sequences of hIFN-
MAXdAb and hIFN-CTRLdAb  
Aligned amino acid sequences of hIFN-MAXdAb and hIFN-CTRLdAb highlighting the protein 
composition including sequence parental origin – hIFN, MAXdAb and CTRLdAb – sequence 
homology and loci of lysine residues. 
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3.2.2.1 Sodium Bicarbonate Dialysis Buffer Exchange 
The recovery from the dialysis tube was greater than 90% with the remaining 
losses incurred on the membrane. The concentration decreased during dialysis, 
probably due to a positive osmotic potential across the membrane (Table 3.2). 
 
3.2.2.2  SCN-Bn-NOTA Conjugation Reaction Development 
The SCN-Bn-NOTA acylation conjugation reaction comprised the pH9.2 
bicarbonate buffer dialysed fusion protein with a 10:1 molar excess of SCN-Bn-
NOTA. The reaction was performed at room temperature in the dark with gentle 
rocking for 4 hours, followed by refrigeration.  
The molar excess of SCN-Bn-NOTA was a balance between ensuring 
sufficient NOTA conjugation to enable high efficiency radiolabelling, whilst not 
promoting conjugation of multiple NOTA groups to individual fusion protein units. 
A 20:1 molar excess of SCN-Bn-NOTA did not improve In-111 labelling versus a 
10:1 molar excess. This indicated that the amount of fusion protein was a limiting 
factor above 10:1, perhaps as all available conjugation sites were saturated. 
Furthermore as the likelihood of multiple conjugations was increased, a 20:1 molar 
excess was deemed not advantageous. On the other hand, a 5:1 molar ratio yielded a 
lower radiolabelling efficiency, which indicated that this was an insufficient 
concentration of NOTA. The lower concentration likely decreased the initial rate of 
reaction, which, in addition to the high pH, potentially increased the competing 
hydrolysis of SCN-Bn-NOTA. Hydrolysed thiocarbamic acid SCN-Bn-NOTA 
Table 3.2  
NOTA Conjugation Metrics  
Fusion 
Protein Theoretical pI 
Stock 
Concentration 
(μM) 
Post Dialysis 
Concentration 
(μM) 
Post Dialysis 
Recovery (%)  
 
hIFN-
MAXdAb 
 
8.46 27.0 24.3 ±1.25 91.0 ±3.70 
 
hIFN-
CTRLdAb 
 
6.60 204 200 ±8.08 92.0 ±1.73 
 n≥3 
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derivative can no longer react by alkylation (Introduction 1.7.4.1), decreasing the 
yield of NOTA-hIFN-dAb. Hence, a 10:1 molar excess of NOTA was utilised. 
The reaction time of four hours was to maximise reaction time whilst 
minimising protein degradation from room temperature incubation and 
acknowledged the likely low reactive half-life of the NOTA owing to hydrolysis. The 
pH of 9.2 offered a balance between promoting conjugation with lysine groups in an 
unprotonated state (Introduction 1.7.4), without overly favouring hydrolysis nor 
erring too close to the predicted pI of the fusion proteins (Table 3.2). Also, the 
reaction was performed in the dark to minimise potential photolytic degradation via 
the benzyl group. Rocking ensured reaction homogeneity and likely improved the 
reaction kinetics. However, the effects of these variables were not quantitatively 
analysed.  
 
3.2.2.3 Protein A Purification of NOTA Conjugates 
Protein A is a recombinant protein derived from a microbial surface 
component recognising adhesive matrix molecule adhesin proteins expressed on the 
surface of Staphylococcus aureus bacteria, covalently attached to a Sepharose matrix467. 
Protein A has a high affinity for VH3 family protein sequences (Introduction 1.2.1), 
and hence can be utilised to purify VH3 derived dAb fusions by packed bed affinity 
capture chromatography.  
Purification of the NOTA-hIFN-dAbs served to remove excess SCN-Bn-
NOTA, increase the protein concentration and buffer exchange into NaAc. Any 
contamination from SCN-Bn-NOTA or other species thereof would have reduced 
subsequent radiolabelling efficiencies by complexing the radioactive metal. An 
increase in concentration would likely enable higher achievable specific activities 
owing to lower reaction volumes and higher hIFN-dAb reaction concentrations 
therein. The hIFN-dAbs were reported to be highly stable, monomeric and less 
aggregation-prone, in slightly acidic NaAc buffer* and therefore the NaAc elution 
method enabled convenient protein purification in pH4.5 0.14M NaAc. Hence, the 
aim was to achieve maximum concentrations with no SCN-Bn-NOTA 
breakthrough.  
The elution was fractionated into six elutions with the most concentrated 
fraction being utilised for further experimentation (Table 3.3). Protein lost at each 
                                                
* Unpublished data Dr Adam Walker & Dr Edward Coulstock, GSK. 
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stage of the purification was monitored, with minimal detectable protein losses by 
SDS-PAGE (Appendix Figure 6.7). There was no detectable SCN-Bn-NOTA 
breakthrough observed by AM iTLC (Appendix Figure 6.15) nor SE-HPLC (data 
not shown). 
 
Almost 90% of the NOTA-hIFN-MAXdAb was recovered from the 
purification process over the four-fraction elution peak. Any loss in protein was 
attributed to loss on plasticware or aggregation. There was an average of 53% ±7 of 
recovered protein present in the most concentrated fraction for NOTA-hIFN-
MAXdAb. On the other hand, only an average of 62% of loaded NOTA-hIFN-
CTRLdAb was recovered. However, this was offset by 61% ±16 recovery in the top 
fraction. The NOTA-hIFN-MAXdAb top fraction was on average two times more 
concentrated than the original dialysed hIFN-MAXdAb protein, whereas the 
NOTA-hIFN-CTRLdAb elution concentration was below the 204µM starting 
concentration. In both instances the elution concentration achieved in the top 
fraction was sufficient for subsequent radiolabelling.  
Table 3.3  
NOTA-hIFN-dAb Purification Metrics  
NOTA 
Conjugate 
Pre-
Purification 
Conc. (μM) 
Post-Purification Fraction Concentrations 
(μM) 
Post-
Purification 
Total 
Recovery 
(%)  1 2 3 4 5 6 
 
NOTA-
hIFN-
MAXdAb 
 
24.3 ±1.25 0.0 
±0.0 
14.5 
±7.40 
50.9 
±9.44 
24.9 
±8.20 
6.1 
±3.90 
0.0 
±0.0 86.0 ±3.61 
 
NOTA-
hIFN-
CTRLdAb 
 
200 ±8.08 0.0 
±0.0 
12.2 
±10.24 
48.9 
±33.5 
18.9 
±6.20 
3.73 
±3.83 
0.74 
±1.47 61.8 ±13.7 
 n≥3 
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The high variability reflected the improvements achieved as the protocol was 
refined. The maximum achieved concentrations of the top fractions, for instance, 
improved with each batch production up to a maximum of 59.5μM for hIFN-
MAXdAb and 98.9µM for hIFN-CTRLdAb*, which represented increases from the 
first batches of 46% and 211% respectively. This was possibly due in particular to 
switching to utilising UltraPure reagents without Chelexing, leading to a more 
reliable elution buffer pH.  
                                                
* These were the batches utilised in vivo (Section 3.5.1) 
Figure 3.2 – Non-Reducing SDS-PAGE of pre-conjugation and post-
Protein A purification hIFN-dAbs  
hIFN-dAb fusion proteins migrate as predicted to an apparent molecular mass of between 30-
33kDa, without any detectable aggregation either before undergoing the conjugation reaction with 
SCN-Bn-NOTA or subsequently after Protein A purification.   
hIFN-MAXdAb (3µg), NOTA-hIFN-MAXdAb (1µg), hIFN-CTRLdAb (3µg), and NOTA-hIFN-
CTRLdAb (1µg) with Novex Sharp Pre-stained Protein Standard.  
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Non-reducing SDS-PAGE also confirmed that the concentrated fractions of 
hIFN-dAb did not promote protein aggregation as only a monomeric species at the 
expected molecular masses (Table 3.1) of approximately 30-33kDa were obtained 
(Figure 3.2).  
Hence, the Protein A purification protocol was successful in the recovery of 
concentrated NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb proteins. 
 
3.2.2.4 Mass Spectrometry 
Electrospray ionisation time of flight (ESI-TOF) MS was used to analyse the 
composition of the NOTA-hIFN-dAb species present in the top fraction from Protein 
A purification (Table 3.3). The MS data showed that the purified stock of NOTA-
hIFN-MAXdAb was a heterogeneous mix of species composed of a number of 
glycosylation and NOTA-conjugated species (Table 3.4, Figure 3.3, Table 3.5).  
 
Table 3.4  
Mass Spectrum of hIFN-MAXdAb Post NOTA Conjugation  
Peak Mass Protein Identity O-linked Glycan Percentage of Total Protein (%) 
32547* 
hIFN-MAXdAb 
N/A N/A N/A 
33197 GalNAc-Gal-Neu5Ac 4.8 
39.1 33491 GalNAc-Gal-Neu5Ac2 
31.6 
33511 2.7 
33648 
NOTA-hIFN-MAXdAb 
GalNAc-Gal-Neu5Ac 3.2 
60.9 
33942 
GalNAc-Gal-Neu5Ac2 
31.0 
33996 5.3 
34392 NOTA2-hIFN-MAXdAb 
15.0 
34445 3.7 
34842 NOTA3-hIFN-MAXdAb 2.7 
 *hIFN-MAXdAb predicted mass based on amino acid sequence for reference 
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The hIFN-MAXdAb has no N-linked glycosylation sites (Figure 3.1), only an 
O-glycosylation site present at Thr109 in the hIFNα2b portion of the hIFN-
MAXdAb (Introduction 1.5.1). The expected molecular mass of the hIFN-MAXdAb 
protein was 32547Da, whereas the first detectable species above the analysis relative-
abundance threshold was 33197Da (Figure 3.3) representing a difference of 943Da, 
and accounted as a 948Da O-GalNAc-Gal-Neu5Ac glycan (Table 3.5). There was a 
discrepancy of 5Da between the predicted value and the measured hIFN(GalNAc-
Gal-Neu5Ac)-MAXdAb glycoprotein but it was decided the 5Da was within an 
acceptable margin of error because foremost the ‘expected value’ was estimated from 
the amino acid sequence, the literature supported the presence of O-GalNAc-Gal-
Neu5Ac239 and the machine error was ±3Da. This hIFN(GalNAc-Gal-NeuAc)-
MAXdAb species accounted for 12.3% of the total unconjugated hIFN-MAXdAb 
glycoprotein (Table 3.4). There was also a conjugated 33648kDa NOTA-
hIFN(GalNAc-Gal-Neu5Ac)-MAXdAb species. 
The predominant glycosylation state was O-GalNAc-Gal-Neu5Ac2, which 
was consistent with previous observations239, as demonstrated by the 294Da mass 
increase from the presence of an additional Neu5Ac. The three NOTA-conjugated 
species of hIFN(GalNAc-Gal-Neu5Ac2)-MAXdAb were identified by a mass increase 
of 450/451Da corresponding to 33942Da NOTA-hIFN-MAXdAb, 34392Da 
NOTA2-hIFN-dAb, and 34842Da NOTA3-hIFN-MAXdAb. These three NOTA-
hIFN(GalNAc-Gal-Neu5Ac2)-MAXdAb fully-sialyted glycoprotein species account 
for 94.7% of the NOTA-conjugated species representing 57.7% of the total purified 
NOTA-hIFN-MAXdAb  stock. Of these conjugated species 62.9% were singly 
conjugated, accounting for 36.3% of the total purified NOTA-hIFN-MAXdAb stock. 
Table 3.5  
Group Molecular Masses 
Group Name Group Mass (Da) 
(Lys)-SCN-Bn-NOTA +451 
(Thr)-GalNAc-Gal-Neu5Ac +948 
(Gal)-Neu5Ac +294 
Cr3+ +53/54 
(Lys)-OH +16 
*brackets indicate parent molecule attachment and do not count to mass 
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Therefore, the most abundant species was NOTA-hIFN(GalNAc-Gal-Neu5Ac2)-
MAXdAb. 
 
The 33511Da minor peak from the 33491Da parental hIFN-MAXdAb peak 
with an increase in mass of 20Da was consistent with a small modification such as the 
hydroxylation of a lysine group which were free to react in the unconjugated hIFN-
MAXdAb. The 33996Da and 34445Da minor peaks of the respective parental 
33942Da NOTA-hIFN-dAb and 34392Da NOTA2-hIFN-dAb peaks showed an 
average increase in mass of 53.5Da. This was explained as the potential chelation of 
an iron or chromium ion isotope468, which may have been present as a contaminant 
from the MS machine. There was no indication that there was metal contamination 
in the stock sample based on subsequent labelling successes. Therefore all the 
measurable +~53.5Da minor peaks were assumed to be congruent with their 
parental peak. 
 
The main caveat regarding this data was that it could only be viewed as an 
accurate reflection of the composition of species that actually ionised and were 
detected on the machine. A different species ratio or the presence of other species 
could not be ruled out, although it clearly indicated heterogeneity.  
The presence of the multiple conjugated NOTA2-hIFN-MAXdAb and 
NOTA3-hIFN-MAXdAb species complicated potential quantitation of targeting in 
vivo as there will would not be a 1:1 relationship between detected radioactive events 
and the number of NOTA-hIFN-dAb molecules. However there was the possibility 
to apply the determined proportions to create a correction factor.  
Furthermore, the locus of the NOTA conjugation on the hIFN-MAXdAb 
structure was uncontrolled. Therefore the exact lysine group(s) being conjugated 
were unknown. The conjugated lysine group may have been situated in or adjacent 
to a dAb CDR or hIFN receptor interaction domain. Therefore this uncontrolled 
potential to affect hIFN-MAXdAb function was a concern. The hIFN-MAXdAb 
sequence was known to contain fourteen lysine groups with three within the CDR 
sequences (Figure 3.1), although this gave no indication of their accessibility in a 
tertiary conformation. There are several lysines essential to hIFN function469, and so 
the hIFN function appeared to be most at risk from undirected NOTA conjugation. 
Therefore if there were any observed differences between hIFN-MAXdAb and 
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NOTA-hIFN-MAXdAb in vitro then it was bore in mind that it may be due to a 
NOTA group impinging on a functional site.  
 The asialoglycoproteins hIFN(GalNAc-Gal-Neu5Ac)-MAXdAb and NOTA-
hIFN(GalNAc-Gal-Neu5Ac)-MAXdAb species were acknowledged for their potential 
for unintended ASGPR interactions through the O-GalNAc-Gal-Neu5Ac and 
subsequent degradation of the protein through the endocytotic lysosomal pathway. 
However as there was only one NOTA-hIFN(O-GalNAc-Gal-Neu5Ac)-MAXdAb 
species, which accounted for 3.2% of total NOTA-hIFN-MAXdAb stock. Any 
asialoglycan mediated targeting of ASGPR was thought unlikely to be of noticeable 
magnitude and moreover controlled for by the NOTA-hIFN-CTRLdAb which also 
has O-linked glycosylation.  
 
These conjugation complications could have potentially been avoided with a 
different chelation strategy. A pH of 7.5 would have promoted less lysine ε-amine 
deprotonation, whilst simultaneously increasing the likelihood of N-terminal α-amine 
conjugation and thus decreasing the likelihood of multiple conjugations whilst 
avoiding the pI of both hIFN-MAXdAb and hIFN-CTRLdAb (Table 3.2) to prevent 
possible aggregation. The N-terminus is part of the hIFN portion of the fusion 
protein and is sterically unhindered by the fusion protein superstructure, so the lower 
pH may have been a feasible option.  
Another expedient approach would be to control the conjugation through the 
introduction of a cysteine group at the C-terminus to enable conjugation by thiol 
reaction, such as with maleimido-mono-amide-NOTA. A similar approach was 
successfully applied to C-terminally conjugate a nanobody to DTPA470. However, 
introducing a new amino acid residue into the sequence risks adding more 
complications, altering the hIFN-MAXdAb tertiary structure and thus function, plus 
cysteine could promote dimer formation. 
In conclusion, the purified NOTA-hIFN-MAXdAb was a heterogeneous mix 
of unconjugated and multiple conjugated species in addition to two glycosylation 
states. This equated to an average of 0.86 NOTAs per hIFN-MAXdAb. The 
predominating species was O-linked glycosylated NOTA1-hIFN-MAXdAb and the 
majority of the protein was NOTA conjugated. Therefore, as a tracer for in vivo 
biodistribution and imaging, the hIFN-MAXdAb conjugation was successful. The 
heterogeneous stock will continue to be referred to as NOTA-hIFN-MAXdAb. 
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The NOTA-hIFN-CTRLdAb fraction proved more troublesome because 
mass spectra were not obtained by either ESI-TOF MS nor Liquid Chromatography 
Time of Flight MS. Previously, treatment with Endo-Hf under reducing conditions to 
remove the glycosylation had been observed to improve mass spectrum acquisition of 
DOTA conjugated dAb fusions*; however in this instance that method failed to yield 
interpretable data. The O-linked glycosylation of hIFNα2b is not high-mannose and 
so Endo-Hf was not liable to be effective.  
Hence, it was only possible to speculate that the NOTAx-hIFN-CTRLdAb 
profile was similar to that of the NOTA-hIFN-MAXdAb (Table 3.4). The two 
proteins differ by 43AA in their dAb sequences (Figure 3.1), including three lysine 
residues, and so the conjugation profiles had the potential to be different given the 
likely different ε-amino groups’ pKa within the likely differing tertiary structures. 
However, a similar radiolabelling pattern with In-111 for both conjugates provided 
confidence that NOTA-hIFN-CTRLdAb was generated. 
 
3.2.3 Biacore Surface Plasmon Resonance  
Surface Plasmon Resonance (SPR) as detected in this study with a Biacore 
machine, allowed label-free real-time observation of interactions between the target 
ligand immobilised on the surface of an adherent substrate matrix coated gold chip 
and the protein analytes flowed over the surface in solution. Subsequently kinetic and 
affinity parameters based on the detected on-rate, off-rate and binding equilibrium 
could be computed from the observed sensogram binding curves. This was achieved 
by analysing the binding curves of several analyte concentrations to create a model of 
the binding interaction, from which the kinetic parameters were fitted. In this 
investigation, as hIFN-MAXdAb was designed to have dual affinity for both the 
ASGPR and hIFNAR, Biacore was utilised to determine the binding parameters for 
both ASGPR-H1-CRD and hIFNAR2 (Method 2.2.2). 
  
                                                
* Personal communication by Dr Edward Coulstock 
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3.2.3.1 ASGPR Binding Assay 
Immobilised CRD from the ASGPR-H1 comprised of a 160AA portion of 
the ECD was used to enable in vitro modelling of the interaction of NOTA-hIFN-dAb 
with ASGPR-H1. A recombinant ASGPR-H1-CRD was expressed and purified 
(Appendix Figure 6.8)471 with a highly pure final recovery of 700µg. 
A Biacore S-Series CM5 chip was coated with approximately 500RU of the 
recombinant ASGPR-H1-CRD ligand by amine coupling to the carboxymethylated 
dextran surface in pH5.5 NaAc*†. Sample analytes NOTA-hIFN-MAXdAb, hIFN-
MAXdAb, MAXdAb, and hIFN (Table 3.1) were prepared in HBS-P+ in a serial 
dilution series and run on a Biacore T200‡ (Figure 3.5). The resultant binding curves 
were analysed by Biacore Evaluation software assuming a 1:1 Langmuir binding 
model.  
 
The differences between the analytes’ binding interactions with ASGPR-H1-
CRD were exemplified at a concentration of 10nM (Figure 3.5). Qualitatively the 
results conveyed the MAXdAb’s ability to confer ASGPR-H1-CRD binding to the 
hIFN protein as part of a fusion protein. Without the MAXdAb, the hIFN protein 
alone demonstrated no discernable affinity for the ASGPR-H1-CRD. Moreover, this 
ASGPR-H1-CRD binding capability was overall maintained in spite of 
                                                
* Kindly provided by Peggy Luong and Dr Thil Batuwangala 
† Established by pH Scouting (data not shown) 
‡ The Biacore T200 provides high sensitivity to binding interactions, a high rate of data collection 
(hertz) and advanced curve integration algorithms for accurate KD computation 
Figure 3.4 – Analyte interactions with ASGPR-H1-
CRD CM5 Chip in SPR Experiment 
Representation of NOTA-hIFN-MAXdAb binding and NOTA-hIFN-
CTRLdAb non-binding to immobilised ASGPR-H1-CRD as detected 
by Biacore SPR.  
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heterogeneous NOTA conjugated species. Conversely, as intended, the CTRLdAb 
fusion proteins had no detectable binding affinity for ASGPR-H1-CRD. The 
apparent differences in the magnitude of the binding curves of MAXdAb, hIFN-
MAXdAb and NOTA-hIFN-MAXdAb were attributed to an increase in the 
molecular mass increasing the SPR signal. Hence, qualitatively, the data 
demonstrated that the analyte binding reflected the expected ASGPR binding 
properties (Table 3.1). 
Quantitative analysis of the binding kinetics (Table 3.6) was performed by 
sampling a range of analyte concentrations from 100nM to 0.01nM* (Figure 3.6) over 
multiple experiments†, as calculated by integrative analysis by the BIAevaluation 
software.  
 
 
 
                                                
* In practice only analyte concentrations ranging from 10nM to 0.03nM were utilised to compute the 
kinetic data as higher concentrations decreased the goodness of fit for the modelled data 
† Between 4 and 10 experiments with n=3 for each data point 
Figure 3.5 – Biacore T200 SPR Analysis of Analytes’ binding 
interaction with recombinant ASGPR-H1-CRD 
Biacore T200 SPR with ASGPR-H1-CRD immobilised on a CM5 chip assessed the ASGPR-H1-
CRD binding curves of 10nM analytes NOTA-hIFN-MAXdAb, NOTA-hIFN-CTRLdAb, hIFN-
MAXdAb, MAXdAb and hIFN injected over the chip surface at 30µlmin-1. The data shows 
MAXdAb can bind ASGPR-H1-CRD and can confer this property to hIFN as part of a fusion 
protein, compared to the CTRLdAb and hIFN alone showing no binding to ASGPR-H1-CRD. 
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Table 3.6  
Biacore T200 ASGPR-H1-CRD Binding Kinetics  
Protein Kon (x107 M-1s-1) Koff (x10-2 s-1) KD (nM) Rmax (RU) Chi2 (RU2) 
 
NOTA-hIFN-MAXdAb 
 
1.78 ±0.67 1.26 ±0.40 0.73 ±0.13 44.5 ±12.0 0.40 ±0.25 
 
hIFN-MAXdAb 
 
21.0 ±8.50 6.78 ±2.67 0.33 ±0.03 30.6 ±10.0 0.03 ±0.01 
 
MAXdAb 
 
23.8 ±9.68 5.48 ±2.15 0.24 ±0.04 20.6 ±5.59 0.04 ±0.03 
 n≥4, SD values displayed 
 
 
NOTA-hIFN-MAXdAb’s 0.73nM KD binding affinity for ASGPR-H1-CRD 
was considered high*. The binding interaction profile consisted of a fast on-rate (kon) 
combined with a fast off-rate (koff) which suggested a strong, transient interaction 
between the MAXdAb component and ASGPR-H1-CRD (Table 3.6, Figure 3.6). 
The implications for the NOTA-hIFN-MAXdAb in vivo were favourable as it 
suggested that the NOTA-hIFN-MAXdAb could potentially rapidly concentrate in 
                                                
* Drug-target binding affinities are generally considered high between 0.1nM-10nM 
Figure 3.6 – Biacore T200 SPR Analysis of NOTA-hIFN-MAXdAb 
binding to ASGPR-H1-CRD 
Biacore T200 SPR with ASGPR-H1-CRD immobilised on a CM5 chip assessed the ASGPR-H1-
CRD binding kinetics of a 64-0.5nM 1:2 serial dilution of NOTA-hIFN-MAXdAb injected over 
the chip surface at 30µlmin-1.  
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ASGPR-expressing tissues but would be readily re-released for hIFN-mediated 
interaction with hIFNAR. The data also compared favourably with the published 
binding affinity result of 0.6nM for an ASGPR binding dAb fusion74. 
Comparison of NOTA-hIFN-dAb with hIFN-MAXdAb and MAXdAb 
demonstrated significant (p=0.00008) differences in the binding kinetics of each protein 
for ASGPR-H1-CRD (Table 3.6, Appendix Figures 6.9 & 6.10). The presence of 
NOTA conjugates significantly decreased the MAXdAb’s KD for ASGPR-H1-CRD. 
There was a significant (p=0.002) decrease in the kon with the presence of NOTA 
conjugates, which appeared to be offset by a significant (p=0.004) improvement in the 
koff rate. This suggested the result likely reflected the overall binding of the 
heterogeneous NOTA-hIFN-MAXdAb stock, whereby the 61% subset of NOTA-
conjugated species decreased the overall binding efficiency value. The addition of 
NOTA may have impeded binding to ASGPR-H1-CRD, but once the NOTA-
hIFN-MAXdAb was bound the NOTA conjugation served to increase the stability of 
the interaction. The presence of NOTA may have modified the tertiary structure of 
the NOTA-hIFN-MAXdAb fusion protein subset to the extent that the CDRs of the 
MAXdAb had an ameliorated binding alignment with the ASGPR-H1-CRD 
epitope.  
Indeed, although the differences were mathematically significant, they were 
not of practical qualitative significance as the NOTA-hIFN-MAXdAb overall still 
bound the ASGPR-H1-CRD at a sub 1nM KD binding affinity in spite of NOTA 
conjugation, and the crucial factor for this study was the highly significant (p<0.0001) 
contrast with the non-ASGPR binding NOTA-hIFN-CTRLdAb.  
 
The SD values showed low variance and so there was a high degree of 
confidence that the kinetic values were consistent. The low Rmax below 50RU was an 
indication the observed results were unlikely augmented by the mass-transport effect*, 
which enhanced confidence in the robustness of the result. Furthermore, the low Chi2 
values below 0.5RU2 equating to less than 1% of the Rmax† indicated a high 
confidence in the curve fit, and so any differences between data points and fitted 
values may have been just due to background noise.  
                                                
* The mass-transport effect is the phenomena whereby the analyte accumulates at the chip surface by 
diffusion from the bulk solution, caused by the reduced flow rate close to the chip surface, thus 
creating false positive ligand association results. 
† Less than 10% of the Rmax is considered appropriate 
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Nevertheless, the SDs showed that there was some sensitivity to sample 
concentration change, as reflected in the kon and koff values (Table 3.6). However, the 
results were not attained consecutively but over many months and so the small 
variability appeared to be temporal. This correlated with variation in the Rmax 
indicating a decrease in chip binding capacity over time.  
There was an observed lack of steady-state equilibrium during the association 
phase (0-60s) with binding continuing after the apparent ligand saturation point had 
been reached. This was most pronounced in the NOTA-hIFN-MAXdAb data due to 
the slower kon (Figure 3.6). A possible explanation was that the reaction conditions 
were conducive to non-specific MAXdAb-mediated self-associations, a property 
known to afflict dAb technologies (Introduction 1.2.1), and so there was an 
accumulation on the chip surface of dimers over time. Another explanation was that 
there was a second, lower-affinity epitope on ASGPR-H1-CRD for MAXdAb that 
had a considerably lower kon rate, which would also account for the continuing 
increase in binding signal. In both explanations though it was the saturation of the 
specific ASGPR binding that appeared to make this secondary interaction kinetically 
favourable.  
 
In summary, NOTA-hIFN-MAXdAb demonstrated a 0.73nM binding 
affinity for the recombinant ASGPR-H1-CRD in this in vitro Biacore SPR analysis 
model. The addition of NOTA significantly affected the binding kinetics of the hIFN-
MAXdAb fusion protein, notwithstanding a significant improvement in koff. However 
in practical terms the modulation was not meaningful as the KD remained 
significantly higher than the non-binding control NOTA-hIFN-CTRLdAb.  
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3.2.3.2 hIFNAR Binding Assay 
A Biacore CM5 chip was coated with approximately 500RU of recombinant 
R&D Systems hIFNAR2 ligand by amine coupling to the carboxymethylated dextran 
surface in pH4.0 NaAc*. Sample analytes NOTA-hIFN-MAXdAb, NOTA-hIFN-
CTRLdAb, hIFN-MAXdAb, MAXdAb and hIFN were prepared in HBS-P+ at in a 
logarithmic 1:3/1:3.33 serial dilution series and run on a Biacore 3000† (Figure 3.7). 
The resultant binding curves were analysed by Biacore Evaluation software assuming 
a 1:1 Langmuir binding model. 
 
The binding profiles of the analytes against hIFNAR2 were exemplified at 
250nM (Figure 3.8). A qualitative analysis of the profiles showed that the NOTA-
hIFN-MAXdAb and the NOTA-hIFN-CTRLdAb had an intrinsic binding capacity 
for the hIFNAR2. However, there was a strong suggestion that their binding to 
hIFNAR2 was reduced by the NOTA conjugation as their magnitudes were 
substantially reduced.  
The hIFN positive control showed rapid binding before reaching a constant 
equilibrium. The hIFN-MAXdAb showed a similar binding profile to the hIFN, 
albeit with a greater intensity owing to its increased mass and lack of equilibrium 
(Section 3.2.3.1). The MAXdAb negative control appeared to show some non-
specific interaction with the chip surface. 
                                                
* Established by pH Scouting (data not shown) 
† The Biacore 3000 was utilised as a Biacore T200 was unavailable. 
Figure 3.7 – Analyte interactions with hIFNAR2 
CM5 Chip in SPR Experiment 
Representation of NOTA-hIFN-MAXdAb and hIFN binding to 
immobilised hIFNAR2 as detected by Biacore SPR. 
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Quantitative analysis of the binding kinetics (Table 3.7) was performed by 
sampling a range of analyte concentrations from 100nM to 0.01nM over multiple 
experiments. The kinetic data confirmed a significant (p=0.02) decrease in KD with the 
presence of NOTA conjugated species decreasing hIFNAR binding. For instance, the 
NOTA-hIFN-MAXdAb binding affinity was over a 1000-fold reduced at 46.9µM 
compared to 30nM for hIFN-MAXdAb. The source of this effect was attributable to 
a significant (p=0.002) decrease in the kon association rate of hIFN-MAXdAb and 
NOTA-hIFN-MAXdAb of 29.2x104 M-1s-1 to 0.02x104M-1s-1, respectively. This 
contrasted with the koff values of hIFN-MAXdAb and NOTA-hIFN-MAXdAb which 
were not significantly (p=0.79) different at 0.88x10-2 s-1 and 0.83x10-2 s-1, respectively. 
This showed that once bound to the hIFNAR2 the NOTA-hIFN-MAXdAb would 
actually dissociate significantly (p=0.01) slower than hIFN alone. The mechanism for 
this extra binding stability was not clear, but it was evidently related to the presence 
of the MAXdAb in the dAb fusion protein as the NOTA-hIFN-CTRLdAb and the 
hIFN both had similar, faster koff values. Thus, the data suggested that the negative 
Figure 3.8 – Biacore 3000 SPR Analysis of Analytes’ binding 
interaction with recombinant hIFNAR2 
Biacore 3000 SPR with hIFNAR2 immobilised on a CM5 chip assessed the hIFNAR2 binding 
curves of 250nM analytes – NOTA-hIFN-MAXdAb, NOTA-hIFN-CTRLdAb, hIFN-MAXdAb, 
MAXdAb and hIFN – injected over the chip surface at 30µlmin-1. The data shows hIFN can bind 
hIFNAR2 and can confer this property to MAXdAb and CTRLdAb as part of the respective 
fusion proteins, which compares to the MAXdAb alone showing no measurable binding to 
hIFNAR2 above background noise. 
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effect of NOTA conjugation was related to the association phase of binding and once 
bound, the NOTA-hIFN-CTRLdAb bound strongly to the hIFNAR2.  
Table 3.7  
Biacore 3000 hIFNAR2 Binding Kinetics  
Protein Kon (x104 M-1s-1) Koff (x10-2 s-1) KD (µM) Rmax (RU) Chi2 (RU2) 
 
NOTA-hIFN-MAXdAb 
 
0.02 ±0.00 0.83 ±0.02 46.9 ±20.9 8020 ±2490 0.38 ±0.07 
 
hIFN-MAXdAb 
 
29.2 ±3.81 0.88 ±0.23 0.03 ±0.01 22.5 ±5.93 0.53 ±0.03 
 
NOTA-hIFN-CTRLdAb 
 
0.03 2.97 86.4 3460 0.26 
 
hIFN 
 
354 ±77.3 3.26 ±0.55 0.01 ±0.00 10.8 ±0.50 0.25 ±0.04 
 n≤3, SD values displayed 
 
To control for their differing ASGPR targeting, NOTA-hIFN-MAXdAb and 
NOTA-hIFN-CTRLdAb were intended to have equal hIFN activity (Figure 3.1). 
Indeed they were both shown to share similar kon rates and double-digit µM KD 
values (Table 3.7). However, they differed in their koff rates as NOTA-hIFN-
CTRLdAb dissociated 3.6 times faster than NOTA-hIFN-MAXdAb. The 
CTRLdAb has three fewer lysine residues in its sequence than MAXdAb, and so 
perhaps the conjugation of hIFN-CTRLdAb was weighted towards the lysines of the 
hIFN as a result. The hIFN function may have thus been affected to a greater extent 
in the NOTA-hIFN-CTRLdAb from NOTA conjugation.  Therefore, although the 
binding affinities remained non-significantly different overall, the difference in koff 
was noted for possible ramifications on the potency of the NOTA-hIFN-CTRLdAb. 
A different conjugation strategy may have circumvented this control drawback.   
The hIFN positive control KD of less than 10nM conformed to previously 
published KD values263,269,472. Furthermore, in one study pegylated hIFN (an increase 
in molecular weight of 40kDa) demonstrated a two-fold decrease in binding affinity 
compared to the hIFN alone472, which is not dissimilar to the three-fold decrease 
witnessed between hIFN-MAXdAb and hIFN.  
 
The data appeared to be relatively noisy compared to the ASGPR-H1-CRD 
binding data (Table 3.7). Indeed the Chi2 values ranged from 0.21-0.56RU2 equated 
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to less than 1% of the Rmax* thus indicating confidence in the curve fit, but also an 
increase in signal-noise. The increased noise was the decreased Rmax making 
background noise more significant (p=0.009), which in addition to the decreased 
binding affinities was attributable to the decreased sensitivity of the Biacore 3000. 
The very high Rmax of the NOTA-hIFN-MAXdAb and NOTA-hIFN-
CTRLdAb were indicative of mass-transport effects, which may have also accounted 
for the apparently poor respective KD values. The mass-transport effect may have 
precluded confidence in the hIFNAR2 KD quantitation, however it did not 
undermine the qualitative assessment that NOTA-hIFN-MAXdAb had a higher kon 
affinity than NOTA-hIFN-CTRLdAb.  
As was seen with the ASGPR-H1-CRD experiments (Section 3.2.3.1), the 
lack of steady state equilibrium was also apparent for the hIFNAR2 binding, 
particularly for the NOTA-hIFN-MAXdAb result. As the hIFN alone binding was 
unaffected by this problem, this suggested that this was a dAb-mediated problem.  
 
In summary, NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb were 
shown to interact with the hIFNAR2 in this in vitro Biacore SPR analysis model. The 
koff data supported that NOTA conjugated dAb fusions can bind hIFNAR2. 
However, the addition of NOTA appeared to have significantly decreased the kon of 
the hIFN-mediated interaction with hIFNAR2 resulting in lower KD values of 
NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb for hIFNAR2 compared to 
hIFN alone. Moreover, the very high Rmax undermined the confidence in the 
binding values of the NOTA conjugates. 
  
                                                
* Less than 10% of the Rmax is considered appropriate 
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3.2.4 HEK-Blue hIFN Potency Assay 
The HEK-Blue hIFNα/β in vitro cellular assay was utilised as a highly 
sensitive reporter assay for the activation of the hIFN signalling pathway and thus the 
quantification of hIFN bioactivity. HEK-Blue cells stably transfected with the human 
IFN signalling pathway (Figure 3.9) plus ISRE dependent ISG54 promoter linked to 
a secreted embryonic alkaline phosphatase (SEAP) reporter gene were cultured. 
Secreted SEAP was detected in the supernatant by the addition of QUANTI-Blue 
medium, which turns purple/blue with an OD640 proportional to the amount of 
SEAP present, and thus is also proportional to the potency of the hIFN bioactivity. 
Hence, sampling a logarithmic concentration dilution series of the relevant analytes 
of 1:3/1:3.33 1nM-3fM and incubating with HEK-Blue cells, followed by plotting 
the resultant spectrophotometric OD readouts allowed the derivation of the EC50 
values of the respective analytes (Method 2.2.3).  
 
The normalised data* demonstrated only minor differences in the potency of 
the hIFN-dAb fusions compared to hIFN alone (Table 3.8, Figure 3.10). The 
NOTA-hIFN-MAXdAb was only 68.9% less potent than the hIFN alone (Table 3.8) 
in spite of the apparent 1000 fold poorer binding affinity for the hIFNAR2 (Table 
3.7). Also, the unconjugated hIFN-MAXdAb showed a 45% increase in potency over 
                                                
* The data across different plates was normalised using the hIFN control on each plate, thus 
controlling for the any differences in colourimetric development time, so that plates could be cross 
compared. 
Figure 3.9 – HEK-Blue 
hIFN Potency Assay 
Representation of NOTA-hIFN-
MAXdAb stimulating the 
production of SEAP through 
binding the IFNAR of a HEK-Blue 
cell, with subsequent colourimetric 
readout after the addition of 
QUANTI-Blue reagent.  
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hIFN. The lack of significant difference between the potency values of the 
heterogeneously 60.9% conjugated NOTA-hIFN-MAXdAb stock (Figure 3.3, Table 
3.4) and the homogeneous 100% unconjugated hIFN-MAXdAb stock demonstrated 
that although NOTA conjugation lead to a significant decrease in hIFNAR2 KD, the 
NOTA had not overall inhibited the potency of hIFN-MAXdAb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.8  
HEK-Blue hIFN Bioactivity Reporter Assay  
Protein EC50 (pM) 
NOTA-hIFN-MAXdAb 6.79 
hIFN-MAXdAb 2.78 
MAXdAb - 
NOTA-hIFN-CTRLdAb 37.5 
hIFN-CTRLdAb 6.87 
hIFN 4.02 
 n≥6 
Figure 3.10 – HEK-Blue hIFN Potency Assay 
HEK-Blue in vitro reporter assay for hIFN bioactivity utilised to calculate EC50 values of hIFN-
dAb fusions and controls – NOTA-hIFN-MAXdAb, hIFN-MAXdAb, MAXdAb, NOTA-hIFN-
CTRLdAb, hIFN-CTRLdAb, and hIFN – demonstrating a decrease in potency with the presence 
of NOTA but broadly comparable potencies to hIFN alone.  
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These results suggested that the koff may be the most important factor 
influencing the potency of the hIFN-MAXdAbs as both NOTA-hIFN-MAXdAb and 
hIFN-MAXdAb had improved koff rates for hIFNAR2 than hIFN but significantly 
lower kon rates and concomitant lower KD binding affinities. This suggested their koff 
rates disproportionately maintained the NOTA-hIFN-MAXdAb and hIFN-
MAXdAb potencies at a similar level to hIFN alone. This result conformed to the 
model of the hIFN interaction with hIFNAR (Introduction 1.5.2) whereby hIFNAR1 
binding is the rate limiting step for signalling and therefore one could hypothesise 
that a slow koff increases the likelihood of formation of the full hIFN-hIFNAR JAK-
STAT signalling complex, thus compensating for the low kon rates. 
The exception to these small potency changes was NOTA-hIFN-CTRLdAb 
because its potency decreased more than four-fold compared to unconjugated hIFN-
CTRLdAb. However, considering the NOTA-hIFN-CTRLdAb had such poor 
kinetics (slow on-rate, and fast off-rate) in the Biacore SPR experiments (Section 
3.2.3.2), this had impacted its potency to a lesser extent than was anticipated. Again 
it was apparent that large differences in the binding affinity and kinetic values are not 
linked to significant knock-on effects on the potency. Although it was nevertheless an 
unwelcome variable, in vivo this difference with the potency of NOTA-hIFN-
MAXdAb was expected to be even less relevant owing to a blood concentration in 
the nM range, far in excess of the pM EC50. It appeared reasonable to assume that 
this pM difference in potency between NOTA-hIFN-MAXdAb and NOTA-hIFN-
CTRLdAb was unlikely to be a significant determinant of hIFN-mediated bioactivity 
in vivo, but rather the binding affinities for ASGPR. Hence, this decrease in potency 
was deemed within acceptable limits and did not preclude NOTA-hIFN-CTRLdAb 
as an effective control for NOTA-hIFN-MAXdAb. 
In summary, the HEK-Blue hIFN reporter assay data has shown that the 
NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRL-dAb remain bioactive in spite of 
the presence of NOTA. The pM potencies demonstrate the effectiveness of NOTA-
hIFN-MAXdAb for activating the hIFN pathway. 
 
  
III – Xenograft Targeting of 68Ga-NOTA-hIFN-dAb 
Alex G. Papple - 127 - Ph.D. 2014 
3.2.5 Flow Cytometry  
Flow Cytometry was utilised in this investigation to profile cell binding of the 
hIFN-dAb derivative analytes to populations of the ASGPR-positive hIFNAR-
positive cell line HepG2 (Figure 3.11) and the ASGPR-negative hIFNAR-positive 
U937 histiocytic lymphoma monocyte cell line. The two cell lines, differing in their 
ASGPR expression, were chosen to establish the whole cell binding capabilities of 
hIFN-MAXdAb, NOTA-hIFN-MAXdAb, hIFN-CTRLdAb and NOTA-hIFN-
CTRLdAb as well the MAXdAb and hIFN controls, and how the presence of 
ASGPR influences this binding (Method 2.24).  
 
 
 
 
Figure 3.11 – Flow Cytometry with HepG2 cells 
Representation of NOTA-hIFN-MAXdAb binding HepG2 cells by both ASGPR and hIFNAR, 
detected by the secondary anti-dAb mAb and tertiary Alex647 fluorescence.  
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3.2.5.1 HepG2 Whole Cell Binding 
The data confirmed that HepG2 cells express both ASGPR and hIFNAR 
(Table 3.9, Figure 3.12). There was a strong indication that ASGPR expression levels 
were significantly (p<0.0001) higher than the hIFNAR levels on HepG2 cells, and the 
broad peak indicated that there was a range of ASGPR expression levels within the 
cell population. Moreover, that hIFNAR2 expression was higher than hIFNAR1, as 
was expected (Introduction 1.5.2).  
 
  
Table 3.9  
Flow Cytometric Analysis of hIFN-dAbs’ HepG2 Cell Binding  
Protein Analyte Detection mAbs Staining 
Mean 
Fluorescence 
Intensity (MFI) 
NOTA-hIFN-MAXdAb 
α-hIFN 
PI 
+ 
Alexa647 
671 ±261 
hIFN-MAXdAb 977 ±291 
MAXdAb α-dAb 1373 ±122 
NOTA-hIFN-CTRLdAb 
α-hIFN 
23.3 ±2.19 
hIFN-CTRLdAb 35.5 ±1.84 
hIFN 101 ±2.33 
RECEPTOR CTRLS 
α-ASGPR 814 ±50.0 
α-hIFNAR1 12.5 ±2.12 
α-hIFNAR2 92.5 ±14.6 
ANTIBODY CTRLS 
α-dAb 9.86 ±1.37 
α-hIFN 10.47 ±0.65 
IgG 9.45 ±1.54 
STAINING CTRL 10.17 ±1.46 
 n≥2 
Figure 3.12 – Flow Cytometry 
for Receptor detection on 
HepG2 
Histogram of flow cytometric analysis of 
live HepG2 cell staining with anti-
receptor mAbs – α-ASGPR, α-hIFNAR1, 
and α-hIFNAR2 – plus an irrelevant-IgG 
non-specific control, detected with anti-
mAb Alexa647. Data demonstrates that 
HepG2 cells express hIFNAR1, 
hIFNAR2 and ASGPR at respectively 
increasingly levels. 
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The hIFN-dAb HepG2 binding data (Figure 3.13) demonstrated that 
MAXdAb could significantly (p=0.005) increase HepG2 cell binding of a hIFN-dAb in 
vitro, such as NOTA-hIFN-MAXdAb compared to NOTA-hIFN-CTRLdAb and up 
to ten-fold higher binding than hIFN alone (Table 3.9). It was thus reasonable to 
conclude that this improved HepG2 binding was mediated by MAXdAb’s ASGPR 
affinity. Indeed, the MAXdAb alone also had a high binding to the HepG2 cells 
(Figure 3.14). 
Comparison with the irrelevant IgG1 control showed that there was some 
specific binding of the NOTA-hIFN-CTRLdAb to the HepG2 cells (p=0.02) (Figure 
3.13).  However, this was twenty-nine fold less than NOTA-hIFN-MAXdAb, which 
strongly suggested that hIFN-mediated binding via hIFNAR likely did not form a 
major part of the NOTA-hIFN-MAXdAb HepG2 cell binding. This result was 
therefore consistent with the 0.73nM KD for ASGPR and 46.9µM KD for hIFNAR2 
of NOTA-hIFN-MAXdAb, and the relative expression levels of the ASGPR and 
hIFNAR2 (Figure 3.12). Furthermore, the NOTA-hIFN-CTRLdAb binding was 
Figure 3.13 – Flow Cytometry of hIFN-dAb Fusions with HepG2 
Histogram of flow cytometric analysis of live HepG2 cell staining with hIFN-dAb fusions – NOTA-
hIFN-MAXdAb, hIFN-MAXdAb, NOTA-CTRLdAb and hIFN-CTRLdAb – detected with anti-
hIFN mAb and anti-mAb Alexa647, plus an irrelevant-IgG representing non-specific binding. 
Data demonstrates that MAXdAb-mediated HepG2 cell binding significantly increases binding 
versus CTRLdAb, with NOTA conjugation not significantly altering binding. 
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significantly (p<0.0001) lower than hIFN alone to HepG2 cells (Figure 3.14). This was 
consistent with the lesser binding kinetics for NOTA-hIFN-CTRLdAb compared to 
hIFN (Table 3.7). 
 
 
 
 
 
 
 
 
 
 
Consistent with the previous data, it was apparent that NOTA conjugation 
for hIFN-MAXdAb and hIFN-CTRLdAb appeared to have decreased their ability to 
bind to ASGPR on HepG2 whole cells (Figure 3.13) with a non-significant (p=0.25) 
decrease of 31.3% and a significant (p=0.002) decrease of 34.4%, respectively. The 
non-significance of the NOTA-hIFN-MAXdAb binding decrease is owing to the 
highly variable total cell binding values which is likely due to the influence of ASGPR 
receptor number on the binding. 
 
3.2.5.2 U937 Whole Cell Binding 
The U937 cell line was selected for its lack of ASGPR expression. Indeed, the 
U937 control stainings (Table 3.10, Figure 3.15) showed the lack of detectable 
ASGPR as the cell staining was not different to the non-specific staining with the 
irrelevant IgG. The presence of hIFNAR2 and hIFNAR1 was confirmed with the 
latter appearing to be less strongly expressed, as was seen on the HepG2 cells.  
 
The U937 data backed up the conclusions from the HepG2 cells. The 
difference between the NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb was 
reduced (Figure 3.16), thus indicating specific ASGPR binding was the driver behind 
the high binding of NOTA-hIFN-MAXdAb to HepG2 cells. As the U937 cells had a 
different expression level of hIFNAR compared to the HepG2 cells (Figure 3.15) and 
likely a different cell surface protein expression profile, it was not an ideal control for 
Figure 3.14 – Flow Cytometry of 
MAXdAb & hIFN with HepG2 
Histogram of flow cytometric analysis of live 
HepG2 cell staining with MAXdAb and 
hIFN alone detected with anti-dAb anti-hIFN 
mAb respectively and anti-mAb Alexa647, 
plus an irrelevant-IgG representing non-
specific binding. Data demonstrates that 
MAXdAb can bind to HepG2 cells to a 
greater extent than hIFN alone, seemingly 
reflecting receptor copy number. 
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specific ASGPR binding. For instance, it did not entirely rule out that the observed 
HepG2 cell binding could have been non-specific MAXdAb-mediated cell binding. 
Comparison of ASGPR-positive and ASGPR-negative cell lines from the same 
parental lineage whether transfection, siRNA or full recombination derived, may 
have provided more robust data for the effect of ASGPR on cell binding. 
 
The MAXdAb appeared to have some non-specific affinity for the U937 cells 
(Table 3.10). It had no hIFN and so ought not to have bound. This was consistent 
with the non-specific binding seen in the hIFNAR2 Biacore SPR data (Section 
3.2.3.2). Nevertheless, staining with the anti-dAb mAb secondary alone showed anti-
dAb itself is somewhat non-specifically cross-reactive with the U937 cells (Table 3.10) 
Figure 3.15 – Flow Cytometry 
for Receptor detection on 
U937 cell line 
Histogram of flow cytometric analysis of 
live U937 cell staining with anti-receptor 
mAbs – α-ASGPR, α-hIFNAR1, and α-
hIFNAR2 – plus an irrelevant-IgG non-
specific control, detected with anti-mAb 
Alexa647. Data demonstrates that U937 
cells express hIFNAR1, hIFNAR2 at 
respectively increasingly levels but do not 
express detectable levels of ASGPR above 
background staining. 
 
Figure 3.16 – Flow Cytometry of 
hIFN-dAb Fusions with U937 
Histogram of flow cytometric analysis of live 
U937 cell staining with hIFN-dAb fusions – 
NOTA-hIFN-MAXdAb, hIFN-MAXdAb, 
NOTA-CTRLdAb and hIFN-CTRLdAb – 
detected with anti-dAb mAb and anti-mAb 
Alexa647, plus MAXdAb, hIFN and an 
irrelevant-IgG representing non-specific 
binding. Data demonstrates that with only 
hIFN-mediated cell binding, there is no 
significant difference in binding between 
NOTA-hIFN-MAXdAb, hIFN-MAXdAb, 
NOTA-hIFN-CTRLdAb and hIFN-
CTRLdAb with binding no greater than hIFN 
alone. 
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and so likely accounted for some of the staining signal in the MAXdAb sample. 
The pattern of hIFNAR binding seen on the U937 cells reflected the HEK-
Blue hIFN potency results with hIFN-MAXdAb > hIFN > NOTA-hIFN-MAXdAb 
> hIFN-CTRLdAb > NOTA-hIFN-CTRLdAb. This further evidenced the assertion 
that KD for hIFNAR2 was not an accurate reflection of binding to the full hIFNAR 
(Section 3.2.4). In light of the apparent MAXdAb alone binding, the higher binding 
of the hIFN-MAXdAb compared to hIFN may be due to some MAXdAb-mediated 
non-specific binding to the U937 cells. 
 
In summary, the flow cytometry results showed that NOTA-hIFN-MAXdAb 
could bind whole HepG2 cells. This was most likely through its MAXdAb-mediated 
binding to ASGPR with an indication that hIFN-mediated hIFNAR binding was less 
relevant to total cell binding. These binding results also reflected the relative surface 
expression of ASGPR and hIFNAR1, indicating that receptor copy number was an 
important variable. The data suggested that NOTA-hIFN-CTRLdAb bound HepG2 
cells through its hIFN-mediated hIFNAR only and so was considerably less targeted 
to HepG2 cells as a result. The results indicated that any observed HepG2 tissue 
targeting in vivo would likely be driven by ASGPR binding, and concordantly that 
any observed significant difference between NOTA-hIFN-MAXdAb and NOTA-
hIFN-CTRLdAb uptake in a HepG2 xenograft would likely be overwhelmingly 
ASGPR-targeting mediated. Furthermore, the results show that HepG2 cells were an 
appropriate choice for in vivo xenograft modelling with hIFN-ASGPRdAbs.  
 
3.2.6 Radioligand Binding Assay 
A radioligand binding assay allowed the in vitro quantitation of specific 
binding of the radioligands 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-
CTRLdAb to their target receptors ASGPR and hIFNAR on a population of whole 
HepG2 cells (Method 2.2.5). This was achieved through incubating the HepG2 cells 
with the radioligands, removing unbound radioligand through a series of wash steps, 
and then measuring the bound radioactivity of the cells. The specific binding was 
determined by running two experiments in parallel, measuring both the total binding 
to the cells and the non-specific binding, with the difference between these values 
representing the specific binding. The non-specific binding was calculated by 
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blocking the specific target receptors by pre-treating the HepG2 cells with an excess 
of cold hIFN-MAXdAb blocking ligand, therefore providing a measure of only non-
specific binding such as to other membrane proteins or uptake in the lipid bilayer. 
Performing these measurements at varying concentrations of radioligand allowed the 
creation of binding curves for total and non-specific binding, and thus the resolution 
of the specific binding curve. Subsequently an estimate of KD could be calculated 
from the maximum binding Bmax. The assay was performed in a 96-well format, 
developed specifically for this work. The binding values were expressed as amount of 
bound radioligand per amount of assay protein (fmol/mg) to enable assays to be 
compared in spite of varying cell counts. 
 
The total binding appeared to demonstrate a typical single-phase exponential 
association profile (Figure 3.17). The observed specific binding for 68Ga-NOTA-
hIFN-MAXdAb reached saturation between approximately 5nM and 10nM at a 
Bmax of approximately 400fmol/mg. This corresponded to a calculated KD of 
approximately 1.9nM for HepG2 cell binding. This value was representative of 
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Figure 3.17 – 68Ga-NOTA-hIFN-MAXdAb Binding Assay 
Radioligand binding assay with 68Ga-NOTA-hIFN-MAXdAb binding HepG2 cells including total 
binding (Total Binding) and 1µM blocking with hIFN-MAXdAb (Non-Specific Binding) for the 
calculation of the Specific Binding. Data shows an apparent Bmax of 410fmol/mg for Specific 
Binding, representing a KD of 1.9nM for HepG2 cell binding. Non-specific binding increases at a 
linear concentration-dependent rate (R2=0.98). Specific binding decreases with increasing 
concentration possibly representing an increase in non-specific self-association. 
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binding to both ASGPR and hIFNAR. This compared to the Biacore quantitated KD 
values for NOTA-hIFN-MAXdAb of 0.7nM for ASGPR (Table 3.6) and 46.9µM for 
hIFNAR (Table 3.7), with the lower KD values representing the post-labelling 
reaction affinities. The KD value of 1.9nM thus indicated that the majority of HepG2 
cell binding is through MAXdAb-mediated ASGPR binding, and concurs with the 
emerging model established by the flow cytometry data. This hypothesis was further 
supported by the 68Ga-NOTA-hIFN-CTRLdAb data (representing hIFNAR binding 
only) which demonstrated no detectable HepG2 binding above non-specific binding 
at the sampled concentrations (Figure 3.18). Therefore, it appeared that any hIFN-
mediated hIFNAR binding to HepG2 cells in the 68Ga-NOTA-hIFN-MAXdAb 
assay was likely to have a broadly negligible overall influence on total binding and so 
the observed binding is likely to only reflect MAXdAb-mediated ASGPR HepG2 
binding. 
 
A Scatchard plot (Figure 3.19) of the total bound ligand against the ratio of 
bound and free ligand showed a linear relationship with an R2 = 0.92 that was 
indicative of the ligand binding with a single affinity. This was supported by a Hill 
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Figure 3.18 – 68Ga-NOTA-hIFN-MAXdAb vs 68Ga-NOTA-hIFN-
MAXdAb in a HepG2 Binding Assay 
Radioligand binding assays with 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-CTRLdAb 
total binding to HepG2 cells for the calculation of the MAXdAb mediated binding. This includes 
both specific and non-specific binding. The data demonstrates that hIFN-mediated binding either 
specifically to hIFNAR or non-specifically does not significantly (p>0.05) contribute to HepG2 
binding by 68Ga-NOTA-hIFN-MAXdAb. 
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coefficient of 0.92, which was indicative of binding to one binding site. The 
Scatchard plot and Hill coefficient data appeared to support the assertion that an 
ASGPR binding was the primary driver of the observed NOTA-hIFN-MAXdAb 
HepG2 interaction. The Scatchard plot also indicated a KD of 4.58nM for HepG2 
cells, which again demonstrated that NOTA-hIFN-MAXdAb had a low nM affinity 
for HepG2 cells. 
 
In summary, the radioligand binding assay provided additional data to 
support evidence from previous experiments. It concurred with the Biacore SPR data 
and Flow Cytometry data showing that the predominating MAXdAb-mediated low 
nM affinity ASGPR HepG2 binding of NOTA-hIFN-MAXdAb contrasts with the 
low HepG2 binding of the NOTA-hIFN-CTRLdAb.  
 
 
  
R² = 0.92222
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.0 100.0 200.0 300.0 400.0 500.0 600.0 700.0 800.0
H
ep
G
2 
Bi
nd
in
g 
/ 
Fr
ee
 L
ig
an
d
HepG2 Cell Binding (fmol/mg)
Figure 3.19 – Scatchard Plot of 68Ga-NOTA-hIFN-MAXdAb  
Radioligand binding assay with 68Ga-NOTA-hIFN-MAXdAb represented as a Scatchard plot of 
the ratio of HepG2 bound ligand to the free assay ligand against the total bound protein 
(fmol/mg). The linear plot demonstrates that the HepG2 binding was with a single affinity, most 
likely the ASGPR-mediated interaction. The slope indicates a KD of approximately 4.58nM. 
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3.4 GA-68 RADIOLABELLING DEVELOPMENT 
The chosen radiolabelling strategy for this work was utilising gallium-68 
(Introduction 1.7.2) to radiolabel the NOTA conjugated dAb fusions. The Ga-68 
radiolabelling of dAb proteins had never been previously performed prior to this 
investigation. Therefore, the reaction conditions required extensive optimisation to 
attain high labelling efficiencies at low protein concentrations, in order to achieve the 
maximum specific activities. 
 
3.4.1 Reaction Development 
The EZ IG100 370MBq 68Ge/68Ga generator was used to produce Ga-68 for 
the radiolabelling reactions (Method 2.3.1). The generator set-up underwent 
numerous iterations towards a system of elution for efficient collection of the most 
radioactive fraction and minimised failed runs. Airlocks in particular prevented failed 
runs and potential damage to the generator due to air in the system.  
The optimum radioactive yields were attained from the first elution of the day 
if the generator was eluted in the previous evening. Regular daily elution also 
improved labelling reliability, likely by preventing the build up of impurities. Manual 
injection of 0.1M HCl at a rate of 1ml/min was found to yield the most consistent 
elution profile. The elution output profile was periodically monitored to attain the 
highest radioactive fraction possible for reaction (Appendix Figure 6.12) by collecting 
the eluate conforming to the top of the peak. The generator yields were observed to 
deteriorate faster than the Ge-68 half-life may suggest (Appendix Figure 6.13) and so 
generator care was a high priority. 
TraceSelect reagents were used for all the reaction reagents, including 
making all reagents in TraceSelect UltraPure water, which improved the labelling 
consistency by presumably reducing metal contaminants. The use of LoBind 
plasticware improved radiolabelling by an estimated 3-5% and also reduced losses 
during recovery by an unquantified amount, likely due to less protein sticking to the 
tubes. The order of reactant addition appeared important to prevent colloid 
formation. Radiolabelling efficiencies improved by adding the buffer to the aliquot of 
Ga-68 with instant mixing to prevent pockets of high pH, lastly followed by the 
conjugated protein.  
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Radiolabelling efficiencies for a time during the investigation dropped 
markedly. The problem was traced to the use of rubber in syringes and the airlocks. 
After subsequently switching to non-rubber equivalents the radiolabelling efficiencies 
were restored.  
Initial indications about optimum reaction conditions were explored with 
NOTA alone labelling. These confirmed that 10 minutes at room temperature was 
optimum (37˚C increased labelling efficiency but also colloid) and was further 
observed to label optimally at pH3.5. The sampling of a titration of reaction pHs for 
hIFN-MAXdAb with 5M NaOH buffering identified pH4.4 as the optimal 
(Appendix Figure 6.14). The pH4.4 was likely the optimum pH between protein 
degradation at low pH and colloid formation at higher pH. The colloid was observed 
to increase up to an average of 13.8% with an increase in pH of only between 0.5 
and 1.0 units. 
 
3.4.2 Ga-68 Radiolabelling Reactions 
Three reaction condition protocols were optimised based on buffering 
conditions to maintain the pH 4.4 reaction conditions: 5M NaOH (Appendix 
6.1.5.1), 5M NaAc (Appendix 6.1.5.2) and 1M NaAc (Method 2.3.2). 
The results demonstrated the contrasting efficacies of the different strategies 
(Table 3.11). The 5M NaOH method did not achieve sufficiently high specific 
activities above 0.5MBq/µg for NOTA-hIFN-MAXdAb. Similarly, the 5M NaAc 
method did not achieve specific activities consistently above 1.25MBq/µg. The logic 
behind utilising strong 5M NaOH and 5M NaAc buffers was to minimise the volume 
of the added buffer in the reaction, thus allowing more radioactivity to be included 
for the maximum potential specific activity. However, in practice both these methods 
proved unreliable because utilising small volumes increased the likelihood of pH 
variability and the highly concentrated alkaline was hypothesised to create a 
temporal pocket of high pH prior to shaking, which would increase colloid. It was 
apparent from the results that these methods resulted in a significant (p=0.0002) 5.8 
fold greater formation of colloid when labelling NOTA-hIFN-MAXdAb compared 
to the 1M NaAc method, and thus the maximum potential labelling efficiencies were 
not attained. 
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Table 3.11  
Ga-68 Labelling Method Results  
Protein$ Radiolabelling Method* 
Labelling Parameters 
Radiolabelling 
Efficiency (%) 
Specific 
Activity 
(MBq/µg) 
Colloid 
(%) 
NOTA-hIFN-
MAXdAb 
 
5M NaOH 
 
83.0 ±8.9 0.53 ±0.04 18.3 ±7.47 
 
5M NaAc 
 
75.8 ±10.3 1.23 ±0.21 23.7 ±7.24 
 
1M NaAc 
 
88.9 ±2.5 2.37 ±0.08 3.64 ±0.49 
NOTA-hIFN-
CTRLdAb 
 
5M NaOH 
 
- - - 
 
5M NaAc 
 
87.1 ±1.9 0.77 ±0.18 11.4 ±2.19 
 
1M NaAc 
 
95.4 ±8.9 2.47 ±0.11 1.28 ±0.92 
*Method 2.3.2 & Appendix 6.1.5, n>3, $~16µg at 1µM 
 
 
The 1M NaAc method yielded significantly (p<0.0001) higher specific activities 
for both NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb, with labelling 
sufficient for potential PET imaging given consistent specific activities above 
~2.4MBq/µg owing to reliably low colloid formation (Table 3.11, Figure 3.20). The 
increased volume reduced the likelihood of pipetting errors and alleviated the colloid 
formation problems with reductions up to 85%. Moreover, utilising UltraPure 
reagents and Lo-Bind Eppendorf tubes further increased the achievable 
radiolabelling efficiencies at lower concentrations of hIFN-dAb down to 1µM. At this 
concentration, incubating at 37˚C also helped increase the radiolabelling efficiency 
consistency (Section 3.6.1).  
The NOTA-hIFN-CTRLdAb consistently labelled to a higher specific 
activity than the NOTA-hIFN-MAXdAb regardless of the method employed. The 
reason for this was unclear, but was likely to be due to a differing NOTA conjugation 
state (Section 3.2.2.4). 
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Biacore SPR analysis (Section 3.2.3.1) was utilised with NOTA-hIFN-
MAXdAb to ascertain that the ASGPR binding properties were still active after 
undergoing the 1M NaAc labelling protocol*. The data demonstrated that there was 
a negative effect on the MAXdAb-mediated ASGPR binding of the protein after 
undergoing the radiolabelling reaction (Figure 3.21). The KD for unreacted NOTA-
hIFN-MAXdAb was determined to be 0.85nM† and post-reaction was determined to 
be 1.66nM ±0.07. This latter decrease in affinity compares with the 1.9nM result 
from the radioligand binding assays (Section 3.2.6). Hence, the labelling reaction had 
                                                
* This was performed with just 0.1M HCl rather than Ga-68 eluate 
† Compares to 0.73nM from the previous work, which was a fresher batch of conjugated protein 
Figure 3.20 – Ga-68 NOTA-hIFN-MAXdAb Radiolabelling Reactions 
with 1M NaAc Method 
Phosphorimaging of typical 0.02M CA-EDTA and WEA-(2%BSA(w/v)) TLCs of a 68Ga-NOTA-
hIFN-MAXdAb radiolabelling reaction and a Buffer Only radiolabelling reaction control. The 
CA-EDTA TLC relative intensities allow the computation of the 68Ga-EDTA as a measure of free 
Ga-68 whereas the WEA-TLC allows computation of the radiolabelled product – the 68Ga-colloid 
is calculated from both TLCs. 
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a detrimental effect on the binding affinity but the ASGPR binding was nevertheless 
maintained at a low nM level.  
 
In summary, a radiolabelling method involving buffering with 1M NaAc was 
designed and optimised to enable the reaction of NOTA-hIFN-dAbs with Ga-68 at 
pH4.4. This achieved reliably high labelling efficiencies and concurrently high 
specific activities, with only a minor affect on binding affinity.  
 
3.4.3 Further Reaction Optimisation 
3.4.3.1 Reaction Purification 
The maximum radiolabelling efficiencies and specific activities achieved with 
the 1M NaAc method were sufficient for in vivo work. However, there was still colloid 
present and free 68Ga-EDTA and so purification of the reaction was optimised 
(Appendix 6.1.7 & Method 2.3.2). 
Filtration with a syringe-driven 0.22µm filter unit was utilised based on the 
principle that the filter membrane would retain the 68Ga-colloid. This method 
showed a recovery of 50.6% ±14.0 and in over half of instances there was a net 
decrease in purity owing to lost 68Ga-NOTA-hIFN-dAb. Hence, this method was not 
appropriate.  
A modified Protein A method for purifying the radiolabelled NOTA-hIFN-
dAbs proved ineffectual, with a recovery of 3.4% ±2.1 purified 68Ga-NOTA-hIFN-
MAXdAb. This was owing to only about 10% of the loaded radiolabelling reaction 
Figure 3.21 – Biacore T200 SPR Analysis of the NOTA-hIFN-MAXdAb 
pre- and post-reaction 
Biacore T200 SPR with ASGPR-H1-CRD immobilised on a CM5 chip assessed the ASGPR-H1-
CRD binding kinetics of a 64-0.25nM 1:2 serial dilution of NOTA-hIFN-MAXdAb both pre- and 
post-reaction with Ga-68 injected over the chip surface at 30µlmin-1. Demonstrates decrease in 
binding affinity for ASGPR-H1-CRD but MAXdAb function remains active. 
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binding to the column and a poor elution profile. This method was also ineffectual 
because the NaAc buffer still required pH adjustment from pH4.5 to pH7.0. 
Illustra NAP-5 column purification was the standard purification method for 
radiolabelled dAb fusions74, however the highest yield achieved with 68Ga-NOTA-
hIFN-MAXdAb was a 25.8% loaded protein recovery in the 0.7ml fraction with a 
68.8% reduction in colloid and overall a 56.8% increase in the purity of the 68Ga-
NOTA-hIFN-MAXdAb. This method thus proved again ineffectual in spite of 
positive purity improvements because there was too much product retained on the 
column and the recovered fraction was too dilute for PET imaging. 
The MiniTrap G25 column purification method yielded consistently pure 
product (Figure 3.22) at sufficiently high concentrations for subsequent PET imaging. 
Figure 3.22 – G-25 MiniTrap Purification of a Ga-68 NOTA-hIFN-
MAXdAb Radiolabelling Reaction  
Example of 0.02M CA-EDTA and WEA (2%BSA(w/v)) TLC phosphoimaging of a 68Ga-NOTA-
hIFN-MAXdAb radiolabelling reaction and the primary fraction from the subsequent G-25 
MiniTrap purification. The radiochemical impurities were observed to decrease in G-25 with 
purification, most apparent in the CA-EDTA TLC result. 
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Radiochemical impurities were decreased by an average of 78.1% ±12.1, allowing 
68Ga-NOTA-hIFN-MAXdAb purified up to 97.8% and 68Ga-NOTA-hIFN-
CTRLdAb up to 99.4%, as quantified by iTLC (Figure 3.22) and confirmed by 
HPLC (Figure 3.23). Furthermore, the process simultaneously buffer exchanged into 
physiological buffer PBS and as a two step method was also rapid. 
 
Hence, a method of quickly and reliably purifying the 68Ga-NOTA-dAbs to 
almost 100% purities was developed utilising MiniTrap G25 columns, whilst also 
conveniently buffer exchanging into PBS.  
 
3.4.3.2 Cationic Exchange Reactions 
The elution of the Ga-68 generator with 0.1M HCl allowed the direct 
collection of the most radioactive fraction of Ga-68 based on the top of the elution 
activity peak. However, the eluate is a relatively dilute solution of Ga-68. Therefore, 
concentrating this fraction and the radioactivity from the whole elution would enable 
a higher concentration of radioactivity available within the same or a lower reaction 
Figure 3.23 – SE-HPLC of G25-Purified 68Ga-NOTA-hIFN-MAXdAb 
Fraction 
SE-HPLC YMC-DIOL-60 column separation, and 220nm UV and radio detection of 68Ga-
NOTA-hIFN-MAXdAb purified in the primary fraction of the G25 MiniTrap purification.  The 
observed results demonstrate the 100% purity of the 68Ga-NOTA-hIFN-MAXdAb eluting at 12.62 
minutes on the UV trace and as detected on the radio-trace at 13.53 minutes. The remaining UV 
trace peaks correspond to buffer reagents. 
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volume, thus potentially allowing higher achievable specific activities. Cationic 
exchange allowed scrubbing of the Ga-68 from the eluate and then re-elution in a 
considerably smaller volume (Appendix 6.1.6). 
Bond-Elut SCX cationic exchange columns were successfully used to extract 
the Ga-68 from the eluate. The Ga-68 elution was optimised to elute at a markedly 
higher concentration in ~40µl of 5M NaCl 0.1M HCl pH1.0. This enabled the 
average MBq per reaction to increase from 20.4MBq ±2.21 to 49.6MBq ±3.70 in spite 
of a greater than 400% decrease in reaction volume. Buffering with 1M NaAc to 
pH4.0 was established as the optimum reaction conditions for labelling NOTA-
hIFN-CTRLdAb to high labelling efficiencies followed by G25 purification (Table 
3.12).  
 
 
The achievable specific activities for 68Ga-NOTA-hIFN-CTRLdAb were 
increased by over 50%, in spite of a decrease in radiolabelling efficiency, and were 
efficiently purified to close to 100% radiochemical purity as shown by iTLC 
(Appendix Figure 6.16).  
However, the reduction in labelling efficiency was indicative of a problem. 
Indeed, when it came to radiolabelling NOTA-hIFN-MAXdAb, the task proved 
insurmountable. Closer analysis of the NOTA-hIFN-MAXdAb post-reaction by 
Biacore SPR analysis revealed that the reaction conditions were too stringent and the 
MAXdAb-mediated ASGPR binding was lost (Figure 3.24). Therefore, it was 
possible that the high salt conditions may have caused denaturation. 
Table 3.12  
Ga-68 Bond-Elut SCX Labelling Method Results  
Protein$ Radiolabelling Method 
Labelling Parameters 
Radiolabelling 
Efficiency (%) 
Specific 
Activity 
(MBq/µg) 
Max. 
Purified 
(%) 
NOTA-hIFN-
CTRLdAb 
1M NaAc 95.4 ±8.90 2.47 ±0.11 99.4 
SCX 79.1 ±3.70 3.79 ±0.18 99.1 
n≥3 
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Decreasing the salt concentration in the elution buffer from 5M to 1M (a final 
reaction concentration of ~3M to ~0.5M respectively) did not ameliorate the loss of 
ASGPR-binding function. Moreover, below 2.5M, the column elution was less 
efficient, eluting over a larger volume range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, the Bond-Elut SCX cationic exchange protocol may yield high 
specific activity labelling with proteins that can survive the high salt concentrations 
but cationic exchange methods proved inappropriate for hIFN-MAXdAb 
radiolabelling.    
 
Figure 3.24 – Biacore T200 SPR Analysis of the NOTA-hIFN-MAXdAb 
post SCX Cationic Exchange Radiolabelling Reaction 
Biacore T200 SPR with ASGPR-H1-CRD immobilised on a CM5 chip was carried out to assess 
the ASGPR-H1-CRD binding kinetics of a 64-0.25nM 1:2 serial dilution of NOTA-hIFN-
MAXdAb post-reaction with SCX cationic Ga-68, injected over the chip surface at 30µlmin-1. 
Result demonstrates that the SCX Ga-68 radiolabelling reaction conditions render the MAXdAb 
unable to bind ASGPR.  
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3.5 BIODISTRIBUTION STUDIES 
Radioligand biodistribution analyses are complicated experiments involving 
integrating numerous time-critical steps (Appendix Figure 6.3). They were used to 
quantify in vivo NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb HepG2 
xenograft tissue uptake, in addition to uptake in other tissues (Method 2.4.3). SCID 
Beige HCC HepG2 models were created for this purpose. The uptake values for the 
dissected tissues were converted to %ID/g so as to control for the mass of the tissue. 
 
3.5.1 Ga-68 Radiolabelling 
Utilising the 1M NaAc method developed for the reliable labelling of the 
NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb (Method 2.3.2) plus G-25 
MiniTrap purification to remove radiochemical impurities, radiolabelled doses of the 
NOTA-hIFN-dAbs were prepared at RT immediately prior to injection thus 
maximising the dose radioactivity of the short-lived Ga-68.  
The average specific activity achieved with a ~2µM reaction (Table 3.13) for 
both NOTA-hIFN-MAXdAb (1.40MBq/µg) and NOTA-hIFN-CTRLdAb 
(1.24MBq/µg) was sufficient for subsequent gamma counting in all instances. 
 
A final radiochemical purity of greater than 96% was achieved in all instances 
utilising G-25 MiniTrap purification. The purified fraction was further diluted with 
PBS(1% BSA (w/v)) to yield the desired mass of radiolabelled protein per 200µl dose 
as appropriate.  
 
 
Table 3.13  
Ga-68 Radiolabelling for Biodistribution Studies 
Protein Reaction Conc. (µM) 
Radiolabelling 
Efficiency (%) 
Specific Activity 
(MBq/µg) 
Radiochemical 
Purity (%)* 
NOTA-hIFN-
MAXdAb 2.19 89.2 ±4.56 1.40 ±0.63 98.0 ±1.63 
NOTA-hIFN-
CTRLdAb 2.08 93.4 ±8.34 1.24 ±0.39 99.4 ±0.50 
 n≥3, SD values displayed, *post-G25 purification 
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3.5.2 Dosing Biodistribution Study 
A dosing study was initially performed to determine whether receptor 
saturation* was a significant effect with increasing dose. The aim was to have an 
effective concentration to observe xenograft targeting without saturating the 
receptors. Doses of 1µg, 6µg and 16µg of 68Ga-NOTA-hIFN-MAXdAb were selected 
for biodistribution analysis at three hours post-injection.  
 
The 1µg dose demonstrated the highest xenograft tissue uptake values at 
2.42%ID/g ±0.69 (Figure 3.25). There was no observed significant difference between 
1µg and 16µg (p=0.25), and similarly the 6µg and 16µg doses (p=0.23). There was, 
however, a minor significant decrease (p=0.03) in the tumour xenograft uptake 
between 1µg and 6µg. This decrease was not perceived to indicate receptor 
                                                
* Non-radiolabelled ligand within the same administered dose outcompeting the radioligand* for 
receptor binding 
Figure 3.25 – Biodistribution of 68Ga-NOTA-hIFN-MAXdAb in SCID 
Beige HepG2 Xenograft Model at 3hr with varying dose 
Mean %ID/g in selected tissues at 1µg, 6µg, and 16µg injected dose of 68Ga-NOTA-hIFN-
MAXdAb at 3 hours post- IV administration as determined by Gamma Counting. No relevant 
significant differences in tissue uptakes observed at any of the doses tested but for minor decrease in 
tumour uptake between 1µg and 6µg. 
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saturation because there was not then a concurrent decrease in xenograft uptake 
from 6µg to 16µg. The xenograft uptake data thus did not appear to present any 
clear indication about whether receptor saturation was occurring. Nonetheless, it did 
show that observable xenograft uptake was quantifiable with a 1µg dose of 68Ga-
NOTA-hIFN-MAXdAb. The reliability of the radiolabelling reaction to achieve 
specific activities sufficient for a 1µg dose* was highly reproducible and so there was 
no impediment to using a 1µg dose. Hence, on the balance of probabilities, it 
appeared prudent to proceed with further in vivo experimentation using a 1µg dosing 
strategy.  
 
The remaining tissues showed no discernable pattern of uptake relative to the 
dose and so will be analysed in more detail in further sections. However, the liver and 
kidney tissues showed very large uptakes.  
The liver tissue demonstrated approximately 50%ID/g uptake of the 68Ga-
NOTA-hIFN-MAXdAb. This corresponded to an average of 44.9% of the total 
injected dose (ID). Therefore, the liver was a very large sink for the 68Ga-hIFN-
MAXdAb. Some uptake was expected to be attributable to the small amount of 
remaining 68Ga-colloid impurity in the dose. Moreover, some off-target MAXdAb-
mediated cross-reactivity was anticipated because the amino acid sequences of Homo 
sapiens ASGPR1/ASGPR2 and the Mus musculus ASGPR1/ASGPR2 are 79%/64% 
identical and 89%/84% similar, respectively†. Murine ASGPR1/ASGPR2 are also 
present in the murine liver at a very high level of 222/180FPKM‡, respectively. 
Hence, the probability of the hypothesised off-target interaction of MAXdAb with 
murine ASGPR (mASGPR) was high and indeed dAb cross-species reactivity was 
previously observed in vitro with Biacore SPR and in vivo with SPECT imaging74. 
There may also be IFNAR cross-reactivity (discussed in Section 3.5.3.3). However, 
the observed extent of uptake was not anticipated. This was problematic for the 
model because the mouse liver removed a high proportion of the injected dose from 
the system. This complicated the model because this dose was unavailable for uptake 
in the xenograft tissue (Section 3.5.4). In this instance, however, it had no affect on 
                                                
* Dose is limited by still having adequate radioactivity for gamma counter readings at 3h post-injection 
† UniProt analysis performed on P07307 ASGR2_HUMAN and P24721 ASGR2_MOUSE 
‡ Average value from three studies for Asgr1 and in Mus musculus as determined by www.ebi.ac.uk 
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the conclusions because the uptake was not significantly (p=0.87) different for each 
concentration of NOTA-hIFN-MAXdAb and so could be considered a constant.  
The highest observed uptake of any tissue sampled was approximately 
130%ID/g in kidney and was representative of the 33kDa 68Ga-NOTA-hIFN-
MAXdAb being under the renal clearance threshold of 66kDa. This represented an 
average of 17.2% of the injected dose. This loss was unavoidable without introducing 
a blocking agent such as serum albumin or performing a nephrectomy. These were, 
however, deemed likely to just introduce further unknown variables. 
 
In summary, the experiment yielded ambiguous data concerning to effect of 
dose on tissue uptake and so firm conclusions on receptor saturation could not be 
drawn. Therefore it appeared logical to continue with the lowest reproducible dose, 
which was 1µg.   
 
3.5.3 Time Course Biodistribution Study 
 The NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb tissue uptake in 
the SCID Beige HepG2 xenograft model was examined at 1h, 3h and 24h post-
injection time points utilising a 1µg dose to determine how tissue uptake changes over 
time. 
 
3.5.3.1 In-111 Labelling  
 The 68Ga radiolabelling was not appropriate for a 24h time point and thus 
In-111 radiolabelling was employed to attain the 24h time point data (Table 3.14). 
  
Table 3.14  
In-111 Radiolabelling for Biodistribution Studies 
Protein Reaction Conc. (µM) 
Radiolabelling 
Efficiency (%) 
Specific Activity 
(MBq/µg) 
Radiochemical 
Purity (%)* 
NOTA-hIFN-
MAXdAb 3.00 94.4 0.91 99.0 
NOTA-hIFN-
CTRLdAb 3.00 98.7 1.05 100.0 
 n=1, 3µM reaction, SD values displayed, *post-G25 purification 
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3.5.3.2 Xenograft Uptake Analysis 
The HepG2 xenografts from the SCID Beige model demonstrated 
significantly different temporal radioligand uptake of the 68Ga-NOTA-hIFN-
MAXdAb compared to 68Ga-NOTA-hIFN-CTRLdAb (Figure 3.26) with the uptake 
of 68Ga-NOTA-hIFN-MAXdAb significantly higher at each time point. Thus this 
strongly suggested that the MAXdAb-mediated ASGPR binding was responsible for 
the increased uptake over the non-ASGPR targeted 68Ga-NOTA-hIFN-CTRLdAb. 
 
At 3h the difference between 68Ga-NOTA-hIFN-MAXdAb and 68Ga-
NOTA-hIFN-CTRLdAb uptake in the HepG2 xenografts of 2.42%ID/g versus 
0.68%ID/g, respectively (Table 3.15), was extremely significant (p=0.0008) (Figure 
3.26). This significance represented a decrease in variability in 68Ga-NOTA-hIFN-
MAXdAb uptake at 3h, as denoted by the tighter percentiles and the mean and 
median converging, compared to 1h post-injection where the range of results was 
Figure 3.26 – Xenograft Uptake of 68Ga-NOTA-hIFN-MAXdAb and 
68Ga-NOTA-hIFN-CTRLdAb in SCID Beige HepG2 Xenograft Model 
with 1µg dose over time 
Mean %ID/g in xenograft tissue at 1µg injected dose of 68Ga-NOTA-hIFN-MAXdAb and 68Ga-
NOTA-hIFN-CTRLdAb at 1 and 3 hours post-IV injection, in addition to 111In-NOTA-hIFN-
MAXdAb and 111In-NOTA-hIFN-CTRLdAb at 24 hours post-IV-injection, as determined by 
gamma counting. Demonstrates significantly higher xenograft uptake with MAXdAb-mediated 
ASGPR targeting compared to only hIFN-mediated hIFNAR targeting. 
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Figure 3.27 – Xenograft Uptake versus Blood Concentration of 68Ga-
NOTA-hIFN-MAXdAb in SCID Beige HepG2 Xenograft Model with 
1µg dose over time 
Mean %ID/g in xenograft tissue and blood at 1µg injected dose of 68Ga-NOTA-hIFN-MAXdAb 
at 1 and 3 hours post-IV injection, in addition to 111In-NOTA-hIFN-MAXdAb at 24 hours post-
IV-injection, as determined by Gamma Counting. Demonstrates significantly higher levels of 
radioligand in xenograft at 3h and 24h versus in blood, therefore indicating that xenograft uptake 
is not a product of a high blood concentration. 
much greater. The xenograft uptake variability at 1h (Figure 3.26) was thought likely 
to be due to non-specific uptake promoted by a high blood concentration, as the 
xenograft to blood ratio was 0.9:1 at 1h prior to effective renal clearance. This 
contrasted with the uptake of 68Ga-NOTA-hIFN-MAXdAb in the xenograft at 3h 
being significantly (p=0.005) higher than the concentration in blood (Figure 3.27) at a  
3.5:1 xenograft to blood ratio. This strongly suggested that xenograft uptake was due 
to specific binding rather than being an artificial effect of the blood concentration. 
Therefore, 3h represented a consistent stable uptake value and was likely mediated 
by specific binding. 
There was a significant (p=0.014) decrease in xenograft uptake of the NOTA-
hIFN-MAXdAb between 3h and 24h (Figure 3.28) from 2.42%ID/g to 1.23%ID/g, 
which suggested that the half-life in the xenograft is approximately 24 hours. The 
difference in xenograft uptake versus 68Ga-NOTA-hIFN-CTRLdAb was nevertheless 
still highly significant (p=0.0005) (Figure 3.26), which demonstrated that MAXdAb-
mediated ASGPR binding could still promote xenograft retention at 24h. Moreover, 
the uptake was also extremely significant (p<0.0001) compared to the blood 
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concentration (Figure 3.27) with a xenograft to blood ratio of 7.1:1. The 68Ga-
NOTA-hIFN-CTRLdAb xenograft to blood ratios were 0.71:1 at 1h, 2:1 at 3h and 
10.6:1 at 24h, which suggested that there was perhaps some hIFN-mediated hIFNAR 
targeted xenograft tissue retention with efficient blood wash out. 
In conclusion, the xenograft uptake data strongly suggested that MAXdAb-
mediated ASGPR targeting increased specific xenograft uptake of a hIFN-dAb fusion 
versus hIFN-mediated hIFNAR targeting alone.  
 
3.5.3.3 Full Tissue Analysis 
The uptake in the liver of the 68Ga-NOTA-hIFN-MAXdAb was consistent 
with the dosing assay at approximately 50%ID/g (Figure 3.25), and did not show a 
significant (p=0.09) change over time (Table 3.15). The 68Ga-NOTA-hIFN-CTRLdAb 
on the other hand demonstrated a consistent significant (p=0.002) decrease in liver 
tissue uptake over time. The consistently higher liver retention of NOTA-hIFN-
MAXdAb compared to NOTA-hIFN-CTRLdAb was consistent with an additive 
effect by MAXdAb-mediated ASGPR binding on mouse liver uptake.  
However, there was no significant difference (p=0.12) in liver uptake at 1h with 
both equally high. The 24h NOTA-hIFN-CTRLdAb uptake was still 39.5%ID/g. 
Therefore, it could not be MAXdAb-mediated ASGPR binding that accounted for 
the majority of liver uptake, but rather was a factor common to both radioligands. 
Both molecules contained hIFN and so the primary consideration was a cross-
reactivity of hIFN with murine IFNAR (mIFNAR) because hIFNAR and mIFNAR 
are 65.5% similar*. The in vitro assays strongly suggested that neither NOTA-hIFN-
MAXdAb nor NOTA-hIFN-CTRLdAb had a high affinity for hIFNAR and so a 
high affinity for mIFNAR seemed unlikely. The mIFNAR copy number in the mouse 
liver was likely to be cumulatively high so may have resulted in a high retention in 
spite of the relatively poor kinetics of the hIFN-hIFNAR2 interaction identified in 
vitro. However, this would contradict previous data which showed that a mIFN-
CTRLdAb did not demonstrate liver uptake74 and a reported mIFNAR expression 
level of only 10.5FMPK in liver compared to 22.5FMPK for spleen for instance.  
                                                
* UniProt analysis performed on P17181 INAR1_HUMAN and P33896 INAR1_MOUSE, and 
P48551 INAR2_HUMAN and O35664 INAR2_MOUSE 
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Figure 3.28 – Biodistribution of NOTA-hIFN-MAXdAb and NOTA-
hIFN-CTRLdAb in SCID Beige HepG2 Xenograft Model at 1h, 3h and 
24h 
Mean %ID/g in selected tissues at 1h, 3h, and 24h post 1µg injection of 68Ga/111In-NOTA-hIFN-
MAXdAb (A) or 68Ga/111In-NOTA-hIFN-CTRLdAb (B). Various significant differences in 
biodistribution were observed over time. 
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The presence of the O-linked glycosylation is also common to both 
radioligands and so the presence of asialyted sugars, as observed in the NOTA-hIFN-
MAXdAb MS results (Section 3.2.2.4), may have resulted in mASGPR-mediated 
liver uptake and endosomal degradation. This may have partially accounted for the 
persistently high liver uptake values if the radioactivity was retained in the tissue.  
Other considerations included 68Ga-colloid, although this was purified out of 
the dose prior to injection and so was unlikely to have contributed significantly to the 
uptake. Hepatic protein degradation pathways may have concentrated the 
radioligands, however other similar antibody fusion proteins do not concentrate in 
the liver to the same extent so this seemed an unlikely factor. User error was ruled 
out owing to the significant differences in xenograft uptake (Figure 3.26) and batch 
checks by Biacore SPR analysis (data not shown). 
Therefore, the unexpected liver uptake of 68Ga-NOTA-hIFN-CTRLdAb was 
not definitively defined.  
 
The clearance routes for both radioligands were identifiable as kidney and 
intestine. The kidney uptake in both instances showed a pattern of increasing 
between 1h and 3h subsequently decreasing between 3h and 24h. For instance from 
an average of 88.8%ID/g for 68Ga-NOTA-hIFN-MAXdAb at 1h up to 138%ID/g 
at 3h. This was concurrent with the significant decrease in blood radioligand 
concentration, and most likely represented the primary route of excretion of 
Table 3.15  
Time Course Biodistribution Analysis Tissue Uptake Values 
Tissue 
(%ID/g) 
1h 3h 24h 
68Ga-NOTA-hIFN-
MAXdAb 
68Ga-NOTA-hIFN-
CTRLdAb 
68Ga-NOTA-hIFN-
MAXdAb 
68Ga-NOTA-hIFN-
CTRLdAb 
111In-NOTA-hIFN-
MAXdAb 
111In-NOTA-hIFN-
CTRLdAb 
Xenograft 2.56 ±0.87 0.75 ±0.05 2.42 ±0.69 0.68 ±0.11 1.23 ±0.08 0.67 ±0.21 
Intestine 1.30 ±0.22 1.71 ±0.21 3.21 ±1.06 3.49 ±0.50 2.25 ±0.20 1.61 ±0.58 
Pancreas 1.05 ±0.34 0.88 ±0.87 0.99 ±0.25 1.1 ±0.17 0.93 ±0.10 1.05 ±0.37 
Spleen 4.61 ±0.27 7.80 ±1.96 4.07 ±1.27 5.73 ±1.18 9.43 ±1.12 8.43 ±1.57 
Stomach 0.55 ±0.87 0.89 ±0.35 0.82 ±0.60 0.91 ±0.69 0.89 ±0.22 0.86 ±0.17 
Kidneys 88.8 ±8.21 91.5 ±11.5 138 ±36.82 113 ±17.2 102 ±11.7 86.1 ±11.4 
Liver 52.8 ±12.65 64.7 ±3.28 49.7 ±14.67 49.4 ±5.35 65.1 ±4.18 39.5 ±5.63 
Heart 1.59 ±0.04 1.31 ±0.11 1.24 ±0.37 1.42 ±0.31 1.05 ±0.36 1.2 ±0.25 
Lung 5.21 ±2.29 1.59 ±0.32 1.74 ±1.00 1.03 ±0.52 1.23 ±0.43 1.13 ±0.75 
Blood 2.87 ±0.60 1.13 ±0.32 0.76 ±0.32 0.35 ±0.09 0.18 ±0.03 0.10 ±0.04 
Muscle 0.37 ±0.06 0.28 ±0.05 0.53 ±0.35 0.53 ±0.31 0.32 ±0.07 0.27 ±0.13 
 ~1µg dose, n≥3 
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unbound radioligand. However, there was a strong indication of kidney retention 
given the tissue concentration continuing to be above 80%ID/g for both radioligands 
at 24 hours post injection. Indeed renal uptake has also been reported for EGFR-
targeting nanobodies473. 
The statistically significant increases of both radioligands in the intestine 
between one and three hours were not through ingestion and so was implicated as 
hepatobiliary excretion of the breakdown products of the 68Ga-NOTA-hIFN-dAbs 
after the degradation in the liver. The presence of this effect for both NOTA-hIFN-
MAXdAb and NOTA-hIFN-CTRLdAb was thus a common degradation route. 
Moreover it could have been symptomatic of a breakdown of the Lys-NOTA-68Ga 
complex either as a chelation unit or Ga-68 alone. The latter would be unlikely as the 
complex is so stable (Introduction 1.7.4.1). However, given the high liver uptake of 
both radioligands in the liver it was concluded to be the result of an active breakdown 
mechanism, perhaps active asialoglycoprotein mASGPR mediated degradation.  
The spleen showed a relatively high uptake of both radioligands, although 
particularly the 68Ga-NOTA-hIFN-CTRLdAb, peaking with a significant increase 
up to 24h. This was most likely a hIFN-mediated interaction as it is present for both 
radioligands and the hIFNAR copy number is relatively high. Also, perhaps as the 
spleen is a primary recycler of Fe3+, free analogous 68Ga3+ or 111In3+ from breakdown 
of the radioligand were also concentrated by ferritin in the spleen*.  
 
A problem with utilising In-111 to label NOTA for the 24hr time point was 
that 111In-NOTA-hIFN-dAb radioligand was likely not pharmacologically identical 
to 68Ga-NOTA-hIFN-dAb. However, the assumption was that they were not 
significantly different. The data appeared to support that assumption, as there were 
no obviously anomalous results between 1h, 3h and 24h in all tissues. The spleen 
showed a significant increase in spleen radioactivity between 3h and 24h and so this 
could have been free In-111 uptake from NOTA-111In dissociation474,475. Basic in vitro 
stability experiments showed that the 111In-NOTA-hIFN-MAXdAb radioligand was 
99% stable for 24 hours at RT. Nevertheless, if further work were performed utilising 
this radioligand, analysis of 111In-NOTA-hIFN-dAbs’ biodistribution at the earlier 
time points and a full in vivo serum stability analysis would be appropriate. 
                                                
* This is the principle of Ga-67 scanning (Section 1.7.2.1) 
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Biodistribution: 68Ga-NOTA-hIFN-MAXdAb Blocking Study
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3.5.4 Receptor Blocking 
The equivalent of an ASGPR-negative HepG2 xenograft model with 
blocking the ASGPR specific binding through the injection of an excess of cold 
MAXdAb ligand was attempted to ascertain whether the observed xenograft uptake 
of the 68Ga-NOTA-hIFN-MAXdAb radioligand was specific. If the uptake was 
MAXdAb-mediated by specifically binding ASGPR then the excess of MAXdAb was 
expected to reduce the observed uptake in the biodistributed xenograft tissue. 
Therefore, the 1µg 68Ga-NOTA-hIFN-MAXdAb 3hr time point was repeated 
utilising SCID Beige HepG2 xenograft models both without (0.04mg/kg dose) and 
with a 347µg excess of concentrated unlabelled MAXdAb *  (16.5mg/kg †  dose) 
(Method 2.4.3.1) (Figure 3.29). 
                                                
* The binding activity of the MAXdAb batch was confirmed in vitro using Flow Cytometry and so it 
was capable of binding ASGPR. 
† This was the maximum achievable dose as at higher concentrations the MAXdAb would precipitate 
out of solution  
Figure 3.29 – Tissue Uptake of 68Ga-NOTA-hIFN-MAXdAb 
in SCID Beige HepG2 Xenograft Model with and without 
MAXdAb Blocking Dose 
Mean %ID/g in selected tissues of 68Ga-NOTA-hIFN-MAXdAb at 3h post 
injection of 1µg dose (0.04mg/kg) or in addition to 347µg of MAXdAb 
(16.5mg/kg) ASGPR-blocking dose. Demonstrates no significant difference in 
ASGPR expressing tumour xenograft and liver tissues – although significant 
differences observed in non-specific tissues such as pancreas, indicating increased 
bioavailability of radioligand. 
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The results showed no significant difference in 68Ga-NOTA-hIFN-MAXdAb 
xenograft uptake in spite of the presence of an additional 16.46mg/kg of MAXdAb 
alone at greater than a 1000-fold excess. Superficially, the data indicated that the 
68Ga-NOTA-hIFN-MAXdAb xenograft uptake observed in previous sections was 
likely due to non-specific interactions. Also, there was an indication that the uptake in 
liver was also non-specific as there was no significant difference in liver.  
However, further analysis revealed there was significantly higher uptake of 
68Ga-NOTA-hIFN-MAXdAb with the blocking dose in non-specific tissues such as 
the pancreas, spleen and muscle, in addition to a highly significant increase in renal 
filtration. These latter results strongly suggested that there was more 68Ga-NOTA-
hIFN-MAXdAb available in the system with the blocking dose at 3hr compared to 
the normal dose.  
The reason for increased systemic availability was not apparent from the 
%ID/g values. The expression of data as %ID/g is intended to control for tissue 
mass, but assumes a non-saturable linear horizontal relationship between uptake 
(%ID) and mass (g). However, when uptake against mass was analysed for liver 
uptake in this investigation, the relationship was diagonal (Figure 3.30).  By 
comparison, intestinal uptake, for instance, conformed to the expected horizontal 
relationship (Figure 3.30). The data strongly indicated that the liver was saturable 
because an increase in mass did not equate to an increase in uptake, with a 
Figure 3.30 – Liver Tissue Uptake 
and Intestinal Tissue Uptake 
relative to Tissue Mass  
Liver and intestinal uptake (%ID/g) of 68Ga-
NOTA-hIFN-MAXdAb and 68Ga-NOTA-
hIFN-CTRLdAb plotted against respective 
tissue mass. Demonstrates non-linear 
relationship between liver mass and uptake – a 
larger mass does not equate to a proportional 
increase in uptake – and the corollary of a 
linear relationship represented by intestinal 
mass and uptake.  
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maximum uptake of 45.4%ID ±2.99 at 1µg injected dose in spite of the masses 
ranging from 0.71g to 1.45g with a variance of 21.1%. Therefore this would skew the 
data to give lower %ID/g uptake values for liver at higher masses and so if two 
groups have different average liver masses then their %ID/g values cannot be 
directly compared. The concurrent conclusion for uptake being independent of mass 
was that the capillary endothelium interface expressing ASGPR must be discrete and 
finite. 
Comparison of the liver uptakes from the blocking experiment without 
correcting for mass revealed a high significant difference in uptake (p=0.002) (Figure 
3.31). This suggested that the specific liver uptake of the 68Ga-NOTA-hIFN-
MAXdAb had indeed been blocked by the presence of the MAXdAb. Thus there 
was on average 12.4% more of the ID available systemically in the blocking dose 
animals. Hence, this potentially explained the non-significant differences in xenograft 
uptake, and the higher uptake in the kidneys and non-specific tissues. It was possible 
that the xenograft uptake in the blocking dose animals had been artificially inflated 
by the increased systemic available dose. Correcting the available dose resulted in a 
reduced xenograft uptake in the MAXdAb blocking subjects of 2.25%ID/g to 
2.61%ID/g in the normally treated subjects. 
 
Hence, the blocking result revealed that liver uptake of the NOTA-hIFN-
MAXdAb was likely to be partially specific ASGPR binding. Moreover, further 
highlighted the limitations the liver, as a large sink for specific uptake, places on the 
model for quantitating xenograft uptake. Hence, the specificity of xenograft uptake 
was not confirmed by this assay. 
 
Figure 3.31 – Liver Tissue Uptake 
of 68Ga-NOTA-hIFN-MAXdAb in 
SCID Beige HepG2 Xenograft 
Model with and without MAXdAb 
Blocking Dose 
Mean %ID in liver tissue of 68Ga-NOTA-hIFN-
MAXdAb at 3h post injection of 1µg dose 
(0.04mg/kg) or in addition to 347µg of 
MAXdAb (16.5mg/kg) ASGPR-blocking dose. 
Demonstrates the significant decrease in uptake 
in the presence of a blocking dose indicating the 
specificity of the liver uptake.   
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3.5.5 TaqMan mRNA Expression Profiling 
A significantly higher xenograft uptake of NOTA-hIFN-MAXdAb compared 
to NOTA-hIFN-CTRLdAb was observed (Section 3.5.3.2) indicating effective 
targeting, likely due to MAXdAb-mediated ASGPR binding. TaqMan was employed 
to link targeting to a quantifiable measure of the bioactivity of the attached hIFN* 
(Methods 2.5). The expression levels of various mRNA sequences from genes 
associated with the downstream effector proteins of the hIFN pathway (Introduction 
1.5.3) were measured. 
The mRNA was isolated from homogenised cryo-preserved xenograft tissue 
from the biodistribution experiments (Section 3.5.3.2) and applied to TaqMan array 
plates containing sequence-specific primers and TaqMan MGB probe (6-FAMTM 
dye-labelled). Plates were normalised to the expression levels of control GAPDH 
utilising the ΔCt-method to yield relative gene copy numbers expressed as percentage 
values for each gene476.  
In addition to the xenograft samples from the hIFN-MAXdAb and hIFN-
CTRLdAb treated models, xenografts from SCID Beige HepG2 xenograft models 
receiving only a 200µl PBS injection were utilised to attain a baseline level of 
expression for all mRNAs. 
 
The data demonstrated that both hIFN-MAXdAb and hIFN-CTRLdAb had 
modified the HepG2 xenograft transcriptome when compared to the untreated 
control xenograft tissue (Table 3.16, Figure 3.32). It was also apparent that the 
increased MAXdAb-mediated tumour xenograft uptake with hIFN-MAXdAb versus 
hIFN-CTRLdAb appeared to broadly correlate with a greater xenograft response 
(Figure 3.33). 
The mRNA copy numbers of several IFN pathway proteins were modified, 
such as IRF9 and STAT1 (Introduction 1.5.3). Upregulation of these proteins would 
be necessary for the integration of the IFN signalling pathways into creating an anti-
proliferative proteome. IRF9 was up 516% with hIFN-MAXdAb, which would be 
required for formation of the ISRE for promoting ISG transcription. STAT1 mRNA 
copies were increased by 231% with hIFN-MAXdAb, which would be integral to 
JAK-STAT signalling by forming part of the ISRE, promoting transcription of the 
                                                
* Monetary limitations prevented performing TaqMan on more than one xenograft for each variable 
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IFNϒ stimulated genes as a phosphorylated homodimer and cross-talk with the ERK 
signalling pathway to inhibit cell replication. Therefore increasing IRF9 and STAT1 
mRNA copy numbers may have increased their translation and thus ameliorated 
limitations on IFN signal amplification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3.16  
Percentage Difference in mRNA Copy Number 
relative to untreated Xenograft Tissue 
Gene Name 
Fusion Protein  
hIFN-MAXdAb 
(1.69%ID/g) 
hIFN-CTRLdAb 
(0.60%ID/g) 
ARHGEF Family  -25.8 -4.8 
CREB Family -20.1 3.5 
EIF4 Family -35.7 -55.2 
HIST Family -3.7 64.5 
IFNAR1/2 -34.9 -4.7 
IFNGR1/2 -28.4 -10.1 
IRF9 516 475 
IRS1 -42.6 -19.6 
JAK1/2 -40.3 -5.1 
MAPK Family -28.5 -2.8 
MTOR -15.4 -51.7 
NET1 26.2 -42.7 
PI3K Family -35.7 -15.0 
PRKCD -30.7 10.1 
RAC1 -44.9 -17.1 
RPS6 Family -33.3 -7.9 
STAT1 230.9 89.9 
TYK2 -10 21.6 
VAV2/3 -17 -7.4 
 Percentage differences compared to untreated control xenograft tissues 
red = decrease, green = increase 
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There was also evidence for the down-regulation of the hIFN signalling 
complex with an observed decrease in all four of the IFNα receptor complex 
proteins’ mRNA gene copy numbers. IFNAR1, IFNAR2, Tyk2 and Jak1 were down 
by an average of 28.4% with hIFN-MAXdAb. This observation was concurrent with 
the evidence that hIFN self-regulates by inhibiting the hIFNAR complex 
(Introduction 1.5.2). Moreover, down-regulating Jak1 may have inhibited the 
phosphorylation of PI3K. 
There was no evidence that the synthesis of mRNA encoding the various IFN 
subtypes was increased, as may have been expected. This could have been due to the 
lack of alternative pathways converging to amplify the signal for IFN production, 
such as the detection of dsRNA by PKR increasing the activity of NFκB or TLR 
stimulated pathways. Further, perhaps the downregulation of the mTOR pathway 
preventing IRF7 translation477 or it may be that the genes have a low copy number 
relative to protein expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32 – TaqMan RT-PCR of 
hIFN Pathway associated mRNA 
sequences in Xenografts targeted by 
hIFN-dAbs 
A – IFN Signalling Pathway 
B – Transcription/Translation Factors 
C – Cell Growth Pathway Factors 
Percentage change in mRNA gene copy number of 
HepG2 xenograft tissue treated with hIFN-
MAXdAb or hIFN-CTRLdAb, versus an untreated 
control. Demonstrates greater anti-proliferative 
transcriptome correlates with increased dAb-
mediated ASGPR targeting.  
III – Xenograft Targeting of 68Ga-NOTA-hIFN-dAb 
Alex G. Papple - 161 - Ph.D. 2014 
There was a decrease in copy number of PI3K family members with NOTA-
hIFN-MAXdAb treatment, in addition to a decrease in PI3K-activating IRS1. As 
PI3K is responsible for conducting cell survival growth signals by the indirect 
phosphorylation of AKT, which in turn inhibits the action of numerous pro-
apoptotic factors such as p53 (Introduction 1.5.4), down-regulation of PI3K may 
have primed the HepG2 xenograft tissue for apoptosis.  
PRKCD is known to be anti-apoptotic in instances of cytokine mediated cell 
death and so the decrease of PRKCD in hIFN-MAXdAb treated xenograft tissue 
inferred an apoptotic HepG2 phenotype. By contrast there was an increase in 
mRNA transcription of NET1, a protein associated with instigating RhoB-mediated 
cell death after DNA damage478, in the hIFN-MAXdAb treated xenograft tissue 
further indicating an apoptotic phenotype.   
The initiation of transcription through the MAP/ERK pathway was possibly 
curtailed through the decrease in genes encoding MAPK related genes, ARHGEF 
family, RAC1, VAV2/3, in addition to the CREB transcription factors. The 
MAP/ERK pathway is associated with uncontrolled growth in malignant tumours 
and therefore a decrease in the pathway’s mRNA potentially represented a stalling of 
cell growth.   
The global initiation of translation was possibly inhibited by the decreases in 
the transcription of the genes encoding the mTOR pathway including MTOR, EIF4 
related genes and RPS6 related genes. This may have represented an efficient stress 
response that resulted in the discrete translation of only mRNA sequences crucial to 
cell survival.  
 
Generally the data showed high hIFN-MAXdAb and low hIFN-CTRLdAb 
uptake correlated with concomitant effects on mRNA expression, with hIFN-
MAXdAb just having a stronger effect (Figure 3.33). However, there were some 
interesting exceptions that may have indicated hIFN-MAXdAb and hIFN-
CTRLdAb stimulated discrete cellular phenotypes as a result of their differing 
localised xenograft concentrations. For instance, the MTOR and EIF4 family of 
genes showed a greater decrease in the hIFN-CTRLdAb targeted xenograft, which 
may have resulted in a greater retardation of translation. The hIFN-CTRLdAb also 
differed from the hIFN-MAXdAb with a decrease in NET1 mRNA, an increase in 
PRKCD mRNA and a large increase in histone mRNA. These differences indicated 
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that there was even tighter control on protein expression with hIFN-CTRLdAb, such 
as the increase in transcription suppressing histone transcripts and a repression of the 
apoptotic phenotype, as evidenced by the decrease in pro-apoptotic NET1 and 
increase in anti-apoptotic PKRCD.  
 
  Figure 3.33 – TaqMan mRNA Copy Number Changes in HepG2 
Xenografts with hIFN-MAXdAb or hIFN(A)-ASGPRdAb Treatment 
Percentage increases (green arrows) and decreases (red arrows) in mRNA gene copy number of 
HepG2 xenograft tissue treated with hIFN-MAXdAb or the hIFN(A)-ASGPRdAbs versus an 
untreated control. Diagram represents the anti-proliferative transcriptome instigated by the action 
of the hIFN pathway including upregulation of mRNAs encoding hIFNα/β and hIFNγ pathway 
components, self-regulation through down-regulation of receptor mRNA, and the down regulation 
of translation and survival pathways.  
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It could also have been argued that the differences in the response to hIFN-
CTRLdAb were related to its decreased potency compared to hIFN-MAXdAb 
(Section 3.2.4) of 37.5pM and 6.79pM, respectively, rather than the differences in 
uptake. However, the resultant concentrations in the xenografts were likely to be in 
the nM range given the uptake concentrations of 0.60%ID/g and 1.69%ID/g, 
respectively, and so above the effective concentrations required for interacting 
effectively with the IFNAR complex.  
TaqMan data always carries a caveat regarding mRNA expression levels not 
necessarily equating to the encoded protein expression level and the action of RNases 
such as OAS instigated RNase L. However, the conclusions in this instance do not 
hinge on the upregulation of one gene but rather are a reflection of a trend across 
whole gene families covering several regulatory pathways, providing a broad and 
consistent consensus of the instigation of an anti-proliferative state in the xenograft. 
Therefore, the results, although not statistically significant, are rendered qualitatively 
significant owing to the comprehensive examination of the hIFN related 
transcriptome. The results could have been augmented by proteomics analyses such 
as by matrix-assisted laser desorption/ionization (MALDI) MS, ELISA or western 
blotting. 
 
The TaqMan results correlated with the reported discrete cellular responses 
relative to the temporal ternary structure stability of the IFNAR-IFN interaction263. 
This would be a restrained low-toxicity antiviral response to low hIFN concentrations 
and an apoptotic anti-proliferative response to higher hIFN concentrations. The data 
thus strongly suggested that in this model, through increased xenograft uptake 
mediated by MAXdAb ASGPR targeting, hIFN could be a more efficacious 
instigator of anti-proliferation.  Hence, hIFN-MAXdAb is a more effective potential 
targeted anti-cancer agent than non-targeted fused hIFN.  
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3.6 PET-CT IMAGING 
SCID Beige HepG2 HCC xenograft models were created for in vivo PET-CT 
quantitation of NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb xenograft 
targeting. However, in order to improve image interpretation xenografts were grown 
on the shoulder* and the injected radiolabelled protein was allowed to distribute for 
one hour prior to imaging to allow some clearance through the bladder for greater 
uptake resolution. 
 
3.6.1 Ga-68 Radiolabelling 
NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb were Ga-68 
radiolabelled utilising the high specific activity 1M NaAc radiolabelling protocol to 
attain the highest radioactivity possible from the purification (Table 3.17). The 
reaction was incubated at 37˚C, achieving highly reliable specific activities with 
minimum radiochemical impurities (Method 2.3.2). These results enabled sufficient 
activity for imaging 3 hours post-injection. The injected dose was approximately 4µg 
as a result of balancing activity with the lowest possible dose. 
 
Table 3.17  
Ga-68 Radiolabelling for PET-CT Imaging 
Protein 
Reaction 
Conc. 
(µM) 
Radiolabelling 
Efficiency (%) 
Specific 
Activity 
(MBq/µg) 
Radiochemical 
Purity (%)* 
Injected 
Activity 
(MBq)  
Injected 
Mass 
(µg) 
 
NOTA-
hIFN-
MAXdAb 
 
1.1 90.1 ±1.72 1.99 ±0.09 97.3 ±0.92 6.22 ±0.53 3.92 ±0.48 
 
NOTA-
hIFN-
CTRLdAb 
 
1.1 98.4 ±0.60 2.33 ±0.12 99.4 ±0.07 7.37 ±0.65 3.88 ±0.28 
 n≥3, SD values displayed, *post-G25 purification 
 
 
                                                
* Flank tumour imaging proved unfeasible, as the high background radioactive signal from the uptake 
in the liver, kidneys and bladder did not allow thresholds capable of visualising tumour uptake. 
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3.6.2 PET-CT Quantitation of Xenograft Uptake 
The xenograft dose uptake between one hour and three hours post-injection 
was examined by reconstruction of the PET-CT images as 10 minute frames, with 
manual selection of the xenograft tissue as a region of interest (ROI), in addition to a 
muscle ROI as a control. After the two hour acquisition, the subjects were sacrificed 
and biodistributions performed for comparison at three hours post-injection. 
The PET-CT data demonstrated tumour uptake of 68Ga-NOTA-hIFN-
MAXdAb and a relatively lower uptake of 68Ga-NOTA-hIFN-CTRLdAb over the 
two-hour imaging period (Table 3.18). This could be visualised through thresholding 
the data to highlight the xenograft uptake (Figure 3.34). At three hours, the PET-CT 
results corroborated a pattern of significantly (p=0.03) higher uptake of 68Ga-NOTA-
hIFN-MAXdAb than 68Ga-NOTA-hIFN-CTRLdAb, as seen in the 4µg dose 
biodistribution results in this instance (Table 3.18) and at a 1µg dose previously 
(Figure 3.26). The ratio of xenograft uptake relative to muscle uptake was maintained 
for 68Ga-NOTA-hIFN-MAXdAb at about double that of 68Ga-NOTA-hIFN-
CTRLdAb.  
However, there appeared to be a discrepancy in the magnitude of the results 
comparing %ID/g and %ID/ml, considering that liver has a density of 
approximately 1.06g/ml. This could in part be accounted for as overestimation of 
the area of the xenograft tissue compounded by the presence of blood, which would 
have been absent from the biodistribution data, as together these factors would both 
serve to underestimate the %ID/ml values.  
 
Table 3.18  
PET-CT Imaging Xenograft Uptake Quantitation and Biodistributions 
Protein Tissue 
Biodistribution PET-CT Imaging 
Uptake (%ID/g) Mean Ratio Uptake (%ID/ml) 
Mean 
Ratio 
 
68Ga-NOTA-hIFN-
MAXdAb 
 
Xenograft 1.23 ±0.07 
3.9:1 
0.56 ±0.09 
2.9:1 
Muscle 0.31 ±0.05 0.19 ±0.16 
 
68Ga-NOTA-hIFN-
CTRLdAb 
 
Xenograft 0.65 ±0.17 
2.2:1 
0.38 ±0.06 
1.4:1 
Muscle 0.30 ±0.06 0.28 ±0.10 
 n=3, SD values displayed, ~4µg dose, t=3h 
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Figure 3.34 – PET-CT Imaging 
of HepG2 Xenograft Uptake of 
68Ga-NOTA-hIFN-MAXdAb 
and 68Ga-NOTA-hIFN-
CTRLdAb 
 
A – Example coronal slice images of 
HepG2 tumour uptake representing 
cumulative detected events between one 
and three hours post-injection of a 4µg 
dose of 68Ga-NOTA-hIFN-MAXdAb or 
68Ga-NOTA-hIFN-CTRLdAb.  
 
B – Example axial slice images of HepG2 
tumour uptake representing cumulative 
detected events between one and three 
hours post-injection of a 4µg dose of 68Ga-
NOTA-hIFN-MAXdAb or 68Ga-NOTA-
hIFN-CTRLdAb. 
 
Xenograft tissue indicated with white 
arrow. 
68Ga-NOTA-hIFN-MAXdAb 68Ga-NOTA-hIFN-CTRLdAb 
68Ga-NOTA-hIFN-MAXdAb 
68Ga-NOTA-hIFN-CTRLdAb 
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The PET-CT results also showed that between one hour and three hours 
post-injection the uptake of the radioligands had apparently plateaued (Figure 3.35), 
with a non-significant decrease in the presence of radioligand over the two hour 
acquisition. This correlated with the biodistribution results for the xenografts at one 
hour and three hours, which appeared to show a plateauing of the uptake too and 
thus that the majority of uptake was in the initial hour post-injection (Figure 3.28). 
Moreover, the concentration of 68Ga-NOTA-hIFN-MAXdAb was significantly 
higher (p<0.001) than in the muscle tissue throughout the acquisition, whereas the 
68Ga-NOTA-hIFN-CTRLdAb concentration was apparently not significantly greater 
than that of the non-specific muscle control tissue. It was clear though that for more 
meaningful observations of the kinetics of the tissue clearances then a longer imaging 
acquisition period would be required. 
Overall the PET-CT offered a proof-of-principle demonstration of in vivo 
computation of xenograft uptake that broadly correlated with the ex vivo 
biodistribution data for three hours post-injection. There was a clear indication that 
quantitative temporal uptake data in xenograft tissue could enable a greater 
understanding of the uptake dynamics of dAb fusions if analysed over a broader time 
period. 
 
 
 
 
 
 
 
 
Figure 3.35 – Xenograft Uptake of 68Ga-NOTA-hIFN-MAXdAb and 
68Ga-NOTA-hIFN-CTRLdAb between 1h and 3h post-injection 
Concentrations of 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-CTRLdAb in HepG2 
xenograft tissue and muscle tissue, between 1h and 3h post-injection analysed as 10 minute frames 
expressed as %ID/ml. The uptake in xenograft tissue of both radioligands appears to have 
plateaued to a steady decrease with time, with the highest xenograft uptake observed with the 
ASGPR-targeted 68Ga-NOTA-hIFN-MAXdAb in comparison to 68Ga-NOTA-hIFN-CTRLdAb. 
Compared to a muscle tissue control, 68Ga-NOTA-hIFN-MAXdAb showed a sustained higher 
uptake over time to the uptake of 68Ga-NOTA-hIFN-CTRLdAb in xenograft tissue versus muscle 
uptake. The data demonstrates how PET-CT imaging can be quantitated to provide data on tissue 
uptake over time, and again demonstrate the superiority of the ASGPR/hIFNAR-targeted 68Ga-
NOTA-hIFN-MAXdAb radioligand to target and be retained in HepG2 xenograft tissue versus 
the hIFNAR-targeted 68Ga-NOTA-hIFN-CTRLdAb. (n=3) 
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IV 
 
Optimising HepG2 Xenograft 
Targeting of hIFN-dAbs 
 
What is the optimum combination of hIFN and 
dAb affinities to maximise hIFN-dAb efficacy in 
a HepG2 xenograft model? 
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4.1 INTRODUCTION 
In Chapter III, it was demonstrated that MAXdAb could mediate increased 
xenograft uptake of a hIFN-MAXdAb fusion protein construct compared to the non-
targeted hIFN-CTRLdAb. Additionally, this increased uptake correlated with an 
apparent increase in anti-proliferative bioactivity of the attached hIFN. This now 
raised the question of whether this observed ASGPRdAb-mediated efficacy could be 
further refined by the manipulation of the binding affinities of the ASGPRdAb and 
hIFN for their respective receptors ASGPR and hIFNAR to conclude on the 
optimum strategy for targeting dAb fusions. This required generating a panel of 
mutant hIFN-ASGPRdAbs with differing intrinsic binding affinity combinations for 
ASGPR and hIFNAR followed by the same profiling and modelling experimentation 
as was performed for hIFN-MAXdAb and hIFN-CTRLdAb (Figure 4.0). This would 
hopefully enable a more nuanced view of the influence of the two binding affinities 
on the overall efficacy of hIFN-dAb fusion protein.  
 
 
 
 
 
  
Figure 4.0 – Outline of Experimental Development 
Experimental steps involved in producing validated mutant 68Ga-NOTA-hIFN-dAbs and 
subsequent in vivo modelling, towards in vivo xenograft targeting quantitation  
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4.2 MUTANT EXPRESSION & PURIFICATION 
 4.2.1 Mutant hIFN-dAb Fusion Proteins 
Three ASGPRdAb DNA sequences *  were selected for their encoded 
ASGPRdAbs’ differing affinities to ASGPR and named HidAb, MidAb, and LodAb 
(Table 4.1). Three hIFN DNA sequences† were selected from a subset of hIFN site 
directed mutagenesis sequences designed to reduce the interaction with hIFNAR, 
and were named hIFN(A), hIFN(C), and hIFN(E). Therefore, spliced combinations of 
these DNA sequences were intended to yield nine hIFN-dAb fusions (Table 4.1) 
(Methods 2.1) with differing affinity combinations for the target receptors (Table 4.2).  
 
Table 4.1  
Mutant hIFN-ASGPRdAb Fusion Proteins 
Protein* HidAb (KD 5nM) 
MidAb 
(KD 25nM) 
LodAb 
(KD 300nM) 
hIFN(A) 
(Koff  0.018 / EC50 0.75pM) 
hIFN(A)-HidAb hIFN(A)-MidAb hIFN(A)- LodAb 
hIFN(C) 
(Koff  0.254 / EC50 36.8pM) hIFN(C)-HidAb hIFN(C)-MidAb hIFN(C)-LodAb 
hIFN(E) 
(Koff  0.000 / EC50 16nM) hIFN(E)-HidAb hIFN(E)-MidAb hIFN(E)-LodAb 
*Kinetics data for individual proteins kindly provided by Dr Thil Batuwangala and Dr Armin Sepp 
 
4.2.2 hIFN-ASGPRdAb Expression Constructs 
High fidelity Pwo PCR reactions were performed to clone the individual 
mutant hIFN and ASGPRdAbs from their holding vectors, before SOE PCR to 
create a spliced linear constructs of the hIFN-ASGPRdAbs (Table 4.1). DNA gel 
electrophoresis (Figure 4.1) demonstrated that all sequences were successfully cloned 
although MidAb was relatively poorly amplified despite repeated attempts to increase 
yields. However, the DNA present was sufficient to proceed.  
All SOE PCR reactions produced banding at the expected MW of ~900kb 
(Figure 4.2), in addition to various other abortive amplification species from the 
individual sequences. The hIFN-ASGPRdAb constructs were now amplified in the 
pCR-Blunt holding vector before being recombined into pDOM50 vectors. 
                                                
* DNA constructs and original data courtesy of Dr Armin Sepp  
† DNA constructs and original data courtesy of Dr Thil Batuwangala  
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Table 4.2  
Mutant hIFN-ASGPRdAb Fusion Proteins  
Fusion Protein 
Predicted 
Molecular 
Weight 
(Da) 
Relative Targeting Affinity 
ASGPR hIFNAR 
hIFN(A)-HidAb 32476 +++ +++ 
hIFN(C)-HidAb 32420 +++ ++ 
hIFN(E)-HidAb 32448 +++ + 
hIFN(A)-MidAb 32684 ++ +++ 
hIFN(C)-MidAb 32628 ++ ++ 
hIFN(E)-MidAb 32656 ++ + 
hIFN(A)- LodAb 32746 + +++ 
hIFN(C)-LodAb 32690 + ++ 
hIFN(E)-LodAb 32718 + + 
 
 
Figure 4.1 – Gel Electrophoresis of PCR Purification products of 
individual DNA sequences of ASGPRdAb and hIFN mutants 
2% Agarose E-Gel showing migration of PCR reaction products encoding HidAb, MidAb and 
LodAb, in addition to hIFN(A), hIFN(C) and hIFN(E), including the NEB 1kb Marker and NEB 
100bp markers (M). Result demonstrates purity of final PCR products. 
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Expression vector pDOM50, based on pTT5 vector derivative with an N-
terminal Kozak consensus sequence and a murine-derived secretion V-J2-C signal 
sequence (Appendix Figure 6.6), was chosen for its proven efficiency for hIFN-dAb 
expression in HEK293E mammalian cell culture74*.  
High yields of 2.80mg ±0.4 (Table 4.4) purified endotoxin-free transfection 
grade recombinant pDOM50-hIFN-dAb DNA were subsequently attained by 
MegaPrep. The supercoiled and uncoiled pDOM50-hIFN-ASGPRdAb plasmids 
were the only apparent purified products (Figure 4.3).  
Sequencing confirmed the final sequences contained all specific mutations, 
additive sequences such as the mammalian cleavage sequence ACCGGC and the 
                                                
* Dr Andrew Sanderson, GSK, personal communication 
Figure 4.2 – Gel Electrophoresis of SOE PCR products of DNA 
sequence fusions of ASGPRdAb and hIFN mutants  
2% Agarose EX-Gel showing migration of PCR reaction products encoding hIFN(A)-HidAb, 
hIFN(C)-HidAb, hIFN(E)-HidAb, hIFN(A)-MidAb, hIFN(C)-MidAb, hIFN(E)-MidAb, hIFN(A)-
LodAb, hIFN(C)-LodAb and hIFN(E)-LodAb, including the NEB 100bp markers (M). Result 
demonstrates presence of full genetic fusions  at ~900kb for excision and purification 
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double stop codon TAATGA, and were in the correct open reading frame for 
expression. 
 
4.2.3 Expression and Purification of hIFN-
ASGPRdAb Mutant Fusion Proteins 
The pDOM50-hIFN-ASGPRdAb constructs were utilised to transiently 
transfect HEK293 mammalian cells with 293Fectin transfection reagent. After 5 days 
Table 4.4  
Mutant hIFN-dAb Fusion Protein Production Data 
Fusion Protein 
DNA Expression 
Construct Yields 
(mg) 
Protein Purification 
Expression 
Yield (mg/L) 
Post-Conjugation 
Concentration 
(µM) 
hIFN(A)-HidAb 2.34 48.4 55.4 
hIFN(C)-HidAb 3.20 29.0 34.1 
hIFN(E)-HidAb 3.49 20.4 49.9 
hIFN(A)-MidAb 2.86 32.4 50.6 
hIFN(C)-MidAb 2.29 14.2 60.4 
hIFN(E)-MidAb 2.53 46.4 84.8 
hIFN(A)- LodAb 2.37 35.4 55.1 
hIFN(C)-LodAb 2.82 15.2 31.2 
hIFN(E)-LodAb 2.58 81.8 60.3 
 
 
Figure 4.3 – Gel Electrophoresis of MegaPrep DNA products for 
pDOM50-hIFN-ASGPRdAb expression constructs  
2% Agarose E-Gel showing migration of MegaPrep products for the purification of the various 
pDOM50-hIFN-ASGPRdAb expression constructs. Result demonstrates presence of fully 
recombinant plasmid products in both super-coiled and uncoiled state. 
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the supernatants of the cultures were harvested. The contents consisted of multiple 
protein species, including prominent banding for the expressed hIFN-ASGPRdAbs 
at around 30kDa and a dimer at around 60kDa (Figure 4.4A).  
 The fusions proteins were purified from the supernatants by ÄKTA 
chromatography into fractionated eluate from a HiTrap mAb-Select Xtra Protein A 
column (Figure 4.4B). The peak fractions contained very high concentrations of the 
respective hIFN-ASGPRdAb species, including unwanted dimers, with some 
lingering contaminant protein species notable at 50kDa. The most concentrated 
fractions were pooled. 
 The resultant stocks of the respective hIFN-ASGPRdAb mutants were >95% 
pure (Figure 4.4C), although attained at a variety of yields (Table 4.4). The 
Figure 4.4 – SDS-PAGE of 
hIFN-ASGPRdAb ÄKTA 
Purification Steps 
 
1 hIFN(A)-HidAb 
2 hIFN(C)-HidAb 
3 hIFN(E)-HidAb 
4 hIFN(A)-MidAb 
5 hIFN(C)-MidAb 
6 hIFN(E)-MidAb 
7 hIFN(A)-LodAb 
8 hIFN(C)-LodAb 
9 hIFN(E)-LodAb 
M = Novex Sharp Pre-stained Protein 
Standard. 
 
A – Non-reducing SDS-PAGE of raw 
HEK293e supernatants containing 
expressed hIFN-ASGPRdAbs. 
(Lanes as above) 
 
B – ÄKTA HiTrap mAb-Select Xtra 
purified hIFN(A)-HidAb 
(Lanes in order fractionated) 
 
C – Reducing SDS-PAGE of ÄKTA 
HiTrap mAb-Select Xtra purified pooled 
hIFN-ASGPRdAb stocks post 0.22µM 
filtering 
(Lanes as above) 
 
Results demonstrate full purification of all 
mutant hIFN-ASGPRdAbs from the 
heterogeneous protein supernatant to fully 
purified glycosylation species. 
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expression yield data broadly showed that the mutant fusion proteins were expressed 
at above 20mg/L within this HEK293 mammalian expression system, which were 
average yields for antibody fragments technologies479. However, the hIFN(C) lineage 
fusion mutants had the weakest expression in this system with hIFN(C)-MidAb and 
hIFN(C)-LodAb achieving yields of approximately 14mg/L, possibly due to poorer 
transfection efficiencies or secretion properties480. These yields were nonetheless 
sufficient for further experimentation. The concentrations achieved from the HiTrap 
mAb-Select Xtra stock purifications were significantly (p=0.0001) higher than the 
hIFN-MAXdAb stocks (Table 3.2) and so were known to be sufficient for NOTA 
conjugation reactions. The SDS-PAGE (Figure 4.4C) indicated the presence of up to 
four different glycosylation species of hIFN-ASGPRdAb monomer. This was 
representative of the presence of both N-linked and O-linked glycosylation sites in the 
hIFN-ASGPRdAb amino acid sequences, as shown by PNGase F and site directed 
mutagenesis (SDM) experimentation (Appendix 6.2.3).  
Hence, all hIFN-ASGPRdAbs were successfully expressed and purified from 
the HEK293e mammalian expression system. 
 
4.2.4 SCN-Bn-NOTA Conjugation and 
Purification 
For Ga-68 radiolabelling, the hIFN-ASGPRdAb mutant fusion proteins 
underwent conjugation with SCN-Bn-NOTA (Methods 2.2.1). The conjugation 
reactions were purified by Protein A batch purification (Table 4.4).  
The SDS-PAGE of the resultant most concentrated fractions (Figure 4.5) 
demonstrated the purity of the attained NOTA-hIFN-ASGPRdAbs. The 
glycosylation heterogeneity was indicated by the different migration characteristics. 
The apparent heavier glycosylated products were due to N-linked glycosylation, as 
was determined by PNGase F enzymatic degradation (Appendix Figure 6.17) and the 
loss of the glycosylated products after the removal of the NGS glycosylation site by 
SDM to NGA (Appendix Figure 6.18) (Appendix 6.1.9). There remained a small 
amount of dimer migrating at approximately 60kDa in each sample in spite of 
0.22µm filtration.  
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The MS data proved to be of inadequate quality to reliably estimate the levels 
of NOTA conjugation of the hIFN-ASGPRdAbs as insufficient levels of ionised 
protein were detected. All traces demonstrated high levels of noise and indistinct 
mass peaks (Figure 4.6). However, it was possible to determine that NOTA was 
present on each hIFN-ASGPRdAb as multiple species in a pattern similar to that 
witnessed for NOTA-hIFN-MAXdAb (Section 3.2.2.4), but at indeterminate overall 
levels as the N-linked glycosylates were not detected. This was exemplified by 
NOTA-hIFN(E)-LodAb (Figure 4.6), the trace of which suggested a parental peak 
(33664) with up to three NOTA conjugation species (34110, 34566, and 35023) and 
the presence of an asialyted NOTA species (33819). 
In conclusion, a purified, heterogeneous, NOTA-conjugated mix of each 
hIFN-ASGPRdAb was attained for further experimentation.  
 
 
 
Figure 4.5 – Non-Reducing SDS-PAGE of post-Protein A purification hIFN-
ASGPRdAbs  
hIFN-ASGPRdAb mutant fusion proteins present as multiple glycosylation species migrate as 
predicted to an apparent molecular mass of between 30-33kDa, without any significant detectable 
aggregation after Protein A purification.  
All hIFN-ASGPRdAbs at 3µg, with Novex Sharp Pre-stained Protein Standard.  
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Figure 4.6 – Mass Spectrum of NOTA-hIFN(E)-LodAb 
Mass spectrum of Protein A purified post-conjugation, 500µg/ml NOTA-hIFN(E)-LodAb fraction 
3. Multiple glycosylated and NOTA- conjugated species identified, but high noise indicates poor 
ionisation and flight resulting in a reduced robustness 
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4.4 IN VITRO CHARACTERISATION 
All the hIFN-ASGPRdAb mutants were designed to have varying dual 
affinity for both the ASGPR and hIFNAR (Table 4.2). It was necessary to establish 
the kinetic variables achieved for each of these novel hIFN-ASGPRdAb fusion 
proteins .  
 
4.4.1 Biacore Surface Plasmon Resonance 
Biacore SPR was utilised to determine the binding parameters of each hIFN-
ASGPRdAb to both ASGPR-H1-CRD and hIFNAR2 (Methods 2.2.2). 
 
4.4.1.1 ASGPR Binding Assay 
 Utilising a Biacore T200, the KD values for the unconjugated hIFN-
ASGPRdAbs binding ASGPR-H1-CRD demonstrated that the designed stepwise 
binding affinity differences (Table 4.2) had been broadly achieved (Table 4.5). The 
kon values suggested a small effect of the fused hIFN mutant on the association of the 
hIFN-ASGPRdAb to ASGPR-H1-CRD because the higher the designed hIFN 
affinity, the faster the rate of association. The koff values appeared not to conform to a 
discernable pattern. Comparison with the previously determined values (Table 4.2) of 
5nM, 25nM and 300nM for HidAb, MidAb and LodAb respectively, and a value of 
7.88nM for HidAb observed in this investigation, showed an unfavourable effect on 
Table 4.5  
Biacore T200 ASGPR Binding Kinetics of Mutant hIFN-ASGPRdAbs 
Protein Kon (x104 M-1s-1) Koff (x10-2 s-1) KD (nM) Rmax (RU) Chi2 (RU2) 
HidAb 113 0.89 7.88 129.4 0.06 
hIFN(A)-HidAb 56.9 3.97 69.7 62.6 0.26 
hIFN(C)-HidAb 13.4 0.84 63.0 67.5 0.07 
hIFN(E)-HidAb 2.10 0.98 468 360 0.19 
hIFN(A)-MidAb 11.7 0.94 80.0 30.0 0.06 
hIFN(C)-MidAb 6.35 3.97 626 524 0.11 
hIFN(E)-MidAb 53.3 0.79 149 36.9 0.02 
hIFN(A)-LodAb 23.6 0.20 505 137 0.74 
hIFN(C)-LodAb 16.4 6.07 371 179 1.26 
hIFN(E)-LodAb 5.03 2.65 528 45.3 0.11 
 n≤3 
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KD by fusing the ASGPRdAbs to the hIFN mutants. For the HidAb fusion proteins it 
appeared that decreases in the kon rates were responsible for the ten-fold decrease in 
KD.  
There were two anomalous results for hIFN(E)-HidAb and hIFN(C)-MidAb, 
where lower KD  values were observed of 468nM and 626nM, respectively, than was 
expected based on the affinity of the other similar hIFN-HidAb and hIFN- MidAb 
fusion proteins which averaged 66.4nM and 115nM, respectively. It was apparent 
from the high Rmax values that this was likely due to the mass transport effect (Section 
3.2.3) as the low Chi2 values indicated that the data fit was sufficient.  
Overall the data confidence level was high and the results indicated the 
desired binding affinity profile for ASGPR-H1-CRD of HidAb>MidAb>LodAb.  
 
The binding profiles of the analytes against ASGPR pre- and post-
conjugation (Figure 4.7) demonstrated an apparent decrease in ASGPR-H1-CRD 
binding with the conjugation of NOTA. This was exemplified by NOTA-hIFN(A)-
HidAb, hIFN(A)-HidAb, NOTA-hIFN(C)-MidAb, hIFN(C)-MidAb, NOTA-
hIFN(E)-LodAb, hIFN(E)-LodAb, along with hIFN-MAXdAb and hIFN as positive 
controls and dAb as a negative control.  
 
 
 
  
 
  
Figure 4.7 – Biacore 3000 SPR Analysis of Analytes’ binding 
interaction with recombinant ASGPR-H1-CRD 
Biacore 3000 SPR with ASGPR-H1-CRD immobilised on a CM5 chip assessed the ASGPR-H1-
CRD binding curves of 250nM analytes – representative selection of hIFN-ASGPRdAbs, hIFN-
MAXdAb, MAXdAb and hIFN – injected over the chip surface at 30µlmin-1. The data shows 
HidAb, MidAb and LodAb can bind ASGPR-H1-CRD with varying affinities and can confer this 
property to hIFN as part of a fusion protein, compared to hIFN alone showing no binding to 
ASGPR-H1-CRD, plus an apparent decrease in affinity with NOTA-conjugation. 
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The qualitative data for a decrease in affinity for the ASGPR-H1-of the 
NOTA-hIFN-ASGPRdAbs compared to the hIFN-ASGPRdAbs (Figure 4.7), 
however, could not be substantiated by quantitative values. The data for the NOTA-
hIFN-ASGPRdAbs was performed on a Biacore 3000 and produced unreliable data 
because good data fits could not be ascertained. This was due to the insensitivity of 
the readout at low concentrations and the binding data not reaching equilibrium 
between association and dissociation, as was visible in the 250nM data (Figure 4.7) 
comparing for example NOTA-hIFN(A)-HidAb with MAXdAb. Based on the 
evidence from the NOTA-hIFN-MAXdAb, it was possible to suggest that the lack of 
equilibrium was again due to self-association. However, as observed with the hIFN-
MAXdAb and NOTA-hIFN-MAXdAb, the primary NOTA conjugation sites were 
likely to be on the hIFN portion of the hIFN-ASGPRdAb fusion protein and the 
effect on the ASGPRdAb portion’s KD for the ASGPR-H1-CRD was likely to be 
relatively unchanged. 
In conclusion, the desired stepwise variations in ASGPR binding affinity were 
achieved for the unconjugated hIFN-ASGPRdAb mutants. However, the ASGPR 
binding KD values for the NOTA-hIFN-ASGPRdAbs could not be obtained, thus 
FACS analysis was required to confirm if the binding pattern had been maintained 
post-NOTA conjugation. 
 
4.4.1.2 hIFNAR Binding Assay 
The binding profiles of the analytes against hIFNAR2 (Figure 4.8) were 
exemplified at 250nM by NOTA-hIFN(A)-HidAb, hIFN(A)-HidAb, NOTA-
hIFN(C)-MidAb, hIFN(C)-MidAb, NOTA-hIFN(E)-LodAb, hIFN(E)-LodAb, along 
with hIFN-MAXdAb and hIFN as positive controls and dAb as a negative control. 
They demonstrated differing binding affinities for hIFNAR were achieved. A 
qualitative analysis of the profiles showed that the expected stepwise affinity decrease 
for hIFNAR2 had been achieved, as conferred to the attached ASGPRdAb by the 
fused hIFN(A), hIFN(C) and hIFN(E). However, there was a suggestion that the 
binding to hIFNAR2 by each hIFN-ASGPRdAb was reduced by the NOTA 
conjugation, as their binding magnitudes were reduced post-conjugation. 
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Table 4.6  
Biacore 3000 hIFNAR2 Binding Kinetics  
Protein Kon (x104 M-1s-1) Koff (x10-2 s-1) KD (µM) Rmax (RU) Chi2 (RU2) 
hIFN(A)-HidAb 2.89 ±3.45 0.35 ±0.00 0.42 ±0.49 265 ±299 1.21 ±0.03 
NOTA-hIFN(A)-HidAb 3.98 ±1.92 0.46 ±0.07 0.13 ±0.04 55.6 ±13.2 0.49 ±0.02 
hIFN(A)-MidAb 9.47 ±2.23 0.56 ±0.05 0.06 ±0.01 30.7 ±1.59 0.57 ±0.08 
NOTA-hIFN(A)-MidAb 10.3 ±3.02 1.08 ±0.08 0.11 ±0.00 21.2 ±5.69 0.23 ±0.03 
hIFN(A)-LodAb 13.6 ±3.91 0.94 ±0.01 0.07 ±0.02 30.6 ±3.21 0.69 ±0.10 
NOTA-hIFN(A)-LodAb 18.2 ±3.99 1.13 ±0.16 0.06 ±0.02 19.0 ±1.53 0.29 ±0.06 
hIFN(C)-HidAb 0.87  ±0.00 0.42  ±0.00 0.29 ±0.27 110  ±0.00 0.42  ±0.13 
NOTA-hIFN(C)-HidAb 6.31 ±8.34 0.28 ±0.00 0.06 ±0.07 80.0 ±110 0.29 ±0.00 
hIFN(C)-MidAb 6.63 ±3.22 0.57 ±0.14 0.10 ±0.04 19.6 ±11.5 0.33 ±0.13 
NOTA-hIFN(C)-MidAb 0.02 ±0.00 0.002 ±0.00 0.07 ±0.01 337 ±127 0.27 ±0.00 
hIFN(C)-LodAb 8.74 ±0.92 1.70 ±1.07 0.20 ±0.14 27.2 ±9.62 0.54 ±0.42 
NOTA-hIFN(C)-LodAb 8.14 ±4.76 4.03 ±1.90 0.53 ±0.35 17.5 ±3.18 0.29 ±0.00 
 n≤3, SD values displayed 
Figure 4.8 – Biacore 3000 SPR Analysis of Analytes’ binding 
interaction with recombinant hIFNAR2 
Biacore 3000 SPR with hIFNAR2 immobilised on a CM5 chip assessed the hIFNAR2 binding 
curves of 250nM analytes – representative selection of hIFN-ASGPRdAbs, hIFN-MAXdAb, 
MAXdAb and hIFN – injected over the chip surface at 30µlmin-1. The data shows hIFN(A) and 
hIFN(C) can bind hIFNAR2 with varying affinities and can confer this property to their respective 
ASGPRdAb as part of a fusion protein, compared to hIFN(E) conferring no such characteristic. 
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The kinetics data (Table 4.6) did not support the qualitative analysis though 
because no significant decreases in KD between the NOTA-conjugated and 
unconjugated variants were observed. In fact the hIFN(A)-ASGPRdAbs appeared to 
have improved kinetics post-conjugation. However, the error was often very high.  
Furthermore, the average KD values for the hIFN(A)-ASGPRdAbs and 
hIFN(C)-ASGPRdAbs did not demonstrate the intended significant decrease in 
binding affinity for hIFNAR2. Nevertheless, a 1.9-fold decrease in the average kon 
and a 1.9-fold increase in the average koff were indicative of the KD hIFNAR2 
binding values perhaps not being an accurate reflection of underlying differences in 
hIFN potency.  
NOTA-hIFN(A)-HidAb, NOTA-hIFN(A)-MidAb and NOTA-hIFN(A)-
LodAb were intended to have identical binding affinity parameters towards the 
hIFNAR2 given that each had the same hIFN(A) sequence. Indeed, their respective 
0.13µM, 0.11µM, and 0.06µM KD values did not differ significantly. Similarly, the 
NOTA-hIFN(C)-HidAb and NOTA-hIFN(C)-MidAb both demonstrated a KD of 
0.06µM whereas at 0.53µM the hIFN(C)-LodAb had a notably lower average affinity 
for the hIFNAR2. The reason for this latter difference appeared to be owing to a 
faster off-rate owing to an unknown factor arising from the fusion to the LodAb.  
The hIFN(E)-HidAb, hIFN(E)-MidAb and hIFN(E)-LodAb with their 
planned lack of affinity for hIFNAR yielded no detectable hIFNAR interaction 
within these reaction conditions.  
 
Overall, the Biacore SPR analysis did not yield high confidence data. The 
standard deviations were generally large in all instances whereby a number of 
samples produced data up to an order of magnitude difference between replicates. 
This reflected the large amount of inconsistency within the data set. The Chi2 values 
ranged from 0.02-1.26 for ASGPR and 0.23-1.21 RU2 for hIFNAR2, in addition to 
being broadly in excess of 1% of the Rmax, reflecting a higher noise in the data and 
thus reduced confidence. The Rmax results themselves showed that the results were 
largely free from the additive mass transport effect. The data suggested that the 
reaction conditions did not suit these particular proteins, perhaps leading to 
modifications of the tertiary structure or aggregation, which may have accounted for 
the data inconsistencies.  
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In conclusion, the Biacore data failed to clearly demonstrate significant 
quantitative patterns with which to conclude on the effect of NOTA conjugation on 
the binding affinities of the hIFN-ASGPRdAb mutants for ASGPR and hIFNAR2. 
However, the qualitative data strongly suggested that the different relative affinities 
for ASGPR and hIFNAR binding of the hIFN-ASGPRdAbs were distinctly different 
as intended.  
 
4.4.2 HEK-Blue hIFN Potency Assay 
The HEK-Blue hIFNα/β in vitro cellular assay was utilised to quantitate the 
potency of the hIFN-ASGPRdAb mutants as conferred by their fused hIFN(A), 
hIFN(C) and hIFN(E) proteins (Method 2.2.3, see also Section 3.2.4). 
The normalised data* demonstrated that conjugation of NOTA has had a 
negative effect on the potency of each unconjugated hIFN-ASGPRdAb (Table 4.7)  
versus the NOTA-hIFN-ASGPRdAb (Table 4.8) (with the exception of NOTA-
hIFN(A)-HidAb, which increased slightly), however this effect was not substantial. 
This data conformed to the pattern of hIFN bioactivity expected with hIFN(A) > 
hIFN(C) > hIFN(E) (Figure 4.9). Therefore, in spite of non-significantly different KD 
values for hIFNAR2 binding for hIFN(A)-ASGPRdAbs and hIFN(C)-ASGPRdAbs 
(Section 4.4.1), this was not reflected in the potency. This was similar to the lack of 
correlation between KD and EC50 seen with the hIFN-MAXdAb (section 3.2.3.4).  
The result for the hIFN(E)-ASGPRdAbs were only an estimate based on data 
projections but the low nM range would conform to the 16nM result registered for 
hIFN(E) alone † . Therefore, in spite of the hIFN(E)-ASGPRdAbs having had 
incalculable binding affinities for hIFNAR in the SPR experiments, they were not 
inactive proteins but rather were severely inhibited in their ability to engage with the 
hIFNAR binding complex. Therefore, it was noted that they may have a detectable 
effect on xenografts in vivo. 
Therefore this data suggested that, from a hIFN potency perspective, the 
design of the hIFN-ASGPRdAbs having a stepwise difference in hIFN interaction has 
been successful.  
                                                
* The data across different plates was normalised using the hIFN control on each plate – thus 
controlling for the any differences in colourimetric development time – so that plates could be cross 
compared. 
† Data for hIFN(E) kindly provided by Dr Thil Batuwangala  
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Table 4.7  
HEK-Blue EC50 of Unconjugated hIFN-ASGPRdAbs 
hIFN-ASGPRdAb HidAb MidAb LodAb 
 
hIFN(A) 
 
10.7 16.2 13.6 
 
hIFN(C) 
 
99.2 118.3 112.5 
 
hIFN(E) 
 
~792 ~5499 ~897 
n≥6, (pM) 
 
 
Figure 4.9 – HEK-Blue hIFN Potency Assay 
HEK-Blue in vitro reporter assay for hIFN bioactivity 
utilised to calculate EC50 values of hIFN-ASGPRdAb 
fusions and hIFN control. Demonstrates a decrease in 
potency with the conjugation of NOTA but no 
substantial shifts in EC50.  
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Table 4.8  
HEK-Blue EC50 of Conjugated NOTA-hIFN-ASGPRdAbs 
NOTA-hIFN-
ASGPRdAb HidAb MidAb LodAb 
 
hIFN(A) 
 
9.01 19.0 19.9 
 
hIFN(C) 
 
164 145 148 
 
hIFN(E) 
 
~3856 ~3676 ~3872 
n≥6, (pM) 
 
4.4.3 Flow Cytometry 
Flow Cytometry was utilised with the hIFN-ASGPRdAb mutants to profile 
cell binding to the HepG2 and U937 cell lines (Method 2.2.4, see also Section 3.2.5). 
The NOTA-hIFN-ASGPRdAb HepG2 semi-quantitative binding data 
(Table 4.9) demonstrated that the intended affinity profiles were achieved. HidAb 
conferred to the NOTA-hIFN-HidAb fusions a significantly (p<0.002) greater 
interaction with ASGPR-expressing HepG2 cells than MidAb did to the NOTA-
hIFN-MidAb fusions. Concurrently, MidAb (with the exception of the anomalous 
NOTA-hIFN(E)-MidAb) facilitated significantly (p<0.0005) higher HepG2 binding 
than LodAb did to the NOTA-hIFN-LodAbs. This pattern was visualised by the 
distinct cell binding peaks above the level of IgG denoted non-specific cell binding 
(Figure 4.10). This data suggested, as similarly concluded for hIFN-MAXdAb and 
hIFN-CTRLdAb (Section 3.2.5), that the ASGPRdAb portion of the hIFN-
ASGPRdAb fusion protein was the primary determinant of HepG2 cell binding. 
Indeed, with the presence of the lower affinity hIFN(C) or hIFN(E) mutant analogues 
in the mutant hIFN-ASGPRdAb there was a clear indication that the hIFN 
contributed no significant HepG2 binding capability. So, for instance, there was no 
significant (p>0.14) difference between the HepG2 binding values of hIFN(A)-HidAb, 
hIFN(C)-HidAb and hIFN(E)-HidAb (Table 4.9).  
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Table 4.9  
Flow Cytometric Analysis of NOTA-hIFN-ASGPRdAbs’  
HepG2 Cell Binding 
NOTA-hIFN-
ASGPRdAb HidAb MidAb LodAb 
 
hIFN(A) 
 
998 ±195 223 ±111 101 ±15.1 
 
hIFN(C) 
 
794 ±8.00 325 ±21.5 137 ±13.0 
 
hIFN(E) 
 
821 ±111 39.3 ±3.55 73.5 ±4.00 
Live/Dead – PI stain, Primary Antibody – α-dAb, Secondary Antibody – Alexa647 α-Murine n=3 
  
Figure 4.10 – Flow Cytometry of hIFN-dAb Fusions with HepG2 
Histogram of flow cytometric analysis of live HepG2 cell staining with representative hIFN-
ASGPRdAb fusions – NOTA-hIFN(A)-HidAb, NOTA-hIFN(C)-MidAb, NOTA-hIFN(E)-LodAb 
– detected with anti-dAb mAb and Alexa647, plus an irrelevant-IgG representing non-specific 
binding. Data demonstrates that HepG2 cell binding reflects the designed decreasing dAb-
mediated ASGPR binding affinities – HidAb > MidAb > LodAb. 
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However, there was an indication from the U937 binding data that in the 
absence of ASGPRdAb-mediated ASGPR binding then the hIFN mutants could 
mediate cell binding via hIFNAR (Figure 4.11) with NOTA-hIFN(A)-HidAb at 
46.5A, NOTA-hIFN(C)-MidAb at 13.3A, and hIFN(E)-LodAb at 9.26A. Moreover, 
the level of binding correlated with the designed affinities of the hIFN mutants 
(hIFN(A) > hIFN(C) > hIFN(E)) which was a further indication that the designed 
stepwise affinity for hIFNAR had been achieved. The cell binding of NOTA-
hIFN(E)-LodAb was barely above the irrelevant IgG non-specific binging control and 
so again suggests it has severely inhibited binding to hIFNAR. This was also 
indicated by the inability to integrate a KD value (Table 4.6). Nevertheless, it was still 
observed to be able to bind to some degree, which would explain the estimated nM 
potency values (Table 4.8).  
  
Figure 4.11 – Flow Cytometry of hIFN-dAb Fusions with U937 
Histogram of flow cytometric analysis of live U937 cell staining with representative hIFN-
ASGPRdAb fusions – NOTA-hIFN(A)-HidAb, NOTA-hIFN(C)-MidAb, NOTA-hIFN(E)-LodAb 
– detected with anti-dAb mAb and Alexa647, plus an irrelevant-IgG representing non-specific 
binding. Data demonstrates that U937 cell binding broadly reflects the designed decreasing hIFN-
mediated hIFNAR binding affinities – hIFN(A) > hIFN(C) >hIFN(E). 
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Overall, the flow cytometry data corroborated the conclusions made from the 
ASGPR binding Biacore SPR data (Section 4.4.1), confirming that the binding 
pattern of the NOTA-hIFN-ASGPRdAbs through the ASGPRdAb-mediated 
ASGPR binding was maintained in spite of the presence of the conjugated NOTA.  
In conclusion the flow cytometry data strongly suggested that the mutant 
NOTA-hIFN-ASGPRdAbs could bind to whole HepG2 cells. Moreover, their ability 
to bind HepG2 cells was likely predominantly mediated by the affinity of the 
respective ASGPRdAb for ASGPR with hIFN-mediated binding to hIFNAR also 
contributing to a lesser extent to the overall stepwise binding profile of the mutant 
hIFN-ASGPRdAb fusion protein subset.  
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4.5 BIODISTRIBUTION STUDIES 
4.5.1 Ga-68 Radiolabelling 
Utilising the 1M NaAc method developed for the reliable labelling of the 
NOTA-hIFN-MAXdAb and NOTA-hIFN-CTRLdAb (Section 3.4.1), Ga-68 
radiolabelled doses of the NOTA-hIFN-ASGPRdAbs were prepared at RT 
immediately prior to injection (Method 2.3.2).  
The average specific activity achieved for all mutant NOTA-hIFN-
ASGPRdAbs with a 2µM reaction was 1.07MBq/µg ±0.07 with an average efficiency 
of 85.9% ±2.76 and was thus sufficient for subsequent gamma counting in all 
instances, which was sufficient for quantifiable biodistribution data at 3 hours post-
injection. A final radiochemical purity of greater than 90% was achieved in all 
instances.  
 
4.5.2 Tissue Uptake Biodistribution Study 
HepG2 xenograft SCID Beige models were prepared in the same manner as 
previously described (Section 3.5.3). The tissue uptake of a 1µg dose of the mutant 
68Ga-NOTA-hIFN-ASGPRdAbs was analysed as %ID/g at 3 hours post-injection by 
gamma counting and tissue mass. All mutants were tested apart from hIFN(C)-
HidAb and hIFN(C)-LodAb as there were insufficient SCID Beige animals available. 
 
4.5.2.1 Full Tissue Analysis 
The full data set demonstrated that there were differences in tissue uptake 
potentially related to the mutant 68Ga-NOTA-hIFN-ASGPRdAbs’ respective 
affinities for the ASGPR and hIFNAR receptors (Table 4.10, Figure 4.12,).  
In the chapter III, the liver was identified for its specific ASGPR targeted 
uptake of NOTA-hIFN-MAXdAb and also speculated hIFN-mediated uptake. The 
liver uptake with the affinity mutants demonstrated ASGPRdAb-mediated 
differences in uptake (HidAb > MidAb > LodAb). In addition there was also a higher 
uptake with strong mIFNAR binding mediated by hIFN(A) versus hIFN(E). For 
instance, the uptake of the 68Ga-NOTA-hIFN(A)-LodAb was significantly (p<0.0001) 
higher than 68Ga-NOTA-hIFN(E)-LodAb with an average of 52.9% more. This 
strongly suggested that mIFNAR interactions could account for a high proportion of 
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the liver tissue uptake. A stronger ASGPRdAb mediated uptake was shown to 
account for a 44.4% increase in liver uptake when comparing uptake of 68Ga-
NOTA-hIFN(E)-HidAb and 68Ga-NOTA-hIFN(E)-LodAb. Therefore this suggested 
that the ASGPRdAb-mediated binding to ASGPR could also further increase liver 
tissue uptake.  
 
 
However, if there was already a strong hIFNAR binding influence, such as 
from hIFN(A), then the effect of improving ASGPR binding had less impact as 
demonstrated by only a 13.8% increase in liver uptake between 68Ga-NOTA-
hIFN(A)-LodAb and 68Ga-NOTA-hIFN(A)-HidAb. Overall, as the liver uptake is 
predominantly related to ASGPR and hIFNAR receptor affinity and hIFN observed 
to have the largest influence on liver tissue uptake, the data strongly suggested that 
liver uptake was specifically influenced by both the ASGPRdAb and hIFN. 
The intestine results show a significant (p<0.01) level of variability with no 
apparent pattern correlating with either ASGPR or hIFNAR receptor affinities. 
Therefore, as described previously (Section 3.5.2), this may reflect the respective 
68Ga-NOTA-hIFN-ASGPRdAbs’ susceptibility to degradation in the liver. There is 
no correlation with liver uptake, and so again suggests that there is an undetermined 
mechanism of hepatic degradation unrelated to either ASGPR or hIFNAR binding. 
Table 4.10 
Mutants Biodistribution Study Tissue Uptake Values 
Tissue 
(%ID/g) 
3h 
68Ga-NOTA-
hIFN(A)-HidAb 
68Ga-NOTA-
hIFN(E)-HidAb 
68Ga-NOTA-
hIFN(A)-MidAb 
68Ga-NOTA-
hIFN(C)-MidAb 
68Ga-NOTA-
hIFN(E)-MidAb 
68Ga-NOTA-
hIFN(A)-LodAb 
68Ga-NOTA-
hIFN(E)-LodAb 
Xenograft 1.48 ±0.41 1.62 ±0.64 1.59 ±0.39 1.46 ±0.61 1.48 ±0.11 1.36 ±0.27 1.15 ±0.51 
Intestine 3.23 ±0.15 4.26 ±0.40 4.13 ±0.20 4.67 ±0.71 3.40 ±0.42 4.10 ±0.61 4.00 ±0.33 
Pancreas 0.57 ±0.06 0.75 ±0.10 0.68 ±0.04 0.80 ±0.13 0.83 ±0.11 0.66 ±0.08 0.70 ±0.07 
Spleen 5.84 ±0.97 5.01 ±0.48 5.86 ±1.29 4.10 ±0.60 5.27 ±0.79 2.75 ±0.21 2.61 ±0.30 
Stomach 0.92 ±0.19 0.73 ±0.12 0.66 ±0.29 1.78 ±1.39 0.58 ±0.19 0.76 ±0.24 0.73 ±0.07 
Kidneys 31.9 ±6.29 47.0 ±2.17 47.2 ±3.37 49.6 ±1.13 58.6 ±6.54 88.8 ±8.85 89.4 ±6.74 
Liver 39.1 ±2.22 33.1 ±0.97 33.7 ±3.40 29.4 ±0.56 28.9 ±2.77 33.7 ±0.48 18.4 ±1.04 
Heart 1.02 ±0.15 1.23 ±0.13 1.07 ±0.13 1.11 ±0.06 1.15 ±0.09 0.89 ±0.08 0.85 ±0.13 
Lung 1.65 ±0.77 1.93 ±0.72 1.04 ±0.05 1.16 ±0.11 1.41 ±0.27 1.42 ±0.83 1.52 ±1.29 
Blood 1.23 ±0.05 1.25 ±0.29 0.78 ±0.03 1.68 ±0.09 1.42 ±0.10 1.25 ±1.11 0.89 ±0.42 
Muscle 0.25 ±0.03 0.33 ±0.04 0.34 ±0.09 0.28 ±0.02 0.36 ±0.03 0.31 ±0.05 0.26 ±0.03 
 n≥3 (%ID/g) 
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The uptake in the kidneys showed extremely significant differences (p<0.0001) 
for the mutant 68Ga-NOTA-hIFN-ASGPRdAbs with reduced targeting with both to 
ASGPR and hIFNAR, ranging from 39.1%ID/g for 68Ga-NOTA-hIFN(A)-HidAb 
up to 89.4%ID/g for 68Ga-NOTA-hIFN(E)-LodAb. This difference was not due to 
varying kidney size as the average kidney size varied little at 215.4µg ±8.80, but rather 
appeared to be related to renal filtration (or indeed retention to an unknown extent). 
This was apparent because for the 68Ga-NOTA-hIFN(A)-HidAb an average of 
68.0% of the total ID was accounted for in the harvested tissues whereas by 
comparison for the 68Ga-NOTA-hIFN(E)-LodAb an average of 56.4% of the total ID 
was in the harvested tissues. Therefore, assuming the difference was not residing in 
uncounted tissues, there was increased urinary excretion of the lesser-targeted 68Ga-
NOTA-hIFN-ASGPRdAbs. This may perhaps have been accountable for in part by 
the reduced liver tissue uptake. Hence, targeting to ASGPR increased systemic 
retention of the mutant hIFN-ASGPRdAbs. 
The spleen uptake demonstrated a significant difference (p<0.001) between the 
hIFN-HidAb mutants and the hIFN-LodAb mutants, which was indicative of the 
spleen tissue uptake being linked to the ASGPRdAb affinity. This was speculated to 
Figure 4.12 – Biodistribution of 68Ga-NOTA-hIFN-MAXdAb in SCID 
Beige HepG2 Xenograft Model at 3hr with varying dose 
Mean %ID/g in selected tissues with 1µg injected dose of 68Ga-NOTA-hIFN-ASGPRdAbs at 3 
hours post-IV administration as determined by Gamma Counting. Demonstrates that modifying 
the affinity of hIFN-ASGPRdAbs for the ASGPR and hIFNAR receptors can significantly change 
the tissue uptake profile of the fusion protein.  
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be specific ASGPR binding or a non-specific interaction with the white pulp 
correlating with affinity. These possible hypotheses were supported by the increased 
bioavailability of the lesser-targeted 68Ga-NOTA-hIFN-ASGPRdAbs not correlating 
with increased spleen tissue uptake. Hence, it was not increased concentration in the 
system. Moreover, the levels were significantly higher than in blood. However, this 
data contradicted the data for 68Ga-NOTA-hIFN-CTRLdAb, which demonstrated a 
higher uptake in spleen than the ASGPR targeted 68Ga-NOTA-hIFN-MAXdAb. 
Therefore, the exact nature of the spleen uptake remained unresolved. 
 
4.5.2.2 Xenograft Uptake 
The %ID/g data showed the tumour xenograft uptake was observed to not 
be significantly different (Figure 4.12, Table 4.12), although there was a downward 
trend with decreasing receptor affinities. However, as demonstrated in the hIFN-
MAXdAb blocking study (Section 3.5.4) the liver uptake could have been 
significantly affecting the bioavailability of the 68Ga-NOTA-hIFN-ASGPRdAbs in 
the system as a large specific sink. The hypothesis being that a low liver uptake 
resulted in more radioligand in the system for xenograft uptake, thus potentially 
inflating xenograft tissue uptake values for lesser targeted radioligands. There was a 
highly significant difference (p<0.0001) in liver uptake over the range of 39.1%ID/g 
±2.22 to 18.4%ID/g ±1.04 for the 68Ga-NOTA-hIFN-ASGPRdAbs analysed (Section 
4.5.2.1). So for instance, there was an average of 25.2% more 68Ga-NOTA-hIFN(E)-
LodAb available for xenograft tumour uptake in the system of the respective SCID 
Beige model than the respective model with 68Ga-NOTA-hIFN(A)-HidAb owing to 
the increased specific liver uptake of the latter. Therefore it was appropriate to apply 
a correction to the xenograft data. 
Applying this correction to control for systemic availability by removing the 
liver counts from the total available %ID, ensured that the xenograft uptake values 
were relative to the systemic bioavailability of the respective hIFN-ASGPRdAb. This 
sub-analysis revealed that there was a significant difference (p=0.04) between the 
xenograft uptake between 68Ga-NOTA-hIFN(A)-HidAb and 68Ga-NOTA-hIFN(E)-
LodAb of 2.90%ID/g ±0.75 versus 1.56%ID/g ±0.69, respectively, reflecting their 
respective high and low targeting status (Table 4.13, Figure 4.13).  
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Table 4.11  
Xenograft Tissue Uptake of  Mutant 68Ga-NOTA-hIFN-
ASGPRdAbs at 3h with Liver Uptake Correction 
NOTA-hIFN-
ASGPRdAb* HidAb MidAb LodAb 
 
hIFN(A) 
 
2.90 ±0.75 2.67 ±0.52 2.17 ±0.42 
 
hIFN(C) 
 
- 2.31 ±1.00 - 
 
hIFN(E) 
 
2.78 ±1.19 1.48 ±0.12 1.56 ±0.69 
n≥3 (%ID/g), *insufficient resources for hIFN(C)-HidAb and hIFN(C)-LodAb 
Figure 4.13 – Xenograft Uptake of mutant 68NOTA-hIFN-ASGPRdAbs 
in SCID Beige HepG2 Xenograft Model  
Mean %ID/g (corrected for liver uptake dose) in xenograft tissue at 1µg injected dose of mutant 
68Ga-NOTA-hIFN-ASGPRdAbs, plus 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-
CTRLdAb, at 3h post-IV injection. Demonstrates significantly higher uptake of fusion protein with 
increased ASGPR and hIFNAR targeting affinities. 
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Comparison with the 68Ga-NOTA-hIFN-MAXdAb and 68Ga-NOTA-hIFN-
CTRLdAb demonstrated the broadly stepwise decrease in the mean tumour 
xenograft targeting from the highly targeted hIFN-MAXdAb down through the 
HidAb, MidAb and LodAb mutant fusions to the hIFN-CTRLdAb (Figure 4.13). 
This indicated that tumour xenograft uptake of the hIFN-ASGPRdAbs was specific 
to both the ASGPR and hIFNAR.  
However, this hypothesis was undermined by a lack of significant difference 
between the blood content versus the tumour xenograft (Figure 4.12). This could 
have been interpreted as the tumour uptake being a product of the highly 
vascularised nature of the tumour xenograft rather than dAb-mediated specific 
uptake. Nevertheless, there was no correlation between the blood content and there 
was an evident pattern of 68Ga-NOTA-hIFN-ASGPRdAb tumour xenograft uptake 
correlating with ASGPR and hIFNAR affinity, thus suggesting that the blood uptake 
and tumour xenograft uptake were independent.  
 
An additional conclusion from the lack of significant difference between 
xenograft uptakes of the mutant 68Ga-hIFN-ASGPRdAbs before liver correction was 
that this data demonstrated that if there was a large off-target sink for a targeted dAb 
fusion protein (represented in this data set by the liver uptake) then a reduced 
receptor affinity was an appropriate strategy to reduce off-target uptake whilst 
maintaining uptake in the target tissue. So for instance, there was no significant 
difference (p=0.71) in specific xenograft uptake between 68Ga-NOTA-hIFN(A)-HidAb 
and 68Ga-NOTA-hIFN(A)-MidAb, but 68Ga-NOTA-hIFN(A)-MidAb had a 
significantly (p=0.04) lower liver uptake. Therefore, in spite of its lower affinity for 
ASGPR, 68Ga-NOTA-hIFN(A)-MidAb was shown to be the optimum choice to 
reduce off-target uptake.  
 
Hence, in conclusion, this data set provided additional confidence in the 
assertion that HepG2 xenograft uptake was mediated by ASGPRdAb affinity for 
ASGPR. Furthermore, that reducing the affinity for ASGPR, and concurrently 
hIFN’s affinity for hIFNAR, could decrease off-target uptake whilst maintaining 
HepG2 xenograft uptake.  
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4.5.3 TaqMan mRNA Expression Profiling 
The xenograft targeting results for the mutant hIFN-ASGPRdAbs 
demonstrated an observable affinity dependent uptake in the HepG2 tumour 
xenograft tissues (Section 4.5.2.2). Previously, it was shown that the significantly 
different xenograft uptake of hIFN-MAXdAb and hIFN-CTRLdAb was congruent 
with discrete modifications to the HepG2 xenograft transcriptome with increased 
anti-viral or anti-proliferative mRNA expression profiles (Section 3.5.5). Therefore, 
TaqMan was also used to discern the bioactivity of the mutant hIFN-ASGPRdAbs 
relative to their xenograft uptake (Methods 2.5). 
 
The hIFN-MAXdAb, hIFN(A)-HidAb, hIFN(A)-MidAb, hIFN(A)-LodAb and 
hIFN-CTRLdAb all had a low pM EC50 hIFN potency but differed in their affinity 
for the ASGPR receptor (MAXdAb > HidAb > MidAb > LodAb > CTRLdAb, as 
reflected in their xenograft uptake values (Table 4.12)) and so were compared to 
elucidate the influence of ASGPR affinity (Figure 4.14). The data demonstrated that 
the hIFN(A)-HidAb, hIFN(A)-MidAb and hIFN(A)-LodAb instigated a similar 
pattern of mRNA expression in the HepG2 tumour xenografts to hIFN-MAXdAb 
but with an even greater effect on mRNA copy number. For instance, on average the 
hIFN-MAXdAb decreased mRNA related to transcription and translation by 23.2% 
whereas hIFN(A)-MidAb registered a decrease of 40.3%. Similarly, the mRNA copy 
number of genes associated with cell survival and motility (excluding NET1) were on 
average 16.8% lower with the application of hIFN(A)-MidAb compared to hIFN-
MAXdAb. For six gene results the lowest affinity targeted hIFN(A)-LodAb had the 
greatest effect on the respective mRNA copy number. In the modification of 
apoptotic gene mRNAs such as PRKCD and NET1 the hIFN(A)-MidAb 
demonstrated the largest anti-tumour effect. There was overall, however, little 
difference between hIFN(A)-HidAb, hIFN(A)-MidAb, and hIFN(A)-LodAb as each 
had on average a 29.3% ±2.8 greater effect on cellular mRNA responses compared to 
hIFN-MAXdAb 
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Table 4.12  
Percentage Difference in mRNA Copy Number relative to untreated 
Xenograft Tissue 
 
Fusion Protein 
hIFN-
MAXdAb 
hIFN(A)-
HidAb 
hIFN(A)-
MidAb 
hIFN(C)-
MidAb 
hIFN(E)-
MidAb 
hIFN(A)-
LodAb 
hIFN-
CTRLdAb 
Tumour 
Xenograft 
Uptake 
(%ID/g)* 
3.11	   3.06	   2.55	   2.31	   2.20	   2.16	   1.00	  
Gene Name 	   	   	   	   	   	   	  
ARHGEF 
Family  -­‐25.8 -­‐50.7 -­‐49.6 -­‐40.4 -­‐39.8 -­‐48.3 -­‐4.8 
CREB 
Family -­‐20.1 -­‐34.3 -­‐39.6 -­‐25.1 -­‐40.1 -­‐41.6 3.5 
EIF4 Family -­‐35.7 -­‐44.0 -­‐55.6 -­‐58.3 -­‐45.9 -­‐37.1 -­‐55.2 
HIST Family -­‐3.7 -­‐8.8 -­‐16.5 25.5 63.6 -­‐10.0 64.5 
IFNAR1/2 -­‐34.9 -­‐46.2 -­‐45.1 -­‐43.7 -­‐45.0 -­‐47.1 -­‐4.7 
IFNΥR1/2 -­‐28.4	   -­‐41.4	   -­‐41.5	   -­‐33.9	   -­‐44.3	   -­‐43.3	   -­‐10.1	  
IRF9 516	   426	   344	   593	   -­‐27	   356	   475	  
IRS1 -­‐42.6	   -­‐58.2	   -­‐51.1	   -­‐55.1	   -­‐54.8	   -­‐58.2	   -­‐19.6	  
JAK1/2 -­‐40.3	   -­‐51.9	   -­‐49.3	   -­‐45.1	   -­‐44.8	   -­‐48.8	   -­‐5.1	  
MAPK 
Family -­‐28.5 -­‐45.5 -­‐43.8 -­‐35.2 -­‐40.9 -­‐45.7 -­‐2.8 
MTOR -­‐15.4 -­‐39.8 -­‐52.3 -­‐46.4 -­‐47.8 -­‐47.9 -­‐51.7 
NET1 26.2	   13.8	   115.3	   98.3	   36.5	   38.9	   -­‐42.7	  
PI3K Family -­‐35.7 -­‐50.1 -­‐48.4 -­‐43.9 -­‐47.4 -­‐51.2 -­‐15.0 
PRKCD -­‐30.7 -­‐39.1 -­‐38.5 -­‐15.6 -­‐5.3 -­‐25.9 10.1 
RAC1 -­‐44.9 -­‐35.4 -­‐39.3 -­‐43.6 -­‐30.1 -­‐49.4 -­‐17.1 
RPS6 Family -­‐33.3 -­‐50.8 -­‐49.3 -­‐36.3 -­‐40.1 -­‐47.6 -­‐7.9 
STAT1 230.9 333.0 147.3 328.1 -­‐43.2 251.8 89.9 
TYK2 -­‐10.0 -­‐42.3 -­‐39.2 -­‐11.1 -­‐9.3 -­‐39.4 21.6 
VAV2/3 -­‐17.0 -­‐55.5 -­‐52.2 -­‐49.6 -­‐37.3 -­‐51.3 -­‐7.4 
 n=1, *individual xenografts utilised  
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The higher apoptotic effect of hIFN(A)-MidAb was indicative of an increased 
concentration of bioavailable hIFN(A)-MidAb in the xenograft in spite of its relatively 
lower uptake compared to hIFN-MAXdAb with 2.31%ID/g versus 3.11%ID/g 
respectively. A possible hypothesis for this occurrence was that MAXdAb’s higher 
affinity for ASGPR mediated an increase in degradation of the hIFN-MAXdAb 
owing to entering the ASGPR degradation pathway (Introduction 1.4.2). Therefore, 
having a lower affinity for ASGPR, such as with hIFN-MidAb, could have facilitated 
binding to ASGPR but with a higher rate of subsequent dissociation before 
degradation could occur. This would enable more interactions with hIFNAR to 
possibly occur. Moreover, this would likely facilitate greater tissue percolation and 
thus increase potential hIFNAR interactions.  
Therefore, the results indicated that hIFN(A)-MidAb appeared to provide the 
optimum balance between specific tumour xenograft targeting, relatively low liver 
uptake and kidney loss, and maximising the potency of the hIFN bioactivity possibly 
through facilitating increased hIFNAR interaction.  
 
  
Figure 4.14 – TaqMan RT-PCR of 
hIFN Pathway associated mRNA 
sequences in Xenografts targeted by 
mutant hIFN-dAbs 
A – IFN Signalling Pathway 
B – Transcription/Translation Factors 
C – Cell Growth Pathway Factors 
Percentage change in mRNA gene copy number of 
HepG2 xenograft tissue treated with hIFN-dAbs 
differing in affinity for ASGPR versus an untreated 
control. Demonstrates greater anti-proliferative 
transcriptome correlates with lower dAb-mediated 
ASGPR targeting.  
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The hIFN(A)-MidAb, hIFN(C)-MidAb, and hIFN(E)-MidAb differed in their 
affinities for hIFNAR and also EC50 potency from low pM to high nM (Table 4.8) 
(hIFN(A) > hIFN(C) > hIFN(E)) and so they were analysed to elucidate the role of 
reduced hIFN potency on the HepG2 cellular response. 
The data demonstrated that in general the mutation of the hIFN did not 
exclude the adoption of a modified transcriptome by the HepG2 tumour xenograft 
tissue (Table 4.12, Figure 4.15). This suggested that the concentration of the hIFN-
MidAbs and hIFN-LodAbs in the xenografts was sufficient to overcome the 
deficiencies in potency. 
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Figure 4.15 – TaqMan RT-PCR of HIST, NET1 and PRKCD mRNA 
sequences in Xenografts targeted by hIFN-MidAbs 
Percentage change in mRNA gene copy number of HepG2 xenograft tissue treated with hIFN-
MidAbs differing in affinity for hIFNAR versus an untreated control. Demonstrates greater anti-
proliferative transcriptome correlates with higher hIFN potency.  
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However, there were some crucial differences that indicated there was a 
discrete effect akin to that observed for the differences between the hIFN-MAXdAb 
and hIFN-CTRLdAb (Section 3.5.5). Precisely, that the hIFN(C) and hIFN(E) 
instigated a less apoptotically-primed phenotype as was argued for hIFN-CTRLdAb. 
For instance, the decrease in anti-apoptotic PRKCD mRNA correlated with the 
increasing hIFN potencies of the hIFN-MidAbs, as did the decrease in histone 
mRNA and the increase in pro-cell death NET1 mRNA (Figure 4.15). Hence, this 
suggested that the hIFN mutants have phenotypically distinct effects on the HepG2 
xenograft tissue, with a reduced potency correlating with a reduced apoptotic 
transcriptome. 
 
This data set was insufficient to make statistically significant assertions as it 
was performed on single xenografts, but rather identified potential patterns of mRNA 
expression to further guide the emerging hypothesis that creating the most efficacious 
dAb fusion may not be a case of having the highest possible affinity for both targets. 
Nevertheless, several repeats would have needed to be performed before the 
TaqMan data could have been utilised to conclusively guide dAb fusion design.  
 
Therefore, in conclusion, the data suggested that a reduced affinity for 
ASGPR compared to MAXdAb could in fact increase the efficacy of the fused hIFN 
to signal an anti-apoptotic phenotype in HepG2 xenograft cells. This contrasted with 
a decreased affinity of the hIFN for the hIFNAR appearing to correlate with a less 
anti-apoptotic transcriptome. Based on this data, it was concluded that hIFN(A)-
MidAb was likely the optimum balance of targeting and bioactivity. 
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5.1 CONCLUDING DISCUSSION 
5.1.1 Investigation Overview 
This investigation was conceived to investigate the optimum binding affinity 
strategy for maximising the efficacy of new dAb fusion therapies. This was a 
necessary line of enquiry owing to the presence of two likely competing binding 
affinities within the single dAb fusion protein.  The hypothesis was thus: 
 
Hypothesis 
The efficacy – targeting selectivity and localised potency – of a 
dAb fusion protein will be significantly influenced by its two intrinsic 
binding affinities 
 
The hepatic endothelium tissue selective ASGPRdAb and the potent 
therapeutic hIFN with its contrasting systemically distributed hIFNAR were selected 
to form the model dAb fusion. A panel of hIFN-ASGPRdAbs with varying 
engineered binding affinity combinations were to be evaluated (Table 5.1). The 
chosen in vivo model to investigate the differing pharmacology of these hIFN-
ASGPRdAbs was a SCID Beige HepG2 xenograft model, facilitated by 
radiolabelling the dAb fusions with Ga-68 through conjugated NOTA chelator. 
 
Table 5.1 
Mutant hIFN-dAb Fusion Proteins’  
Relative Receptor Affinities 
Fusion Protein 
Relative Targeting Affinity 
ASGPR hIFNAR 
hIFN-MAXdAb ++++ +++ 
hIFN(A)-HidAb +++ +++ 
hIFN(C)-HidAb +++ ++ 
hIFN(E)-HidAb +++ + 
hIFN(A)-MidAb ++ +++ 
hIFN(C)-MidAb ++ ++ 
hIFN(E)-MidAb ++ + 
hIFN(A)- LodAb + +++ 
hIFN(C)-LodAb + ++ 
hIFN(E)-LodAb + + 
hIFN-CTRLdAb - +++ 
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5.1.1.1 hIFN-dAb Characterisation 
The in vitro work focussed on the production of characterised NOTA-
conjugated hIFN-ASGPRdAbs for their subsequent use in vivo. Where necessary, the 
hIFN-ASGPRdAbs were genetically engineered, expressed and purified (Sections 
4.2.1, 4.2.2 & 4.2.3). Their respective interactions with ASGPR and hIFNAR, and 
hIFN potency were analysed against isolated target receptors and on whole cells to 
construct an in vitro pharmacokinetic model of the NOTA-hIFN-ASGPRdAbs’ 
behaviour (Figure 5.1).  
 
The NOTA-conjugation reaction was shown by MS analysis to yield a 
heterogeneous mix of species, dominated by singly conjugated species (Table 3.4), 
which were consistently recovered at concentrations of 52.9µM ±14.1 (Table 3.3 & 
Table 4.4) for subsequent radiolabelling to high specific activities with Ga-68 (Table 
3.11) in the instances of hIFN-MAXdAb and hIFN-CTRLdAb. The heterogeneity 
may have affected the pharmacokinetics of the various species as reflected in the SPR 
data. However, it did not appear to affect the validity of subsequent results assuming 
the distribution of the different conjugate species is equal, as the radiotracer will likely 
still have been proportionally representative of biodistribution of the heterogeneous 
species (Section 5.2).  
Figure 5.1 – In vitro binding data for NOTA-
hIFN-MAXdAb and NOTA-hIFN-CTRLdAb 
In vitro data for HepG2 cellular interactions of the NOTA-
hIFN-MAXdAb and NOTA-hIFN-CTRLdAb conjugated 
proteins. 
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The conjugation of NOTA significantly decreased the binding of hIFN-
ASGPRdAbs to ASGPR and hIFNAR (Table 3.6 and Table 3.7) including on whole 
cells (Table 3.9). However, in practical terms the presence of conjugated NOTA did 
not impact the potency of the hIFN moiety (Figure 3.10 & Figure 4.9), and the 
desired differences in ASGPR binding were maintained  (Figure 3.13 & Figure 4.9).  
The exception was a significant decrease in the potency of hIFN-CTRLdAb 
with NOTA conjugation of 6.87pM to 37.5pM, compared to the decrease from 
2.78pM to 6.79pM for hIFN-MAXdAb, which was likely due to increased NOTA 
conjugation of the hIFN lysines of hIFN-CTRLdAb impacting its interaction with 
hIFNAR2. This also highlighted that the hIFNAR2 binding was likely driven by the 
koff of the dAb fusion as the relative potencies (Table 3.8) were ameliorated by slower 
koff values in spite of reduced KD values (Table 3.7).  
It was shown that HepG2 interactions were predominantly dictated by 
ASGPR binding in vitro. Comparison of MAXdAb, HidAb, MidAb, LodAb and 
CTRLdAb fusions’ binding to whole HepG2 cells showed significant differences 
(Table 3.9 & Table 4.9, Figure 3.18), which were attributable to dAb-mediated 
ASGPR binding correlating with the binding affinity for ASGPR. The hIFNAR 
binding through hIFN, on the other hand, was shown to not contribute significantly 
to HepG2 binding (Table 4.9). This strongly indicated that HepG2 xenograft uptake 
in vivo would likely be driven by ASGPR binding.  
Attaining robust and reproducible in vitro data for a number of the dAb 
fusions proved troublesome, especially in the Biacore SPR analyses. A possible 
explanation was an apparent concentration dependent self-association dimerisation 
of the dAb fusions, seemingly promoted by the MAXdAb moiety, as dAbs were 
known to have the potential to dimerise (Introduction 1.2.1). This was apparent from 
the lack of equilibrium in the SPR traces (Figure 3.5) and the high non-specific 
binding in spite of blocking on whole cells (Figure 3.17). Therefore, quantitative 
kinetic data was not as robust as would have been liked, particularly for the hIFN-
ASGPRdAb mutants. This was counteracted by the comprehensive QC analytical 
package as a whole but unfortunately there was insufficient time for radioligand 
binding assays with the hIFN-ASGPRdAb mutants.  
Thus, in vitro it was shown that the hIFN-dAbs selected for investigation had 
the necessary characteristics for answering the hypothesis in vivo.  
  
V – Conclusions & Future Work 
Alex G. Papple - 204 - Ph.D. 2014 
5.1.1.2 Gallium Radiolabelling 
An effective and reliable Ga-68 radiolabelling protocol was optimised from 
scratch. The most effective reaction conditions were found to be 1M NaAc buffering 
to pH4.40 in the minimum volume. Radiolabelling NOTA-hIFN-ASGPRdAbs at 
concentrations as low as 1µM (Table 3.11), for high specific activity radiolabelling up 
to 2.47MBq/µg and radiolabelling efficiencies up to 98.4%. These reaction 
conditions enabled specific activities sufficient for quantitative biodistribution 
analyses (Table 3.15) and PET imaging between one and three hours, with 
quantifiable measures of xenograft uptake recorded over time (Table 3.18) and 
quantitative images of xenograft uptake acquired (Figure 3.35). 
The Ga-68 radiolabelling specific activities were high enough to attain useful 
radiotracer data on the biodistribution of all the hIFN-ASGPRdAbs. However, the 
1.99MBq/µg for NOTA-hIFN-MAXdAb in Chapter III inhibited experimentation 
at concentrations below 1µg in vivo (Section 3.5.2). Furthermore, in Chapter IV at 
1.07MBq/µg the specific activities precluded imaging the mutant hIFN-
ASGPRdAbs’ biodistribution by PET-CT imaging (Section 4.5.1). Further refining 
the NOTA conjugation reaction and in particular utilising a higher activity generator 
could have potentially ameliorated the specific activities by allowing lower reaction 
concentrations of protein.  
In summary, a facile, reliable and reproducible Ga-68 radiolabelling protocol 
for NOTA conjugated dAb fusions was successfully optimised. 
 
5.1.1.3 hIFN-dAb Xenograft Targeting  
The in vivo data demonstrated that the HepG2 xenograft targeting of a hIFN-
dAb fusion could be significantly increased by selective ASGPR targeting (Figure 
3.26, Figure 3.35) with increased xenograft uptake correlating with increasing 
binding affinity for ASGPR (Figure 4.13). The improved uptake was most 
pronounced at 3 hours post-injection between the ASGPR targeted hIFN-MAXdAb 
and the non-ASGPR targeted hIFN-CTRLdAb with 2.42%ID/g ±0.69 vs. 
0.68%ID/g ±0.11, respectively. It was also shown that in vitro targeting was driven by 
receptor number. 
The 68Ga-NOTA-hIFN-MAXdAb biodistribution analyses for dosing did not 
comprehensibly determine whether there was self-blocking of xenograft uptake and 
so a 1µg dose was selected as it provided the highest xenograft uptake in the 
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experiments and was readily feasible from a practical perspective. Although the in 
vitro data showed the interaction with HepG2 cells was very likely to be a specific 
interaction (Figure 3.17), the significant in vivo xenograft uptakes were analysed for 
their specificity. The notion that increased uptake was an artificial consequence of 
high blood concentration was not supported by the data (Figure 3.27), with 
significant differences after three hours post-injection between the xenograft and 
blood, with the hIFN-dAbs apparently cleared by renal filtration, liver and perhaps 
spleen (Figure 3.28). An attempt to block the uptake of hIFN-MAXdAb in the 
xenografts with an excess of MAXdAb protein proved inconclusive owing to the 
influence of the murine liver uptake, seemingly masking any differences in xenograft 
uptake.  
PET-CT was demonstrated to enable temporal in vivo quantitation of 
xenograft uptake. The results showed the higher uptake of 68Ga-NOTA-hIFN-
MAXdAb between 1h and 3h post-injection compared to 68Ga-NOTA-hIFN-
CTRLdAb, and to a control tissue. There was clear potential to develop this 
technique into compartmental modelling with the correct model.  
 
The primary problem with the chosen model for assessing HepG2 xenograft 
uptake was the significantly high murine liver uptake. The dAbs were matured for 
affinity towards human ASGPR and the hIFN variants based on the endogenous 
human protein with affinity for hIFNAR, so the extent of this uptake was 
unanticipated.  This uptake was significantly influenced by the affinity for ASGPR, as 
demonstrated by hIFN-MAXdAb versus hIFN-CTRLdAb (Figure 3.28), and most 
conclusively by the significant decrease in uptake of hIFN-MAXdAb with excess 
MAXdAb blocking (Figure 3.31). However, the affinity for the hIFNAR was a more 
significant driver of murine liver uptake, as evidence by the over 50% increase in 
liver uptake between hIFN(E)-LodAb and hIFN(A)-LodAb (Figure 4.12). Therefore it 
was likely that cross-reactivity with both mASGPR and mIFNAR was occurring.  
The liver was thus shown to act as a significant, apparently saturable sink for 
the hIFN-dAbs correlating with affinity for both ASGPR and hIFNAR (Figure 3.30. 
Foremost this will have restricted the maximum attainable xenograft uptake. 
Moreover, comparing, for instance, hIFN(A)-HidAb with hIFN(E)-LodAb xenograft 
uptake is more difficult because logically there would be more hIFN(E)-LodAb 
available in the system owing to decreased liver uptake and thus an increased 
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likelihood of HepG2 xenograft uptake purely by the virtue that there is more in the 
system (Figure 4.12). Indeed, once corrected for liver uptake, it transpired there was a 
significant difference in xenograft uptake (Figure 4.13).  
Another perspective on this effect was the liver actually created a convenient 
proxy for off-target specific uptake. Hence, it was possible to conclude that by 
reducing the affinity for ASGPR and hIFNAR it was possible to increase uptake in 
the xenograft tissue relative to off-target uptake, which may reduce side effects whilst 
maintaining efficacy.  
In summary, tissue targeting of hIFN-dAb fusion proteins could be mediated 
by ASGPRdAbs, increasing uptake in proportion to the affinity for ASGPR. This 
was in spite of high liver uptake driven by the hIFN. Overall the liver-targeting 
model itself proved ineffective for picking apart the finer intricacies of targeting with 
modified binding affinities.  
 
5.1.1.4 Targeting and Efficacy 
The increased ASGPRdAb-mediated uptake in HepG2 xenografts was shown 
to correlate with a hIFN-mediated, increasingly anti-proliferative xenograft mRNA 
expression profile (Figure 3.32, Figure 3.33). Lower uptake of hIFN-CTRLdAb or a 
reduced hIFN affinity for hIFNAR, represented by hIFN(C) and hIFN(E), led to an 
mRNA expression profile akin to an anti-viral response. This is congruent with the 
established literature detailing the differential hIFN pathway gene expression 
integration specific to the stimulation of the hIFNAR (Introduction 1.5.1). Thus, 
there was a strong indication that there could be discretely measurable cellular 
responses relative to the binding affinities of both the ASGPRdAb and the hIFN.  
Indeed there was also a strong indication that the balance between ASGPR 
targeting affinity for maximum tissue uptake and hIFNAR stimulation is not 
straightforward. For example, in spite of a higher uptake, the hIFN-MAXdAb did 
not stimulate a greater increase in anti-proliferative gene transcription compare to 
hIFN(A)-HidAb or hIFN(A)-MidAb (Table 4.14). Therefore, it was possible to 
hypothesise that higher binding affinity for ASGPR in fact likely impedes its ability to 
interact with the hIFNAR. This could be explained by the increased binding affinity 
for ASGPR increasing the frequency of entering the endosomal degradation pathway 
rather than the likelihood of dissociation and recycling to the cell surface to interact 
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with hIFNAR (Introduction 1.4.4.1), or possibly allowing greater xenograft tissue 
percolation and thus increased hIFNAR interactions.  
As the hIFN(C)-MidAb and hIFN(E)-MidAb fusion proteins are not as potent 
as hIFN(A)-MidAb for producing an anti-proliferative transcriptome, it appeared 
that in the case of hIFN engineering a reduced hIFNAR binding affinity was 
counterproductive. However, this need to maximise potency in the target tissue must 
be balanced with the need to reduce side effects in off-target tissues. 
In summary, the results showed that dAb-mediated tissue uptake could 
increase the anti-proliferative efficacy of the attached therapeutic hIFN but that a too 
high a binding affinity may be self-defeating.   
 
5.1.2 Final Thoughts 
 
Hypothesis 
The efficacy – targeting selectivity and localised potency – of a 
dAb fusion protein will be significantly influenced by its two intrinsic 
binding affinities 
 
The data thus strongly indicated that the hypothesis could be accepted. The 
dAb targeting significantly increased tissue uptake, and thus also localised potency of 
the attached therapeutic hIFN. The binding affinity of both the dAb and the 
attached hIFN had a significant influence on the overall efficacy of the fusion protein. 
A dAb fusion therapeutic may have significant off-target uptake, but reducing the 
affinity for its target receptor may ameliorate this with the caveat that this may be at 
the expense of a more potent response in the target tissue.  
The implications for future dAb fusion design are evident, with increased 
consideration for how two binding affinities can be best harnessed for overall efficacy. 
The ability to target xenograft tissue also indicates that future research could include 
metastatic cancers or cancer cell subtypes with distinct marker profiles.  
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5.2 FUTURE WORK 
5.2.1 NOTA Conjugations 
The NOTA reaction would have perhaps benefitted from a more controlled 
conjugation strategy. There remained scope for further optimisation of the 
conjugation reaction to promote a homogeneous singly conjugated species by for 
instance lowering the reaction to pH7.5 (assuming the pI is avoided) which may 
promote less lysine ε-amine deprotonation, whilst simultaneously increasing the 
likelihood of N-terminal α-amine conjugation and thus decreasing the likelihood of 
multiple conjugations458. Another approach to explore is introducing a cysteine 
group at the C-terminus to enable conjugation by thiol reaction, such as with 
maleimido-mono-amide-NOTA470,481,482, in conjunction with necessary stability in 
vivo data483. This latter strategy would circumvent the problem of having differing 
numbers of lysine groups (14 in hIFN-MAXdAb and 11 in hIFN-CTRLdAb), which 
may have resulted in the decreased hIFN potency of the hIFN-CTRLdAb. 
 
5.2.2 Ga-68 and Sc-44 Radiolabelling 
The limiting factor on the specific activities achievable was the concentration 
of Ga-68 in the fraction utilised for reaction. A larger generator of the order 1.11GBq 
or higher, compared to the 370MBq utilised in this investigation, would yield higher 
radioactivities for reaction thus allowing higher achievable specific activities382,484. 
The difference the generator state can make on labelling was apparent from 
comparing the 1µM/16µg NOTA-hIFN-MAXdAb 1M NaAc Ga-68 labelling 
optimisation results attained with a relatively new generator (Table 3.11) with the 
same reactions performed for PET-CT with the same decaying generator. There was 
a significant (p<0.0001) decrease in specific activity from 2.37MBq/µg ±0.08 to 
1.99MBq/µg ±0.09 respectively, in spite of a constant radiolabelling efficiency. 
Hence, experimentation with a larger generator would be a high priority for future 
work to push the specific activities to the highest possible level achievable.  
In order to continue utilising PET-CT for imaging over longer time periods it 
would be necessary to utilise a longer lived isotope. Sc-44 has a half-life of 3.97 hours, 
positron emissions constituting 94.3%, a 1.47 EMAX  and can be conveniently eluted 
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from a 44Ti/44Sc generator485. Therefore, Sc-44 exceeds all the advantages of Ga-68 
labelling, particularly with a more suitable half-life. Hence, this could enable greater 
experimental flexibility for longitudinal in vivo imaging.  
 
5.2.3 Serum Stability  
The in vivo state of the dAb fusions was somewhat in question during the 
investigation analyses. In future work the blood samples and urine should be 
subjected to SE-HPLC analysis486 and iTLC381 to quantify any breakdown of the 
dAb fusions and of the 68Ga-NOTA complex. Also, radio-SDS-PAGE could also 
differentiate between any potential aggregates.  
 
5.2.4 mRNA TaqMan Repeats 
The significance of the mRNA TaqMan results was hampered by the lack of 
repeat data, relying heavily on the agreement of a number of analysed genes to 
provide legitimacy to the conclusions. Therefore, with further resources allocated to 
the acquisition of this data it would be straightforward to analyse the mRNA 
expression profiles of the remaining RNAlater cryo-frozen xenograft tissues.  
 
5.2.4 Evidence of Anti-Proliferative Therapeutic 
Action  
The mRNA data indicated an anti-proliferative phenotype in the xenografts, 
which correlated with increased xenograft uptake through dAb-mediated ASGPR 
targeting. Whether the increases in mRNA copy number were translated into anti-
proliferative protein expression could be explored ex vivo by performing western 
blotting for proteins such a p53, OAS and PKR, in addition to those genes sampled 
in the TaqMan experiment. Furthermore, quantitative enzyme-linked 
immunosorbent assays or MALDI could be easily used to screen for numerous 
protein markers simultaneously.  
Tumour regression analysis would add to the robustness by adding data on a 
tangible effect on the tumour progression through a repeat dosing regime. This could 
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perhaps either be by calliper measurements with survival times149 or time course ex 
vivo size measurements143. There is also the possibility of FDG scans to monitor 
changes in xenograft metabolism487. Moreover, xenograft uptake could be monitored 
over time using PET-CT with a longer time frame beginning from t=0. 
The xenograft percolation by the dAb fusions should be assessed by 
immunohistochemistry. The hypothesis that the increased anti-proliferative 
phenotype was linked to greater xenograft penetration by the reduced affinity 
ASGPRdAbs could be assessed. This could be achieved by staining for the dAb or 
hIFN component, as demonstrated in the flow cytometry experiments. This would 
also serve to confirm that the uptake is not just free Ga-68. It would also facilitate a 
greater understanding of the xenograft vascular organisation.  
 
5.2.5 Novel dAb Fusion Tumour PET-CT 
Modelling & Targets 
Novel targets for dAb fusions could be explored whilst improving the in vivo 
model. The full extent of PET-CT’s capabilities for in vivo compartmental modelling 
could not be utilised effectively in this investigation. This was due to the low 
xenograft uptakes compared to the liver from the off-target murine cross-reactive 
liver uptake and the unquantified effect the liver had on the bioavailability of the dAb 
fusions for xenograft uptake. There were too many variables. Therefore, to model 
dAb fusions with in vivo PET-CT imaging, target receptors must be chosen that do 
not have high expression levels in the host. Moreover, MRI facilities are now 
available so PET-CT-MRI is now a feasible option for further exploration. 
Hence, choosing a dAb target that is a high-copy number tumour marker 
predominantly/exclusively expressed in the xenograft tissue would perhaps provide 
data with less variables. For instance, targeting xenografts overexpressing HER2488-
490, melanoma xenografts expressing the tumour marker MCSP142,491, glioblastoma 
xenografts over-expressing EGFR141,225, or actively growing xenograft tissue through 
B-FN143,145,492. Such dAbs would require selection by phage-display and subsequent 
maturation, plus the full analytical package of assays before in vivo investigations using 
the methodology optimised in this investigation.  
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6.1 METHODS APPENDIX 
6.1.1 Consumable Materials 
Table 6.1  
Chemical Reagents 
  Key Data 
Reagent Manufacturer (Order Number) Formula 
Mr 
(g/mol) 
293 Freestyle 
Expression 
Medium 
Gibco 
(12338-018) - - 
2X YT Microbial 
Medium 
EZMix Powder 
Sigma 
(Y2627) - - 
Acetate 4.0 GE Healthcare (BR-1003-49) - - 
Acetate 4.5 GE Healthcare (BR-1003-50) - - 
Acetate 5.0 GE Healthcare (BR-1003-51) - - 
Acetate 5.5 GE Healthcare (BR-1003-52) - - 
Acetic Acid 
(TraceSelect Ultra) 
Sigma Aldrich 
(07692) CH3CO2H 60.05 
Ammonia Solution 
35% 
Fisher Scientific 
(A/3280/PB15) NH3 17.03 
Ammonium 
Acetate 
Sigma Aldrich 
(A1542) CH3CO2NH4 77.08 
Antifoam 204 Sigma Aldrich (A8311) - - 
Bovine Serum 
Albumin 
Sigma Aldrich 
(A7906) - 66463 
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Cell Dissociation 
Buffer 
Gibco 
(13151-014) - - 
Chelex 100 
Analytical Grade 
Bio-Rad 
(142-2832) - 3500 
Citric Acid 
Monohydrate 
Sigma Aldrich 
(C1909) 
HOC(COOH)(CH2COOH)2 
•H2O 
210.1 
Dulbecco’s 
Modified Eagle 
Medium  
Gibco 
(41966-029) - - 
Dulbecco’s 
Phosphate Buffered 
Saline without 
CaCl2 and MgCl3 
Sigma Aldrich 
(D8537) - - 
EDTA Sigma Aldrich (EDS) C10H16N2O8 292.2 
EDTA Solution 
(0.1M) 
NHS 
(BNS10506) - - 
Ethanol 100% VWR (20821.321) C2H6O2 46.07 
Foetal Bovine 
Serum 
(Heat Inactivated) 
Gibco 
(10082147) 
- - 
Gallium-68 Eckert & Ziegler (3131-0902) 
68GaCl3 176.1 
Geneticin Invitrogen (10131027) - - 
Glycine 2.0 GE Healthcare (BR-1003-55) - - 
Glycine 3.0 GE Healthcare (BR-1003-57) - - 
Guanidine 
Hydrochloride 
Sigma Aldrich 
(50950) CH6ClN3•HCl 95.53 
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HBS-P+ Buffer 
10X 
GE Healthcare 
(BR-1006-71) - - 
HEPES VWR (AAA14777) C8H18N2O4S
 238.3 
Hydrochloric Acid 
30% 
(TraceSelect Ultra) 
Sigma Aldrich 
(96208) HCl 36.46 
Imidazole Sigma Aldrich (I2399) C3H4N2 68.06 
Indium-111 
Mallinckrodt 
Medical 
(DRN4901) 
111InCl3 221.2 
Isofluorane 
Baxter 
International 
(1001936060) 
C3H2ClF5O 184.5 
L-Glutamine Sigma Aldrich (G7513) C5H10N2O3 146.1 
Methanol Fisher (M/4056/17) CH3OH 32.04 
Nickel Chloride Sigma Aldrich (451193( NiCl2 129.6 
NuPAGE 
Antioxidant 
Invitrogen 
(NP0005) - - 
NuPAGE LDS 
Sample Buffer 4X 
Invitrogen 
(NP0007) - - 
NuPAGE MOPS 
SDS Running 
Buffer 20X 
Invitrogen 
(NP0001) - - 
p-SCN-Bn-NOTA Macrocyclics (147597-66-8) C20H26N4O6S•3HCl 559.9 
Phosphate Buffered 
Saline 1X 
Agilent 
Technologies - - 
Propan-2-ol Fisher Scientific (10497070) C3H8O
 60.10 
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Propidium Iodide Molecular Probes (P3566) - - 
Quanti-Blue Invivogen (rep-qb1) - - 
Quick Coomassie 
Stain 
Generon 
(GEN-QC-STAIN-
1L) 
- - 
Reference 
Standard pH10.0 
Sigma Aldrich 
(B5020) - - 
Reference 
Standard pH4.0 
Sigma Aldrich 
(B5020) - - 
Reference 
Standard pH7.0 
Sigma Aldrich 
(B4770) - - 
RNAlater Solution 
Life 
Technologies 
(AM7020) 
- - 
RPMI 1640 
Medium 
Gibco 
(A10491-01) - - 
Sodium Acetate Sigma Aldrich (71183) CH3COONa 82.03 
Sodium Acetate 
(TraceSelect) 
Sigma Aldrich 
(59929) CH3COONa 82.03 
Sodium 
Bicarbonate 
Sigma Aldrich 
(S6014) NaHCO3 84.01 
Sodium Chloride 
(TraceSelect) 
Sigma Aldrich 
(204439) NaCl 58.44 
Sodium Hydroxide Sigma Aldrich (S8045) NaOH 40.00 
Sodium Phosphate 
dibasic 
Sigma Aldrich 
(S7907) Na2HPO4 142.0 
Sodium Phosphate 
monobasic 
Sigma Aldrich 
(S8282) NaH2PO4 120.0 
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Trypan Blue Bio-Rad (145-0021) - - 
Water 
(TraceSelect Ultra) 
Sigma Aldrich 
(14211-1L-F) H2O 18.00 
Water (PCR 
Grade) 
Sigma Aldrich 
(W3500) H2O 18.00 
Water (Sterile) Baxter (UKF7114) H2O 18.00 
 
 
Table 6.2  
Biological Reagents 
Reagent 
 
Manufacturer 
(Order Number) 
 
Alexa Fluor 647 Goat Anti-Mouse IgG Invitrogen (A21235) 
Anti-hIFN Mouse mAb  PBL Interferon Source  (21105-1) 
Anti-IFNAR1 Mouse mAb PBL Interferon Source  (21375-1) 
Anti-IFNAR2 Mouse mAb PBL Interferon Source  (21385-1) 
Anti-rat-ASGPR Mouse mAb Hycult Biotech  (HM3020) 
Anti-dAb Mouse mAb GSK In-House (GRITS33516) 
BL21(DE3) Competent E. coli New England Biolabs (C2527) 
Blasticidin Invivogen (ant-bl-1) 
DNA 100bp Ladder New England Biolabs (N3231L) 
DNA 1kb Ladder New England Biolabs (N3232L) 
HEK-Blue IFNα/β Cells Invivogen (hkb-ifnab) 
HepG2 Hepatocellular Carcinoma 
Epithelial Cells 
ATCC 
(HB-8065) 
hIFNAR2 Fc Chimera R&D Systems (4015-AB-050) 
IgG1 Mouse λ Isotype Control BD Biosciences (553452) 
One Shot MAX Efficiency DH5α-T1R 
Competent E. coli 
Invitrogen 
(12297-016) 
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Platinum Blue PCR SuperMix Invitrogen (12580-023) 
Pwo Master Mix Roche (03789403001) 
TaqMan Universal PCR Master Mix Applied Biosystems (4304437) 
U-937 Histiocytic Lymphoma  
Monocyte Cells 
ATCC 
(CRL-1539.2) 
WThIFN-His6 GSK (-) 
Zeocin Invivogen (ant-zn-1) 
 
Table 6.3  
Lab Consumables 
Consumable 
 
Manufacturer 
(Order Number) 
 
0.5ml Protein Lo-Bind Tube Eppendorf (0030108094) 
0.5ml Safe-Lock Microcentrifuge Tube Eppendorf (0030121023) 
1-200μl Gel Loading Tips Corning (CLS4853) 
1-200µl Round Gel Loading Tips Corning (4853) 
1.5ml Safe-Lock Microcentrifuge Tube Eppendorf (0030 120.086) 
1000ml Rapid-Flow 0.2µm Filter Unit Nalgene (567-0020) 
10ml Stripette Corning (4101) 
15ml Tubes Corning (430791) 
2.0ml Protein Lo-Bind Tube Eppendorf (0030108132) 
2.0ml Safe-Lock Microcentrifuge Tube Eppendorf (0030120094) 
250ml Rapid-Flow 0.2µm Filter Unit Nalgene (568-0020) 
25ml Stripette Corning (4251) 
2ml Cryotube Corning (430488) 
300μl Fused Glass Insert Vial Chromacol (03-FISV) 
30ml Tube Sterilin (128C) 
500ml Centrifuge Tube Corning (431123) 
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500ml Erlenmeyer Flask Corning (430422) 
500ml Rapid-Flow 0.2µm Filter Unit Nalgene (566-0020) 
50ml Disposable  
Vacuum Filtration System 
Millipore 
(SCGP00525) 
50ml Reagent Reservoir Corning (4870) 
50ml Tubes Corning (430829) 
5ml Stripette Corning (4051) 
96 Square Well Storage Plate Thermo Scientific (AB-0661) 
96 Well V-bottom Plate Greiner Bio-One (651101) 
96-Well Microplate Foils GE Healthcare (28-9758-16) 
96-Well Round Bottom  
Cell Culture Plate 
Corning 
(3799) 
96-Well V-Bottom Microtitre Plate Sterilin (612V96) 
9mm Screw Cap with PTFE pre-cut seal Chromacol (9-SC(GY)-BST1X) 
AirOtop Enhanced 
Ultra Yield Flask Seal 
Thomson 
(899425) 
Anti-Static Microspatula VWR (231-0106) 
Aspirating Pipettes Corning (4486) 
Centrifugal Filter Ultrafree-MC HV Millipore (UFC30HV25) 
Column Adaptor  Phenomenex (AHO-7191) 
Counting Slides Bio-Rad (145-0015) 
E-Gel 0.8% Agarose Invitrogen (G501808) 
E-Gel 2% Agarose Invitrogen (G501802) 
E-Gel Double Comb 2% Agarose Invitrogen (G601802) 
E-Gel EX 2% Agarose Invitrogen (G401002) 
FEP Tubing Sigma Aldrich (58695-U) 
Flat Deck Thermo-Fast 96 
Detection PCR Plate 
Thermo Scientific 
(AB-1400) 
Gas Permeable Microplate Seals Thermo Scientific (AB-0718) 
gentleMACS M Tubes Miltenyi Biotec (130-093-236) 
Glass Vials 16mm (4ml) GE Healthcare  (BR-1002-09) 
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HiLoad 26/60 
Superdex 200 prep grade Column 
GE Healthcare 
(17-1071-01) 
Illustra NAP-5 Columns GE Healthcare (17-0853-01) 
Injekt Solo 1ml Syringe Beckton, Dickinson & Company (?) 
Injekt Solo 2ml Syringe Beckton, Dickinson & Company (A/3280/PB15) 
Injekt Solo 5ml Syringe Beckton, Dickinson & Company (?) 
Inoculation Loop Nunc (254410) 
Insulin Syringe 0.5ml with Needle Terumo (SS05M2913) 
iTLC-SG Chromatography Medium Varian (SGI0001) 
IV Safelon Catheter BD Biosciences (391651) 
Kimcare Medical Wipes Kimberly-Clark Professional (3020) 
LabXpert Perm Nylon Cloth Labels LabXpert (X-131-499) 
Maxi GeBAflex-tube 
3.5kDa MWCO Dialysis Tube 
Gene Bio-Application 
(D035) 
MicroAmp Optical Adhesive Film Applied Biosystems (4360954) 
Midi GeBAflex-tube 
3.5kDa MWCO Dialysis Tube 
Gene Bio-Application 
(D010) 
Millex-GS 0.22µm Syringe Filter Millipore (SLGSV255F) 
Millex-GV 0.22µm Syringe Filter Millipore (SLGV004SL) 
Minisart 0.2μm Filter Sartorius Stedim Biotech (16534) 
Myjector U-100 Insulin Syringe Terumo (BS05M2913) 
Novex Sharp Pre-Stained Protein Standard Life Technologies (LC5800) 
NuPAGE 12% Bis-Tris Gel 
1.0mm x 12 well 
Life Technologies 
(NP0342BOX) 
NuPAGE 12% Bis-Tris Gel 
1.0mm x 17 well 
Life Technologies 
(NP0349BOX) 
Parafilm Wrap Pechiney Plastic Packaging (PM-992) 
PCR Microplate Film Eppendorf (0030127811) 
PD MiniTrap G-25 GE Healthcare (28-9180-07) 
Perm Nylon Cloth Tube Label Brady (X-131-499) 
Petri Dish Sterilin (101VR20) 
pH0.0-6.0 Strips Sigma-Aldrich (P-4661) 
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pH4.5-10 Strips Sigma-Aldrich (P-4536) 
Plastic Vials 7mm (0.8ml) GE Healthcare  (BR-1002-12) 
Poly-Prep Chromatography Columns Bio-Rad (731-1550) 
PP Female-Female Luer Adaptors Cole-Parmer (EW-45500-22) 
PTFE Tubing GE Healthcare (P5360JE) 
PVDF 3-way Valves Cole-Parmer (EW-31200-80) 
Rubber Caps 7mm GE Healthcare  (BR-1005-55) 
Rubber Caps Type 2 GE Healthcare (BR-1004-11) 
Scintillation Vial & Cap Sterilin (505) 
Sensor Chip CM5 GE Healthcare (BR-1000-12) 
Sensor Chip CM5 (Series S) GE Healthcare (BR-1005-30) 
Sepharose 4 FastFlow Protein A Amersham (17-0974-04) 
Septa Caps 16mm GE Healthcare (BR-1002-11) 
Silica Gel 2.5-6.0mm 4-7 Fisher (S/0720/53) 
Steriflip 0.22μm 50ml 
Vacuum Filtration System 
Millipore 
(SCGP00525) 
Sterile Disposable Scalpels 10 Swann-Morton (0501) 
Strata-XC Cationic Exchange Columns Phenomenex (8B-S029-TAK) 
T175 Flask Corning (431080) 
T25 Flask Corning (430639) 
T75 Flask Corning  (430641) 
TaqMan Array  
Human Interferon Pathway Fast  
96-well Plate 
Applied Biosystems 
(4418799) 
Titer-Tops Microplate Seals Diversified Biotech (T-TOPS-50) 
Ultrafree MC-HV Centrifugal Filters Millipore (UFC30HV25) 
Vivaspin 20 5kDa MWCO Sartorius Stedim Biotech (VS2012) 
Vivaspin 6 5kDa MWCO Sartorius Stedim Biotech (VS0611) 
YMC-Diol-60 SE-HPLC Column YMC (DL06505-3008WT) 
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Table 6.4  
Reagent Kits 
Consumable 
 
Manufacturer 
(Order Number) 
 
Amine Coupling Kit GE Healthcare (BR100050) 
BIA Maintenance Kit GE Healthcare (BR-1006-66) 
DC Protein Assay Kit II Bio-Rad (500-0112) 
Endo Hf New England Biolabs (P0703L) 
EndoFree Plasmid MegaPrep Qiagen (12381) 
High Capacity cDNA Reverse 
Transcription Kit 
Applied Biosystems 
(4375575) 
NucleoSpin Plasmid MiniPrep Kit Macherey-Nagel (740588-250) 
PNGase F New England Biolabs (P0704S) 
QIAGEN Plasmid MaxiPrep Qiagen (12162) 
QIAprep Spin MiniPrep Qiagen (27104) 
QIAquick Gel Extraction Qiagen (28706) 
QIAquick PCR Purification Qiagen (28104) 
RNeasy Maxi Total RNA Isolation Kit Qiagen (75162) 
T4 DNA Ligase Kit New England Biolabs (M0202L) 
Zero Blunt TOPO PCR Cloning Kit, 
with One Shot MAX Efficiency  
DH5α-T1R E. coli 
Invitrogen 
(K2820-20) 
 
Table 6.5  
Restriction Enzymes 
Restriction Enzyme Units (U/μl) Buffer Manufacturer 
BamHI 10 SuRE/Cut B Roche (10220612001) 
DpnI 20 CutSmart New England Biolabs (R0189L) 
HindIII 10 SuRE/Cut B Roche (10656313001) 
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Table 6.6 
Plasmid Vectors 
Plasmid 
Vector Resistance 
Forward 
Primer 
Reverse 
Primer Manufacturer 
pCR-BLUNT Kanamycin M13F M13R Invitrogen 
(Paisley, UK) 
pDOM50 Carbenicillin DT039 DT045 Domantis 
(-) 
 
 
Table 6.7 
Buffer & Reagent Recipes 
Buffer / 
Reagent Concentration pH 
Ingredients 
Chemical Mass (g) 
Volume 
(ml) 
Citric Acid 0.04M - Citric Acid Monohydrate 0.42 - ddH2O - 50 
EDTA 0.1M - EDTA 1.46 - ddH2O - 50 
EtOH 20% - Ethanol 100% - 10 ddH2O - 40 
HCO3- 0.05M * 9.2 
NaHCO3 3 - 
ddH2O - 1000 
GuHCl 6M - CH6ClN3•HCl 573.2 - H2O - ~1000 
HCl 
0.1M - HCl (TS) - 10.58 H2O (TS) - 989.4 
5.5M - 0.1M HCl (TS)  21 HCl (TS) - 29 
HEPES 1M * 7.0 
HEPES 238.3 - 
NaOH 5M -  
ddH2O -  
Imidazole 
25mM - Imidazole 0.303 - PBS - ~100 
1M 8.0 Imidazole 6.81 - Tris-HCl-NaCl 0.1M - ~100 
NaAc 
25mM * 
3.3 
NaAc (TS) 0.015 - 
CH3CO2H (TS) - 708x10-3 
ddH2O - ~500 
6.0 
NaAc (TS) 0.098 - 
CH3CO2H (TS) - 33.4x10-3 
ddH2O - ~500 
1M 
6.0 
NaAc (TS) 7.95 - 
CH3CO2H (TS) - 178x10-3 
ddH2O - 100 
- NaAc (TS) 0.978 - 
 ddH2O - ~2 
NaCl 5M 1.0 NaCl (TS) 1.46 - HCl 0.1M (TS) - ~5 
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NaOH 5M - NaOH   ddH2O   
NiCl2 0.25M - 
NiCl2 3.24 - 
ddH2O - ~100 
Tris-HCl-
NaCl 0.1M 8.0 
Tris 1.21 - 
NaCl 0.58 - 
HCl 1M - 6.45 
ddH2O - ~93.6 
*+10g/L Chelex (0.2um filtered out) 
 
 
Table 6.8 
 HPLC Solvent Recipe 
Solvent 
Name Reagent 
Variables & Measurements 
Final 
Concentration pH 
Mass 
(g) 
Volume 
(ml) 
PO43- NaCl 
Buffer 
Na2HPO4 0.2M 
6.8 
17.5 - 
NaH2PO4 9.23 - 
NaCl 0.15M 8.77 - 
H2O - - 1000 
*H2O = Baxter Water 
 
6.1.2 Method Outlines 
 
  
Figure 6.1 – NOTA Conjugation 
and Analytical in vitro Assays 
 
Figure 6.2 – Ga-68 Radiolabelling 
Reaction 
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  Figure 6.3 – In vivo Xenograft 
Biodistribution Modelling 
 
Figure 6.4 – DNA In-Line Fusions 
 
Figure 6.5 – Expression Construct 
and Protein Expression 
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6.1.3 Common Molecular Biology Methodologies 
6.1.3.1 PCR Product DNA Purification 
The Qiagen QIAquick PCR Purification system was utilised to purify PCR 
products. The samples were pipetted onto QIAquick spin columns and loaded by 
vacuum filtration. The column was washed with Buffer PB at 5x sample volume and 
0.75ml Buffer PE, each followed by microcentrifugation at 13000rpm for 1min. An 
additional centrifugation at 13000rpm for 1min was performed. The purified DNA 
was eluted into a fresh 2ml tube by the addition of 50μl cgH2O, which was allowed 
to settle for 4min, followed by centrifugation at 13000rpm for 1min. 
 
6.1.3.2 Analytical DNA Gel Electrophoresis  
A 2% E-Gel Agarose Gel was inserted into an Invitrogen E-Gel iBase™ and 
was pre-run for the pre-programmed time. Sample aliquots of 10μl were loaded 
directly into the gel lanes as required. A 10μl 100bp and/or 1kb 1X DNA Ladder 
mix (2μl 6x DNA Ladder, 2μl 6x Loading Buffer, 8μl double deionized H2O 
(ddH2O)) was also loaded adjacent to the samples, as appropriate. Gels were run at 
room temperature for ~30min. Gels were imaged with a 600ms ultraviolet (UV) 
exposure on a Syngene Gene Genius UV imager. Images were captured using 
Syngene GeneSnap software. 
 
6.1.3.3 Gel Extraction DNA Purification 
A 2% SYBRSafe Agarose EX-Gel was loaded into an Invitrogen E-Gel iBase 
and pre-run for the pre-programmed time. DNA samples were loaded to a maximum 
of 20μl per well, being split over several wells as necessary. A 10μl 100bp and/or 1kb 
1X DNA Ladder mix (2μl 6x DNA Ladder, 2μl 6x Loading Buffer, 8μl ddH2O) was 
also loaded adjacent to the samples, as appropriate. Gels were run at room 
temperature for ~30min. Gels were imaged with a 600ms UV exposure on a 
Syngene Gene Genius UV imager. Images were captured using Syngene GeneSnap 
software. 
The EX-Gel was loaded onto an Invitrogen Safe Imager to illuminate DNA 
banding for excision. A fresh clean scalpel blade was used to excise each DNA band 
of interest contained within the agarose, and were transferred to 2ml polypropylene 
tubes. The Qiagen QIAquick Gel Purification system was utilised to purify DNA 
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from the gel samples. Tubes were weighed to establish the volume of the extracted 
gel band, and QB buffer added to 3x sample volume before incubation in a 42°C 
waterbath for ~10min with intermittent vortex agitation to ensure all agarose was 
dissolved. The QB-agarose-DNA mix was loaded onto a QIA-column and 
microcentrifuged at 13000rpm for 1min. The column was washed by centrifugation 
at 13000rpm for 1min with 0.5ml Buffer QB followed by 0.75ml Buffer PE. An extra 
centrifugation at 13000rpm for 1min was performed to remove any remnants of 
buffers. DNA elution was achieved by the addition of 50μl cgH2O, which was 
allowed to settle for 4min, followed by centrifugation at 13000rpm for 1min into a 
fresh 2ml tube. 
 
6.1.3.4 DH5α E. coli Cell Transformation 
All procedures were carried out utilising sterile technique. A 50μl vial of 
Invitrogen One Shot MAX Efficiency DH5α-T1R chemically Competent E. coli was 
thawed on ice. The E. coli were transformed by the gentle addition of 1μl of 
recombinant DNA plasmid sample with incubation on ice for 20min to 1hr. The vial 
was then immersed for 35s in a waterbath heated to precisely 42°C and immediately 
returned to ice for ~10min.  
The transformed E. coli were revived with the addition of 250μl room 
temperature optimal broth with catabolite suppression (SOC) Medium, before 
incubation at 37°C for 1hr with horizontal shaking at 250rpm. Aliquots of this starter 
culture were spread onto selective 2YT Agar plates pre-warmed 37°C at varying 
concentrations using the 'Franz' technique to ensure single transformed DH5α colony 
growths. Infected plates were incubated inverted at 37°C for ~20hours or until 
discrete colonies could be identified. 
 
6.1.3.5 Colony Screening Taq PCR 
Six colonies were preselected from the agar plates based on their lack of 
proximity to other colonies, large relative size and shape regularity. They were 
partially picked using a pipette tip, which was then immersed in an individual plated 
PCR reaction mixture.  
The 96-well plated 50μl PCR reaction mixtures consisting of one colony pick, 
48μl Taq SuperMix, 1μl sense primer and 1μl α-sense primer underwent PCR 
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thermal cycling in a Bio-Rad DNA Engine Tetrad 2 Peltier Thermal Cycler as 
outlined in Table 6.6. 
The temperature decrease between the denature step and anneal step was 
slowed using a cooling gradient of 2.5C/s. The PCR machine lid temperature 
tracked at least 5°C above sample temperature. 
 
Table 6.9  
Taq PCR for Colony Screening 
STEP TEMPERATURE (°C) TIME (min:s) # CYCLES 
Initial Denaturation 94 2:00 1 
Denature 94 0:30 
30 Anneal 55 0:30 
Extension 72 2:00 
Final Extension 72 10:00 1 
Soak 4 ∞ 1 
 
6.1.3.6 DNA Sequencing 
The DNA (25ng) was made up with cgH2O as appropriate to a volume 
≥25μl/well in a Flat Deck Thermo-Fast 96 Detection PCR Plate. Plates were heat-
sealed with using a Thermo Scientific ALPS 3000. Raw sequence data was acquired 
utilising an Applied Biosciences 3730xl DNA analyser with addition of appropriate 
primers, and conducted by GSK GenePortal Sequencing Service (Stevenage, UK). 
The raw data files were analysed using Biosoft Bioedit software. 
 
6.1.3.7 DNA MiniPrep  
All procedures were carried out utilising sterile technique. The Qiagen 
QIAprep MiniPrep system was utilised. A positive colony was picked from a plate to 
inoculate 5ml of 50μg/ml selective 2YT Broth in a 15ml tube. The tube lid was 
loosely reattached and the culture incubated overnight at 37°C for 16 hours with 
shaking at 250rpm.  
The E. coli cells were harvested centrifuging the cell culture for 15min at 
3600rpm 4°C, with the supernatants subsequently decanted to waste. Pellets were 
thoroughly resuspended in 250μl Buffer P1 and transferred to a 2ml tube. Cells were 
lysed by the addition of 250μl Buffer P2, with inversion mixing, until homogenously 
blue in colour as indicated by LyseBlue. Introduction of 350μl Buffer N3 neutralised 
the reaction mix with immediate inversion mixing until homogeneously colourless. 
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The mixes were microcentrifuged for 10min at 13000rpm to remove lysed cellular 
debris. The supernatants were loaded onto QIAprep spin columns and 400mbar 
vacuum filtrated. The columns were washed with 500μl Buffer PB, followed by 750μl 
Buffer PE, with microcentrifugation for 1min at 13000rpm. An extra 
microcentrifugation for 1min at 13000rpm was performed to remove any remnants 
of buffers. DNA elution was achieved by the addition of 100μl H2O, which was 
allowed to settle for 4min, before microcentrifugation for 1min at 13000rpm into a 
fresh 2ml tube. The DNA was stored at -20°C. 
 
 
 
 
 
 
6.1.3.8 Restriction Digest 
The 50μl reaction mix of 40μl DNA (~1μg), 5μl 10X Buffer, 2.5μl ddH2O 
and finally 1.25μl of each relevant restriction enzyme (Appendix Table 6.5) was 
incubated at 37°C for 12 hours followed by incubation at 4°C.  
Figure 6.6 – pDOM50-hIFN-ASGPRdAb Expression Vector Construct 
The hIFN-ASGPR expression unit was cloned into the pDOM50 plasmid vector as a 
BamHI/HindIII fragment. The vector contains an Ampicillin/Carbenicillin resistance gene for 
prokaryotic cell selection.  
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6.1.3.9 DNA MegaPrep 
All procedures were carried out utilising sterile technique. The Qiagen 
EndoFree MegaPrep system was utilised. 
A positive colony was picked from a plate to inoculate a 15ml starter culture 
of 50μg/ml selective (Table 6.6) 2YT Broth in a 50ml tube. The tube lid was loosely 
reattached and the culture incubated at 37°C for 8hours with shaking at 250rpm. 
The entire starter culture was then added to 500ml of 50μg/ml selective 2YT Broth 
in a 2L glass baffled flask for overnight incubation with 250rpm shaking.  
E. coli cells were harvested by centrifuging the culture for 30min at 3600rpm 
4°C with the supernatants decanted to waste. Cells were fully resuspended by 
vigorous pipetting and vortex in 50ml Buffer P1 containing 100μg/ml RNase A. 
Addition of 50ml Buffer P2 lysed the cells by gentle swirl mixing and incubation for 
5min at room temperature, until homogenously blue in colour as indicated by 
LyseBlue. Cell debris was precipitated by adding 50ml chilled neutralisation buffer 
P3 with gentle inversion mixing until homogeneously colourless.  
The mixture was immediately transferred to the QIAfilter Mega-Giga 
cartridge attached to a 500ml Schott bottle, allowing the precipitate to accumulate at 
the meniscus over 10min. A 400mbar vacuum was applied to filter the lysate from 
the precipitate. A 50ml Buffer FWB2 aliquot was then added to the QIAfilter 
cartridge, and the precipitate carefully washed without dispersal with a 400mbar 
vacuum applied to pull through all remaining liquid. The filtered lysate was mixed 
with 12.5ml Buffer ER by inversion mixing, followed by 30min incubation on ice. 
A QIAGEN-tip 2500 resin column was equilibrated with 35ml Buffer QBT 
by gravity flow. The chilled filtered lysate was applied to the column by gravity flow. 
The QIAGEN-tip was subsequently washed with 200ml Buffer QC by gravity flow. 
The previous three steps’ eluates were discarded. Plasmid DNA was eluted from the 
column with 30ml buffer QN into a sterile 50ml tube.  
The DNA was precipitated through the addition of 21ml Propan-2-ol, gently 
mixed, and immediately centrifuged for 1 hour at 3600rpm 4°C. The supernatant 
was decanted without disturbing the pellet. The pellet was washed with endotoxin-
free 70% ethanol and centrifuged again for 20min at 3600rpm 4°C. The supernatant 
was carefully decanted without disturbing the pellet. The pellet was now allowed to 
air dry with excess accumulations of ethanol being swabbed away with a Kimcare 
tissue wrapped around forceps, with great care taken not to touch the pelleted DNA. 
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The DNA was redissolved in 1ml buffer TE, and transferred to a fresh 2ml 
eppendorf.  
The eluted DNA was resolved by DNA Gel Electrophoresis (Appendix 
6.1.3.1), the concentration measured via a 1:100 TE dilution sample by UV 
spectrophotometry at 260nm and DNA sequencing performed. The DNA was stored 
at -20°C. 
 
6.1.3.10 SDS-PAGE 
Proteins were resolved by SDS-PAGE analysis, performed utilising the 
Invitrogen NuPAGE SDS-PAGE System. The set up was optimised for proteins 
between 30kDa-36kDa, as described. 
A Pre-Cast NuPAGE 12% Bis-Tris Gel was loaded into an XCell SureLock 
Mini-Cell containing 1X MOPS Running Buffer. If protein samples were reduced, 
200μl NuPAGE antioxidant was added into the cathode chamber.  
A 9µl aliquot of sample protein (normally 2µg) was mixed with 3µl 4x LDS 
Sample Buffer in a 96-Well plate. The plate was sealed with a PCR Microplate Film, 
the plate gently vortexed and centrifuged for 1min at 1000rpm. The plate was loaded 
into a Bio-Rad DNA Engine Tetrad 2 Peltier Thermal Cycler and heated to 70°C 
for 10min. The plate was again centrifuged for 1min at 1000rpm. A 10μl sample was 
loaded into a gel well using gel loading tips. A 10μl Novex Sharp Pre-Stained 
molecular weight marker aliquot was loaded adjacent to samples.  
Gels were run at 160V for 58min at room temperature or until the dye front 
reached the base of the gel. Post electrophoresis the gel was rinsed in ddH2O and the 
wells trimmed. The gel was stained in Generon Quick Coomassie Stain for 1hr at 
room temperature with 70rpm rocking. The gel was washed twice with ddH2O at 2 
hour intervals with 70rpm rocking. Gels were imaged with the Licor Odyssey Imager 
at 700nm with 64dpi high quality settings and analysed with Image Studio software. 
 
6.1.3.11 Protein Ethanol Flash Freezing 
Purified proteins were aliquoted into 0.5ml Lo-Bind tubes. An ethanol bath 
was prepared by placing dry ice in a vat of 100% ethanol. The protein tubes were 
arranged in a rack, and then immersed in the chilled ethanol. The tubes were then 
immediately placed in -20°C storage.  
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6.1.3.12 Biacore Chip Coating 
A Biacore CM5 chip was primed with degassed HBS-P+ buffer until a stable 
baseline sensogram was attained. The receptor ligand was diluted 1:200 in GE 
Healthcare Biacore Acetate immobilisation buffers pH4.0, pH4.5, pH5.0 and pH5.5. 
The pH Scouting application wizard was run, with a rack arranged as prescribed 
with ligand samples, 1M Ethanolamine-HCl surface regeneration, and 2min ligand-
surface contact time. The buffer pH conducive to maximum stable RU gain was 
chosen. 
The Biacore CM5 chip was primed with degassed HBS-P+ buffer until a 
stable baseline sensogram was attained. The receptor ligand was diluted 1:200 in the 
optimum pH Acetate buffer. The Surface Preparation Immobilisation application 
wizard was run, with a rack arranged as prescribed with ligand samples, NHS/EDC 
surface activation and 1M Ethanolamine-HCl. Flow cell (FC) 1 was assigned as a 
blank reference cell, and the receptor ligands assigned as appropriate to FC2-4. The 
target RUs was set at 500* and the flow at 50μl/min. A final RU ±20% was accepted 
and the surface tested with 100nM analyte with Glycine 3.0 regeneration. 
 
6.1.3.13 Biacore 3000 Program Method  
! MICROPLATE FULL RUN by ALEX PAPPLE 
! Timestamp:     08-may-13 10:00 
! Software:      BIACORE 3000 Control Software 
! Version:       3.2 
! Configuration: IFC6 
! ---- 
 
DEFINE LOOP cycle 
 
    LPARAM  %sample   %position     %volume 
 
BLANK_HBS-P+  R2H12 30 
DMS6305_0.98nM  R2G9 30 
DMS6305_1.95nM  R2G8 30 
DMS6305_3.91nM  R2G7 30 
DMS6305_7.81nM  R2G6 30 
DMS6305_15.63nM R2G5 30 
DMS6305_31.25nM R2G4 30 
DMS6305_62.5nM  R2G3 30 
DMS6305_125.0nM R2G2 30 
DMS6305_250.0nM R2G1 30 
BLANK_HBS-P+  RR6 30 
BLANK_HBS-P+    R2B1 30 
END 
 
DEFINE APROG analyse 
    PARAM %sample   %position %volume 
                                                
* Optimum binding kinetic data generally achieved with minimal coated RUs 
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    KEYWORD sample %sample 
    CAPTION sample %sample 
    FLOW 30 
    RPOINT baseline 
 
  * KINJECT %position   %volume  300 
    QUICKINJECT RR2   5 
END 
 
MAIN 
  RACK 1 MICRO 
  RACK 2 MICRO 
  RACK R Reag_A 
 
  DETECTION 2-1,3-1,4-1 
 
  LOOP cycle STEP 
    APROG analyse %sample %position   %volume 
 
  ENDLOOP 
  APPEND Standby 
END 
 
6.1.4 Mammalian Cell Culture 
6.1.4.1 Cell Sub-Culturing 
For adherent cells HEK-Blue and HepG2 (Table 6.10) the following protocol 
was followed:  
The necessity for passaging was determined by light microscopy. If the cell 
monolayer was <70% confluent, the media would be replaced with an equal volume 
of fresh media (Table 6.10 & Table 6.11). If the cell monolayer was ≥70% confluent, 
the cells would be passaged. 
Cell culture medium and dissociation buffer were pre-heated to 37°C. Fresh 
T175 flasks were filled with culture medium for a final volume of 28ml. Antibiotic 
pressure was added as appropriate (Table 6.10). 
The old media was aspirated followed by a 10ml sterile PBS monolayer wash 
at room temperature. A 5ml dissociation medium aliquot was added to detach cells in 
combination with incubation in a humidified incubator at 37°C 5%-CO2 for 10min. 
An additional 10ml of cell culture medium was added to the flask and the cells 
completely resuspended by gentle pipetting shear force and washing of the T175 cell 
culture surface. A fraction of the cell resuspension was used to inoculate the fresh 
T175 flasks to complete the passage. Excess cells were aspirated to waste. Cells were 
cultured in a humidified incubator at 37°C 5%-CO2. 
For the suspended cell line U937 the following protocol was followed:  
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The necessity for passaging was determined by light microscopy. If the cell 
density was <70% confluent, the media would not be changed. If the cell density was 
≥70% confluent, the cells would be passaged. Cell culture medium and dissociation 
buffer were pre-heated to 37°C. Fresh T175 flasks were filled with culture medium 
for a final volume of 30ml. The old cell-containing media was pipetted into a 50ml 
tube. The cell suspension was centrifuged at 1250rpm 4°C for 5min. The 
supernatant was aspirated and the cell pellet resuspended in 20ml fresh culture 
medium. 1ml was used to inoculate the T175 flasks to complete the passage. Cells 
were cultured in a humidified incubator at 37°C 5%-CO2. 
6.1.4.2 Defrosting Cell Lines for Culture 
The culture medium was pre-heated to 37°C in a waterbath. The cell 
cryotube was removed from liquid nitrogen vapour storage into dry ice. A 10ml 
aliquot of culture medium was pipetted to a 15ml tube. 
The cell cryotubes was rapidly thawed by immersion in 37°C water and the 
thawed contents immediately pipetted to a 15ml tube containing 10ml media. The 
tube was centrifuged at 1250rpm 4°C for 5min. The supernatant was aspirated to 
waste. The cell pellet was resuspended in 5ml culture medium. The resuspension was 
transferred to T25 flask and incubated in a humidified incubator at 37°C 5%-CO2. 
Cells were passaged as appropriate to respective cell line via a T75 flask, 
before proceeding with T175 full-scale culture. 
  
Table 6.10  
Sub-culturing Cell Lines 
Cell Line Culture Dissociation Medium 
Passage 
Dilution 
Selection 
Pressure 
HEK-Blue Adherent Culture Medium 1/15 
Blasticidin 
(30μg/ml) 
Zeocin 
(100μg/ml) 
HepG2 Adherent 
Cell 
Dissociation 
Buffer 
1/6 - 
U937 Suspension - 1/20 - 
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Table 6.11  
Culture Medium Recipes 
Cell Line Reagents Volume (ml) 
HEK-Blue 
DMEM 500 
HI-FBS 50 
L-Glutamine* 5 
HepG2 DMEM 500 HI-FBS 50 
U937 RPMI-1640 500 HI-FBS 50 
*Final concentration = 2mM 
 
6.1.4.3 Liquid Nitrogen Cryopreservation  
The cell sub-culturing protocol was followed to attain pelleted cells. Cells 
were resuspended in 15ml of cell culture medium supplemented with 5% (v/v) 
DMSO and immediately aliquoted in 1.5ml fractions into 2ml cryotubes and placed 
into dry ice. Cryotubes were stored at -80°C for one week before transferring to 
liquid nitrogen vapour phase storage. 
 
6.1.4.4 Trypan Blue Live/Dead Cell Counting 
The total live cell count was determined by very gently shake mixing 20μl of 
cell suspension with 20μl of 0.4% Trypan Blue solution, pipetting into the chamber 
of a TC10 Counting Slide (n=2), and read with a Bio-Rad TC10 Automated Cell 
Counter. The output values of total cell count and viability were used to compute the 
total live cell count. 
 
6.1.5 Alternative Radiolabelling Strategies 
All the following strategies’ radiolabelling efficiencies were quantitated by 
0.02M CA-EDTA iTLC and WEA-iTLC, in addition to SE-HPLC (Method 2.3.2 & 
Appendix 6.1.8). 
 
6.1.5.1 5M NaOH 68Ga-NOTA-hIFN- dAb Labelling 
The generator was eluted with 0.1M HCl at a rate of 1ml/min. A 500μl 
fraction covering the top of the elution peak was collected in a 2ml tube followed by 
the addition of 8.2μl 5M NaOH and vigorous shaking. A 25μl aliquot of NOTA 
conjugated protein was pipetted into a 2ml polypropylene tube and a 225μl aliquot of 
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the pH-adjusted 68GaCl3 was carefully pipetted from the high activity fraction 
followed by gentle swirling to ensure homogeneity and the total activity measured. 
The reaction was incubated at room temperature for 10min. The reaction was 
quenched by addition of 13.16μl 0.1M EDTA. 
 
6.1.5.2 5M NaAc 68Ga-NOTA-hIFN-dAb Labelling 
The generator was eluted with 0.1M HCl at a rate of 1ml/min. A 500μl 
fraction covering the top of the elution peak was collected in a 2ml tube containing 
17.5µl of 5M NaAc pH5.5, and mixed vigorously. An aliquot of NOTA conjugated 
protein relative to the final desired reaction concentration in a total reaction volume 
of 250μl was pipetted into a 2ml polypropylene tube and made up to 25μl using 
ddH2O. A 225μl aliquot of the pH-adjusted 68GaCl3 was carefully pipetted from the 
high activity fraction followed by gentle swirling to ensure homogeneity and the total 
activity measured. The reaction was incubated at room temperature for 10min. The 
reaction was quenched by addition of 13.16μl 0.1M EDTA. 
 
6.1.6 Bond-Elut SCX Cationic Exchange 68Ga-
NOTA-hIFN-dAb Labelling 
This method was adapted from the work of Schultz et al493,494. All buffers 
were formulated with TraceSelect reagents. 
An Agilent Technologies Bond Elut SCX 100mg 1ml Cationic Exchange 
Column* was equilibrated with 1ml of 5.5M HCl, followed by washing with 10ml 
ddH2O and liquid expulsion with air. The pre-equilibrated column was affixed to the 
generator outflow by a column-luer adaptor.  
A 5ml aliquot of 0.1M HCl was injected into the generator at 2ml/min, and 
thus through the attached SCX column. Remaining 0.1M HCl in the column was 
expelled with air and the waste checked for Ga-68 breakthrough. The SCX column 
was eluted by the injection of 5M NaCl 0.1M HCl pH1.0 buffer totalling 0.5ml. The 
elution was collected as drop-wise fractions in 0.5ml polypropylene tubes. 
                                                
* Columns were adapted for this system set-up by cutting off the shaft of the cartridge above the matrix 
using a clean scalpel  
VI – Appendices 
Alex G. Papple - 236 - Ph.D. 2014 
Elution fractions 2 and 3 were combined, and 40μl pipetted into a 0.5ml Lo-
Bind tube. This was followed by 25μl of 1M NaAc buffer, pipetted slowly with gentle 
swirling to ensure homogeneity. NOTA conjugated protein for 2µM in a total 
reaction volume of 60μl with remaining volume capacity made up with 0.14M NaAc 
pH4.5. The reaction mix was given a gentle shake and the total activity measured. 
The reaction was incubated at room temperature for 10min. A control reaction with 
a relevant volume of 0.14M pH4.5 NaAc replacing the protein was run in parallel. 
A PBS equilibrated PD MiniTrap G-25 column was subsequently used to 
purify labelled product from radiochemical impurities and NaCl into PBS (Method 
2.3.2). Labelling was quantified by CA-EDTA and WEA iTLC plus SE-HPLC 
(Method 2.3.3 & Appendix 6.1.8) 
 
6.1.7 Radiolabelled NOTA-hIFN-dAb Purification 
6.1.7.1 0.22μm Filtration Purification 
The entire radiolabelling reaction was passed through a Millipore Millex 
0.22μm syringe filter using a 1ml syringe and positive pressure, the eluate was 
collected in a 2ml tube.  
6.1.7.2 Protein A Spin Purification 
0.1ml of Protein A Sepharose 4 FastFlow was bedded on a Millipore Ultrafree 
Centrifugal Filter and equilibrated with 15CV 25mM pH6 NaAc with centrifugation 
at 12000rpm for 1min.  
The radiolabelling reaction was loaded onto the column before 
microcentrifugation at 12000rpm for 1min. The eluate was reloaded twice more with 
centrifugation at 12000rpm for 1min. The column was washed with 15CV 25mM 
pH6 NaAc with centrifugation at 12000rpm for 1min. The column was eluted with 
fractions of 1CV 25mM pH3.3 NaAc into 0.02CV 1M pH6 NaAc in a 2.0ml 
polypropylene tube. The fractions were measured for radioactive recovery. 
 
6.1.7.3 Illustra NAP-5 Column Purification  
A clamped GE Healthcare illustra NAP-5 column was equilibrated with 10ml 
PBS without Ca2+/Mg2+ by gravity flow. The whole radiolabelling reaction was 
loaded onto the column by gravity flow. The purified radiolabelled product was 
eluted in a 0.7ml PBS primary fraction by gravity flow.  
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6.1.8 Radioactive SE-HPLC 
A Beckman Coulter System Gold HPLC machine’s liquid lines and pumps 
were purged of air and YMC-Diol-60 SE-HPLC column equilibrated with phosphate 
elution buffer (Table 6.8). The UV detector and GABI Raytest activity monitor were 
calibrated to the local conditions. A constant elution rate of 0.5ml/min was 
maintained and a 20µl sample injected onto a 200μl loop. The UV elution spectrums 
at A260, and 280nm, and the gamma radiation signal were recorded for 30min using 
Beckman Coulter 32 Karat analysis software. 
 
6.1.9 Additional Methodologies 
6.1.9.1 SDM of hIFN-ASGPRdAbs to Mutate NGS Glycosylation Site 
to NGA  
Three of the nine hIFN-ASGPRdAb mutants underwent SDM: hIFN(A)-
HidAb, hIFN(C)-MidAb and hIFN(E)-LodAb. 
The 50µl PCR reaction mixture of 1µl (~25ng) the pCR-BLUNT-hIFN-
ASGPRdAb, 1μl (0.25µM) sense primer GCGATTGGCCGCAACGGGGCGC-
AGACATACTACGCAGACTCC, 1μl (0.25µM) anti-sense primer 
GGAGTCTGCGTAGTATGTCTGCGCCCCGTTGCGGCCAATCGC, 25μl 
Roche Pwo MasterMix, 22μl cgH2O underwent PCR thermal cycling in a Bio-Rad 
DNA Engine Tetrad 2 Peltier Thermal Cycler  as outlined in Table 6.6. 
 
Table 6.12 
SDM Pwo PCR to mutate NGS Glycosylation to NGA 
Step Temperature (°C) Time (min:s) # Cycles 
Initial Denaturation 94 2:00 1 
Denature 94 0:30 
30 Anneal* 55 1:00 
Extension 68 5:00 
Final Extension 68 15:00 1 
Soak 4 ∞ 1 
 
The temperature decrease between the denature step and anneal step was 
slowed using a cooling gradient of 2.5°C/s. The PCR machine lid temperature 
tracked at least 5°C above sample temperature. The amplified DNA (~2µg) was then 
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subjected to DPNI (25U) restriction digest in CutSmart buffer (Appendix 6.1.3.8). 
The cut plasmids were EX-Gel purified (Appendix 6.1.3.3). 
The encoded SDM mutants were then expressed and purified following the 
exact same process as Methods 2.1.1.3 and 2.1.3. The result was proteins hIFN(A)-
HidAb(SDM), hIFN(C)-MidAb(SDM) and hIFN(E)-LodAb(SDM). 
 
6.1.9.2 PNGase F Deglycosylation Assay 
All reagents were defrosted prior to beginning the assay aliquoting. The assay 
was performed in two stages (Table 6.13). The denaturation stage consisted of 2μg 
glycoprotein, 1µl 10X Glycoprotein Dithiothreitol (DTT) Denaturing Buffer with 
cgH2O added to a final volume of 10µl. Following the denaturation step, 2μl 10X G7 
Reaction Buffer, 2µl NP40, 1µl PNGase F and 5μl cgH2O were added to the relevant 
samples. The incubations were performed in a Bio-Rad DNA Engine Tetrad 2 
Peltier Thermal Cycler. 
 
Controls, each totalling 20μl, included ‘glycoprotein only’, ‘denaturing step 
only’, and ‘PNGase F only’ (no glycoprotein). Assays were analysed by SDS-PAGE 
(Appendix 6.1.3.10) including 200μl NuPAGE antioxidant buffer in the cathode 
chamber. 
 
6.1.9.3 ASGPR-H1-CRD Expression and Purification 
 A recombinant ASGPR-H1-CRD, the binding target of the ASGPRdAbs, 
was expressed by HEK293e mammalian cellular expression of the pDOM50-
ASGPR-H1-CRD vector* (in the same manner as Method 2.1.2), except purified by 
Nickel-Sepharose immobilised metal ion affinity chromatography (IMAC) into 
                                                
* Kindly provided by Dr Thil Batuwangala, GSK. 
Table 6.13  
PNGase F Deglycosylation  
Step Temperature (°C) Time (hours:min) # Cycles 
Denaturation 95 00:10 1 
Incubation 4 ∞ 1 
***ADD PNGase F Stage Reagents*** 
PNGase F 37 12:00 1 
Incubation 4 ∞ 1 
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several fractions, polished by ÄKTA chromatography and concentrated by 5kDa 
MWCO spin concentrated. 
Washed Nickel Sepharose High Performance HisTrap HP resin was 
resuspended in 50ml ddH2O and added to a 2L Duran Bottle along with the 250ml 
harvested ASGPR-H1CRD expression supernatant and 1L of ddH2O. The mixture 
was incubated for ~16hrs overnight on a roller in a cold room at 4°C.  
The Nickel Sepharose was allowed to settle for ~1hr to the bottom of the 
bottle at 4°C, and the supernatant was carefully removed by pipette. The Nickel 
Sepharose was resuspended in ~10CV of 25mM Imidazole- PBS and bed in a 25ml 
Bio-Rad Poly-Prep Chromatography Column. The Nickel Sepharose was further 
washed with 20CV 25mM Imidazole-PBS.  
The column was eluted in a total of 5 1CV fractions using increasing 
concentrations of Imidazole in 100mM Tris-HCl-NaCl (50mM, 100mM, 250mM, 
500mM & 1M). A sample of each fraction was then analysed by SDS-PAGE for the 
presence of the purified protein. A 50μl sample was removed at each stage of the 
purification process from all waste flows for analysis on SDS-PAGE 
(Appendix6.1.3.10) to monitor potential protein loss. 
All fractions containing ASGPR-H1-CRD were pooled into a VivaSpin-20 
5kDa MWCO protein concentrator spin filter and centrifuged at 4600rpm 4°C until 
<1ml remained. The concentrated protein dialysed with a GeBAflex-Midi 800µl 
3.5kDa-MWCO Dialysis Tube into PBS for 3hrs at room temperature, with three 
buffer changes. 
All lines and pumps of an ÄKTA Purifier were purged with 6M GuHCl 
followed by EtOH 20% by executing the SamlplePumpPurify protocol. The pooled 
partially purified ASGPR-H1-CRD sample was injected into a Superloop. The 
method parameters, as assigned in UNICORN software, included a continuous 
0.05M pH5 NaAc 0.15M NaCl buffer flow rate of 2.5ml/min with a 2CV>x<4CV 
column equilibration followed by 9.8ml Superloop load, and 2ml fraction collection 
in a 96-well Deep-Well plate with a serpentine elution pattern. The plate was sealed 
and stored at 4°C. 
SDS-PAGE was performed on those wells containing protein eluate as 
indicated by UV the elution trace to qualify the amount of protein present and purity 
(Appendix 6.1.3.10). All fractions with a high concentration of ASGP-H1-CRD were 
pooled and 0.22μm filtered. The concentration was determined by UV 
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spectrophotometry at 280nm and purity by SDS-PAGE. Samples were aliquoted and 
stored at -20°C. 
 
6.3 RESULTS APPENDIX 
6.3.1 Analytical QC Data 
 
  
Figure 6.7 – Non-Reducing SDS-
PAGE of Protein A Batch 
Purification steps  
SDS-PAGE of samples (1µl) from each step of the 
purification of NOTA-hIFN-MAXdAb and 
NOTA-hIFN-CTRLdAb by the Protein A batch 
method, including the Novex Sharp Pre-stained 
Protein Standard. Result demonstrates the 
efficiency of protein recovery by the Protein A 
batch method as shown by the concentrated 
recovery in the final eluate and the minimal losses 
in the flow-through from the load step and the 
lack of detectable loss during the wash steps.  
 
Figure 6.8 – Non-Reducing SDS-PAGE of IMAC 
purified and ÄKTA polished ASGPR-H1-CRD 
Ni2-Sepharose IMAC co-purification of ASGPR-H1-CRD (raw 
eluate) with multiple high molecular weight species, followed by 
ÄKTA purification resulting in two ASGPR-H1-CRD species 
(8.34µM, 1.3µg loaded). The purity of the final product was 
confirmed by SDS-PAGE (Figure 3.4) as a mix of two species at 
approximately the predicted mass of 17.2kDa. The two species 
were attributed to glycosylation as a similar banding pattern had 
been previously attributed to differing post-translational 
modifications. ASGPR is known to be glycosylated in vivo and so 
multiple glycosylation states with a mammalian expression system 
was not an unexpected result. As the conditions were non-reducing 
there was also a possibility they were two different stable structural 
isoforms with their respective differing migration or cleavage 
product 
M = Novex® Sharp Pre-stained Protein Standard.  
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Figure 6.9 – Biacore T200 SPR 
Analysis of hIFN-MAXdAb 
Biacore T200 SPR with ASGPR-H1-CRD 
immobilised on a CM5 chip assessed the 
ASGPR-H1-CRD binding kinetics of a 64-
0.5nM 1:2 serial dilution of hIFN-MAXdAb 
injected over the chip surface at 30µlmin-1.  
Figure 6.10 – Biacore T200 SPR 
Analysis of MAXdAb 
Biacore T200 SPR with ASGPR-H1-CRD 
immobilised on a CM5 chip assessed the 
ASGPR-H1-CRD binding kinetics of a 64-
0.5nM 1:2 serial dilution of MAXdAb injected 
over the chip surface at 30µlmin-1.  
Figure 6.11 – Flow 
Cytometry HepG2 Cell 
Gating 
Example gating of HepG2 cells 
incubated with hIFN-MAXdAb 
stained with PI and Alexa647 
binding . 
A – whole HepG2 cell gating by 
scatter 
B – PI live cell gating 
VI – Appendices 
Alex G. Papple - 242 - Ph.D. 2014 
0
10
20
30
40
50
60
70
80
90
100
3 3.2 3.4 3.6 3.8 4 4.2 4.4 4.6 4.8 5
R
ad
io
la
be
lli
ng
 E
ffi
ci
en
cy
 (%
)
pH
y = -0.633x + 235.49
R² = 0.88879
160
180
200
220
240
260
280
0 20 40 60 80 100 120
To
ta
l E
lu
tio
n 
Ac
tiv
ity
 (M
Bq
)
Days
Figure 6.14 – Optimum pH 
Scouting for NOTA-hIFN-
MAXdAb  Ga-68 Radiolabelling 
NaOH 5M Ga-68 radiolabelling reactions for 
NOTA-hIFN-MAXdAb with varying pH 
(monitored with a calibrated pH meter) at a 
final concentration of 4µM and at room 
temperature. The results indicated that pH4.4 
provided the optimal radiolabelling pH. 
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Figure 6.12 – EZ IG100 68Ge/68Ga 
Generator Elution Profile 
 Elution profile of generator set-up measured in 
~0.1ml fractions (exact volume determined by 
mass in weighed tubes) up to ~4.5ml. Profile 
shows, in this instance, a 0.5ml eluate fraction 
between ~2.7ml and ~3.2ml ought to be 
collected for maximum activity.  n≥3  
6.3.2 Gallium Labelling Data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.13 – EZ IG100 68Ge/68Ga 
Generator Decay Monitoring 
Total activity eluted in full 10ml elutions over 
time, as monitored for 115 days up to three 
times daily. Demonstrates temporally variable 
yield, which is decreasing with an apparent half 
life of the Ge-68 core of 161 days compared to 
the Ge-68 half-life of 271 days.  
Figure 6.15 – AM-iTLC Example 
AM-iTLC of 68Ga-NOTA-hIFN(A)-HidAb pre-
EDTA quench for examining NOTA 
contamination from inefficient Protein A 
purification. Result demonstrates no substantial 
NOTA break-through into purified eluate, 
which would appear approximately two-thirds 
up the strip.  
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Figure 6.17 – SDS-PAGE of PNGaseF Assay with Mutant hIFN-
ASGPRdAbs including SDM Mutants lacking N-linked Glycosylation 
SDS-PAGE of hIFN-ASGPRdAb mutants – hIFN(A)-HidAb, hIFN(C)-MidAb and hIFN(E)-LodAb – 
and their respective SDM mutant variants lacking N-linked glycosylation – hIFN(A)-HidAb(SDM), 
hIFN(C)-MidAb(SDM) and hIFN(E)-LodAb(SDM) – having undergone PNGaseF deglycosylation, 
including DTT-only control and untreated controls alongside the PNGaseF protein control (36kDa) 
and Novex Sharp Pre-stained Protein Standard.  The reduced hIFN-ASGPRdAbs show a tri-banding 
pattern migrating between ~32-38kDa, whereas the SDM mutants have a clear dual banding pattern 
migrating ~32-34kDa. Through the action of PNGaseF, the heaviest band of the hIFN-ASGPRdAb 
samples is lost and the banding now matches that of the SDM mutants, upon which PNGaseF 
appears to have no effect. The results overall demonstrate that one of the glycosylation species is N-
linked glycosylation because the species represented by the heaviest migrating band is lost through the 
action of PNGaseF or SDM.  
 
 
 
 
 
 
 
 
6.3.3 Site Directed Mutagenesis Data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16 – G-25 MiniTrap 
Purification of a SCX Cationic 
Exchange Ga-68 NOTA-hIFN-
CTRLdAb Radiolabelling 
Reaction  
Phosphorimaging of typical 0.02M CA-
EDTA and WEA (2%BSA(w/v)) iTLCs of a 
68Ga-NOTA-hIFN-MAXdAb radiolabelling 
reaction utilising the SCX Cationic Exchange 
method and the primary fraction from the 
subsequent G-25 MiniTrap purification. The 
observed results show the effective Ga-68 
radiolabelling utilising the cationic exchange 
concentrated Ga-68 and effective removal of 
radiochemical impurities by purification.  
 
Figure 6.18 – Sequencing of NGS to NGA SDM Mutant 
GC rich SDM primer has introduced single T>G mutation in the DNA sequence of the SDM 
mutant thus mutating the serine residue to an alanine residue in the final protein sequence, 
removing the N-linked glycosylation site. 
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